"Rank","NCT Number","Title","Recruitment","Study Results","Conditions","Interventions","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Types","Study Designs","Other IDs","First Received","Start Date","Completion Date","Last Updated","Last Verified","Results First Received","Acronym","Primary Completion Date","Outcome Measures","URL"
1,"NCT00102648","Sarasar and Temodar for Glioblastoma Multiforme Patients","Active, not recruiting","No Results Available","Glioblastoma Multiforme|Gliosarcoma|Brain Tumors","Drug: Sarasar|Drug: Temodar","M.D. Anderson Cancer Center|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 1","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-0424|SPRI # P04084|NCI-2012-01311","January 31, 2005","December 2004","null","June 7, 2016","June 2016","No Study Results Posted","null","December 2017","Maximum tolerated dose (MTD) Sarasar when combined with Temodar in an alternating week schedule|6-month Progression-Free Survival","https://ClinicalTrials.gov/show/NCT00102648"
2,"NCT00619112","Temozolomide in Treating Patients With Recurrent High-Grade Glioma","Completed","Has Results","Recurrent Central Nervous System Neoplasm","Drug: temozolomide","University of California, San Francisco|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000572434|UCSF-H44867-31182-01|UCSF-07107|SPRI-UCSF-H44867-31182-01","February 19, 2008","October 2007","September 2012","October 29, 2013","October 2013","June 17, 2013","null","December 2011","Efficacy, as Measured by 6-month Progression-free Survival, of the Dose-intense Temozolomide Treatment Schedule; This Endpoint Was Measured From the First Day of Treatment Until Progression or 6month Mark From Treatment Initiation.|Toxicity Associated With the Dose-intense Temozolomide Treatment Schedule as Assessed by NCI CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00619112"
3,"NCT01067066","A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma","Terminated","No Results Available","Melanoma","Drug: TPI 287|Drug: Temodar (Temozolomide)","M.D. Anderson Cancer Center|Cortice Biosciences, Inc.","All","15 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-0357|NCI-2011-00558","February 9, 2010","February 2010","July 2016","July 7, 2016","July 2016","No Study Results Posted","null","July 2016","Maximum Tolerated Dose (MTD) of TPI 287 in Combination with Temodar|Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01067066"
4,"NCT00574964","Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme","Terminated","No Results Available","Primary Glioblastoma Multiforme","Other: Gliadel Wafer, Temodar and Radiotherapy","University of Iowa|Eisai Inc.","All","18 Years to 85 Years   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200408035","December 14, 2007","October 2005","June 2008","October 25, 2016","March 2010","No Study Results Posted","Temodar","November 2007","Determine the safety and feasibility of Gliadel 3.85% wafers plus surgery and limited field radiation therapy with concomitant temozolomide, followed by adjuvant temozolomide, in subjects undergoing initial surgery for newly-diagnosed malignant gliomas.|Determine the progression free survival at 6 months, medial survival, and one year survival rate of this subject population. Determine objective response rate.","https://ClinicalTrials.gov/show/NCT00574964"
5,"NCT00304200","Temodar and Sutent as Therapy for Melanoma","Terminated","No Results Available","Metastatic Malignant Melanoma","Drug: Temozolomide and SU11248","Northern California Melanoma Center|Pfizer|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","7","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Temodar/Sutent","March 12, 2006","March 2006","January 2009","February 3, 2009","February 2009","No Study Results Posted","null","October 2007","Safety and tolerability of this combination|Determine the Maximum Tolerated Dose (MTD) of this combination|Progression-free survival (PFS) at 6 months|Progression-free survival (PFS)|Overall survival (OS)|Objective Response Rate (RR)in patients with measurable lesions|Duration of Objective Response in patients with measurable lesions|Correlation of outcome with MGMT promoter methylation","https://ClinicalTrials.gov/show/NCT00304200"
6,"NCT00610571","Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas","Completed","No Results Available","Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma","Drug: Oral Topotecan and Temodar","Katy Peters|GlaxoSmithKline|Schering-Plough|Duke University","All","18 Years and older   (Adult, Senior)","Phase 1","62","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00003970|5487","January 28, 2008","April 2004","April 2012","October 23, 2013","October 2013","No Study Results Posted","null","September 2009","maximum tolerated dose|Safety & efficacy","https://ClinicalTrials.gov/show/NCT00610571"
7,"NCT01847235","Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial","Completed","No Results Available","Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma","Drug: Temozolomide","Seoul National University Hospital","All","20 Years and older   (Adult, Senior)","Phase 2","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OD_OA","April 29, 2013","May 2013","March 2016","April 22, 2016","April 2016","No Study Results Posted","null","September 2015","Progression free survival (PFS)|Objective response rate (ORR)|Overall survival (OS)|progression-free survival (PFS)|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT01847235"
8,"NCT00187486","Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors","Completed","Has Results","Glioblastoma Multiforme|Gliosarcoma","Drug: Tarceva|Drug: Temodar|Procedure: Radiation Therapy","University of California, San Francisco|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","66","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CC 04101|OSI 2725s","September 13, 2005","August 2004","March 2011","September 26, 2012","September 2012","April 25, 2011","null","March 2011","Overall Survival|Progression Free Survival","https://ClinicalTrials.gov/show/NCT00187486"
9,"NCT00613093","Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma","Completed","No Results Available","Glioblastoma Multiforme|Anaplastic Glioma","Drug: Temodar and O6-Benzylguanine (BG)","Duke University|Keryx / AOI Pharmaceuticals, Inc.|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Senior)","Phase 2","67","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4260","January 29, 2008","October 2002","August 2008","July 8, 2014","November 2012","No Study Results Posted","null","March 2006","Radiographic evidence of tumor response|6 month progression-free survival|Relationship between tumor AGT at original diagnosis & response to Temozolomide + O6-BG","https://ClinicalTrials.gov/show/NCT00613093"
10,"NCT00313729","Temozolomide in Treating Patients With Low-Grade Glioma","Completed","No Results Available","CNS Tumor, Adult","Drug: temozolomide","University of California, San Francisco","All","18 Years and older   (Adult, Senior)","Phase 2","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000448883|99102|BTRC-9902|H7858-16278-07","April 11, 2006","May 1999","March 2015","May 28, 2015","May 2015","No Study Results Posted","null","January 2015","Response rate (complete and partial response)|Time to tumor progression|Survival|Toxicity","https://ClinicalTrials.gov/show/NCT00313729"
11,"NCT00012116","Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain","Completed","No Results Available","Metastatic Cancer","Drug: temozolomide","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","4","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068485|P30CA016042|UCLA-0004059|SPRI-UCLA-0004059|NCI-G01-1919","March 3, 2001","October 2000","April 2002","October 28, 2015","July 2012","No Study Results Posted","null","April 2002","To assess the rate of response/control of cerebral metastases from solid tumors to extended low dose, continuous oral temozolomide|To assess the safety and tolerability of low dose, continuous oral temozolomide in this patient population|to measure quality of life in patients with cerebral metastases treated with low dose, continuous temozolomide|To measure the rate of response of systemic disease outside the central nervous system to extended low dose continuous oral temozolomide","https://ClinicalTrials.gov/show/NCT00012116"
12,"NCT00165230","Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors","Completed","No Results Available","Neuroendocrine Tumor","Drug: Thalidomide|Drug: Temodar","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-011","September 9, 2005","May 2002","July 2006","April 27, 2009","April 2009","No Study Results Posted","null","July 2006","To assess the response rate in patients with locally unresectable neuroendocrine tumors treated with temodar and thalidomide.|To evaluate overall response and progression free survival of this patient population|to evaluate the safety of temodar and thalidomide.","https://ClinicalTrials.gov/show/NCT00165230"
13,"NCT00629187","Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy","Terminated","No Results Available","Central Nervous System Neoplasms|Neoplasm Metastasis","Drug: Temozolomide","Tufts Medical Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CN-306","February 25, 2008","April 2004","April 2012","April 26, 2012","April 2012","No Study Results Posted","CN-306","April 2012","Determine the maximum tolerated dose of temozolomide with hematopoietic stem cell rescue in patients with recurrent CNS malignancy|Estimate the response rate, response duration and survival according to established response definitions|Determine the pharmacokinetics of high daily dosing of temozolomide in the transplant setting","https://ClinicalTrials.gov/show/NCT00629187"
14,"NCT00400816","Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma","Active, not recruiting","No Results Available","Central Nervous System Tumors|Brain Tumor","Drug: temozolomide","The Cleveland Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE-CCF-4204|P30CA043703","November 16, 2006","August 2005","December 2016","August 6, 2016","August 2016","No Study Results Posted","null","December 2016","Progression-Free Survival|Toxicity","https://ClinicalTrials.gov/show/NCT00400816"
15,"NCT01186406","Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)","Active, not recruiting","Has Results","Glioblastoma Multiforme|Gliosarcoma","Drug: Gliadel|Radiation: Radiation Therapy|Drug: Avastin|Drug: Temodar","Duke University|Genentech, Inc.|Eisai Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Pro00025180","August 19, 2010","April 2011","June 2018","January 27, 2017","January 2017","October 17, 2014","null","May 2014","21-month Overall Survival|Median Overall Survival|Median Progression-free Survival|Unacceptable Toxicity Related to the Treatment Regimen","https://ClinicalTrials.gov/show/NCT01186406"
16,"NCT01242566","Temozolomide in Elderly Patients With KPS < 70","Completed","No Results Available","Primary Brain Tumor|Glioblastoma","Drug: Temozolomide","Assistance Publique - Hôpitaux de Paris|Association de Neuro-Oncologues d’Expression Francaise","All","70 Years and older   (Senior)","Phase 2","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P060102","November 16, 2010","July 2007","September 2010","November 16, 2010","November 2009","No Study Results Posted","TAG","May 2010","Overall survival|Progression-free survival|adverse events|Health-related quality of life|Cognitive functioning|Efficacy according to MGMT Promoter methylation status","https://ClinicalTrials.gov/show/NCT01242566"
17,"NCT01736800","Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors","Unknown status","No Results Available","Central Nervous System (CNS) Metastases|Brain Metastases","Drug: Topotecan|Drug: Temozolomide","The Methodist Hospital System","All","18 Years to 79 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P05200","November 19, 2012","March 2007","null","June 18, 2013","June 2013","No Study Results Posted","null","March 2015","Radiologic Response|Median Overall Survival","https://ClinicalTrials.gov/show/NCT01736800"
18,"NCT00362817","Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases","Completed","Has Results","Brain Tumor|Brain Metastases","Drug: carboplatin|Drug: temozolomide","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","17","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU-0428","August 8, 2006","October 2004","February 2008","May 4, 2015","May 2015","February 26, 2015","null","January 2008","Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide|Analyze Patients Time to Progression|Determine the Overall Survival of Patients|Determine the Cause of Death of Patients After Treatment|The Incidence and Severity of Centeral Nervous System (CNS) Toxicities|Quality of Life Assessment","https://ClinicalTrials.gov/show/NCT00362817"
19,"NCT00582075","Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases","Completed","Has Results","Cancer|Brain Metastases","Drug: temozolomide","University of Alabama at Birmingham|Integrated Therapeutics Group","All","19 Years and older   (Adult, Senior)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","F020522015","December 20, 2007","July 2002","June 2015","February 6, 2017","February 2017","July 6, 2015","RAD0102","October 2008","Percentage of Participants With Distant Brain Failure (DBF) at One Year|Overall Survival","https://ClinicalTrials.gov/show/NCT00582075"
20,"NCT00783393","SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)","Completed","No Results Available","Astrocytoma","Drug: Temozolomide","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","P03745|JPC02-351-21","October 30, 2008","May 27, 2003","June 17, 2005","May 12, 2017","May 2017","No Study Results Posted","null","June 17, 2005","Overall response in Step 1|Incidence rate and severity of adverse events with administration of temozolomide in Step 1|Progression-free survival in Step 1|Overall survival in Step 1|Tumor response in Step 1|Neurological improvement in Step 1|Progression-free survival, overall survival, overall response, effect on neurological symptoms, and safety in Step 2|Progression-free survival in Step 2|Overall survival in Step 2|Overall response in Step 2|Effect on neurological symptoms in Step 2|Safety in Step 2","https://ClinicalTrials.gov/show/NCT00783393"
21,"NCT00643825","Prolonged Adjuvant Temozolomide vs ""Stop & Go"" in Glioblastoma Patients","Unknown status","No Results Available","Glioblastoma","Drug: Temozolomide|Drug: Temozolomide","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","All","18 Years and older   (Adult, Senior)","Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UCL-ONCO 06-004","March 20, 2008","January 2008","January 2012","July 22, 2010","July 2010","No Study Results Posted","PATSGO","January 2011","to determine whether prolonged administration of Temozolomide in glioblastoma patients increase their progression-free and overall survival at 6 months|safety and adverse event profile of prolonged adjuvant Temozolomide","https://ClinicalTrials.gov/show/NCT00643825"
22,"NCT01127594","Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion","Completed","No Results Available","Melanoma","Drug: Temozolomide","Douglas Tyler|Merck Sharp & Dohme Corp.|Duke University|M.D. Anderson Cancer Center|H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Senior)","Phase 1","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00020406","May 19, 2010","July 2010","June 2014","March 6, 2015","March 2015","No Study Results Posted","null","August 2013","Safety Profile of intra-arterial temozolomide and maximum tolerated dose of temozolomide|To define tumor response in field in patients treated with temozolomide","https://ClinicalTrials.gov/show/NCT01127594"
23,"NCT02507232","A Phase II Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas","Recruiting","No Results Available","Glioma","Device: NovoTTF-200A|Drug: Temozolomide","Santosh Kesari|NovoCure Ltd.|John Wayne Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","150158","July 21, 2015","April 2017","April 2022","April 7, 2017","April 2017","No Study Results Posted","null","April 2021","12-month objective response rate (ORR) of NovoTTF-200A alone and combined with temozolomide|Efficacy of NovoTTF-200A alone and combined with temozolomide|Toxicity associated with treatment with NovoTTF-200A alone and combined with temozolomide|Effects of NovoTTF-200A alone and combined with temozolomide on seizure activity|Effects of NovoTTF-200A alone and combined with temozolomide on quality of life (QOL)|Frequency of transformation from low-grade glioma into high-grade glioma","https://ClinicalTrials.gov/show/NCT02507232"
24,"NCT00612651","PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas","Completed","No Results Available","Gliosarcoma|Glioblastoma|Anaplastic Astrocytoma","Drug: Temodar and SCH 66336","Duke University|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 1","37","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00005027|7009/Pro00005027","January 29, 2008","October 2005","June 2011","February 15, 2013","February 2013","No Study Results Posted","null","January 2009","Dose-limiting toxicity|Progression-free survival","https://ClinicalTrials.gov/show/NCT00612651"
25,"NCT01180816","Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA","Active, not recruiting","No Results Available","Glioblastoma Multiforme|Anaplastic Astrocytoma","Drug: Super-Selective Intraarterial Intracranial Infusion of Temozolomide","Northwell Health|Feinstein Institute for Medical Research|Hofstra North Shore","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","14-292A","August 10, 2010","August 2010","December 2017","January 30, 2017","January 2017","No Study Results Posted","null","December 2017","Determine the safety of superselective intra-arterial cerebral infusion of Temozolomide up to a dose of 250 mg/m2 IA.|Composite overall response rate.|Six-month progression-free survival (PFS) and overall survival (OS)","https://ClinicalTrials.gov/show/NCT01180816"
26,"NCT00576680","RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors","Active, not recruiting","No Results Available","Pancreatic Neuroendocrine Tumor","Drug: RAD001|Drug: Temozolomide","Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Massachusetts General Hospital|Novartis|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-325","December 17, 2007","May 2008","July 2016","April 12, 2016","April 2016","No Study Results Posted","null","July 2016","To determine the objective response rate of RAD001 in combination with temozolomide in patients with advanced pancreatic neuroendocrine tumors.|To determine the duration of response to the combination of RAD001 and temozolomide in this patient population.|To determine the safety and tolerability of this drug combination.|To determine the progression free survival and overall survival of patients receiving this combination.","https://ClinicalTrials.gov/show/NCT00576680"
27,"NCT00612339","Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas","Completed","Has Results","Glioblastoma|Gliosarcoma","Drug: Avastin and Temozolomide","Duke University|Genentech, Inc.|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00001022","January 29, 2008","August 2007","May 2012","May 20, 2013","September 2012","August 9, 2012","null","May 2012","Response Rate","https://ClinicalTrials.gov/show/NCT00612339"
28,"NCT00515788","DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis","Terminated","No Results Available","Neoplastic Meningitis","Drug: DepoCyt|Drug: Temozolomide","M.D. Anderson Cancer Center|Enzon Pharmaceuticals, Inc.|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 1","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0135","August 13, 2007","February 2006","June 2009","March 8, 2012","March 2012","No Study Results Posted","null","June 2009","Maximum Tolerated Dose (MTD) for the combination of Temozolomide and DepoCyt","https://ClinicalTrials.gov/show/NCT00515788"
29,"NCT01205828","ABT-888 and Temozolomide for Liver Cancer","Terminated","Has Results","Hepatocellular Carcinoma","Drug: Temozolomide|Drug: ABT-888","Georgetown University|Abbott","All","18 Years and older   (Adult, Senior)","Phase 2","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2009-268","September 18, 2010","August 2010","October 2014","March 11, 2017","January 2017","September 7, 2015","null","October 2014","Clinical Benefit Rate|Overall Survival|Progression Free Survival|Number of Participants Who Had Grade 3 or 4 Adverse Events|Biomarker Analysis","https://ClinicalTrials.gov/show/NCT01205828"
30,"NCT00501891","Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma","Completed","Has Results","Glioblastoma Multiforme","Drug: Bevacizumab|Drug: Metronomic Temozolomide","Duke University|Genentech, Inc.|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","32","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00000404|AVF3821s|P04860","July 13, 2007","July 2007","November 2009","May 17, 2013","March 2013","February 6, 2013","null","December 2007","6-Month Progression-free Survival|Response Rate|Incidence and Severity of CNS Hemorrhage and Systemic Hemorrhage|Incidence of Grade ≥ 4 Hematologic or Grade ≥ 3 Non-hematologic Toxicity","https://ClinicalTrials.gov/show/NCT00501891"
31,"NCT00597493","Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM","Completed","Has Results","Recurrent Glioblastoma Multiforme","Drug: Sorafenib and Temozolomide","Duke University|Bayer|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","32","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00000464","January 9, 2008","September 2007","December 2010","May 3, 2013","May 2013","May 3, 2013","null","February 2009","6 Month Progression Free Survival (PFS)|Safety and Toxicity of Combination|Pharmacokinetics: C-max|Pharmacokinetics: T-max|Pharmacokinetics: AUC-24","https://ClinicalTrials.gov/show/NCT00597493"
32,"NCT00792012","A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma","Completed","No Results Available","Glioblastoma Multiforme","Radiation: Hypofractionated Intensity-Modulated Radiation Therapy|Drug: Temozolomide","University of Colorado, Denver","All","18 Years and older   (Adult, Senior)","Phase 1","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","05-0562.cc","November 13, 2008","November 2005","July 2016","March 23, 2017","March 2017","No Study Results Posted","null","July 2016","To identify the maximum dose per fraction of IMRT a patient can tolerate while keeping the total radiation dose at 60 Gy, provided concurrently with daily oral temozolomide chemotherapy|Progression-free survival","https://ClinicalTrials.gov/show/NCT00792012"
33,"NCT00657267","Dose-Intense Temozolomide in Recurrent Glioblastoma","Completed","Has Results","Glioblastoma|Gliosarcoma","Drug: Temozolomide","Patrick Y. Wen, MD|Brigham and Women's Hospital|Massachusetts General Hospital|University of Pennsylvania|Wake Forest University Health Sciences|Tufts Medical Center|Dartmouth-Hitchcock Medical Center|Schering-Plough|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","58","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-013|P05516","April 8, 2008","May 2008","October 2013","February 13, 2014","February 2014","June 16, 2013","null","November 2011","6 Month Progression Free Survival|Overall Survival|Radiographic Response|Time to Progression.","https://ClinicalTrials.gov/show/NCT00657267"
34,"NCT00389090","A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma","Terminated","No Results Available","Glioma|Astrocytoma|Oligodendroglioma|Oligoastrocytoma","Drug: Temozolomide and O6-Benzylguanine","Keryx / AOI Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","O6BG 202","October 16, 2006","October 2006","February 2009","February 7, 2012","February 2012","No Study Results Posted","null","June 2008","best objective response rate|Safety Assessment|progression-free survival|overall survival","https://ClinicalTrials.gov/show/NCT00389090"
35,"NCT00275002","O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors","Completed","Has Results","Brain and Central Nervous System Tumors","Drug: O6-benzylguanine|Drug: temozolomide","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 2","41","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03050|PBTC-015|NCI-06-C-0089|NCI-P6692|CDR0000455561","January 10, 2006","February 2006","December 2010","July 25, 2014","February 2013","July 13, 2011","null","July 2010","Percentage of Participants With an Objective Response (Complete Response or Partial Response)|Number of Patients With Grade 3 or 4 Adverse Events at Least Possibly Related to the Combination of O6-benzylguanine and Temozolomide","https://ClinicalTrials.gov/show/NCT00275002"
36,"NCT00704080","A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas","Completed","No Results Available","Mixed Gliomas|Malignant Gliomas|Glioblastoma Multiforme","Drug: XL765 (SAR245409)|Drug: Temozolomide","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 1","54","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TED11441|XL765-002","June 20, 2008","August 2008","February 2013","April 9, 2013","April 2013","No Study Results Posted","null","February 2012","Safety, tolerability, and maximum tolerated dose of XL765 administered in combination with temozolomide in subjects with anaplastic gliomas or glioblastoma currently stable on a maintenance temozolomide dose|To evaluate plasma pharmacokinetics and pharmacodynamic effects of XL765 and temozolomide when administered in combination|To evaluate preliminary efficacy of XL765 in combination with temozolomide in adults with anaplastic gliomas or glioblastoma","https://ClinicalTrials.gov/show/NCT00704080"
37,"NCT01114555","Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma","Active, not recruiting","No Results Available","Neuroblastoma","Drug: Bevacizumab, Irinotecan and Temozolomide","Memorial Sloan Kettering Cancer Center|Genentech, Inc.","All","Child, Adult, Senior","Phase 2","63","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","10-015","April 29, 2010","April 2010","April 2018","May 10, 2017","May 2017","No Study Results Posted","null","April 2018","To evaluate tumor responses to combination of irinotecan, temozolomide and bevacizumab in patients with resistant NB.|To determine the toxicity of the combination of irinotecan, temozolomide and bevacizumab in patients with resistant NB.|To evaluate changes in angiogenic markers after treatment with the combination of irinotecan, temozolomide and bevacizumab.|To measure time to progression in patients with resistant NB treated with the combination of irinotecan, temozolomide and bevacizumab.","https://ClinicalTrials.gov/show/NCT01114555"
38,"NCT00365222","Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma","Terminated","No Results Available","Glioblastoma|Gliosarcoma","Drug: Temozolomide","H. Lee Moffitt Cancer Center and Research Institute|Schering-Plough","All","70 Years and older   (Senior)","Phase 2","1","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-14714","August 15, 2006","July 2006","June 2007","January 21, 2009","January 2009","No Study Results Posted","null","June 2007","Evaluate overall survival|Progression-free survival at six and nine months|Response rate measured by a reduction in tumor size|Frequency and severity of adverse events|Quality of life measured at each cycle utilizing the QOL FACT-BR","https://ClinicalTrials.gov/show/NCT00365222"
39,"NCT01107522","Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas","Active, not recruiting","No Results Available","Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas","Drug: CTO|Drug: CTO and Temodar®|Drug: CTO, Temodar®, Radiation therapy","Tactical Therapeutics, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","T09-10644","April 16, 2010","May 2010","null","January 4, 2017","January 2017","No Study Results Posted","null","June 2018","To determine the MTD/RD of single agent CTO in patients with advanced or metastatic solid tumors; or CTO in combination with Temodar® in patients with glioblastoma or other recurrent malignant gliomas|Preliminary tumor response|Pharmacokinetics (maximum concentration, Tmax, AUC, T1/2, clearance, volume of distribution)|Voluntary Exploratory objective|Exploratory Objective","https://ClinicalTrials.gov/show/NCT01107522"
40,"NCT00392171","The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601AM1)(COMPLETED)","Completed","Has Results","Glioma|Astrocytoma|Oligodendroglioma|Glioblastoma","Drug: Temozolomide","Schering-Plough","All","19 Years to 70 Years   (Adult, Senior)","Phase 2","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P04601","October 24, 2006","June 2006","September 2009","June 3, 2010","June 2010","April 21, 2010","null","September 2009","Percentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression.","https://ClinicalTrials.gov/show/NCT00392171"
41,"NCT02113007","Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma","Terminated","Has Results","Primary Central Nervous System Lymphoma","Drug: Rituximab plus Temozolomide","SCRI Development Innovations, LLC|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI CNS 20","April 10, 2014","July 2014","February 2016","December 14, 2016","December 2016","December 14, 2016","null","February 2016","Overall Response Rate|Progression Free Survival (PFS)|Number of Participants With Serious and Non-serious Adverse Events as a Measure of Safety.","https://ClinicalTrials.gov/show/NCT02113007"
42,"NCT02972320","Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic","Recruiting","No Results Available","Extensive Stage Small Cell Lung Cancer","Drug: temozolomide","Yunpeng Liu|China Medical University, China","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLOG1601","October 23, 2016","June 2016","December 2018","November 22, 2016","November 2016","No Study Results Posted","null","December 2017","Progression-Free Survival in the first line of chemotherapy|Overall Survival (OS)|Tumor Response Rate (RR)|Treatment-related adverse events","https://ClinicalTrials.gov/show/NCT02972320"
43,"NCT02446704","Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy","Active, not recruiting","No Results Available","Small Cell Lung Cancer","Drug: Olaparib|Drug: Temozolomide","Massachusetts General Hospital|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","15-121","May 14, 2015","September 2015","April 2022","May 8, 2017","May 2017","No Study Results Posted","null","August 2018","MTD of Olaparib and Temozolomide|Overall Response Rate for Olaparib and Temozolomide|Safety, assessed using CTCAE version 4.0 cirteria|Overall Survival|Progression Free Survival|Methylation promoter methylation status|PAR levels","https://ClinicalTrials.gov/show/NCT02446704"
44,"NCT00492141","Aerosol L9-NC and Temozolomide in Ewing's Sarcoma","Completed","No Results Available","Ewing's Sarcoma","Drug: Temozolomide|Drug: L9-NC","M.D. Anderson Cancer Center","All","10 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0889","June 26, 2007","June 2006","September 2009","August 1, 2012","August 2012","No Study Results Posted","null","May 2007","Toxicity Profile|Number of Participants with Response According to Response Evaluation Criteria In Solid Tumors (RECIST)","https://ClinicalTrials.gov/show/NCT00492141"
45,"NCT01985087","A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70","Recruiting","No Results Available","Glioblastoma","Radiation: Hypofractionated radiotherapy|Drug: Temozolomide","James Graham Brown Cancer Center|University of Louisville","All","70 Years and older   (Senior)","Phase 1|Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BCC-NEU-13 GB70","October 10, 2013","September 2014","May 2019","November 21, 2016","November 2016","No Study Results Posted","null","May 2018","Number of patients who stop treatment due to CTCAE grade 3 or above toxicities|Overall survival|Quality of Life|The number of patients to complete RT+TMZ and a minimum of 3 of the 6 planned cycles of adjuvant chemotherapy","https://ClinicalTrials.gov/show/NCT01985087"
46,"NCT00841555","Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma","Completed","Has Results","Glioblastoma Multiforme/Anaplastic Astrocytoma","Drug: temozolomide|Radiation: Hypofractionated radiation therapy|Radiation: Intensity-modulated radiation therapy","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","OSU-08119|NCI-2011-03149","February 10, 2009","February 13, 2009","November 25, 2014","February 22, 2017","February 2017","March 24, 2016","null","February 13, 2013","Maximum Tolerated Dose(MTD)of Temozolomide(TMZ)|Time to Neuroradiological Evidence of Tumor Recurrence or Progression|Survival Time|Time Spent in a Karnofsky Performance Status of 60-100%","https://ClinicalTrials.gov/show/NCT00841555"
47,"NCT01517776","Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents","Terminated","No Results Available","Gliomas","Drug: Cilengitide|Drug: Temozolomide","Martin-Luther-Universität Halle-Wittenberg|Merck KGaA","All","3 Years to 17 Years   (Child)","Phase 2","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HIT-HGG-CilMetro|2009-011898-33","January 11, 2012","January 2012","April 2014","June 26, 2015","June 2015","No Study Results Posted","HGG-CilMetro","March 2014","Efficacy of a combined treatment with cilengitide and temozolomide as measured by 6 months overall survival after diagnosis of relapsed or refractory high grade glioma or diffuse intrinsic pontine glioma in children and adolescents|Safety and toxicity of the study treatment|Response rates (RR) at 6 months, progression-free survival (PFS) at 6 months, and RR, overall survival (OS), and PFS at 12 months after relapse diagnosis or diagnosis of tumor progression|Peak plasma levels of cilengitide [ng/ml] on day 1 of week 1 and day 4 of week 6","https://ClinicalTrials.gov/show/NCT01517776"
48,"NCT00611247","Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia","Completed","Has Results","Leukemia, Myeloid","Drug: Temozolomide","Bruno C. Medeiros|Schering-Plough|Stanford University","All","60 Years and older   (Adult, Senior)","Phase 2","42","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","07815|97611|SU-12142007-936|HEMAML0004","January 25, 2008","December 2007","January 2010","July 7, 2014","July 2014","April 29, 2014","null","December 2009","Response Rate (CR + CRi + LFS)|Toxicity Profile: Total Number of Drug-related Serious Adverse Events|Toxicity Profile: Individual Subjects With Drug-related SAEs","https://ClinicalTrials.gov/show/NCT00611247"
49,"NCT00080938","Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer","Completed","Has Results","Lung Cancer|Metastatic Cancer","Drug: Temozolomide|Radiation: Radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","26","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000357567|U10CA021115|E1F03","April 7, 2004","October 2005","February 2009","February 12, 2013","February 2013","December 30, 2010","null","August 2008","Number of Patients With Intracranial Response|1-year Neurologic (Central Nervous System, CNS) Progression Free Rate|Time to Non-CNS (Systemic) Progression|Overall Survival Time","https://ClinicalTrials.gov/show/NCT00080938"
50,"NCT00740636","Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer","Completed","Has Results","Lung Cancer","Drug: Temozolomide|Drug: Temozolomide","Memorial Sloan Kettering Cancer Center|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","92","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","08-065","August 22, 2008","August 2008","February 2013","July 1, 2016","June 2016","October 20, 2015","null","February 2013","The Objective Overall Response","https://ClinicalTrials.gov/show/NCT00740636"
51,"NCT00508456","Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM","Terminated","No Results Available","Glioblastoma Multiforme","Drug: Temodar (Temozolomide)|Dietary Supplement: Hominex-2","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID03-0066","July 27, 2007","August 2004","November 2008","January 12, 2012","January 2012","No Study Results Posted","null","November 2008","Time to Disease Progression","https://ClinicalTrials.gov/show/NCT00508456"
52,"NCT00098865","Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma","Completed","Has Results","Central Nervous System Tumor, Pediatric|Neuroblastoma","Drug: temozolomide|Drug: thalidomide","Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Boston Children’s Hospital|Celgene Corporation","All","up to 21 Years   (Child, Adult)","Phase 2","15","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-279 DFCI|P30CA006516|CDR0000396780","December 8, 2004","September 2002","June 2010","September 28, 2014","September 2014","December 15, 2012","null","June 2010","Therapy Completion Rate|Overall Response|Overall Survival","https://ClinicalTrials.gov/show/NCT00098865"
53,"NCT00632203","Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)","Terminated","Has Results","Carcinoma, Non-Small-Cell Lung|Adenocarcinoma|Carcinoma, Large Cell|Carcinoma, Squamous Cell","Drug: Temozolomide","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P05146","February 29, 2008","March 2008","January 2011","August 26, 2015","August 2015","December 22, 2011","null","January 2011","Number of Participants Who Had Brain Metastases|Time to Radiological Central Nervous System (CNS) Progression|Time to Progression|Overall Survival|Number of Participants With Brain Metastases at First Progression|Cancer-related Quality of Life (QoL) as Assessed by The European Organization for Research and Treatment of Cancer (EORTC) QoL Questionnaire C30 Version 3.0 (QLQ-C30), and the EORTC Lung Cancer Module (QLQ-LC13)|Tolerability of Maintenance Temozolomide","https://ClinicalTrials.gov/show/NCT00632203"
54,"NCT00527761","Taxotere/Temodar/Cisplatin Study in Melanoma Patients","Completed","No Results Available","Metastatic Melanoma","Drug: Cisplatin|Drug: Docetaxel|Drug: Temodar","M.D. Anderson Cancer Center|Aventis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","23","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-1037","September 10, 2007","August 2004","November 2007","July 26, 2012","July 2012","No Study Results Posted","null","November 2007","Maximum Tolerated Dose (MTD)","https://ClinicalTrials.gov/show/NCT00527761"
55,"NCT00883298","Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme","Completed","No Results Available","Recurrent Glioblastoma Multiforme|Recurrent Gliosarcoma","Drug: temozolomide and bevacizumab","Center for Neurosciences, Tucson|Genentech, Inc.","All","18 Years to 83 Years   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AVF4514s","April 16, 2009","April 2009","December 1, 2014","March 28, 2017","March 2017","No Study Results Posted","null","December 2014","6-month progression-free survival.|Radiographic response (Gd-MRI) including specialized MRI sequences (T2/FLAIR).|Incidence and severity of toxicity.|Tumor DNA (MGMT) analysis as it relates to survival.","https://ClinicalTrials.gov/show/NCT00883298"
56,"NCT00990652","Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide","Completed","Has Results","Brain and Central Nervous System Tumors","Drug: Bortezomib|Drug: Temozolomide","Northwestern University|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU 08C5|STU00008280","October 6, 2009","May 2009","October 2012","December 11, 2013","December 2013","December 11, 2013","null","April 2011","Number of Patients Surviving Without Disease Progression After 6 Months|Number of Participants Achieving a Response to Treatment (Either Complete or Partial Response) as Defined by MacDonald Criteria|Number of Grade 1, 2, 3, 4, and 5 Adverse Events Observed During Study Treatment (Defined by CTCAE v 3.0)|Overall Survival (in Days)|Overall Survival Rate at 6 Months","https://ClinicalTrials.gov/show/NCT00990652"
57,"NCT02343081","Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System","Completed","Has Results","Brain Neoplasms, Malignant, Primary","Drug: Temozolomide|Drug: Temozolomide","Monte Verde SA|FLENI Instituto de Rehabilitación y Educación Terapéutica, BA, Argentina.|Bioanalytical Unit, Laboratorio Raffo S.A., BA, Argentina.|FLENI Multi-Specialty Research Center, BA, Argentina.","All","21 Years and older   (Adult, Senior)","Phase 4","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","RFF -0208","January 7, 2015","January 2012","October 2013","March 20, 2015","March 2015","February 23, 2015","null","October 2013","Cmax|AUC0-t|AUC0-∞|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)","https://ClinicalTrials.gov/show/NCT02343081"
58,"NCT00925132","Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat","Completed","No Results Available","Metastatic Melanoma","Drug: Temozolomide, Decitabine, Panobinostat","University of Iowa|Holden Comprehensive Cancer Center|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200807728","June 18, 2009","December 2009","December 2016","January 4, 2017","January 2017","No Study Results Posted","null","November 2014","Phase I - to evaluate the safety and tolerability of the proposed schedule of decitabine, temozolomide and panobinostat in the treatment of metastatic melanoma.|Phase 2 - To measure the time to progression of patients treated with this combination in comparison to patients treated historically with DTIC (the current standard of care).|Phase I - to define the dose limiting toxicity and maximum tolerated dose of the combination of decitabine, temozolomide and panobinostat.|Phase 2 - to measure overall survival|Phase 2 - to evaluate treatment response with FDG pET and compare FDG PET with conventional imaging for treatment response assessment.","https://ClinicalTrials.gov/show/NCT00925132"
59,"NCT02209428","A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas","Unknown status","No Results Available","Astrocytoma|Oligodendroglioma|Oligoastrocytoma","Drug: Temozolomide","Huashan Hospital","All","18 Years to 40 Years   (Adult)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Outcomes Assessor)|Primary Purpose: Treatment","KY2014-182","July 30, 2014","June 2014","May 2016","March 21, 2015","March 2015","No Study Results Posted","null","April 2016","Objective Response Rate, ORR|Velocity of Diameter Evolution, VDE|Progression free survival (PFS)-6, -12, -24|Cognitive functions|Quality of life (QoL)|Adverse effect of chemotherapy|Malignant progression-free survival (MPFS) -6, -12, -24|Symptom Burden|Seizure activity","https://ClinicalTrials.gov/show/NCT02209428"
60,"NCT01601184","Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway","Recruiting","No Results Available","Histologically Confirmed Medulloblastoma|Activation of the Sonic Hedgehog (SHH) Pathway","Drug: vismodegib|Drug: Temozolomide","Centre Leon Berard|Ministry of Health, France","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MEVITEM|2011-003372-37","May 15, 2012","June 2012","October 2018","October 31, 2016","October 2016","No Study Results Posted","null","April 2018","To evaluate the safety of a fixed dose of vismodegib in combination with (phase I)temozolomide in adult patients with recurrent, progressive, or refractory to standard therapy medulloblastoma|To estimate the efficacy of vismodegib in combination with temozolomide in adult patients with recurrent, progressive, or refractory to standard therapy medulloblastoma (phase II)|To collect preliminary results on the 6-month progression-free rate of the combination vismodegib + temozolomide (phase I)|To estimate in the two study arms the objective response rate after 6 months of treatment (phase II)|To estimate in the two study arms the duration of treatment response (phase II)|To estimate in the two study arms the best overall response obtained during the study (phase II)|To estimate in the two study arms the progression-free survival (PFS)(phase II)|To estimate in the two study arms the time to treatment failure (phase II)|frequency of adverse events based on the common toxicity criteria (CTC-AE-V4.0) grade","https://ClinicalTrials.gov/show/NCT01601184"
61,"NCT01534845","Efficacy Study of Radiotherapy Alone Versus CCRT With Temozolomide in Grade III Gliomas Without 1p/19q Codeletion","Active, not recruiting","No Results Available","Anaplastic Glioma of Brain|Loss of Chromosomes 1p/19q","Drug: Temozolomide (Temodal)","Jong Hoon Kim|Asan Medical Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KNOG-1101","February 6, 2012","March 2012","February 2017","July 7, 2015","July 2015","No Study Results Posted","null","February 2015","2-year progression free survival(PFS)|5-year overall survival (OS)|5-year progression-free survival (PFS)|Safety (adverse events)|Methylation status of MGMT|IDH mutation","https://ClinicalTrials.gov/show/NCT01534845"
62,"NCT00441142","Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors","Active, not recruiting","Has Results","Glioblastoma Multiforme|Gliosarcoma","Drug: ZD6474|Drug: temozolomide|Radiation: Radiation Therapy","Patrick Y. Wen, MD|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|University of Virginia|Memorial Sloan Kettering Cancer Center|Henry Ford Hospital","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","119","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","06-377|IRUSZACT0018","February 27, 2007","May 2007","December 2017","April 11, 2017","April 2017","February 5, 2015","Zactima","August 2013","Number of Participants That Experienced a Dose-limiting Toxicity (DLT)|Median Overall Survival (OS) of Phase II Patients|Median Progression-free Survival (PFS), as Calculated by the # of Months Patients Remain Progression-free|PHASE II: To Further Evaluate the Safety Profile of ZD6474 (Vandetanib) in Combination With Radiation Therapy and Temozolomide in This Patient Population.|PHASE I: To Define the Safety of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in This Population.","https://ClinicalTrials.gov/show/NCT00441142"
63,"NCT00590681","Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Glioblastoma Multiforme","Drug: Bevacizumab and Temozolomide","University of Chicago|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","62","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","15149A","December 26, 2007","February 2007","September 2014","September 2, 2015","September 2015","No Study Results Posted","null","September 2014","Determine estimates of the objective response and PFS in subjects wtih newly diagnosed GBM who are treated with radiotherapy and daily temozolomide/monthly cycles of temozolomide and Avastin until either disease progression or unacceptable toxicities|Determination of the safety of Avastin in combination with temozolomide in this study population/duration of response/determination of overall survival and changes in relative cerebral blood volume (rCBV) of tumors after (2 infusions) of Avastin","https://ClinicalTrials.gov/show/NCT00590681"
64,"NCT00869050","Capecitabine and Temozolomide for Neuroendocrine Cancers","Completed","Has Results","Neuroendocrine Tumors","Drug: Capecitabine|Drug: Temozolomide","Columbia University","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AAAP4117","March 23, 2009","August 2005","October 2014","June 22, 2016","June 2016","May 3, 2016","null","December 2013","Number of Participants With Partial Response (PR)|Number of Participants With Complete Response (CR)","https://ClinicalTrials.gov/show/NCT00869050"
65,"NCT00612638","Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas","Completed","No Results Available","Glioblastoma|Gliosarcoma","Drug: Temodar, O6-BG, and Irinotecan","Duke University|Keryx / AOI Pharmaceuticals, Inc.|Pharmacia","All","18 Years and older   (Adult, Senior)","Phase 1","96","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00007681","January 29, 2008","January 2005","July 2008","June 18, 2013","January 2009","No Study Results Posted","null","January 2007","Incidence of toxicities|Response rate & progression-free survival","https://ClinicalTrials.gov/show/NCT00612638"
66,"NCT00717275","Study of Temozolomide to Treat Newly Diagnosed Brain Metastases","Terminated","Has Results","Brain Metastases","Drug: Temozolomide","University of Florida","All","18 Years and older   (Adult, Senior)","Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","METS-001","July 15, 2008","September 2008","June 2011","September 14, 2012","July 2012","July 10, 2012","null","January 2011","Number of Participants Who Developed Distant Brain Failure at One Year.","https://ClinicalTrials.gov/show/NCT00717275"
67,"NCT00275067","Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: arsenic trioxide|Drug: temozolomide|Radiation: radiation therapy","Northwestern University|Cephalon|CTI BioPharma","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU 04C1|CDR0000456504|STU00007792","January 10, 2006","May 2005","May 2019","January 10, 2017","January 2017","No Study Results Posted","null","May 2018","Maximum tolerated dose of arsenic trioxide and temozolomide in combination with radiotherapy|Collect data on the toxicity of arsenic and temozolomide during radiation therapy|Assess serum biomarkers and correlate with tumor tissue|Determine progression free survival at 6 and 12 months|Determine time to disease progression|To determine overall survival|To determine radiographic response to study regimen|To collect safety data during the radiation therapy phase|To evaluate a potential surrogate marker for outcomes","https://ClinicalTrials.gov/show/NCT00275067"
68,"NCT01765088","A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas","Recruiting","No Results Available","Anaplastic Oligoastrocytoma|Anaplastic Astrocytoma|Glioblastoma","Drug: Temozolomide|Drug: α-IFN","Sun Yat-sen University|Fudan University|West China Hospital|Tianjin Medical University Cancer Institute and Hospital|Chinese Academy of Medical Sciences","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSNO2012001","January 7, 2013","September 2012","December 2017","December 10, 2015","December 2015","No Study Results Posted","null","December 2017","Over-all survival|Quality of life","https://ClinicalTrials.gov/show/NCT01765088"
69,"NCT02340156","Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma","Recruiting","No Results Available","GLIOBLASTOMA","Genetic: SGT-53|Drug: Temozolomide","SynerGene Therapeutics, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SGT53-02-2","December 18, 2014","December 2014","December 2019","May 19, 2017","May 2017","No Study Results Posted","null","December 2018","Tumor response|Incidence of Treatment-Emergent Adverse Events|Progression-free survival (PFS)|Overall survival (OS)|Anti-tumor Activity|Induction of apoptosis|Nanoparticle tumor delivery","https://ClinicalTrials.gov/show/NCT02340156"
70,"NCT00614978","Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer|Brain Metastases|HER2 Positive","Drug: lapatinib and temozolomide","Jules Bordet Institute|GlaxoSmithKline|Schering-Plough","Female","18 Years to 70 Years   (Adult, Senior)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LAP111172|EuDRACT 2007-005132-83","February 1, 2008","January 2008","June 2011","September 18, 2012","June 2011","No Study Results Posted","LAPTEM","June 2011","Primary - Determine the maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLT) of combining lapatinib and temozolomide|Obtain preliminary information on the clinical anti-tumor activity of lapatinib plus temozolomide on brain metastases secondary to HER-2 positive breast cancer including Objective Response Rate, Clinical Benefit and Duration of Response","https://ClinicalTrials.gov/show/NCT00614978"
71,"NCT00826241","Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma","Unknown status","No Results Available","Brain Tumors|Spinal Cord Tumors","Drug: Temozolomide|Drug: Lapatinib","National Institutes of Health Clinical Center (CC)|CERN Foundation - Collaborative Ependymoma Research Network","All","18 Years and older   (Adult, Senior)","Phase 2","50","NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","999916005|NCI-2012-02131|16-C-N005","January 20, 2009","January 2009","null","October 21, 2015","March 2015","No Study Results Posted","null","January 2017","Time to Progression|Anti-Tumor Activity","https://ClinicalTrials.gov/show/NCT00826241"
72,"NCT03139916","Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma","Not yet recruiting","No Results Available","Glioblastoma","Drug: Temozolomide|Drug: Bavituximab|Radiation: Radiation","Massachusetts General Hospital|Peregrine Pharmaceuticals|National Comprehensive Cancer Network","All","18 Years and older   (Adult, Senior)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","17-037","May 2, 2017","June 30, 2017","December 31, 2024","May 3, 2017","May 2017","No Study Results Posted","null","December 31, 2020","Overall Survival|Radiographic Response|Progression Free Survival","https://ClinicalTrials.gov/show/NCT03139916"
73,"NCT01119508","Ipilimumab + Temozolomide in Metastatic Melanoma","Completed","No Results Available","Metastatic Melanoma","Drug: Ipilimumab|Drug: Temozolomide","M.D. Anderson Cancer Center|Bristol-Myers Squibb","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","64","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-0408|NCI-2011-00565","May 6, 2010","May 2010","August 2016","August 16, 2016","August 2016","No Study Results Posted","null","August 2016","6-Month Progression-Free Survival (PFS) Rate","https://ClinicalTrials.gov/show/NCT01119508"
74,"NCT00516282","VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma","Terminated","No Results Available","Brain and Central Nervous System Tumors","Drug: CLORETAZINE|Drug: temozolomide","Northwestern University|Vion Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU 07C1","August 14, 2007","August 2007","October 2009","August 24, 2011","August 2011","No Study Results Posted","null","October 2009","MTD of CLORETAZINE|Progression-free survival rate|Toxicities of CLORETAZINE when administered with Temodar®.|MGMT Methylation Status|Determine overall survival|Response rate to CLORETAZINE after Temodar® in patients with malignant gliomas in first or second relapse|Record the toxicities of CLORETAZINE when administered after Temodar|Measure the level of AGT expression|CSF penetration of CLORETAZINE","https://ClinicalTrials.gov/show/NCT00516282"
75,"NCT00616005","Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide","Completed","No Results Available","Glioblastoma","Drug: Temodar and Irinotecan","Duke University|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00012939|8044","February 3, 2008","November 2005","June 2009","August 14, 2014","August 2010","No Study Results Posted","null","July 2007","Progression-free survival|Toxicity assessment","https://ClinicalTrials.gov/show/NCT00616005"
76,"NCT00612989","Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM","Completed","No Results Available","Glioblastoma|Gliosarcoma","Drug: Temodar and O6-Benzylguanine","Duke University|Schering-Plough|Keryx / AOI Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","42","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00004058|6788","January 29, 2008","February 2005","July 2008","July 15, 2014","January 2009","No Study Results Posted","null","August 2007","Dose limiting toxicity|Progression-free survival","https://ClinicalTrials.gov/show/NCT00612989"
77,"NCT00525031","Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients","Completed","No Results Available","Melanoma","Drug: Temozolomide (TMZ)|Drug: Pegylated Interferon Alpha-2b (PGI)","M.D. Anderson Cancer Center|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","2005-0143|NCI-2010-00855","August 31, 2007","August 2006","June 2016","June 16, 2016","June 2016","No Study Results Posted","null","June 2016","Pathological Response Rates (pCR+ pPR)","https://ClinicalTrials.gov/show/NCT00525031"
78,"NCT02389738","Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration","Recruiting","No Results Available","Blood Brain Barrier Defect","Drug: Regadenoson|Drug: Temozolomide|Device: Microdialysis catheter","Sidney Kimmel Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","J14155","March 4, 2015","February 2015","December 2016","November 24, 2015","November 2015","No Study Results Posted","null","July 2016","change in AUC0-18 of the temozolomide concentration (AUC-T) in brain interstitium before and after Regadenoson infusion|Evaluation of relationaship between cognitive/mood disorders and expression of biochemical markers post-op day 1","https://ClinicalTrials.gov/show/NCT02389738"
79,"NCT00266812","Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)","Terminated","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Temozolomide and radiotherapy|Procedure: Whole brain radiotherapy","Merck Sharp & Dohme Corp.|AESCA Pharma GmbH","All","18 Years and older   (Adult, Senior)","Phase 2","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P04071","December 16, 2005","March 2005","January 2008","April 29, 2015","April 2015","July 29, 2009","null","January 2008","Number of Participants With Progression-free Survival (6 Month)","https://ClinicalTrials.gov/show/NCT00266812"
80,"NCT00423150","Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)","Terminated","Has Results","Colorectal Neoplasm|Head and Neck Neoplasm|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasm","Drug: Temozolomide","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","86","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P04273","November 30, 2006","January 2007","June 2009","October 30, 2014","October 2014","May 27, 2010","null","June 2009","Tumor Responses (Complete and Partial Response)","https://ClinicalTrials.gov/show/NCT00423150"
81,"NCT02781792","Temozolomide Chronotherapy for High Grade Glioma","Recruiting","No Results Available","Glioma|Glioblastoma Multiforme","Drug: Temozolomide|Other: Functional Assessment of Cancer Therapy - Brain","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","201605081","May 20, 2016","August 11, 2016","November 30, 2018","February 13, 2017","February 2017","No Study Results Posted","null","December 31, 2017","Feasibility of patient treatment compliance as measured by at least 80% compliance with assigned administration time|Duration of response|Number of patients experiencing grade 3 or 4 lymphopenia, thrombocytopenia, neutropenia and anemia in each group as measured by standard blood draws|Quality of life as measured by FACT-Br score|Progression-free survival (PFS)|Overall survival","https://ClinicalTrials.gov/show/NCT02781792"
82,"NCT01124734","High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma","Active, not recruiting","No Results Available","Malignant Melanoma","Drug: Interleukin-2|Drug: Interleukin-2|Drug: Temozolomide","Milton S. Hershey Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PSHCI 09-067","March 4, 2010","May 2010","August 2017","September 12, 2016","September 2016","No Study Results Posted","null","August 2017","Determine clinical response to high dose IL2 followed by low dose temozolomide|Determine effects of high dose IL2 followed by low dose temozolomide","https://ClinicalTrials.gov/show/NCT01124734"
83,"NCT00687323","Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)","Completed","Has Results","Leukemia, Acute Myeloid|Myelodysplastic Syndrome","Drug: temozolomide","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P05052|MK-7365-240","May 27, 2008","July 2007","December 2012","February 12, 2015","February 2015","May 4, 2012","TALL","May 2011","Clinical Response at the End of Temozolomide Induction|Duration of Response in Participants Achieving Complete Response (CR) and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide|Relapse-free Survival in Participants Achieving CR or CRp and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide|Overall Survival (OS) in Participants Achieving CR or CRp and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide|Number of Previously Untreated Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression|MGMT Expression in Leukemic Blasts at the Time of Relapse|Number of Participants With CR, PR, or MLFS Who Received Modified Low Dose Maintenance Therapy (100 mg/m^2/Day x21 Days of Each 28 Day Cycle) and Experienced Toxicity|Progression-free Survival for Participants Achieving PR, MLSF, or MR|Quality of Life (QoL) in Participants Receiving Long Term Temozolomide Therapy Assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-30|Quality of Life (QoL) in Participants Receiving Long Term Temozolomide Therapy Assessed by EORTC QLQ-LC13|Quality of Life (QoL) in Participants Receiving Long Term Temozolomide Therapy Assessed by Functional Assessment of Cancer Therapy (FACT)-G","https://ClinicalTrials.gov/show/NCT00687323"
84,"NCT01004874","Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma","Active, not recruiting","Has Results","Malignant Glioma|Glioblastoma Multiforme|Gliosarcoma","Drug: Bevacizumab|Drug: Temozolomide|Radiation: Radiation Therapy (XRT)|Drug: Topotecan","Duke University|Genentech, Inc.|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Pro00019960","October 28, 2009","December 2009","July 2017","March 7, 2017","February 2017","December 12, 2012","null","July 2012","6-month Progression-free Survival|One and Two Year Overall Survival|Median Overall Survival|Number of Patients Experiencing a Central Nervous System (CNS) Hemorrhage or a Systemic Hemorrhage|Number of Patients Experiencing a Greater Than or Equal to Grade 4 Hematologic or a Greater Than or Equal to Grade 3 Non-hematologic Toxicity|Median Progression-free Survival","https://ClinicalTrials.gov/show/NCT01004874"
85,"NCT01781403","Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer","Active, not recruiting","Has Results","Rectal Cancer","Drug: Temozolomide","Asan Medical Center","All","20 Years and older   (Adult, Senior)","Phase 1","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML28381","January 21, 2013","May 2013","March 2017","June 30, 2016","June 2016","May 17, 2016","null","December 2016","Maximum Tolerated Dose (MTD)|Recommended Dose (RD)|Pathological Complete Response","https://ClinicalTrials.gov/show/NCT01781403"
86,"NCT01051596","A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer","Completed","No Results Available","Colorectal Cancer","Drug: Temozolomide and ABT-888","Georgetown University|Abbott","All","18 Years and older   (Adult, Senior)","Phase 2","75","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-170","January 8, 2010","September 2009","December 2013","February 12, 2014","February 2014","No Study Results Posted","null","June 2013","Disease control rate defined as stable disease, partial response, or complete response according to the Response Evaluation Criteria in Solid Tumors (RECIST).|Progression-free survival defines as the time in days from study study entry until progression or death|Overall survival defined as the time in days from study entry until death|Objective response rate defined as partial response or complete response according to RECIST criteria|Safety as assessed by study drug exposure, adverse events,, serious adverse events, oncology-related events, deaths, and changes in laboratory determinations and vital sign parameters","https://ClinicalTrials.gov/show/NCT01051596"
87,"NCT00083070","Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia","Completed","No Results Available","Leukemia","Drug: temozolomide","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 1","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ADVL0411|CDR0000362059|COG-ADVL0411","May 14, 2004","March 2004","June 2008","February 18, 2014","February 2014","No Study Results Posted","null","September 2004","Maximum tolerated dose and recommended phase II dose|Toxicity as assessed by CTCAE 3.0|Pharmacokinetics as assessed by CI, area under the curve (AUC), and half-life (T ½)|Antitumor activity|Biologic activity and mechanisms of resistance","https://ClinicalTrials.gov/show/NCT00083070"
88,"NCT01550224","Phase II Temozolomide + Vorinostat in Patients With Relapse/Refractory AML","Active, not recruiting","No Results Available","Acute Myeloid Leukemia With 11q23-abnormality in Relapse","Drug: Temozolomide","Stanford University|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HEMAML0017|22794","March 7, 2012","May 1, 2013","December 31, 2017","January 23, 2017","January 2017","No Study Results Posted","null","June 30, 2017","Rate of morphological complete remission","https://ClinicalTrials.gov/show/NCT01550224"
89,"NCT02085304","Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM","Recruiting","No Results Available","Glioblastoma","Procedure: Gross total resection and Gliadel(R) wafers implanted|Radiation: GammaKnife(R) stereotactic Radiosurgery|Radiation: Standard fractionated radiation therapy|Drug: Temozolomide","St. Joseph's Hospital and Medical Center, Phoenix","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12BN101","March 7, 2014","October 2012","December 2017","December 12, 2016","December 2016","No Study Results Posted","null","June 2017","Change in health related quality of life|time without Cognitive impairment|incidence of symptomatic radiation necrosis|Disease-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02085304"
90,"NCT01900951","Temozolomide as Maintenance Therapy in Small Cell Lung Cancer","Active, not recruiting","No Results Available","Carcinoma, Small Cell","Drug: Temozolomide","Chinese PLA General Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TMS-01","July 11, 2013","January 2013","June 2016","January 24, 2016","January 2016","No Study Results Posted","null","February 2016","One-year progress free survival|Overall Response Rate (ORR)|Safety|time to progression","https://ClinicalTrials.gov/show/NCT01900951"
91,"NCT01985451","Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）","Unknown status","No Results Available","Central Nervous System Tumors","Drug: Pemetrexe|Drug: Temozolomide","Rongjie Tao|National Natural Science Foundation of China|Shandong Cancer Hospital and Institute","All","20 Years to 75 Years   (Adult, Senior)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ShandongCHI002|ShandongCHI","November 4, 2013","March 2013","March 2015","November 8, 2013","November 2013","No Study Results Posted","null","March 2015","complete response (CR)|Failure-free survival (PFS)|Toxicity|Overall response rate (ORR)","https://ClinicalTrials.gov/show/NCT01985451"
92,"NCT00941460","Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma","Completed","No Results Available","Glioblastoma","Drug: Temozolomide in both arms|Drug: Temozolomide in both arms","Prof. Dr. Wolfgang Wick|Essex Pharma GmbH|Heidelberg University","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","105","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DIRECTOR|2008-006871-60|ISRCTN68738654","July 16, 2009","September 2009","June 2013","August 13, 2014","August 2014","No Study Results Posted","DIRECTOR","June 2013","Median time to treatment failure. Treatment failure is reached (i) upon tumor progression as outlined in protocol (ii) if treatment has to be terminated due to toxicity or (iii) if the patient dies for any reason.|progression free survival","https://ClinicalTrials.gov/show/NCT00941460"
93,"NCT01120639","PI/II of Temozolomide & Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform","Active, not recruiting","No Results Available","Glioblastoma|Cancer of Brain and Nervous System|Glioblastoma Multiforme","Drug: Temozolomide|Procedure: Stereotactic Radiosurgery","Stanford University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BRN0012|SU-04202010-5726|17774","May 7, 2010","April 2010","November 2020","January 5, 2017","January 2017","No Study Results Posted","null","November 2016","Determine the maximum tolerated dose (MTD) of hypofractionated radiotherapy given in 5 fractions with temozolomide for the treatment of glioblastoma multiforme|Determine the progression-free survival rate.|Determine the short- and long-term adverse effects.|Determine the radiographic response rate.|Determine the overall survival rate.|Perform patterns of failure analysis.|Assess quality of life during treatment.","https://ClinicalTrials.gov/show/NCT01120639"
94,"NCT00575887","Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma","Completed","Has Results","Glioblastoma|Astrocytoma|Oligodendroglioma|Brain Tumor, Recurrent","Drug: Temozolomide","Marmara University|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MU-RO-2005-1","December 17, 2007","August 2006","March 2009","November 3, 2013","November 2013","November 3, 2013","null","March 2009","Progression-free Survival at 6-months","https://ClinicalTrials.gov/show/NCT00575887"
95,"NCT01590082","Doxycycline, Temozolomide and Ipilimumab in Melanoma","Terminated","No Results Available","Melanoma","Drug: Doxycycline|Drug: Ipilimumab|Drug: Temozolomide","M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-1165|NCI-2014-01836","April 30, 2012","November 2012","July 2015","November 10, 2015","November 2015","No Study Results Posted","null","July 2015","Overall Response Rate","https://ClinicalTrials.gov/show/NCT01590082"
96,"NCT02605811","Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer","Enrolling by invitation","No Results Available","Small Cell Lung Cancer|Metastatic Carcinoma","Drug: temozolomide|Radiation: prophylaxis cranial radiotherapy","Guangzhou Medical University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","426","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GACA1501","November 12, 2015","September 2015","April 2021","March 1, 2017","March 2017","No Study Results Posted","null","April 2019","2-year incidence of brain metastases","https://ClinicalTrials.gov/show/NCT02605811"
97,"NCT01473901","A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma","Active, not recruiting","No Results Available","Glioblastoma","Drug: BKM120 + temozolomide|Drug: BKM120 +temozolomide with/without radiotherapy","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1","38","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CBKM120E2101|2011-001157-87","August 18, 2011","December 30, 2011","May 19, 2017","May 4, 2017","May 2017","No Study Results Posted","null","May 19, 2017","Dose Limiting Toxicity (DLT)|No of participants with Adverse events based on abnormal laboratory results, abnormal electrocardiogram (ECG) findings|Objective response rate (ORR)|Progression free survival (PFS)|Overall survival (OS)|Plasma concentration-time profiles and basic pharmacokinetic parameters of BKM120 and temozolomide (Cmax, tmas, AUC, half-life)","https://ClinicalTrials.gov/show/NCT01473901"
98,"NCT02689336","Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors","Recruiting","No Results Available","Glioma|Rhabdomyosarcoma|Osteosarcoma|Medulloblastoma|Neuroectodermal Tumor|Ependymoma|Ewing's Sarcoma|Wilms Tumor","Biological: Erlotinib|Drug: Temozolomide","Washington University School of Medicine","All","1 Year to 21 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201604002","February 12, 2016","August 6, 2016","May 31, 2020","February 8, 2017","February 2017","No Study Results Posted","null","November 30, 2019","Overall response rate|Time to progression|Toxicities of treatment regimen","https://ClinicalTrials.gov/show/NCT02689336"
99,"NCT00005812","Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma","Terminated","No Results Available","Brain Tumors|Central Nervous System Tumors|Leptomeningeal Metastases","Drug: temozolomide","Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D9812|DMS-9812|NCI-G00-1782","June 2, 2000","January 2000","May 2004","May 13, 2013","May 2013","No Study Results Posted","null","May 2004","Objective Response|Pharmacokinetics|Survival|Quality of Life","https://ClinicalTrials.gov/show/NCT00005812"
100,"NCT00436436","O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy","Terminated","Has Results","Brain and Central Nervous System Tumors","Drug: O6-benzylguanine|Drug: temozolomide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","12","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","070052|NCI-07-C-0052|AOI-NCI-07-C-0052|CDR0000529875","February 15, 2007","November 13, 2006","April 14, 2010","February 7, 2017","February 2017","November 25, 2016","null","March 15, 2010","Confirmed Best Objective Tumor Response Rate (Complete or Partial Response) in Patients With Methylguanine Methyltransferase (MGMT)-Positive Tumors as Assessed by Immunohistochemistry (IHC)|Objective Tumor Response Rate in Patients With Methylguanine Methyltransferase (MGMT)-Negative Tumors as Assessed by Immunohistochemistry (IHC)|Toxicity as Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v 3)|Best Overall Response|Progression-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00436436"
101,"NCT02761070","Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III","Recruiting","No Results Available","Glioblastoma|Recurrence|Progression","Drug: Temozolomide|Drug: Bevacizumab","Kyorin University|Japan Clinical Oncology Group","All","20 Years to 75 Years   (Adult, Senior)","Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG1308C","April 28, 2016","July 2016","July 2023","July 11, 2016","July 2016","No Study Results Posted","RE-GEND","July 2022","Overall survival|Progression-free survival (PFS)|6-month progression-free survival (6m-PFS)|Complete response rate|Response rate|Adverse events|Serious adverse events|Progression-free survival (PFS) from bevacizumab (BEV) initiation|6-month progression-free survival (6m-PFS) after initiation of bevacizumab (BEV) (Experimental Arm Only)|Overall survival after initiation of bevacizumab (BEV)","https://ClinicalTrials.gov/show/NCT02761070"
102,"NCT00335075","Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)","Completed","No Results Available","Glioblastoma|Astrocytoma","Drug: Temozolomide|Drug: Semustine","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 3","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","P03644","June 6, 2006","March 2, 2005","February 23, 2006","May 12, 2017","May 2017","No Study Results Posted","null","February 23, 2006","Progression-free survival|Overall survival|Objective response|Scoring of health-related quality of life","https://ClinicalTrials.gov/show/NCT00335075"
103,"NCT01858168","Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma","Recruiting","No Results Available","Ewing Sarcoma","Drug: Olaparib|Drug: Temozolomide|Drug: Irinotecan","Massachusetts General Hospital","All","16 Years and older   (Child, Adult, Senior)","Phase 1","93","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","13-115","May 8, 2013","July 2013","July 2019","May 9, 2017","May 2017","No Study Results Posted","null","July 2018","Determine MTD of olaparib and irinotecan and/or temozolomide|Evaluate safety and tolerability of olaparib/irinotecan and/or temozolomide combination|Objective response in tumor dimensions to olaparib/irinotecan and/or temozolomide|Explore variations in PARP activity and tumor characteristics","https://ClinicalTrials.gov/show/NCT01858168"
104,"NCT00979017","Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme","Completed","Has Results","Glioblastoma Multiforme|Gliosarcoma","Drug: Avastin|Drug: Temozolomide|Drug: Irinotecan","Katy Peters|Genentech, Inc.|Duke University","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00019065","September 15, 2009","November 2009","January 2013","February 5, 2014","February 2014","June 5, 2013","null","February 2011","Response Rate|Incidence and Severity of Central Nervous System (CNS) Hemorrhage and Systemic Hemorrhage|Incidence of Grade ≥ 4 Hematologic and ≥ Grade 3 Non-hematologic Toxicities|Median Progression-free Survival (PFS)|Median Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00979017"
105,"NCT01015534","Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment","Completed","Has Results","Brain Neoplasms","Drug: Temozolomide|Radiation: Whole brain irradiation","Instituto Nacional de Cancerologia de Mexico","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","006/004/TEI","November 17, 2009","January 2006","October 2009","March 25, 2013","March 2013","August 23, 2012","null","October 2009","Objective Response Rates. Assessed With Cranial MRI|Survival Free of Brain Metastases Progression (PFS of BM)|Overall Survival|Number of Grade 3-4 Adverse Events (AE) That Are Definitely or Probably Related to Both Groups of Treatment.","https://ClinicalTrials.gov/show/NCT01015534"
106,"NCT00200161","Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma","Completed","No Results Available","Glioblastoma|Gliomas","Drug: Temozolomide|Drug: Temozolomide","Memorial Sloan Kettering Cancer Center|Schering-Plough|Columbia University|Dana-Farber Cancer Institute","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","05-079","September 12, 2005","August 9, 2005","May 4, 2017","May 9, 2017","September 2016","No Study Results Posted","null","May 4, 2017","To determine the overall survival of patients with newly diagnosed glioblastoma multiforme treated with concurrent temozolomide and radiotherapy followed by dose dense or metronomic dosing of temozolomide and maintenance cis-retinoic acid.|Progression free survival|To evaluate the prognostic impact of methylated MGMT status.|To collect preliminary data on the efficacy of this regimen and impact of MGMT status in other malignant glioma subtypes.","https://ClinicalTrials.gov/show/NCT00200161"
107,"NCT00005037","Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: temozolomide|Drug: Temozolomide","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","51","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067626|P30CA006927|FCCC-99032|NCI-G00-1712","April 6, 2000","January 2000","April 2008","May 5, 2014","May 2014","No Study Results Posted","null","October 2002","response rate in both previously treated and untreated patients.|freedom from progression (FFP) median, 1-year and 2-year survival rates in both groups.","https://ClinicalTrials.gov/show/NCT00005037"
108,"NCT00165360","Prolonged Daily Temozolomide for Low-Grade Glioma","Completed","No Results Available","Glioma|Astrocytoma|Oligodendroglioma","Drug: Temozolomide","Dana-Farber Cancer Institute|Schering-Plough|Brigham and Women's Hospital|University of Virginia","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-111","September 9, 2005","September 2001","September 2009","October 30, 2009","October 2009","No Study Results Posted","null","December 2006","To determine the effects temozolomide has on low-grade gliomas|To determine whether temozolomide is effective in preventing or delaying future tumor growth|to determine the safety of temozolomide","https://ClinicalTrials.gov/show/NCT00165360"
109,"NCT00684567","Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)","Completed","Has Results","Glioblastoma","Radiation: Radiotherapy|Drug: Temozolomide","Merck Sharp & Dohme Corp.","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P04661|JPC-05-351-22","May 22, 2008","September 2005","October 2007","January 19, 2015","January 2015","October 31, 2008","null","October 2007","Adverse Events With an Incidence of Greater Than or Equal to 20%|Adverse Drug Reactions With an Incidence of Greater Than or Equal to 20%|Abnormal Changes in Laboratory Test Values With an Incidence of Greater Than or Equal to 20%|Number of Participants With Progression Free Survival (PFS) for 1 Year|Number of Participants With a Response (Complete Response [CR] + Partial Response [PR]) in Terms of Overall Tumor Response","https://ClinicalTrials.gov/show/NCT00684567"
110,"NCT00005597","S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors","Completed","No Results Available","Gastrointestinal Stromal Tumor","Drug: temozolomide","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067710|S9926|U10CA032102","May 2, 2000","April 2000","October 2005","January 2, 2013","January 2013","No Study Results Posted","null","October 2005","Assess response (confirmed & unconfirmed, complete & partial response)|Toxicities","https://ClinicalTrials.gov/show/NCT00005597"
111,"NCT02766270","CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas","Recruiting","No Results Available","Grade II/III Glioma","Drug: Temozolomide|Radiation: Radiotherapy","Beijing Tiantan Hospital|Beijing Neurosurgical Institute|Beijing Shijitan Hospital","All","18 Years to 70 Years   (Adult, Senior)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CFMD 2016-2-1073","May 4, 2016","September 26, 2016","December 2018","January 18, 2017","January 2017","No Study Results Posted","null","December 2017","Overall survival (OS)|Progression free survival(PFS)|The incidence and severity of adverse events associated with treatment with RT alone and combined with temozolomide chemotherapy; according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0.","https://ClinicalTrials.gov/show/NCT02766270"
112,"NCT01956734","Virus DNX2401 and Temozolomide in Recurrent Glioblastoma","Active, not recruiting","No Results Available","Glioblastoma Multiforme|Recurrent Tumor","Procedure: DNX2401 and Temozolomide","Clinica Universidad de Navarra, Universidad de Navarra|DNAtrix, Inc.","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D24GBM EudraCT: 2011-005935-21","September 27, 2013","September 2013","March 2017","November 12, 2015","November 2015","No Study Results Posted","D24GBM","December 2015","Number of participans with adverse events|Efficacy of the combination: PFS6 and OS12|Tumor response|Quality of life|Biological response","https://ClinicalTrials.gov/show/NCT01956734"
113,"NCT00782756","Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma","Completed","No Results Available","Brain Cancer|Malignant Glioma","Other: radiotherapy (RT) in combination with temozolomide and bevacizumab","Memorial Sloan Kettering Cancer Center|Genentech, Inc.|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","08-126","October 29, 2008","October 28, 2008","March 23, 2017","March 24, 2017","March 2017","No Study Results Posted","null","March 23, 2017","To test the safety and efficacy of bevacizumab and temozolomide in combination with hypo-fractionated radiotherapy inpatients with newly diagnosed glioblastoma in terms of improvements in overall survival.|Progression free survival|Neurocognitive outcome","https://ClinicalTrials.gov/show/NCT00782756"
114,"NCT00686725","Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)","Completed","Has Results","Glioblastoma","Drug: Temozolomide|Radiation: Radiotherapy","Merck Sharp & Dohme Corp.","All","18 Years to 70 Years   (Adult, Senior)","Phase 4","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P05572","May 27, 2008","June 2008","September 2011","December 11, 2015","December 2015","February 25, 2013","null","September 2011","Overall Survival (OS)|Progression-Free Survival (PFS)|Objective Tumor Assessment After Surgery: Overall Response|Relationship Between O6-methylguanine-DNA Methyltransferase (MGMT) Status and Therapy Response: Overall Survival for the MGMT Positive Group|Relationship Between MGMT Status and Therapy Response: Overall Survival for the MGMT Negative Group|Relationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Positive Group|Relationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Negative Group|Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Positive Group|Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Negative Group","https://ClinicalTrials.gov/show/NCT00686725"
115,"NCT00723827","Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)","Completed","Has Results","Glioblastoma|Glioma|Astrocytoma","Drug: Temozolomide|Radiation: Radiotherapy","Merck Sharp & Dohme Corp.","All","Child, Adult, Senior","","682","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P05557","July 25, 2008","March 2008","September 2011","January 19, 2015","January 2015","December 5, 2012","null","September 2011","Number of Participants Experiencing Adverse Events (AEs)|Number of Participants Experiencing Unexpected Adverse Drug Reactions (ADRs)|Number of Temozolomide Misuse or Abuse Events|Number of Temozolomide Drug Interactions|Efficacy: Number of Participants Experiencing Complete Response (CR), Partial Response (PR), or Stable Disease(SD)","https://ClinicalTrials.gov/show/NCT00723827"
116,"NCT01110876","Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)","Terminated","No Results Available","Brain Cancer|Glioblastoma Multiforme","Drug: Vorinostat|Drug: Erlotinib|Drug: Temozolomide","M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","21","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-0651|NCI-2011-00469","April 22, 2010","June 2011","null","November 7, 2014","November 2014","No Study Results Posted","null","July 2014","Maximum Tolerated Dose (MTD) of Vorinostat in Combination with Escalating Doses of Erlotinib and Temozolomide|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01110876"
117,"NCT02898012","Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status","Completed","No Results Available","Glioblastoma Multiforme|Primary Brain Tumor","Drug: Temozolomide|Drug: Bevacizumab","Assistance Publique - Hôpitaux de Paris|Roche Pharma AG","All","70 Years and older   (Senior)","Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P081213","July 31, 2016","October 2010","June 2013","September 7, 2016","July 2016","No Study Results Posted","ATAG","May 2013","Median Overall Survival (OS)|Progression-free survival (PFS)|Toxicity grade according to the National Cancer Institute Common Toxicity Criteria (NCI CTCAE, version 3.0)|Health-related quality of life using QLQ-C30 questionnaire|Health-related quality of life using QLQ-BN20|Cognitive assessment MMSEs|Radiological responses","https://ClinicalTrials.gov/show/NCT02898012"
118,"NCT00050986","Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme","Completed","Has Results","Glioblastoma Multiforme","Drug: Temozolomide|Drug: R115777","M.D. Anderson Cancer Center|Johnson & Johnson","All","Child, Adult, Senior","Phase 1|Phase 2","55","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID02-126","December 31, 2002","December 2002","October 2008","July 27, 2012","July 2012","September 25, 2009","null","October 2008","Maximal Tolerating Dose (MTD for Phase I)|Progression-free Survival (Phase II)","https://ClinicalTrials.gov/show/NCT00050986"
119,"NCT00568048","Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery","Completed","No Results Available","Melanoma (Skin)","Biological: bevacizumab|Drug: temozolomide","Swiss Group for Clinical Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 2","62","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 50/07|SWS-SAKK-50/07|EU-20790|CDR0000577499","December 4, 2007","December 2007","October 2011","April 9, 2013","April 2013","No Study Results Posted","null","December 2010","Clinical benefit number of patients with complete response [CR], partial response [PR], or stable disease) according to RECIST criteria|Best overall response (CR, PR) according to RECIST criteria|Duration of response|Progression free survival|Overall survival|Adverse events","https://ClinicalTrials.gov/show/NCT00568048"
120,"NCT00725010","Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)","Completed","Has Results","Glioblastoma","Drug: Temozolomide|Radiation: Radiotherapy","Merck Sharp & Dohme Corp.","All","Child, Adult, Senior","","64","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P04816","July 25, 2008","April 2007","April 2009","September 8, 2015","September 2015","October 22, 2010","null","April 2009","Safety: Number of Adverse Events in the Indicated Categories|Number of Participants Who Discontinued Due to Toxicity","https://ClinicalTrials.gov/show/NCT00725010"
121,"NCT00109798","Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma","Withdrawn","No Results Available","Central Nervous System Tumors|Lymphoma","Drug: temozolomide|Drug: topotecan hydrochloride","The Methodist Hospital System|Baylor College of Medicine","All","18 Years to 75 Years   (Adult, Senior)","","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BCM IRB#H-16155|CDR0000427313","May 3, 2005","March 2005","July 2006","March 15, 2016","March 2016","No Study Results Posted","null","July 2006","Rate of complete radiologic response (CR)|Median overall survival|Failure-free survival|Toxicity|Overall response rate (CR and partial response)","https://ClinicalTrials.gov/show/NCT00109798"
122,"NCT00521482","Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma","Unknown status","No Results Available","Glioblastoma","Drug: Temozolomide|Drug: Temozolomide plus Thalidomide","University of Zurich","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TMZ/05|P04932","August 27, 2007","September 2007","January 2009","August 27, 2007","August 2007","No Study Results Posted","null","null","Proportion of patients with progression free survival|Proportion of patients with a clinical response. Time to disease progression. Progression free survival.","https://ClinicalTrials.gov/show/NCT00521482"
123,"NCT02315534","A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma","Recruiting","No Results Available","Glioblastoma","Drug: BBI608|Drug: Temozolomide","Boston Biomedical, Inc","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BBI608-251|BBI608-201GBM","December 9, 2014","March 2015","null","April 12, 2017","April 2017","No Study Results Posted","null","June 2017","Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs) (Phase 1 portion)|Progression Free Survival (PFS)-6 (phase 2 portion)|Progression Free Survival (PFS)|Overall Survival (OS)|Disease Control Rate (DCR)|Objective Response Rate (ORR)|Pharmacokinetic profile of BBI608 and temozolomide when administered in combination with temozolomide as assessed by maximum plasma concentration and area under the curve|Pharmacodynamic activity of BBI608 when administered in combination with temozolomide as assessed by tumor biopsy and Cancer Stem Cell assays as well as the concentration of study drug in tumors","https://ClinicalTrials.gov/show/NCT02315534"
124,"NCT01591577","Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme","Recruiting","No Results Available","Newly Diagnosed Glioblastoma Multiforme","Other: Lapatinib/Temozolomide/radiation","Jonsson Comprehensive Cancer Center|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12-000493","May 2, 2012","December 2012","null","September 7, 2016","September 2016","No Study Results Posted","null","April 2017","Overall survival","https://ClinicalTrials.gov/show/NCT01591577"
125,"NCT00311584","Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma","Completed","Has Results","Neuroblastoma","Drug: irinotecan hydrochloride|Drug: temozolomide","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 2","59","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ANBL0421|CDR0000465487|COG-ANBL0421","April 5, 2006","April 2006","December 2013","September 16, 2014","September 2014","December 2, 2013","null","March 2009","Overall Response - Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR)","https://ClinicalTrials.gov/show/NCT00311584"
126,"NCT00525525","Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma","Completed","Has Results","Glioblastoma|Gliosarcoma","Drug: Bevacizumab|Drug: Tarceva|Drug: Temozolomide","University of California, San Francisco","All","18 Years and older   (Adult, Senior)","Phase 2","74","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07105","September 4, 2007","September 2007","May 2013","November 5, 2014","November 2014","October 28, 2014","AVF4120s","May 2013","Overall Survival (OS)|Unexpected Toxicities During First 2 Cycles of Study Drug|Progression-free Survival","https://ClinicalTrials.gov/show/NCT00525525"
127,"NCT00302159","Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors","Completed","Has Results","High Grade Gliomas|Brain Tumors","Procedure: adjuvant therapy|Drug: Temozolomide|Drug: Valproic Acid|Radiation: Radiation therapy","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 90 Years   (Adult, Senior)","Phase 2","43","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","060112|06-C-0112","March 11, 2006","March 2006","November 2014","July 19, 2016","July 2016","May 22, 2014","null","June 2013","Median Progression Free Survival.|Percentage of Participants With Progression Free Survival at 6, 12, and 24 Months|Number of Participants With Best Response|Median Overall Survival|Percentage of Participants With Overall Survival at 6, 12, and 24 Months|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00302159"
128,"NCT00705198","Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)","Completed","No Results Available","Glioma|Astrocytoma","Drug: Temozolomide (for newly diagnosed malignant glioma)|Drug: Temozolomide (for relapsed malignant glioma)|Radiation: Radiotherapy (for patients with newly diagnosed malignant glioma)","Merck Sharp & Dohme Corp.","All","Child, Adult, Senior","","1804","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P05062","June 23, 2008","September 2006","July 2016","November 11, 2016","November 2016","No Study Results Posted","null","July 2016","Safety: observation of hematology, biochemistry, and adverse events (AEs); evaluation of details of occurrence of AEs and unexpected serious AEs, and evaluation of presence or absence of secondary malignancies and causal relationship with temozolomide.|Efficacy in patients registered during Period 1, evaluated as Remarkably Effective, Moderately Effective, Stable Disease, Progression, or Not Evaluable, considering tumor responses, progression free survival, overall survival, among other factors.|Efficacy in all newly diagnosed anaplastic astrocytoma patients:, evaluated as 5 year survival rate and overall survival.","https://ClinicalTrials.gov/show/NCT00705198"
129,"NCT01149109","Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients","Active, not recruiting","No Results Available","Glioblastoma","Drug: Temozolomide and lomustine|Drug: Temozolomide","University Hospital, Bonn","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CeTeG|2009-011252-22","June 14, 2010","October 2010","December 2015","June 3, 2015","June 2015","No Study Results Posted","CeTeG","November 2015","overall survival|progression free survival|best response rate determined by MRI|frequency of delay of the next Lomustine/Temozolomide or Temozolomide course|acute toxicity during radiotherapy and chemotherapy according to CTC AE V3.0|quality of life|Evaluation of late neurotoxicity","https://ClinicalTrials.gov/show/NCT01149109"
130,"NCT01048554","Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System","Completed","No Results Available","Melanoma","Drug: Temozolomide|Drug: Bevacizumab","Mt. Sinai Medical Center, Miami|Northern California Melanoma Center","All","18 Years to 90 Years   (Adult, Senior)","Phase 2","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MEL0107","January 12, 2010","November 2009","September 2011","April 18, 2012","April 2012","No Study Results Posted","MEL0107","September 2011","Primary Outcome Measures: one-year survival rate|Secondary Outcome Measures: response rate and safety profile","https://ClinicalTrials.gov/show/NCT01048554"
131,"NCT00091572","Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)","Completed","Has Results","Melanoma","Drug: Temozolomide|Drug: Dacarbazine","Merck Sharp & Dohme Corp.|European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 3","859","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P03267","September 10, 2004","October 2004","December 2007","April 28, 2015","April 2015","December 19, 2008","null","December 2007","Overall Survival|Progression Free Survival|Objective Response Rate in Subjects With Measurable Lesions|Duration of Objective Response","https://ClinicalTrials.gov/show/NCT00091572"
132,"NCT00527657","Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients","Completed","No Results Available","Brain Neoplasms|Melanoma","Drug: Lomustine|Drug: Temozolomide|Drug: Thalidomide","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 1","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-0595","September 10, 2007","February 2006","February 2012","May 29, 2013","May 2013","No Study Results Posted","null","February 2012","Maximum tolerated dose (MTD)|Objective (CR+PR) response rate at the MTD","https://ClinicalTrials.gov/show/NCT00527657"
133,"NCT00072163","Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma","Completed","No Results Available","Recurrent Melanoma|Stage IV Melanoma|Tumors Metastatic to Brain","Drug: temozolomide|Drug: thalidomide","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","50","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02560|CALGB-500102|U10CA031946|CDR0000335518","November 4, 2003","October 2003","null","January 15, 2013","January 2013","No Study Results Posted","null","September 2006","Response rate (defined as complete or partial)|Time to first progression|Overall survival","https://ClinicalTrials.gov/show/NCT00072163"
134,"NCT01867619","Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients","Withdrawn","No Results Available","Brain Neoplasms|Melanoma","Drug: Lomustine|Drug: Temozolomide|Drug: Thalidomide","M.D. Anderson Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-0595 Phase II","May 29, 2013","February 2006","null","May 29, 2013","May 2013","No Study Results Posted","null","February 2012","Objective (CR+PR) response rate","https://ClinicalTrials.gov/show/NCT01867619"
135,"NCT00268385","Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","Active, not recruiting","No Results Available","Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Recurrent Adult Brain Neoplasm","Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Temozolomide|Drug: Vorinostat","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","83","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2009-00675|CDR0000450762|NABTC 04-03|NABTC04-03|NABTC-04-03|U01CA137443|U01CA062399","December 20, 2005","December 16, 2005","null","May 23, 2017","October 2016","No Study Results Posted","null","October 15, 2011","MTD of vorinostat with temozolomide defined as the dose at which less than one-third of patients experience dose-limiting toxicity based on the CTC severity grading (Part I)|Efficacy in terms of anti-tumor activity based on clinical, radiographic, and biologic assessments (Part II)|Plasma pharmacokinetic parameters of vorinostat","https://ClinicalTrials.gov/show/NCT00268385"
136,"NCT01209442","Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme","Active, not recruiting","No Results Available","Glioblastoma Multiforme","Drug: Bevacizumab|Drug: Temozolomide|Radiation: RT (Radiation Therapy)","University of Colorado, Denver|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10-0274.cc|AVF4733s","September 23, 2010","August 2010","August 2017","January 3, 2017","January 2017","No Study Results Posted","null","August 2017","6-month progression-free survival|Overall survival, measured from the day of initial diagnosis (biopsy or surgery) to the time of death from any cause.","https://ClinicalTrials.gov/show/NCT01209442"
137,"NCT02039778","Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma","Terminated","No Results Available","Glioblastoma|Malignant Glioma|Brain Tumors|Anaplastic Astrocytoma","Radiation: Stem Cell Radiotherapy (ScRT) and Temozolomide","Beth Israel Medical Center|St. Luke's-Roosevelt Hospital Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13-0151","January 16, 2014","December 2013","December 2015","January 6, 2017","August 2015","No Study Results Posted","STRONG","December 2015","Overall Survival|Progression-free Survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Neurocognition|Quality of Life","https://ClinicalTrials.gov/show/NCT02039778"
138,"NCT02530502","Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma","Active, not recruiting","No Results Available","Adult Glioblastoma","Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Radiation: Radiation Therapy|Drug: Temozolomide","Northwestern University|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","50","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU 15C01|NCI-2015-00736|STU00200883|P30CA060553","August 19, 2015","October 2015","null","October 31, 2016","October 2016","No Study Results Posted","null","March 2018","For phase I of the study, the dose-limiting toxicity of Radiation Therapy With Temozolomide and Pembrolizumab will be evaluated|For phase II of the study, PFS (Progression Free Survival) of Radiation Therapy With Temozolomide and Pembrolizumab will be measured|Toxicity of Pembrolizumab (Phase II)|Overall survival (OS) (Phase II)|OS-12 (Overall survival at 12 months)|OS-24 (Overall survival at 24 months)|OS-6 (Overall survival at 6 months)|Response rate (Phase II)|PFS6 (Progression Free Survival at 6 months) of Radiation Therapy With Temozolomide and Pembrolizumab will be measured","https://ClinicalTrials.gov/show/NCT02530502"
139,"NCT00424554","Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)","Completed","Has Results","Glioma","Drug: temozolomide","Merck Sharp & Dohme Corp.","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P04602","January 18, 2007","September 2006","February 2011","June 11, 2015","June 2015","June 3, 2011","null","January 2010","MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery|Safety: Number of Participants Who Experienced Grade 3 or 4 Toxicities|Tolerability: Number of Participants Discontinuing Treatment Due to Adverse Events (AE)|Concentrations of Temozolomide in the Serum, Cerebrospinal Fluid, and Brain Tumor|MGMT Activity in the Brain Tumor Tissues by Temozolomide Levels","https://ClinicalTrials.gov/show/NCT00424554"
140,"NCT02168270","Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma","Terminated","No Results Available","Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma|Gliosarcoma","Dietary Supplement: ascorbic acid|Drug: temozolomide|Other: quality-of-life assessment|Other: laboratory biomarker analysis","University of Nebraska|National Cancer Institute (NCI)","All","19 Years and older   (Adult, Senior)","Phase 1","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","735-13|NCI-2014-01061|P30CA036727","May 29, 2014","June 2014","null","December 3, 2015","December 2015","No Study Results Posted","null","December 2019","Maximum tolerated dose of ascorbic acid in combination with temozolomide, defined as the highest dose tested which results in dose limiting toxicity (DLT) in no more than one of six evaluable patients|Incidence rates of adverse events, graded according to the NCI Common Toxicity Criteria for Adverse Events version 4.0|Changes in serum levels of ascorbic acid (using HPLC with coulometric electrochemical detection)|Using radiologic measurements for tumor response|Progression-free survival (PFS)|Overall survival (OS)|Quality of life, assessed by the EORTC QLQ-C30","https://ClinicalTrials.gov/show/NCT02168270"
141,"NCT00904852","Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme","Withdrawn","No Results Available","Glioblastoma Multiforme","Drug: Tandutinib, bevacizumab, and temozolomide","Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C03003","May 19, 2009","June 2009","June 2010","May 19, 2009","May 2009","No Study Results Posted","null","May 2010","Maximum tolerated dose of tandutinib, adverse events, serious adverse events and dose limiting toxicities, clinical laboratory values and vital sign measurements","https://ClinicalTrials.gov/show/NCT00904852"
142,"NCT00918320","Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours","Completed","No Results Available","Neuroblastoma|Brain Tumors|Solid Tumors","Drug: Temozolomide/Hycamtin (Topotecan)","Gustave Roussy, Cancer Campus, Grand Paris|St. Anna Kinderkrebsforschung|Catholic University of the Sacred Heart|Erasmus Medical Center","All","6 Months to 20 Years   (Child, Adult)","Phase 2","129","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CSET 2008/1378","June 8, 2009","June 2009","August 2015","January 25, 2016","January 2016","No Study Results Posted","TOTEM2","October 2013","Response rate|safety and adverse event profile of the combination safety and adverse event|time-to-event endpoints: duration of response, time to progressive disease, time to treatment failure and overall survival","https://ClinicalTrials.gov/show/NCT00918320"
143,"NCT00804908","A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma","Completed","Has Results","Melanoma|Metastatic Melanoma|Skin Cancer","Drug: temozolomide|Drug: ABT-888|Other: Placebo","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Senior)","Phase 2","346","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","M10-440|2008-004941-27","December 1, 2008","February 2009","January 2016","March 1, 2017","March 2017","December 6, 2016","null","January 2016","Progression-Free Survival (PFS): Time to Event|Overall Survival (OS): Time to Event|12-Month Overall Survival (OS) Rate|6-month Progression-Free Survival Rate|Objective Response Rate|Time to Disease Progression|Disease Control Rate|Time to Neurological/Brain Metastases Progression","https://ClinicalTrials.gov/show/NCT00804908"
144,"NCT01235793","The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma","Recruiting","No Results Available","B-Cell Lymphoma Originating in the CNS","Drug: Temozolomide","Cedars-Sinai Medical Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Pro00019873","November 5, 2010","September 2010","December 2019","January 31, 2017","January 2017","No Study Results Posted","DRBEAT","December 2018","Efficacy of the DRBEAT Regimen|Safest dose of temozolomide for the DRBEAT Regimen","https://ClinicalTrials.gov/show/NCT01235793"
145,"NCT01009788","ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer|Metastatic Breast Cancer|BRCA1 Gene Mutation|brca2 Gene Mutation","Drug: ABT-888|Drug: temozolomide","Steven Isakoff, MD, PhD|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Abbott|Massachusetts General Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","64","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","09-261","November 5, 2009","November 2009","June 2019","April 13, 2017","April 2017","No Study Results Posted","null","June 2018","To determine the objective response rate (ORR) of ABT-888 and temozolomide (TMZ) in metastatic breast cancer.|To determine Safety and Efficacy in an Expansion Cohort of BRCA1/2 Mutation Carriers.|To further characterize the safety and tolerability of ABT-888 and TMZ in patients with metastatic breast cancer.|To evaluate progression free survival.|To evaluate the clinical benefit rate.","https://ClinicalTrials.gov/show/NCT01009788"
146,"NCT01113957","A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer","Completed","No Results Available","Ovarian Cancer","Drug: ABT-888|Drug: pegylated liposomal doxorubicin|Drug: temozolomide","AbbVie (prior sponsor, Abbott)|AbbVie","Female","18 Years and older   (Adult, Senior)","Phase 2","168","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","M10-757|2009-015082-31","February 26, 2010","March 2010","June 2013","June 25, 2014","June 2014","No Study Results Posted","null","June 2013","Objective response rate between the two treatment arms (ABT-888 + temozolomide versus the PLD) will be based on tumor measurements and CA-125 levels.|Evaluate progression free survival, time to progression, overall survival, 12-month survival rate, 6-month progression free survival rate, duration of response|Safety Assessments and tolerability (i.e. ECG, clinical laboratory tests, vital signs, AE assessments, physical exams, CT scans). See section 5 for detailed information.|Evaluate Quality of Life and performance status will be done through the use of FACT-O quality of fife questionnaire, EQ5D questionnaire and ECOG performance status.","https://ClinicalTrials.gov/show/NCT01113957"
147,"NCT00137774","Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors","Completed","No Results Available","Neuroendocrine Tumors","Drug: Bevacizumab|Drug: Temozolomide","Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Genentech, Inc.|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","34","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-272","August 26, 2005","November 2004","December 2012","April 7, 2013","April 2013","No Study Results Posted","null","July 2005","To assess the response to bevacizumab in combination with temozolomide in patients with metastatic neuroendocrine tumors|To assess the time to progression, progression free survival and safety of bevacizumab in combination with temozolomide in this patient population","https://ClinicalTrials.gov/show/NCT00137774"
148,"NCT00301067","Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma","Active, not recruiting","No Results Available","Metastatic Melanoma","Dietary Supplement: calcitriol|Drug: temozolomide","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","28","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU 05M1|P30CA060553|NU-05M1|NU-0310-093|SPRI-NU-05M1","March 8, 2006","May 2005","May 2019","November 16, 2016","November 2016","No Study Results Posted","null","May 2018","Maximum tolerated dose of high-dose calcitriol|Assess toxicity|Tumor response and time to progression|The relationship between vitamin D-receptor gene polymorphisms and tumor response","https://ClinicalTrials.gov/show/NCT00301067"
149,"NCT03011671","Phase I Study of Safety and Tolerability of Acetazolamide With Temozolomide","Not yet recruiting","No Results Available","Malignant Glioma of Brain","Drug: Acetazolamide|Drug: Temozolomide","University of Chicago","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IRB16-0767","January 4, 2017","July 2017","March 2020","April 20, 2017","April 2017","No Study Results Posted","null","February 2020","Number of participants with adverse events|Measure objective response rate (ORR); change in tumor size|Time until progression free survival (PFS)|Time until overall survival (OS)|Analysis of formalin fixed paraffin embedded surgical specimens.","https://ClinicalTrials.gov/show/NCT03011671"
150,"NCT01987830","Bevacizumab w / Temozolomide PET & Vascular MRI For GBM","Recruiting","No Results Available","Recurrent Glioblastoma","Device: MRI-PET|Device: TMZ-PET","Massachusetts General Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","17","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","13-322","November 13, 2013","November 2013","September 2018","April 28, 2016","April 2016","No Study Results Posted","null","January 2017","To assess temozolomide delivery before and after bevacizumab in glioblastoma|To explore the link between flow, permeability, and tumor temozolomide retention.","https://ClinicalTrials.gov/show/NCT01987830"
151,"NCT01601535","Study of MLN8237 in Combination With Irinotecan and Temozolomide","Active, not recruiting","No Results Available","Neuroblastoma","Drug: MLN8237|Drug: Irinotecan|Drug: Temozolomide","New Approaches to Neuroblastoma Therapy Consortium","All","12 Months to 30 Years   (Child, Adult)","Phase 1|Phase 2","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","N2009-03","May 11, 2012","May 2012","December 2017","March 21, 2017","March 2017","No Study Results Posted","null","June 2017","Toxicity|Aurora A Expression|UGT1A1 genotype|AURKA genotype|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01601535"
152,"NCT02934204","Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma","Recruiting","No Results Available","Primary CNS Lymphoma","Drug: methotrexate|Drug: temozolomide","Guangdong General Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","51","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GDREC2015431H(R1)","October 13, 2016","February 2016","February 2019","October 13, 2016","May 2016","No Study Results Posted","null","February 2019","event free survival|Chronic neurotoxicity|Overall survival|Completed response","https://ClinicalTrials.gov/show/NCT02934204"
153,"NCT00433381","Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma","Completed","Has Results","Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor","Drug: irinotecan hydrochloride|Biological: bevacizumab|Drug: temozolomide","National Cancer Institute (NCI)|American College of Radiology Imaging Network","All","18 Years and older   (Adult, Senior)","Phase 2","123","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00743|RTOG-0625|ACRIN-6677|CDR0000528259|RTOG 0625|U10CA021661","February 8, 2007","March 2007","February 2011","May 7, 2014","November 2012","March 14, 2013","null","January 2010","Six-month Progression-free Survival (PFS) for Bevacizumab and Irinotecan Hydrochloride Arm|Rate of Treatment Discontinuation Due to Treatment-related Medical Complications(Bevacizumab and Temozolomide Arm)|Six-month Progression-free Survival (Bevacizumab and Temozolomide Arm)|Best Objective Response Rate (Complete Response, Partial Response, Stable Disease, Progression) in Both Arms|Agreement Between Local Interpretation and Central Interpretation of the Standard MRI on the 6-month Progression-free Survival|Accuracy of Local Interpretation on the 6-month Progression-free Survival Using Central Review as the Reference Standard|Correlation of Degree of Cerebral Blood Volume (CBV) and Lactate (Lac) to N-acetylaspartate (NAA) (Lac/NAA) Ratio|Correlation of Degree of Cerebral Blood Volume (CBV) and Lactate (Lac) to Patient Response|Predictive Value of CBV and Lac/NAA in Assessing 6-month Progression-free Survival","https://ClinicalTrials.gov/show/NCT00433381"
154,"NCT00544817","Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme","Completed","Has Results","Glioblastoma Multiforme","Radiation: Radiation Therapy|Drug: Temozolomide|Drug: Sorafenib","SCRI Development Innovations, LLC|Bayer","All","18 Years and older   (Adult, Senior)","Phase 2","47","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI CNS 09","October 15, 2007","April 2007","August 2010","July 21, 2016","July 2016","November 15, 2012","null","June 2008","Progression-free Survival|Overall Survival|Objective Response","https://ClinicalTrials.gov/show/NCT00544817"
155,"NCT02337426","Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Active, not recruiting","No Results Available","Adult Brain Glioblastoma|Adult Giant Cell Glioblastoma|Adult Gliosarcoma","Drug: Dimethyl Fumarate|Drug: Temozolomide|Radiation: Radiation Therapy","Virginia Commonwealth University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-13-09950|NCI-2014-02619|HM20003022|P30CA016059","January 8, 2015","February 13, 2015","September 21, 2018","May 3, 2017","May 2017","No Study Results Posted","null","November 8, 2016","RP2D for DMF when combined with concurrent temozolomide and radiotherapy determined by the incidence of dose limiting toxicities (DLTs) graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Incidence of adverse events graded according to NCI CTCAE version 4.0|Progression free survival (PFS)|Overall survival (OS)|Response rate assessed as per the Response Assessment in Neuro-oncology for magnetic resonance imaging scans or Macdonald criteria for computed tomography scans","https://ClinicalTrials.gov/show/NCT02337426"
156,"NCT00939991","Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas","Completed","Has Results","Brain Tumor|Glioblastoma","Drug: Vorinostst/Bevacizumab/Temozolomide","Katy Peters|Genentech, Inc.|Merck Sharp & Dohme Corp.|Duke University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","48","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00016446","July 14, 2009","October 2009","April 2013","May 3, 2013","May 2013","May 3, 2013","null","January 2012","Phase I: Determination of the Maximum Tolerated Dose (MTD)|Phase II: 6-month Progression-free Survival (PFS)|Phase II: Radiographic Response.|Phase II: Median Progression-free Survival (PFS)|Phase II: Median Overall Survival (OS)|Phase II: Number of Patients With Grade 2 or Greater, Treatment-related Toxicities","https://ClinicalTrials.gov/show/NCT00939991"
157,"NCT01824875","Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors","Active, not recruiting","No Results Available","Gastrinoma|Glucagonoma|Insulinoma|Islet Cell Carcinoma|Pancreatic Polypeptide Tumor|Recurrent Islet Cell Carcinoma|Somatostatinoma","Drug: temozolomide|Drug: capecitabine|Other: laboratory biomarker analysis","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","145","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E2211|NCI-2012-02007|U10CA021115|U10CA180820","April 2, 2013","May 2013","null","March 8, 2016","March 2016","No Study Results Posted","null","July 2017","PFS|RR defined by revised RECIST criteria version 1.1|Overall survival|Toxicity rates using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0","https://ClinicalTrials.gov/show/NCT01824875"
158,"NCT00660283","A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma","Unknown status","No Results Available","Glioma","Drug: Temozolomide","Kentuckiana Cancer Institute|Eisai Inc.","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KARE003|KARE 003","April 14, 2008","January 2009","December 2010","January 18, 2010","January 2010","No Study Results Posted","KARE003","December 2010","Safety and efficacy of concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide in subjects undergoing initial surgery for newly-diagnosed high grade glioma.","https://ClinicalTrials.gov/show/NCT00660283"
159,"NCT00182819","Radiation Therapy or Temozolomide in Treating Patients With Gliomas","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC|NCIC Clinical Trials Group|British Medical Research Council|Trans-Tasman Radiation Oncology Group (TROG)","All","18 Years and older   (Adult, Senior)","Phase 3","709","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-22033-26033|2004-002714-11|CAN-NCIC-CE5|TROG 06.01|MRC-BR13","September 15, 2005","July 2005","May 2014","October 11, 2016","October 2016","No Study Results Posted","null","August 2013","Progression-free survival|Overall survival|Quality of life as measured by QLQ-C30 v3.0 and EORTC BN-20|Mini-Mental State Examination|Adverse events as measured by CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00182819"
160,"NCT02177578","Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: Temozolomide|Radiation: Subventricular Zone radiation|Radiation: Neural Progenitor Cell Sparing radiation","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J1426|IRB00031466","May 6, 2014","May 2014","null","September 20, 2016","September 2016","No Study Results Posted","null","June 2020","Change from Baseline to Initial Progression|Progression Free Survival|Rate of Distant Brain Progression|Multifocal Disease Development|Location of Disease Progression|Neurocognitive Function Change from Baseline|Composite Cognitive Function Change from Baseline|Cognitive Function Change from Baseline|Quality of Life Change from Baseline|Acute and Late Toxicity Change from Baseline|Pathologically Confirmed Necrosis Change from Baseline|Pseudo-Progression Change from Baseline|Overall Survival","https://ClinicalTrials.gov/show/NCT02177578"
161,"NCT00615186","Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy","Terminated","No Results Available","Glioblastoma Multiforme","Drug: Neuradiab + Radiotherapy + Temozolomide|Drug: Radiation Therapy + Temozolomide","Bradmer Pharmaceuticals Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BRAD-301","February 1, 2008","June 2008","December 2013","February 8, 2011","February 2011","No Study Results Posted","Glass-Art","August 2013","The primary measure of efficacy is overall survival (OS).|Progression-free survival (PFS) is the sole secondary measure of efficacy.","https://ClinicalTrials.gov/show/NCT00615186"
162,"NCT00022711","Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: temozolomide","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FCCC-01020|NCI-G01-2005","August 10, 2001","January 2002","January 2004","July 10, 2013","July 2013","No Study Results Posted","null","January 2004","","https://ClinicalTrials.gov/show/NCT00022711"
163,"NCT00249964","Combination Paclitaxel, Carboplatin and Temozolomide","Completed","No Results Available","Lung Diseases|Cancer","Drug: Combination Treatment - Cohort 1|Drug: Combination Treatment - Cohort 2|Drug: Combination Treatment - Cohort 3|Drug: Combination Treatment - Cohort 4","New Mexico Cancer Care Alliance","All","18 Years and older   (Adult, Senior)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0100C","November 3, 2005","November 2003","March 2011","January 15, 2016","January 2016","No Study Results Posted","null","March 2011","Maximum Tolerated Dose of Temozolomide in Combination with Fixed Doses of Paclitaxel and Carboplatin|Tumor response rate","https://ClinicalTrials.gov/show/NCT00249964"
164,"NCT00881595","Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas","Withdrawn","No Results Available","Soft Tissue Sarcomas","Drug: Chemoradiotherapy Temozolomide|Radiation: Proton therapy|Procedure: Proton Chemoradiotherapy followed by surgery","University of Florida","All","55 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","UFPTI 0803-SA02","April 13, 2009","February 2009","November 2012","February 9, 2017","February 2017","No Study Results Posted","SA02","November 2012","Assess treatment feasibility of neoadjuvant temozolomide-based proton chemoradiotherapy for high-risk soft tissue sarcoma|Evaluate acute and late toxicities","https://ClinicalTrials.gov/show/NCT00881595"
165,"NCT00704808","Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)","Completed","Has Results","Glioblastoma","Procedure: Primary surgical treatment|Radiation: Radiotherapy|Drug: Temozolomide","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","","180","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P04739","June 23, 2008","May 2006","December 2008","September 8, 2015","September 2015","March 17, 2010","null","December 2008","Median Progression Free Survival After Primary Surgical Treatment, Concomitant and Adjuvant Chemotherapy With Temozolomide, for Patients With Newly Diagnosed Glioblastoma Multiforme","https://ClinicalTrials.gov/show/NCT00704808"
166,"NCT03156036","Phase II Study of Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer","Not yet recruiting","No Results Available","Advanced Rectal Cancer","Drug: Capecitabine plus temozolomide VS Capecitabine","Asan Medical Center","All","20 Years and older   (Adult, Senior)","Phase 2","246","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TemoCap","May 3, 2017","May 2017","February 2021","May 15, 2017","May 2017","No Study Results Posted","null","February 2020","Pathologic complete response rate(Pathologic staging and tumor regression grade.)","https://ClinicalTrials.gov/show/NCT03156036"
167,"NCT01505608","Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma","Terminated","Has Results","Neuroblastoma","Drug: TPI 287|Drug: Temozolomide|Drug: Irinotecan","Giselle Sholler|Cortice Biosciences, Inc.|Spectrum Health Hospitals","All","12 Months to 21 Years   (Child, Adult)","Phase 1|Phase 2","14","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","NMTRC 005","January 4, 2012","December 2011","December 2014","September 9, 2016","September 2016","May 10, 2016","null","December 2014","Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Overall Response Rate (ORR) of Participants Using RECIST Criteria|Pharmacokinetics (PK) of TPI 287 in the Phase I Population of This Trial.|Measure Quality of Life of Children Receiving TPI287 Using PedsQL Questionnaires|Progression Free Survival (PFS) of Participants Using Days Until Progression|Median Overall Survival (OS) of Participants","https://ClinicalTrials.gov/show/NCT01505608"
168,"NCT02928575","Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: Sunitinib|Drug: Temozolomide|Radiation: Radiation Therapy","Bassam Abdulkarim|Pfizer|Canadian Cancer Society Research Institute (CCSRI)|McGill University Health Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","McG 1132","January 14, 2016","August 2012","June 2017","October 6, 2016","October 2016","No Study Results Posted","null","December 2016","Tumor Response Rate|Overall Survival|Progression free survival|Biomarkers (Cytokines) response|Adverse Events|level of functioning|Increase use of corticosteroids","https://ClinicalTrials.gov/show/NCT02928575"
169,"NCT02655601","Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001","Recruiting","No Results Available","High Grade Glioma, Glioblastoma","Drug: BMX-001|Radiation: Radiation Therapy|Drug: Temozolomide","BioMimetix JV, LLC|Duke Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","66","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BMX-HGG-001","January 12, 2016","May 2016","February 2022","December 5, 2016","December 2016","No Study Results Posted","BMX-HGG","February 2021","Phase 1 - Maximum tolerated dose (MTD) of BMX-001 in combination with standard radiation therapy and temozolomide, defined as the dose level that has an estimated dose limited toxicity (DLT) rate nearest to 0.25.|Phase 2 - Median overall survival (time to death from randomization) for newly diagnosed HGG patients receiving BMX-001 plus standard radiation therapy and temozolomide.|Safety and tolerability of BMX-001 in combination with standard radiation therapy and temozolomide in newly diagnosed high grade glioma patients will be assessed as the proportion of patients with a DLT.|Median overall survival (time to death from the time protocol treatment is initiated).|Progression-free survival (time between initiation of protocol treatment and the first recurrence of disease or death).|Mean change between baseline and week 24 in normalized scores for cognition using standardized cognitive tests and computerized battery central nervous system (CNS) Vital Signs.|Proportion of patients with radiographic response after treatment with BMX-001 in combination with standard radiation therapy and temozolomide in newly diagnosed high grade glioma patients.|Peak plasma concentrations (Cmax) for BMX-001.|Area under the plasma concentration versus time curve (AUC) for BMX-001.","https://ClinicalTrials.gov/show/NCT02655601"
170,"NCT00362570","Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma","Completed","No Results Available","Oligoastrocytoma, Mixed|Anaplastic Oligodendroglioma","Drug: Temozolomide","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU-0222","August 8, 2006","May 2005","March 2011","May 4, 2015","May 2015","No Study Results Posted","null","April 2007","Determine progression free survival and response rate in patients with newly diagnosed AO and MOA of Temozolomide given every other week.|Assess the quality of life in this patient population using validated quality of life instruments.","https://ClinicalTrials.gov/show/NCT00362570"
171,"NCT00437957","Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases","Terminated","No Results Available","Brain Metastases","Drug: Temozolomide|Drug: Valproic Acid|Procedure: Whole Brain Radiation Therapy","H. Lee Moffitt Cancer Center and Research Institute|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-14886|105003A","February 19, 2007","December 2006","April 2009","February 20, 2017","June 2011","No Study Results Posted","null","April 2009","Safety and tolerability of temozolomide in combination with VPA and Whole-Brain Radiation|Determination of the MTD of VPA in combination with temozolomide and Whole-Brain Radiation|Response rate|Pharmacokinetics|Histone acetylation","https://ClinicalTrials.gov/show/NCT00437957"
172,"NCT01105702","Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma","Terminated","Has Results","Brain Cancer","Drug: Temozolomide|Drug: Bevacizumab|Drug: Lithium Carbonate|Radiation: Radiation","New York University School of Medicine|Genentech, Inc.|Atlantic Health System","All","18 Years and older   (Adult, Senior)","Phase 2","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NYU 07-712","April 12, 2010","May 2010","April 2015","July 6, 2016","July 2016","October 5, 2015","null","April 2014","Median Progression-Free Survival (PFS)|Median Overall Survival (OS)|Number of Patients With Grade 3 or 4 Adverse Events","https://ClinicalTrials.gov/show/NCT01105702"
173,"NCT02477813","Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation","Recruiting","No Results Available","Small Cell Lung Cancer Recurrent","Drug: Temozolomide","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRST162.09","June 16, 2015","January 2015","January 2018","September 28, 2016","September 2016","No Study Results Posted","TeRes","January 2018","Overall Response Rate (ORR):|Time to tumor progression (TTP)|Overall survival time (OS):","https://ClinicalTrials.gov/show/NCT02477813"
174,"NCT00077207","Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma","Completed","Has Results","Brain Tumor|Central Nervous System Tumor","Drug: carboplatin|Drug: temozolomide|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 10 Years   (Child)","","66","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACNS0223|CDR0000350005|COG-ACNS0223|NCI-2012-02572","February 10, 2004","July 2004","December 2013","June 30, 2014","June 2014","January 8, 2014","null","March 2010","Short Term Feasibility Success|Long Term Feasibility Success|Occurrence of Toxic Death|Grade 3 or 4 Thrombocytopenia and/or Neutropenia|Progression-free Survival (PFS)|Event-free Survival (EFS)|Response Rate Categorized as Complete Response, Partial Response, Stable Disease, or Progressive Disease","https://ClinicalTrials.gov/show/NCT00077207"
175,"NCT02502708","Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors","Recruiting","No Results Available","Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor|Ependymoma|Medulloblastoma","Drug: Indoximod|Drug: Temozolomide|Radiation: Conformal Radiation","NewLink Genetics Corporation","All","3 Years to 21 Years   (Child, Adult)","Phase 1","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NLG2105","July 6, 2015","October 2015","July 2018","January 9, 2017","January 2017","No Study Results Posted","null","July 2017","Incidence of regimen limiting toxicities (RLTs)|Objective Response Rate|Pharmacokinetics: Serum concentrations (Cmax/Steady State)|Safety and Tolerability of Indoximod combined with Temozolomide as assessed by incidence and severity of adverse events, dose interruptions and dose reductions.|Progression Free Survival (PFS)|Time to Progression|Overall Survival|Safety and Feasibility of Indoximod combined with conformal radiation as assessed by incidence and severity of adverse events, dose interruptions and dose reductions.","https://ClinicalTrials.gov/show/NCT02502708"
176,"NCT00597402","Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas","Completed","Has Results","Glioblastoma|Gliosarcoma|Brain Tumor","Drug: Avastin|Drug: Temozolomide|Radiation: Radiation Therapy (XRT)|Drug: Irinotecan","Duke University|Genentech, Inc.|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","125","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00000458","January 10, 2008","July 2007","May 2013","April 22, 2014","April 2014","December 12, 2012","null","August 2011","16-month Overall Survival (OS)|12-month Progression-free Survival (PFS)|Number of Patients Experiencing a Central Nervous System (CNS) Hemorrhage or a Systemic Hemorrhage|Number of Patients Experiencing a Grade ≥ 4 Hematologic or Grade ≥ 3 Non-hematologic Toxicity","https://ClinicalTrials.gov/show/NCT00597402"
177,"NCT01294735","Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)","Completed","No Results Available","Recurrence of Solid Tumor|Glioblastoma Multiforme|Melanoma","Drug: MK-4827|Drug: Temozolomide","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4827-014","February 10, 2011","February 2011","May 2012","August 14, 2012","August 2012","No Study Results Posted","null","April 2012","Number of participants with DLTs|Number of participants with an objective response rate of partial or complete response|Number of participants with 6-month progression-free survival|Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01294735"
178,"NCT00553150","Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma","Active, not recruiting","Has Results","Brain and Central Nervous System Tumors","Drug: everolimus|Drug: temozolomide|Radiation: radiation","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","122","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N057K|NCI-2009-00654|CDR0000573917","November 2, 2007","March 2009","null","January 11, 2017","January 2017","November 14, 2016","null","January 2012","Maximum Tolerated Dose (MTD) of Everolimus (RAD001) in Combination With Temozolomide (TMZ) and 3D-conformal Radiotherapy (RT) or Intensity-modulated Radiotherapy (IMRT) Followed by Adjuvant TMZ With or Without RAD001 (Phase I)|Overall Survival at 12 Months (Phase II)|Response Rate, as Measured in Patients Receiving FLT-PET Imaging (Phase II)|Time to Progression (Phase II)|Progression-free-survival at 6 Months (Phase II)|Overall Survival Time","https://ClinicalTrials.gov/show/NCT00553150"
179,"NCT00068666","Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System","Terminated","No Results Available","Melanoma (Skin)|Metastatic Cancer","Drug: temozolomide|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","N0274|CDR0000327811|NCI-2012-02554","September 10, 2003","January 2004","March 2010","December 14, 2016","December 2016","No Study Results Posted","null","March 2005","Confirmed response rate|Progression-free survival|Overall survival|Change in performance status","https://ClinicalTrials.gov/show/NCT00068666"
180,"NCT02209948","Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.","Recruiting","No Results Available","Glioblastoma","Drug: Temozolomide","Grupo Español de Investigación en Neurooncología","All","18 Years and older   (Adult, Senior)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEINO 14-01|2014-000838-39","August 4, 2014","August 2014","July 2017","August 10, 2016","August 2016","No Study Results Posted","null","July 2017","Progression free survival at 6 month|Number of Adverse Events|Number of participant without tumor activity|Number of alive patients|Corticosteroids dose|Barthel questionnaire and Minimental test|Participants with MGMT methylation","https://ClinicalTrials.gov/show/NCT02209948"
181,"NCT00409383","Abraxane and Temodar Plus Genasense in Advanced Melanoma","Unknown status","No Results Available","Melanoma","Drug: Genasense® (oblimersen)|Drug: Abraxane® (paclitaxel protein-bound particles for injectable suspension)|Drug: Temodar® (temozolomide)","Genta Incorporated","All","18 Years and older   (Adult, Senior)","Phase 1","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GM108","December 7, 2006","November 2006","June 2013","November 4, 2011","July 2010","No Study Results Posted","null","June 2013","Safety based on adverse event reports and clinical laboratory findings|Response rate (including rate of complete response)|Duration of response (including the rate of durable response)|Time to disease progression|Incidence of brain metastasis|Survival|Correlations of drug concentrations, intracellular Bcl-2 content, and response","https://ClinicalTrials.gov/show/NCT00409383"
182,"NCT01189643","Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor","Active, not recruiting","No Results Available","Sarcoma|Desmoplastic Small Round Cell Tumor (DSRCT)","Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator","Memorial Sloan Kettering Cancer Center|Genentech, Inc.","All","1 Year to 29 Years   (Child, Adult)","","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10-091","August 25, 2010","August 2010","August 2017","June 29, 2016","June 2016","No Study Results Posted","null","August 2017","To define the tolerability|To define adverse event profile|To estimate the response rate of two cycles of irinotecan, temozolomide and bevacizumab|To estimate survival|To estimate time to progression|To assess use of 18FDG PET-CT","https://ClinicalTrials.gov/show/NCT01189643"
183,"NCT00526617","A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients","Completed","No Results Available","Non-hematologic Malignancies|Metastatic Melanoma|Breast Cancer|Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Hepatocellular Carcinoma","Drug: ABT-888|Drug: Temozolomide","Abbott","All","18 Years and older   (Adult, Senior)","Phase 1","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M06-862","September 5, 2007","August 2007","null","January 12, 2012","January 2012","No Study Results Posted","null","June 2010","Maximum Tolerated Dose|Safety and Tolerability|Pharmacokinetic Profile","https://ClinicalTrials.gov/show/NCT00526617"
184,"NCT01499251","Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma","Terminated","No Results Available","Glioblastoma","Drug: Phase 1 Dose Escalation|Drug: Phase 1b|Drug: Ancillary Study","Actelion","All","18 Years and older   (Adult, Senior)","Phase 1","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AC-055-115","December 20, 2011","January 2012","April 2016","May 4, 2016","May 2016","No Study Results Posted","null","January 2016","To determine the maximum tolerated dose of macitentan in combination with dose-dense temozolomide|Number of patients with treatment-emergent adverse events (AEs) and serious AEs|Number of patients with AEs leading to premature discontinuation of study treatment|Incidence of treatment-emergent* marked laboratory abnormalities|Number of patients with treatment-emergent ECG abnormalities|Change from baseline in vital signs|Occurrence of at least grade 2 ALT and/or AST elevation","https://ClinicalTrials.gov/show/NCT01499251"
185,"NCT00194766","Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer|Soft Tissue Sarcoma","Drug: Temozolomide","University of Washington|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","99-1283-A","September 14, 2005","July 2000","December 2006","November 13, 2007","November 2007","No Study Results Posted","null","null","Response rate|Time to disease progression|Survival|To determine the toxicity of the regimen.","https://ClinicalTrials.gov/show/NCT00194766"
186,"NCT00660621","A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma","Unknown status","No Results Available","Glioma","Drug: Temozolomide and Bevacizumab","Kentuckiana Cancer Institute|Eisai Inc.","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KARE004","April 14, 2008","April 2008","December 2010","January 18, 2010","January 2010","No Study Results Posted","KARE004","December 2010","Safety and efficacy of concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide and bevacizumab in subjects undergoing initial surgery for newly-diagnosed high grade glioma.","https://ClinicalTrials.gov/show/NCT00660621"
187,"NCT00039494","Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors","Completed","No Results Available","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma","Drug: erlotinib hydrochloride|Radiation: 3-dimensional conformal radiation therapy|Drug: temozolomide","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","171","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00640|N0177|CDR0000069388|NCCTG-N0177|U10CA025224","June 6, 2002","December 2002","null","August 1, 2013","August 2013","No Study Results Posted","null","July 2007","Survival|Overall survival distribution|Time-to-disease progression|Maximum toxicity grade, assessed by Common Terminology Criteria for Adverse Events (CTCAE)","https://ClinicalTrials.gov/show/NCT00039494"
188,"NCT02023905","Everolimus With and Without Temozolomide in Adult Low Grade Glioma","Recruiting","No Results Available","Low Grade Glioma|WHO Grade II Astrocytomas|Oligodendrogliomas|Mixed Oligoastrocytomas","Drug: Everolimus|Drug: Temozolomide","University of California, San Francisco","All","18 Years and older   (Adult, Senior)","Phase 2","159","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Novartis- CRAD001CUS225T|Cancer Center # 131012","December 24, 2013","February 2014","January 2019","October 27, 2016","October 2016","No Study Results Posted","null","January 2019","Arm 1 & 2 Progression-free survival|Arm 3 progression-free survival","https://ClinicalTrials.gov/show/NCT02023905"
189,"NCT01849146","WEE1 Inhibitor AZD1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma","Recruiting","No Results Available","Adult Glioblastoma|Recurrent Glioblastoma","Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Radiation: Radiation Therapy|Drug: Temozolomide|Drug: WEE1 Inhibitor AZD1775","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","36","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2013-00858|ABTC 1202|ABTC-1202|UM1CA137443","May 6, 2013","August 19, 2013","null","May 24, 2017","May 2017","No Study Results Posted","null","June 15, 2017","Incidence of toxicities, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Maximum tolerated dose of WEE1 inhibitor AZD1775 with 6 weeks of radiotherapy and temozolomide, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Arm I)|Maximum tolerated dose of WEE1 inhibitor AZD1775 with adjuvant temozolomide, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Arm II)|Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT01849146"
190,"NCT01465659","Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery","Recruiting","No Results Available","Pancreatic Alpha Cell Carcinoma|Pancreatic Beta Islet Cell Carcinoma|Pancreatic Delta Cell Carcinoma|Pancreatic G-cell Carcinoma|Recurrent Islet Cell Carcinoma","Drug: temozolomide|Drug: pazopanib hydrochloride","Northwestern University|Robert H. Lurie Cancer Center|National Comprehensive Cancer Network|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","39","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU 11I03|NCI-2011-02939|STU00053541","October 4, 2011","November 2011","August 2018","October 10, 2016","October 2016","No Study Results Posted","null","August 2017","Number of dose limiting toxicities in patients treated with this regimen|Number of patients responding to treatment|Number of toxicity events noted in patients undergoing this treatment.|Amount of pazopanib in the blood at various timepoints after administration|Number of years that patients survive without experiencing disease progression|Number of years that patients survive after undergoing study treatment|Number of patients experiencing response to treatment or stable disease|Number of months that patients maintain a response to treatment until disease progression or death|Determine the Relationship between tumor blood flow and Overall Response Rate|Amount of a particular tumor biomarker in blood as correlated with progression free survival","https://ClinicalTrials.gov/show/NCT01465659"
191,"NCT00052780","Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors","Completed","No Results Available","Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Childhood Mixed Glioma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma","Drug: O6-benzylguanine|Drug: temozolomide|Biological: filgrastim|Other: pharmacological study|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 1","72","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03174|CDR653709|PBTC-005|U01CA081457","January 24, 2003","October 2002","null","September 27, 2013","September 2013","No Study Results Posted","null","November 2007","MTD of temozolomide|Pharmacokinetic parameters|Acute toxicities|Chronic toxicities|Histological response|Duration of disease control|Survival","https://ClinicalTrials.gov/show/NCT00052780"
192,"NCT02385136","Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases","Not yet recruiting","No Results Available","NSCLC","Drug: Temozolomide","Zhejiang Cancer Hospital|Hangzhou Cancer Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","135","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","zjzlyy 2015-1-5","March 3, 2015","April 2015","December 2018","March 10, 2015","March 2015","No Study Results Posted","null","December 2016","objective response rate|Time to central nervous system progress which was confirmed by MRI|The Quality of Life|Overall Survival|Toxicity as measured by CTCAE V4.0","https://ClinicalTrials.gov/show/NCT02385136"
193,"NCT01102595","Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma","Completed","No Results Available","Glioblastomas","Drug: Temozolomide|Drug: Bevacizumab|Radiation: Standard radiation therapy","Grupo Español de Investigación en Neurooncología","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GENOM-009","April 1, 2010","December 2009","December 2014","August 25, 2015","August 2015","No Study Results Posted","null","October 2013","Response Rate|Percentage of patients who finish treatment|Progression-free survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Percentage of patients without neurological deterioration before radiation therapy.|Overall survival","https://ClinicalTrials.gov/show/NCT01102595"
194,"NCT02133677","A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases","Unknown status","No Results Available","Lung Cancer and Breast Cancer Patients With Brain Metastases","Drug: temozolomide 100mg","Far Eastern Memorial Hospital","All","20 Years to 65 Years   (Adult)","Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FEMH-IRB-102072-F","February 5, 2014","May 2014","May 2016","May 6, 2014","February 2014","No Study Results Posted","null","May 2015","objective response rate (ORR)|Progression free survival (PFS)","https://ClinicalTrials.gov/show/NCT02133677"
195,"NCT02248012","Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)","Recruiting","No Results Available","Neuroendocrine Carcinoma","Drug: Everolimus , temozolomide","Haukeland University Hospital|Skåne University Hospital|Copenhagen University Hospital, Denmark|Rigshospitalet, Denmark|Uppsala University Hospital|Aarhus University Hospital|Sahlgrenska University Hospital, Sweden|Ullevaal University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-002524-16","July 24, 2014","December 2014","December 2018","August 16, 2016","August 2016","No Study Results Posted","null","December 2017","Disease control rate|Number of patients with adverse events","https://ClinicalTrials.gov/show/NCT02248012"
196,"NCT00831545","Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)","Completed","No Results Available","Metastases of Central Nervous System|Melanoma|Breast Neoplasm|Carcinoma, Non-Small-Cell Lung","Drug: Temozolomide","Merck Sharp & Dohme Corp.|Quintiles, Inc.","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","162","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","P02064","January 15, 2009","December 1, 2000","October 20, 2006","May 8, 2017","May 2017","No Study Results Posted","null","October 20, 2006","Best response related to brain metastases observed during the study period.|Progression-free survival, brain progression-free survival, and overall survival.|Adverse events according to NCI CTC grading system of toxicity.","https://ClinicalTrials.gov/show/NCT00831545"
197,"NCT02395692","Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma","Active, not recruiting","No Results Available","Adult Brain Glioblastoma","Other: Laboratory Biomarker Analysis|Drug: Methoxyamine|Drug: Temozolomide","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","66","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2015-00356|1402|ABTC-1402|9839|ABTC 1402|UM1CA137443","March 23, 2015","December 18, 2015","null","May 23, 2017","May 2017","No Study Results Posted","null","August 31, 2017","Objective response as assessed by Response Assessment in Neuro-Oncology (RANO) criteria (Arm I)|Objective response rate (PR+CR) as assessed by RANO criteria (Arm II)|Incidence toxicity graded according to the National Cancer Institute CTCAE version 4.0|Overall survival|Progression-free survival|Progression-free survival at 6 months","https://ClinicalTrials.gov/show/NCT02395692"
198,"NCT00385853","PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs","Completed","No Results Available","Glioblastoma","Drug: PTK787/ZK 222584|Drug: Temozolomide|Procedure: Radiation Therapy","Massachusetts General Hospital|Dana-Farber Cancer Institute|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1","19","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-013","October 6, 2006","September 2006","September 2011","October 18, 2013","October 2013","No Study Results Posted","null","September 2011","To determine the maximal tolerated dose, safety and feasibility of PTK787/ZK 222584 in combination with temozolomide and radiation in patients with newly diagnosed glioblastoma.|Determine the pharmacologic profile of PTK787/ZK 222584 in this patient population|determine the overall survival of patients with recurrent GM treated with PTK787/ZK 222584, when combined with temozolomide and radiation therapy.","https://ClinicalTrials.gov/show/NCT00385853"
199,"NCT00768911","CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme","Unknown status","No Results Available","Glioblastoma Multiforme","Drug: CT-322|Drug: Temozolomide|Procedure: Radiation Therapy","Adnexus, A Bristol-Myers Squibb R&D Company","All","18 Years and older   (Adult, Senior)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT-322.003","October 7, 2008","October 2008","June 2011","October 26, 2010","October 2010","No Study Results Posted","null","October 2010","Evaluate the safety and tolerability of CT-322 administered in combination with standard focal brain RT/TMZ to subjects with newly diagnosed GBM|Establish the recommended Phase 2 dose for the QW schedule of CT-322 for use in this combination|To describe the PK of TMZ and its active metabolite (MTIC) when TMZ is administered alone and when it is co-administered with CT-322 to a subset of approximately 12 subjects with newly diagnosed GBM|To describe the peak and trough concentrations of CT-322 when administered alone and when co-administered with TMZ|To evaluate the immunogenicity of CT-322 when administered in combination with standard focal brain RT/TMZ to subjects with newly diagnosed GBM|To characterize the plasma biomarker response to CT-322 when administered in combination with standard focal brain RT/TMZ to subjects with newly diagnosed GBM","https://ClinicalTrials.gov/show/NCT00768911"
200,"NCT00383851","Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma","Unknown status","No Results Available","Melanoma","Drug: ATN-224|Drug: Temozolomide","Attenuon","All","18 Years and older   (Adult, Senior)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ATN-224-008","October 2, 2006","September 2006","September 2008","December 4, 2007","December 2007","No Study Results Posted","null","null","24-week progression-free survival of the combination of temozolomide with ATN 224 and of temozolomide alone|Evaluate the safety of ATN-224 in combination with or following temozolomide|Response rate (complete and partial response), rate of stable disease for ≥24 weeks, and progression-free survival for treatment with the combination of ATN 224 and temozolomide|Response rate (complete and partial response), rate of stable disease for ≥24 weeks, and progression-free survival for treatment with temozolomide alone|Response rate (complete and partial response), rate of stable disease for ≥24 weeks, and progression-free survival for treatment with ATN 224 alone after progression of disease on temozolomide|Time to treatment failure by progression of disease or death for patients receiving ATN 224 plus temozolomide and for patients receiving temozolomide followed by ATN 224|Explore blood and tumor biomarkers with the potential to correlate with activity","https://ClinicalTrials.gov/show/NCT00383851"
201,"NCT01790503","A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma","Active, not recruiting","No Results Available","Patients With Newly Diagnosed Glioblastoma","Drug: PLX3397|Radiation: Radiation Therapy|Drug: Temozolomide","Plexxikon","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","PLX108-08","February 7, 2013","August 2013","August 2018","April 25, 2017","April 2017","No Study Results Posted","null","August 2017","Phase 1b dose escalation: Identification of Recommended Phase 2 Dose (RP2D)|Phase 2: Efficacy, Comparison of median Progression Free Survival (PFS) to historical control (median PFS of 5.5 months from the RTOG 0525 study)|Efficacy-Overall Survival|Safety-Subject incidence of adverse events|Pharmacokinetic profile (PK)","https://ClinicalTrials.gov/show/NCT01790503"
202,"NCT02330991","A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse","Not yet recruiting","No Results Available","Glioblastoma","Drug: Temozolomide","Beijing Sanbo Brain Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","204","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014062501","December 30, 2014","January 2015","December 2017","January 1, 2015","January 2015","No Study Results Posted","null","December 2016","Progress-Free Survival at 6 months (PFS6)|Overall Survival(OS)|Progression free survival|Objective Response Rate|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT02330991"
203,"NCT00521001","Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery","Completed","Has Results","Melanoma (Skin)","Drug: everolimus|Drug: temozolomide","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","49","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N0675|NCI-2012-02713|CDR0000562166","August 24, 2007","January 2008","December 2010","January 17, 2017","January 2017","January 17, 2017","null","December 2009","9-week Progression-free Survival Rate|Survival Time|Time to Disease Progression|Confirmed Response Rate (Complete Response and Partial Response)","https://ClinicalTrials.gov/show/NCT00521001"
204,"NCT02661113","Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma: Phase II","Withdrawn","No Results Available","Glioblastoma|CNS Disease|Brain Diseases","Drug: Dasatinib|Radiation: RT (Radiotherapy)|Drug: TMZ (Temozolomide)","M.D. Anderson Cancer Center|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-0318 Phase II","January 19, 2016","May 2009","August 2013","January 22, 2016","January 2016","No Study Results Posted","null","August 2013","Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02661113"
205,"NCT00274833","Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","CNS Tumor, Adult","Drug: erlotinib hydrochloride|Drug: temozolomide|Radiation: radiation therapy","David Peereboom|National Cancer Institute (NCI)|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","27","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE3304|P30CA043703|CCF-6320","January 10, 2006","October 2005","September 2012","December 5, 2012","December 2012","No Study Results Posted","null","October 2007","Progression-free survival|Progression Free Survival|Number of patients that experience toxicity (CTCAE V2)|Overall Survival","https://ClinicalTrials.gov/show/NCT00274833"
206,"NCT00895960","Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma","Terminated","No Results Available","Glioblastoma|CNS Disease|Brain Diseases","Drug: Dasatinib|Radiation: RT (Radiotherapy)|Drug: TMZ (Temozolomide)","M.D. Anderson Cancer Center|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 1","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-0318","May 7, 2009","May 2009","August 2013","January 19, 2016","January 2016","No Study Results Posted","null","August 2013","Maximum tolerated dose (MTD)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT00895960"
207,"NCT00638963","Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)","Terminated","Has Results","Breast Neoplasm|Brain Neoplasm|Second Neoplasm","Drug: temozolomide","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","P05225|2007-005491-14","January 10, 2008","October 2008","June 2010","January 19, 2015","January 2015","June 23, 2011","STOP","June 2010","Percent of Participants With Recurrence of Brain Metastases|Number of Days With Progression-free Survival (PFS)|Number of Days With Disease-free Survival (DFS)|Number of Days With Distant Disease-free Survival (DDFS)|Number of Days With Brain Recurrence-free Survival (BRFS)|Number of Days on Temozolomide Treatment|Total Dose of Temozolomide Taken|Number of Participants Who Had at Least One Dose Reduction During Treatment|Number of Participants Who Had at Least One Treatment Omission During Treatment|Number of Participants Who Completed the Third Cycle of Treatment","https://ClinicalTrials.gov/show/NCT00638963"
208,"NCT01043536","Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults","Completed","No Results Available","Glioblastoma","Radiation: radiotherapy|Drug: temozolomide","Centre Georges Francois Leclerc|Ligue contre le cancer, France","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0244-1blni08 / 009.020","January 5, 2010","September 2009","null","September 24, 2012","September 2012","No Study Results Posted","SIB-IMRT","January 2012","To determine the OTR (optimal tolerated regimen) of radiotherapy administered in combination with temozolomide as first-line therapy in patients with de novo glioblastoma","https://ClinicalTrials.gov/show/NCT01043536"
209,"NCT01857752","Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala","Terminated","No Results Available","Retinoblastoma","Drug: Temozolomide","Stanford University","All","up to 21 Years   (Child, Adult)","Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","PEDSEYE0003|22753","March 25, 2013","March 2012","June 2015","January 26, 2017","January 2017","No Study Results Posted","null","June 2015","Response rate|Evaluate the toxicity suffered during each cycle of temozolamide will be evaluated using the CTCAE v3.0","https://ClinicalTrials.gov/show/NCT01857752"
210,"NCT02227901","Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma","Drug: Tipifarnib|Radiation: External Beam Radiation Therapy|Drug: Temozolomide|Other: Laboratory Biomarker Analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","19","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2014-01809|NCI-03-C-0189|NABTC-0202|NABTC02-02|NABTC-02-02|U01CA062399","August 26, 2014","September 2002","April 2014","December 19, 2014","September 2014","No Study Results Posted","null","June 2007","Dose limiting toxicity (DLT) of tipifarnib, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0|MTD of tipifarnib, defined as the dose level at which 0 or 1/6 patients experience DLT with the next higher dose having at least 2/3 or 2/6 patients encountering DLT, graded according to the NCI CTCAE v4.0|Incidence of adverse events of tipifarnib in combination with EBRT and temozolomide, graded according to the NCI CTCAE v4.0|Anti-tumor activity of tipifarnib","https://ClinicalTrials.gov/show/NCT02227901"
211,"NCT02231762","Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET","Active, not recruiting","No Results Available","Gastroenteropancreatic Neuroendocrine Tumors","Drug: Lanreotide Autogel 120 mg|Drug: Temozolomide (TMZ)","Ipsen","All","18 Years and older   (Adult, Senior)","Phase 2","57","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","A-94-52030-268|2013‐001697‐17","September 2, 2014","October 2014","June 2017","February 17, 2017","February 2017","No Study Results Posted","SONNET","December 2016","Disease control rate after 6 months|Disease control rate after 12 months|Time to disease progression or death|Percentage of patients with normalized and stabilized Chromogranin A (CgA) levels after 6 months|Percentage of patients with normalized and stabilized CgA-levels after 12 months|Time to partial response within 12 months|Time to complete response within 12 months|Duration of partial response within 12 months|Duration of complete response within 12 months|Percentage change (greater than or equal to 50%) from baseline in CgA reduction at 12 months|Change from baseline in frequency of symptomatic episodes of diarrhoea after 6 months|Change from baseline in frequency of symptomatic episodes of flushing after 6 months|Change from baseline in frequency of symptomatic episodes of diarrhoea after 12 months|Change from baseline in frequency of symptomatic episodes of flushing after 12 months|Change from baseline in Quality of Life (QoL)","https://ClinicalTrials.gov/show/NCT02231762"
212,"NCT02116777","Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies","Recruiting","No Results Available","Adult Solid Neoplasm|Childhood Solid Neoplasm|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Malignant Solid Neoplasm|Refractory Central Nervous System Neoplasm","Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Talazoparib|Drug: Temozolomide","National Cancer Institute (NCI)","All","13 Months to 30 Years   (Child, Adult)","Phase 1|Phase 2","148","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2014-00804|ADVL1411|UM1CA097452","April 15, 2014","May 16, 2014","null","May 24, 2017","May 2017","No Study Results Posted","null","October 31, 2018","Best response of disease to talazoparib plus temozolomide in Ewing sarcoma or peripheral PNET patients determined according to RECIST v1.1 (Phase II Parts B and C)|Best response of disease to talazoparib plus temozolomide in patients with ALL using the leukemia rating scale and peripheral blood counts (Phase II Parts B and C)|Incidence of toxicities, graded using the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 (Phase II Parts B and C)|MTD of talazoparib and temozolomide, defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicities (Phase I Part A1)|Objective response in patients with Ewing sarcoma or peripheral PNET assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and criteria for CNS tumors (Phase I Part A2)|Pharmacokinetic (PK) parameters of talazoparib (Phase I Part A)","https://ClinicalTrials.gov/show/NCT02116777"
213,"NCT01005472","Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma","Active, not recruiting","No Results Available","Metastatic Melanoma","Drug: sunitinib malate|Drug: temozolomide","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","48","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000634373|P30CA016042|UCLA-0711052|SPRI-P05513|PFIZER-GA6181FZ|10-001406","October 30, 2009","December 2008","July 2017","October 19, 2016","February 2016","No Study Results Posted","null","July 2012","Maximum tolerated dose of sunitinib malate when administered concurrently with temozolomide (Phase I)|Overall safety|Response rate as assessed by modified RECIST criteria (phase II)|Response rate as assessed by modified RECIST criteria (Phase I)|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01005472"
214,"NCT00026494","Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases","Completed","Has Results","Metastatic Cancer","Drug: temozolomide|Drug: vinorelbine tartrate","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Northwestern Memorial Hospital","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","49","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-088|MSKCC-01088A|NCI-G01-2025","November 9, 2001","July 2001","April 2008","December 15, 2015","December 2015","December 15, 2015","null","April 2008","Radiographic Response Assessed by Macdonald Criteria Every 2 Months","https://ClinicalTrials.gov/show/NCT00026494"
215,"NCT00505635","Biochemotherapy With Temozolomide for Metastatic Melanoma","Terminated","Has Results","Melanoma","Drug: Temozolomide|Drug: Velban|Drug: Cisplatin|Drug: Interleukin-2|Drug: Intron-A|Drug: Thalidomide","M.D. Anderson Cancer Center","All","18 Years to 65 Years   (Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM03-0218","July 20, 2007","March 2007","April 2010","May 16, 2016","March 2012","March 26, 2012","null","April 2010","Time to Progression (TTP)|Number of Participants With Response","https://ClinicalTrials.gov/show/NCT00505635"
216,"NCT01076530","Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors","Completed","No Results Available","Childhood Atypical Teratoid/Rhabdoid Tumor|Childhood Central Nervous System Choriocarcinoma|Childhood Central Nervous System Embryonal Tumor|Childhood Central Nervous System Germinoma|Childhood Central Nervous System Mixed Germ Cell Tumor|Childhood Central Nervous System Teratoma|Childhood Central Nervous System Yolk Sac Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Childhood Mixed Glioma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Extra-adrenal Paraganglioma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Central Nervous System Embryonal Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Spinal Cord Neoplasm|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma","Drug: vorinostat|Drug: temozolomide|Other: diagnostic laboratory biomarker analysis|Other: pharmacological study","National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 1","27","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02011|ADVL0819|CDR0000664388|COG-ADVL0819|U01CA097452","February 25, 2010","February 2010","null","May 1, 2013","May 2013","No Study Results Posted","null","October 2012","Maximum tolerated dose defined as the maximum dose at which fewer than one-third of patients experience DLT using NCI CTCAE version 4.0|Pharmacokinetic parameters of vorinostat in combination with temozolomide|Response assessed according to RECIST criteria","https://ClinicalTrials.gov/show/NCT01076530"
217,"NCT00114140","Temozolomide and Radiation Therapy in Treating Patients With Gliomas","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years and older   (Adult, Senior)","Phase 2","136","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG 0424|CDR0000434849|NCI-2009-00723","June 13, 2005","January 2005","null","October 19, 2016","October 2016","No Study Results Posted","null","February 2013","Overall survival at 3 years.|Progression-free survival|Association of survival and progression-free survival with MGMT methylation status|Quality of life|Neurocognitive function","https://ClinicalTrials.gov/show/NCT00114140"
218,"NCT01139970","Veliparib and Temozolomide in Treating Patients With Acute Leukemia","Active, not recruiting","No Results Available","Accelerated Phase of Disease|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A|Adult Acute Promyelocytic Leukemia With PML-RARA|Adult B Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Adult T Acute Lymphoblastic Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Blastic Phase|Chronic Myelomonocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Disease|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia","Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Temozolomide|Drug: Veliparib","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","66","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-01457|GCC 0940|CDR0000674355|JHUJ1051|JHUJ1051; GCC 0940|8456|N01CM00071|N01CM62201|P30CA006973|U01CA062502|U01CA070095","June 8, 2010","May 21, 2010","null","May 23, 2017","November 2016","No Study Results Posted","null","March 21, 2014","MTD of veliparib, determined according to incidence of dose limiting toxicity, graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Average change from baseline level in RAD51 foci|Average change from baseline level in y-H2AX foci|Average expression of MGMT|Changes in levels of poly(ADP-ribose) (PAR)|Double strand break (DSB) repair|Non-homologous end joining repair|Response rate at the MTD, assessed using revised International Working Group response criteria","https://ClinicalTrials.gov/show/NCT01139970"
219,"NCT00077454","Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors","Completed","No Results Available","Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Brain Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Medulloblastoma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Neuroblastoma|Recurrent Osteosarcoma","Drug: erlotinib hydrochloride|Drug: temozolomide|Other: pharmacological study|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 1","95","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01808|ADVL0214|CDR0000350336|COG-ADVL0214|NCI-04-C-0256|U01CA097452","February 10, 2004","February 2004","null","June 4, 2013","June 2013","No Study Results Posted","null","September 2007","Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0|Maximum-tolerated dose (MTD) based on the incidence of DLT as assessed by NCI CTCAE version 3.0|Pharmacokinetics of erlotinib hydrochloride","https://ClinicalTrials.gov/show/NCT00077454"
220,"NCT00104988","S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery","Completed","No Results Available","Melanoma (Skin)","Drug: temozolomide|Drug: thalidomide","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","64","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000412048|S0508|U10CA032102","March 3, 2005","June 2005","August 2009","August 20, 2012","August 2012","No Study Results Posted","null","July 2007","Progression-free survival at 6 months|Objective response (confirmed and unconfirmed complete and partial responses)|6-month overall survival","https://ClinicalTrials.gov/show/NCT00104988"
221,"NCT01435395","Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme","Completed","No Results Available","Glioblastoma Multiforme","Drug: Temozolomide, bevacizumab and bortezomib","Emory University|Schering-Plough|Genentech, Inc.|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00014595|WCI1837-10","September 14, 2011","December 2011","April 2016","April 25, 2016","April 2016","No Study Results Posted","null","April 2016","Determination of progressive disease, complete or partial responses|Assess the time to progression","https://ClinicalTrials.gov/show/NCT01435395"
222,"NCT00003466","Temozolomide in Treating Patients With Progressive Low-Grade Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide","Duke University|National Cancer Institute (NCI)","All","4 Years and older   (Child, Adult, Senior)","Phase 2","100","Other|NIH","Interventional","Primary Purpose: Treatment","1703 (CDR0000066502)|DUMC-1703-04-12R7|DUMC-000693-01-3R1|DUMC-1703-01-94R|DUMC-1502-97-10|DUMC-1569-98-10R1|DUMC-97125|NCI-G98-1469|DUMC-1703-02-9R5","November 1, 1999","March 1998","July 2005","July 7, 2014","February 2013","No Study Results Posted","null","July 2005","Response rate|Activity of temozolomide","https://ClinicalTrials.gov/show/NCT00003466"
223,"NCT02649582","Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients","Recruiting","No Results Available","Glioblastoma Multiforme of Brain","Biological: Dendritic cell vaccine plus temozolomide chemotherapy","University Hospital, Antwerp","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCRG14-001","January 23, 2015","December 2015","December 2019","October 28, 2016","October 2016","No Study Results Posted","ADDIT-GLIO","December 2017","Overall survival|Number of glioblastoma patients post surgical resection with feasible and safe DC vaccine production|Feasibility of DC vaccine administration to glioblastoma patients combined with chemotherapy|Number of participants with adverse events as a measure of safety and tolerability|Immunological responses to the DC vaccine|Objective clinical responses by tumor evaluation (clinical efficacy)","https://ClinicalTrials.gov/show/NCT02649582"
224,"NCT00946335","ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors","Completed","No Results Available","Childhood Atypical Teratoid/Rhabdoid Tumor|Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Childhood Mixed Glioma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Brain Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Spinal Cord Neoplasm|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma","Drug: veliparib|Drug: temozolomide|Other: pharmacological study|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 1","31","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03177|CDR649727|PBTC-027|U01CA081457","July 24, 2009","July 2009","June 2014","July 7, 2014","June 2014","No Study Results Posted","null","October 2011","MTD or recommended phase II dose of veliparib|Acute toxicities|Chronic toxicities|Plasma drug concentrations and pharmacokinetic parameters, including volume of the central compartment (Vc/F), elimination rate constant (Ke), half-life (t1/2), apparent oral clearance (CL/F), and area under the plasma concentration time curve (AUC)","https://ClinicalTrials.gov/show/NCT00946335"
225,"NCT00998010","Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: bortezomib + temozolomide+ radiation therapy","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000657015|P30CA016042|UCLA-X05303|09-03-084|MILLENNIUM-UCLA-X05303|11-002222","October 17, 2009","June 2011","null","November 8, 2016","January 2016","No Study Results Posted","null","December 2017","Overall survival|Toxicity assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.|Time to progression|Survival at 1 year|Tumor response as assessed by MRI and neurologic exam","https://ClinicalTrials.gov/show/NCT00998010"
226,"NCT00100802","Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas","Active, not recruiting","Has Results","Brain Tumors|Central Nervous System Tumors","Drug: lomustine|Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","118","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACNS0423|CDR0000407744|COG-ACNS0423|NCI-2012-02645|U10CA098543","January 6, 2005","July 2005","null","January 12, 2017","November 2016","November 18, 2016","null","September 2012","One Year Overall Survival|Occurrence of Death Attributable to Complications of Protocol Therapy","https://ClinicalTrials.gov/show/NCT00100802"
227,"NCT02044120","ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma","Recruiting","No Results Available","Ewing Sarcoma","Drug: niraparib|Drug: Temozolomide|Drug: Irinotecan","Sarcoma Alliance for Research through Collaboration","All","13 Years and older   (Child, Adult, Senior)","Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ESP1/SARC025","January 21, 2014","May 2014","February 2019","January 19, 2017","January 2017","No Study Results Posted","null","February 2018","Dose-limiting toxicity and maximum tolerated dose|Tumor response rate of patients treated with niraparib and temozolomide.|Progression-free survival at 4 and 6 months of patients treated with niraparib and temozolomide","https://ClinicalTrials.gov/show/NCT02044120"
228,"NCT00528437","Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors","Completed","No Results Available","Brain Tumors","Drug: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid","New York University School of Medicine|Children's Hospitals and Clinics of Minnesota|Schneider Children's Hospital","All","6 Months to 21 Years   (Child, Adult)","Phase 2","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NYU 05-40 H12853|PBMTC ONC-032P","September 10, 2007","October 2005","August 2015","January 25, 2016","January 2016","No Study Results Posted","null","August 2015","• To assess the event-free survival and overall survival of patients with recurrent or refractory medulloblastoma/ primitive neuroectodermal tumors|To evaluate the toxicity of of 13-cis-retinoic acid following high dose temozolomide, thiotepa and carboplatin with ASCR.","https://ClinicalTrials.gov/show/NCT00528437"
229,"NCT01285414","Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Glioblastoma Multiforme","Drug: Verubulin|Drug: Temozolomide & Radiation Therapy","Myrexis Inc.","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MPC-6827-021","January 14, 2011","December 2010","March 2012","April 10, 2012","April 2012","No Study Results Posted","null","March 2012","Part A: Safety|Part B: 9 Mo Progression-free survival|Part A: Pharmacokinetic Parameters|Part B: 6 Mo Progression Free Survival|Overall Survival|Part B: 12 Mo Progression Free Survival","https://ClinicalTrials.gov/show/NCT01285414"
230,"NCT00960492","Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma","Completed","No Results Available","Glioblastoma|Giant Cell Glioblastoma|Gliosarcoma","Drug: XL184|Drug: temozolomide|Drug: temozolomide|Radiation: Radiation Therapy|Drug: temozolomide","Exelixis","All","18 Years and older   (Adult, Senior)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XL184-002","August 13, 2009","September 2009","October 2013","September 19, 2014","September 2014","No Study Results Posted","null","November 2012","Evaluate the safety and tolerability of oral administration of XL184 added to first-line treatment for subjects with newly diagnosed GB|Determine the maximum tolerated dose (MTD) of oral XL184 when added to the concurrent phase of treatment with TMZ and RT and when added to the maintenance phase of treatment with TMZ for subjects with newly diagnosed GB|Determine the safety and tolerability of XL184 when administered in combination with first-line treatment throughout the concurrent, rest and maintenance phases in an expanded MTD cohort|Evaluate the plasma pharmacokinetics of XL184 and TMZ when XL184 is administered in combination with TMZ, and of XL184 when it is administered alone, in subjects with newly diagnosed GB|Evaluate the pharmacodynamic effects of XL184 (with or without TMZ) and RT in the first line treatment of subjects with GB.|Evaluate the preliminary efficacy of XL184 (with or without TMZ) and RT in the MTD expansion cohort in the first line treatment of subjects with GB","https://ClinicalTrials.gov/show/NCT00960492"
231,"NCT00591370","Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma","Completed","Has Results","Melanoma","Drug: Temozolomide (TMZ)","Memorial Sloan Kettering Cancer Center|Schering-Plough","All","16 Years and older   (Child, Adult, Senior)","Phase 2","51","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-138","December 26, 2007","January 2005","June 2008","October 17, 2015","October 2015","January 8, 2015","null","June 2008","Determine the Overall Objective Response Rate (CR and PR).|Overall Survival|Duration of Objective Clinical Responses","https://ClinicalTrials.gov/show/NCT00591370"
232,"NCT01217437","Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors","Active, not recruiting","No Results Available","Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified","Biological: Bevacizumab|Drug: Irinotecan Hydrochloride|Drug: Temozolomide","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 2","120","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-02605|CDR0000686608|ACNS0821|COG-ACNS0821|U10CA180886|U10CA098543","October 7, 2010","November 22, 2010","null","May 23, 2017","May 2017","No Study Results Posted","null","June 30, 2017","Overall survival for each treatment arm|Event-free survival|Response rate for each treatment arm","https://ClinicalTrials.gov/show/NCT01217437"
233,"NCT01907165","Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide","Active, not recruiting","No Results Available","Glioblastoma","Drug: Temozolomide|Drug: Disulfiram|Dietary Supplement: Copper gluconate","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Early Phase 1","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201308038","July 19, 2013","October 10, 2013","March 31, 2018","March 14, 2017","March 2017","No Study Results Posted","null","November 10, 2016","Pharmacological effect of disulfiram in GBM patients|Local tumor control probabilities|Time to tumor progression","https://ClinicalTrials.gov/show/NCT01907165"
234,"NCT00404495","Combination of Irinotecan and Temozolomide in Children With Brain Tumors.","Completed","Has Results","Glioma|Medulloblastoma","Drug: Irinotecan|Drug: Temozolomide","Pfizer","All","6 Months to 18 Years   (Child, Adult)","Phase 2","83","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A5961166","November 27, 2006","April 2007","December 2011","April 16, 2012","April 2012","January 13, 2012","null","January 2011","Percentage of Participants With Objective Response of Complete Response or Partial Response|Percentage of Participants With Objective Response of Complete Response or Partial Response, Investigator's Assessment|Duration of Response|Time to Treatment Failure (TTF)|Time to Tumor Progression (TTP)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00404495"
235,"NCT01466686","Low Dose Radiation Therapy for Glioblastoma Multiforme","Recruiting","No Results Available","High Grade Glioma","Radiation: Low Dose Fractionated Radiation Therapy (LDFRT)|Drug: Temozolomide","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J11120|NA_00065863","November 3, 2011","September 2012","May 2017","September 20, 2016","September 2016","No Study Results Posted","null","May 2017","Response Rate|Time to Progression|Overall Survival Rate|Hematologic Toxicity|Radiation-Associated Long-Term Toxicity","https://ClinicalTrials.gov/show/NCT01466686"
236,"NCT01638546","Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer","Completed","No Results Available","Recurrent Small Cell Lung Carcinoma","Other: Laboratory Biomarker Analysis|Other: Placebo|Drug: Temozolomide|Drug: Veliparib","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","110","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","NCI-2012-01130|IRB #12-021|12-021|CDR0000737062|9026|N01CM00039|P30CA008748|U01CA070095|UM1CA186691","July 9, 2012","June 2012","January 2017","February 9, 2017","February 2017","No Study Results Posted","null","January 2017","Progression-free survival, calculated as the proportion of patients alive and without evidence of disease|Incidence of adverse events, tabulated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.|ORR by RECIST 1.1 criteria|Overall survival","https://ClinicalTrials.gov/show/NCT01638546"
237,"NCT02667587","An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)","Recruiting","No Results Available","Brain Neoplasms","Drug: Nivolumab|Drug: Temozolomide|Radiation: Radiotherapy|Other: Nivolumab Placebo","Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd","All","18 Years and older   (Adult, Senior)","Phase 2","320","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","CA209-548|2015-004722-34","January 26, 2016","May 2016","November 2020","April 17, 2017","April 2017","No Study Results Posted","CheckMate548","August 2018","Overall survival defined as time from the date of randomization to the date of death.|Progression free survival, defined as the time from randomization to the date of the first documented tumor progression or death to any cause.","https://ClinicalTrials.gov/show/NCT02667587"
238,"NCT02416999","Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas","Not yet recruiting","No Results Available","Recurrent High-grade Glioma","Drug: Ultra-low dose Bevacizumab|Drug: Temozolomide","Hebei Yanda Hospital|Beijing Tiantan Hospital","All","18 Years to 70 Years   (Adult, Senior)","","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","YDCR-2015-001","April 1, 2015","May 2015","May 2018","February 17, 2016","February 2016","No Study Results Posted","null","May 2018","6-month survival rate of recurrent glioblastoma multiforme patients under ultra-low dose Bevacizumab plus Temozolomide treatment|12-month survival rate of recurrent WHO-III glioma patients under ultra-low dose Bevacizumab plus Temozolomide treatment|Overall survival of recurrent glioblastoma multiforme patients under ultra-low dose Bevacizumab plus Temozolomide treatment|Overall survival of recurrent WHO-III glioma patients under ultra-low dose Bevacizumab plus Temozolomide treatment|Progression free survival of recurrent glioblastoma multiforme patients under ultra-low dose Bevacizumab plus Temozolomide treatment|Progression free survival of recurrent WHO-III glioma patients under ultra-low dose Bevacizumab plus Temozolomide treatment|6-month life quality as measured by European Organization for the Research and Treatment of Cancer Quality of Life questionnaires(EORTC QLQ-C30 and EORTC QLQ-BN20 together)|12-month life quality as measured by European Organization for the Research and Treatment of Cancer Quality of Life questionnaires(EORTC QLQ-C30 and EORTC QLQ-BN20 together)","https://ClinicalTrials.gov/show/NCT02416999"
239,"NCT00916409","Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)","Completed","No Results Available","Glioblastoma Multiforme","Device: NovoTTF-100A device|Drug: Temozolomide","NovoCure Ltd.","All","18 Years and older   (Adult, Senior)","Phase 3","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","EF-14","June 5, 2009","June 2009","March 2017","April 7, 2017","April 2017","No Study Results Posted","null","December 2016","Progression Free Survival (PFS) time|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT00916409"
240,"NCT01740258","Bevacizumab Beyond Progression (BBP)","Active, not recruiting","No Results Available","Malignant Glioma|Grade 4 Malignant Glioma|Glioblastoma|Gliosarcoma","Radiation: Radiation Therapy|Drug: Temozolomide|Drug: Bevacizumab","Duke University|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","68","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Pro00038098","November 30, 2012","January 2013","December 2019","January 27, 2017","January 2017","No Study Results Posted","BBP","December 2019","Overall Survival|Describe Toxicity|Progression-free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01740258"
241,"NCT00262730","Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","Has Results","Glioblastoma Multiforme","Drug: poly ICLC|Drug: temozolomide|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","97","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NABTT-0501 CDR0000454915|U01CA062475|NABTT-0501","December 6, 2005","January 2006","April 2010","June 16, 2014","June 2014","March 22, 2013","null","August 2009","Survival","https://ClinicalTrials.gov/show/NCT00262730"
242,"NCT02263105","Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas","Recruiting","No Results Available","High-grade Gliomas","Drug: CDDP|Drug: Temozolomide","Huashan Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CAT001|Huashan H","September 28, 2014","October 2014","December 2017","May 12, 2017","May 2017","No Study Results Posted","null","October 2017","progression free survival (PFS)|overall survival(OS)","https://ClinicalTrials.gov/show/NCT02263105"
243,"NCT00544284","Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment","Completed","No Results Available","Brain and Central Nervous System Tumors|Lymphoma|Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: bortezomib|Drug: temozolomide|Other: pharmacological study","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04032|P30CA033572|CHNMC-04032|CDR0000570245","October 13, 2007","January 2005","January 2012","February 14, 2013","February 2013","No Study Results Posted","null","January 2012","Dose-limiting toxicity and maximum tolerated dose|Pharmacokinetics|Confirmed complete or partial response|Percentage of patients with 6-month progression-free survival","https://ClinicalTrials.gov/show/NCT00544284"
244,"NCT00689221","Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status","Completed","Has Results","Glioblastoma","Drug: Cilengitide|Drug: Temozolomide|Radiation: Radiotherapy","EMD Serono|European Organisation for Research and Treatment of Cancer - EORTC|Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 3","545","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMD 121974-011|EORTC 26071-22072|2007-004344-78","May 29, 2008","September 2008","August 2013","October 28, 2014","October 2014","August 28, 2014","CENTRIC","November 2012","Overall Survival (OS) Time|Progression Free Survival (PFS) Time - Investigator and Independent Read|Maximum Observed Plasma Concentration (Cmax)|Time to Maximum Plasma Concentration (Tmax)|Area Under the Plasma Concentration Curve From Time 0 to 6 Hours (AUC [0-6]) After Dose|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Brain Module (EORTC QLQ-BN20) Sub-scale Scores|EuroQol 5-Dimensions (EQ-5D) Questionnaire Index|Number of Participants With Change From Baseline in Work Status at End of Study|Number of Participants With Adverse Events (AEs), Serious AEs, Treatment-Related AEs, Treatment-Related Serious AEs, AEs Leading to Death, Treatment Related AEs Leading to Death, AEs of Grade 3 or 4 and Treatment Related AEs of Grade 3 or 4|Number of Participants With AEs Belonging to Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs) Thromboembolic Events and Hemorrhage With NCI−CTC Toxicity Grade 3 or 4|Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) and Lab Parameters","https://ClinicalTrials.gov/show/NCT00689221"
245,"NCT00147160","Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents","Completed","No Results Available","Glioma","Drug: Temozolomide, Cisplatinum","Gustave Roussy, Cancer Campus, Grand Paris","All","4 Years to 21 Years   (Child, Adult)","Phase 2","87","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CISTEM2|CSET-2002/978","September 6, 2005","October 2003","December 2007","April 10, 2012","September 2006","No Study Results Posted","null","July 2006","Radiological response after two courses of Temozolomide-Cisplatinum|Progression-free survival|Health status and quality of life|Toxicity","https://ClinicalTrials.gov/show/NCT00147160"
246,"NCT01822275","Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme","Recruiting","No Results Available","Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)","Drug: Chemotherapy with Temodar.|Radiation: Radiation therapy","University of Maryland","All","18 Years and older   (Adult, Senior)","Phase 2","47","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HP-00053043","March 22, 2013","May 2013","December 2018","December 5, 2016","December 2016","No Study Results Posted","GCC 1224","December 2017","Efficacy of low-dose whole brain RT (WBRT)in patients with GBM|Radiographic (CT-MRI) response assesment and treatment failure patterns of patients with GBM","https://ClinicalTrials.gov/show/NCT01822275"
247,"NCT02494804","Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas","Not yet recruiting","No Results Available","Cytokine-Induced Killer Cells|Milignant Gliomas","Drug: Temozolomide|Biological: CIK","The First People's Hospital of Changzhou","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","GLICIK001","July 8, 2015","July 2015","July 2030","July 8, 2015","July 2015","No Study Results Posted","null","July 2028","Overall survival|Adverse events","https://ClinicalTrials.gov/show/NCT02494804"
248,"NCT02496988","Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas","Not yet recruiting","No Results Available","Cytokine-Induced Killer Cells|Advanced Milignant Gliomas","Drug: Temozolomide|Biological: CIK","The First People's Hospital of Changzhou","All","18 Years to 80 Years   (Adult, Senior)","Phase 4","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","GLICIK002","July 10, 2015","July 2015","July 2030","July 13, 2015","July 2015","No Study Results Posted","null","July 2028","Overall survival|Adverse events","https://ClinicalTrials.gov/show/NCT02496988"
249,"NCT02392793","Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies","Recruiting","No Results Available","Childhood Solid Tumors","Drug: Talazoparib|Drug: Irinotecan|Drug: Temozolomide|Drug: Filgrastim|Drug: Peg-filgrastim","St. Jude Children's Research Hospital|BioMarin Pharmaceutical|Alliance Pharma|Pfizer","All","12 Months to 25 Years   (Child, Adult)","Phase 1","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BMNIRN|NCI-2015-00255","March 6, 2015","March 25, 2015","March 31, 2020","March 31, 2017","February 2017","No Study Results Posted","null","October 31, 2019","Maximum tolerated dose (MTD) of talazoparib combined with irinotecan|Dose-limiting toxicities (DLT) of talazoparib combined with irinotecan|Maximum tolerated dose (MTD) of temozolomide combined with talazoparib|Dose-limited toxicities (DLT) of combination therapy with temozolomide, talazoparib and irinotecan|Response rate|Irinotecan Cmax|Talazoparib Cmax|Irinotecan AUC|Talazoparib AUC|Irinotecan Clearance|Talazoparib Clearance|Irinotecan Tmax|Talazoparib Tmax|Irinotecan t1/2|Talazoparib t1/2","https://ClinicalTrials.gov/show/NCT02392793"
250,"NCT01977677","Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma","Recruiting","No Results Available","Adult Ependymoblastoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Medulloblastoma|Adult Mixed Glioma|Adult Oligodendroglial Tumors|Adult Pineoblastoma|Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)","Radiation: radiation therapy|Drug: temozolomide|Drug: plerixafor|Other: laboratory biomarker analysis|Other: pharmacological study","Stanford University|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","29","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BRN0023|NCI-2013-02012|P30CA124435","October 31, 2013","July 2014","null","November 8, 2016","November 2016","No Study Results Posted","null","July 2017","Dose-limiting toxicity, defined as the absence of cardiac arrhythmia measured by electrocardiogram (ECG) or grade III or IV adverse events, using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Progression free survival based on the Response Assessment for Neuro-Oncology (RANO) criteria, using both clinical examinations and MRIs with and without contrast","https://ClinicalTrials.gov/show/NCT01977677"
251,"NCT00005954","Temozolomide in Treating Patients With Brain Metastases","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide","Duke University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","2114|DUMC-2114-02-12R3|NCI-G00-1798|CDR0000067934","July 5, 2000","August 2000","June 2003","June 19, 2013","October 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005954"
252,"NCT00588341","Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection","Completed","Has Results","Melanoma|Skin Cancer|Cancer","Drug: Temozolomide","Memorial Sloan Kettering Cancer Center|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-076","December 26, 2007","September 2005","March 2009","December 22, 2015","December 2015","December 22, 2015","null","March 2009","Overall Objective Response (Complete Response or Partial Response)","https://ClinicalTrials.gov/show/NCT00588341"
253,"NCT01812603","A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma","Completed","No Results Available","Cancer","Drug: Sativex","GW Research Ltd","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GWCA1208 Part A","March 14, 2013","September 2013","June 2016","August 10, 2016","August 2016","No Study Results Posted","null","January 2015","The incidence of adverse events in patients receiving Sativex in combination with dose-intense Temozolomide in the open-label phase of the study|The number of patients with Progression Free Survival at six months (PFS6)|Overall Survival","https://ClinicalTrials.gov/show/NCT01812603"
254,"NCT00613028","Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan","Completed","Has Results","Glioblastoma|Gliosarcoma","Drug: Temo + Avastin|Drug: VP-16 + Avastin","Duke University|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","23","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00003768","January 29, 2008","April 2008","January 2011","July 10, 2013","July 2013","December 31, 2012","null","October 2009","The Primary Outcome Measure is 6 Month Progression-free Survival.|Radiographic Response|Median Progression-free Survival (PFS)|Median Overall Survival (OS)|Grade 3 or Greater, Treatment Related, Non-hematologic Toxicities.","https://ClinicalTrials.gov/show/NCT00613028"
255,"NCT01141244","Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors","Completed","No Results Available","Unspecified Childhood Solid Tumor, Protocol Specific","Drug: temsirolimus|Drug: temozolomide|Drug: irinotecan hydrochloride|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","2 Years to 21 Years   (Child, Adult)","Phase 1","72","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02044|COG-ADVL0918|CDR0000674293|ADVL0918|U01CA097452","June 9, 2010","June 2010","null","April 9, 2014","December 2013","No Study Results Posted","null","November 2013","MTD of temsirolimus defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT) as graded by the National Cancer Institute (NCI) CTCAE version 4.0|Incidence of adverse events as graded by NCI CTCAE version 4.0|Disease response (complete or partial response, stable disease, or progressive disease) assessed according to Response Evaluation Criteria in Solid Tumors (RECIST)","https://ClinicalTrials.gov/show/NCT01141244"
256,"NCT02698410","Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.","Recruiting","No Results Available","Neuroendocrine Tumours","Drug: Lanreotide (Autogel formulation) and Temozolomide","Ipsen","All","18 Years and older   (Adult, Senior)","Phase 2","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","A-93-52030-325|2014-005579-10","February 26, 2016","July 2016","October 2018","May 4, 2017","May 2017","No Study Results Posted","ATLANT","October 2018","Response of subjects to the study combination therapy|Progression Free Survival (PFS)|Time to Response (TTR)|Duration of Response|Time to Progression (TTP)|Best Overall response according to RECIST criteria v 1.1 (CR, PR, SD, PD)|Objective Response Rate (ORR) according to RECIST criteria v 1.1 (CR, PR)|Disease Control Rate (DCR) according to RECIST criteria v 1.1 (CR, PR, SD)|Biochemical Response according to decrease in CgA plasma level in subject with baseline CgA level greater than the upper limit of normal (ULN).|Value of Neuron-Specific Enolase (NSE) and Chromogranin A (CgA) biomarkers|Biomarker expression correlated to tumor response for PFS, ORR, and DCR|Tumor radiological response","https://ClinicalTrials.gov/show/NCT02698410"
257,"NCT02344355","A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: Temozolomide|Radiation: radiation therapy|Drug: Ascorbic Acid","University of Iowa|Holden Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","90","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201504786","January 16, 2015","March 13, 2017","December 2021","April 19, 2017","April 2017","No Study Results Posted","null","April 2020","Overall Survival (OS)|Progression Free Survival (PFS)|Adverse Event Frequency","https://ClinicalTrials.gov/show/NCT02344355"
258,"NCT00482677","Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Genetic: DNA methylation analysis|Procedure: quality-of-life assessment|Radiation: Radiation","Canadian Cancer Trials Group|European Organisation for Research and Treatment of Cancer - EORTC|Trans-Tasman Radiation Oncology Group (TROG)","All","65 Years to 120 Years   (Adult, Senior)","Phase 3","562","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CE6|CAN-NCIC-CE6|EORTC-26062-22061|TROG 08.02|SPRI-CAN-NCIC-CE.6|CDR0000547163","June 4, 2007","May 2007","August 2016","August 10, 2016","April 2016","No Study Results Posted","null","March 2016","Overall survival|Progression-free survival|Adverse events|Quality of life|Methylation status of the O6-methylguanine-DNA methyltransferase promoter","https://ClinicalTrials.gov/show/NCT00482677"
259,"NCT00003708","Chemotherapy in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: temozolomide","The University of Texas Health Science Center at San Antonio|National Cancer Institute (NCI)|Cancer Therapy and Research Center, Texas","All","18 Years and older   (Adult, Senior)","Phase 1","32","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066816|P30CA054174|UTHSC-9785011336|SACI-IDD-98-09|SPRI-C98-247|NCI-V98-1502","November 1, 1999","July 1998","May 2000","August 7, 2012","August 2012","No Study Results Posted","null","May 2000","","https://ClinicalTrials.gov/show/NCT00003708"
260,"NCT00049387","Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","Completed","No Results Available","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma","Drug: tipifarnib|Drug: temozolomide|Radiation: radiation therapy","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","19","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03106|NCI-03-C-0189|NABTC-0202|NABTC-02-02|U01CA062399","November 12, 2002","September 2002","June 2007","April 14, 2015","December 2013","No Study Results Posted","null","June 2007","MTD of tipifarnib|Incidence of adverse events|Antitumor activity","https://ClinicalTrials.gov/show/NCT00049387"
261,"NCT01514201","Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas","Active, not recruiting","No Results Available","Childhood Mixed Glioma|Untreated Childhood Anaplastic Astrocytoma|Untreated Childhood Brain Stem Glioma|Untreated Childhood Fibrillary Astrocytoma|Untreated Childhood Giant Cell Glioblastoma|Untreated Childhood Glioblastoma|Untreated Childhood Gliosarcoma","Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Temozolomide|Drug: Veliparib","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 1|Phase 2","66","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2012-00082|PBTC-033|12-C-0213|CDR0000717423|P12978|U01CA081457","January 16, 2012","November 17, 2011","null","May 23, 2017","April 2017","No Study Results Posted","null","August 1, 2019","Feasibility of intra-patient dose escalation of temozolomide during maintenance therapy with veliparib (Phase I and II)|Maximum-tolerated dose of veliparib defined as highest dose level with fewer than 2 dose limiting toxicities in 6 patients as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I)|Overall survival (Phase II)|Number of pseudo progression|PFS (Phase II)|Pharmacokinetic parameters of veliparib","https://ClinicalTrials.gov/show/NCT01514201"
262,"NCT01452854","Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide","Terminated","Has Results","Low Grade Glioma","","University of California, San Francisco|Merck Sharp & Dohme Corp.","Female","18 Years to 44 Years   (Adult)","","2","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","UCSF 10-03288","October 12, 2011","October 2011","November 2013","August 13, 2014","August 2014","June 10, 2014","OVA-LGG","November 2013","Ovarian Aging (AFC and Hormones)","https://ClinicalTrials.gov/show/NCT01452854"
263,"NCT01735747","Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma","Unknown status","No Results Available","Central Nervous System Tumors","Radiation: Radiotherapy|Drug: nedaplatin|Drug: vincristine|Drug: Temozolomide","Rongjie Tao|National Natural Science Foundation of China|Shandong Cancer Hospital and Institute","All","20 Years to 75 Years   (Adult, Senior)","Phase 2","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ShandongCHI 002","November 23, 2012","June 2008","November 2013","March 11, 2013","March 2013","No Study Results Posted","null","November 2013","Rate of complete radiologic response (CR)|Failure-free survival|Toxicity|Overall response rate","https://ClinicalTrials.gov/show/NCT01735747"
264,"NCT01506609","The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer","Active, not recruiting","No Results Available","Metastatic Breast Cancer","Drug: Veliparib|Drug: Temozolomide|Drug: Carboplatin|Drug: Paclitaxel|Drug: Placebo","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","290","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","M12-895|2011-002913-12","January 6, 2012","January 23, 2012","May 30, 2017","April 20, 2017","April 2017","No Study Results Posted","null","May 30, 2017","Progression -Free Survival|Overall Survival|Clinical Benefit Rate (CBR)|Objective Response Rate","https://ClinicalTrials.gov/show/NCT01506609"
265,"NCT00731731","Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Active, not recruiting","Has Results","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Cognitive Side Effects of Cancer Therapy","Radiation: 3-Dimensional Conformal Radiation Therapy|Procedure: Cognitive Assessment|Other: Laboratory Biomarker Analysis|Drug: Temozolomide|Drug: Vorinostat","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","125","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2009-00672|CDR0000609743|ABTC 0902|N0874|U10CA180821|U10CA025224","August 8, 2008","July 2009","null","April 5, 2017","November 2016","April 28, 2015","null","February 2014","Maximum Tolerated Dose of Vorinostat, Defined as the Dose at Which Fewer Than One-third of Patients Experience DLTs, Graded According to NCI CTCAE (Common Toxicity Criteria for Adverse Effects) Version 3.0 (Phase I)|Overall Survival at 15 Months (Phase II)|Incidence of Adverse Events, Based on CTC (Common Toxicity Criteria) Severity Grade|Time to Tumor Progression (Phase II)|Incidence of Adverse Events, as Per NCI CTCAE Version 3.0 (Phase II)","https://ClinicalTrials.gov/show/NCT00731731"
266,"NCT00900757","Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide","Completed","Has Results","Malignant Glioma","Drug: Palonosetron (PALO)","Duke University|Eisai Inc.|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years to 90 Years   (Adult, Senior)","Phase 2","57","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","Pro00015573|P50NS020023","May 11, 2009","August 2009","December 2012","November 3, 2014","March 2014","December 30, 2013","null","December 2012","Safety and Tolerability of Palonosetron as Determined by the Number of Participants Who Experience Unacceptable Toxicity|Complete Response|Change in the Functional Living Index - Emesis (FLIE) Score From Baseline to Each Week of Radiation (XRT) and Temozolomide (TMZ) Treatment|Percentage of Participants With a Osoba Nausea Module Maximum Standardized Score of Zero for Each Week of Radiation (XRT) and Temozolomide (TMZ)|Percentage of Participants With a Osoba Vomiting/Retching Module Maximum Standardized Score of Zero for Each Week of Radiation (XRT) and Temozolomide (TMZ)","https://ClinicalTrials.gov/show/NCT00900757"
267,"NCT01193140","To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors","Completed","No Results Available","Solid Tumor Cancers","Drug: veliparib|Drug: Temozolomide","Abbott","All","18 Years and older   (Adult, Senior)","Phase 2","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M12-273","July 28, 2010","July 2010","November 2011","November 16, 2012","November 2012","No Study Results Posted","null","November 2011","To evaluate the safety and tolerability of veliparib/TMZ combination in subjects with solid tumors|To assess effect of veliparib/TMZ combination regimen on progression free survival, overall survival, the objective response rate, time to progression and Eastern Cooperative Oncology Group (ECOG) performance status in subjects with solid tumors","https://ClinicalTrials.gov/show/NCT01193140"
268,"NCT00033280","Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years to 65 Years   (Adult)","Phase 2","42","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","RTOG-BR-0131|CDR0000069270|RTOG-DEV-1080","April 9, 2002","July 2002","null","March 9, 2017","March 2017","No Study Results Posted","null","April 2005","Rate of progression at 6 months (post-chemotherapy/pre-irradiation progression)|Overall Survival","https://ClinicalTrials.gov/show/NCT00033280"
269,"NCT00970996","Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma","Completed","No Results Available","Melanoma","Drug: Temozolomide|Drug: Abraxane|Drug: Cisplatin|Biological: Interleukin-2|Biological: Interferon alpha 2b","M.D. Anderson Cancer Center","All","18 Years to 65 Years   (Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-0124","September 2, 2009","September 2009","December 2012","December 31, 2012","December 2012","No Study Results Posted","BCAA","December 2012","Response Rate","https://ClinicalTrials.gov/show/NCT00970996"
270,"NCT01044966","A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma","Terminated","No Results Available","Glioblastoma Multiforme|Glioma|Astrocytoma|Brain Tumor","Drug: Intrathecal liposomal Ara-C + Temozolomide","Medical University of South Carolina","All","18 Years to 85 Years   (Adult, Senior)","Phase 1|Phase 2","29","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3542|R01FD003542-01","January 6, 2010","September 2009","September 2014","October 1, 2015","September 2013","No Study Results Posted","null","August 2013","To determine the safety, tolerability and MTD of intraventricular (ITV) liposomal cytarabine (DepoCyt) in combination with oral temozolomide in patients with recurrent glioblastoma multiforme (GBM).|To estimate the proportion of patients with recurrent GBM treated with ITV DepoCyt in combination with oral temozolomide who are progression-free at 16 weeks.","https://ClinicalTrials.gov/show/NCT01044966"
271,"NCT03079440","TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors","Not yet recruiting","No Results Available","Neuroendocrine Tumors|Neuroendocrine Carcinoma|Temozolomide|Capecitabine","Drug: TEMCAP","Asan Medical Center","All","19 Years and older   (Adult, Senior)","Phase 2","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Asan-ONCHBP-2017-002","March 9, 2017","May 2017","October 2020","March 13, 2017","March 2017","No Study Results Posted","null","May 2019","Response rate|Progression-free survival|Overall survival|Toxicity (Adverse events graded by National Cancer Institute-Common Terminology Criteria version 4.03)","https://ClinicalTrials.gov/show/NCT03079440"
272,"NCT02152982","Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Suspended","No Results Available","Glioblastoma|Gliosarcoma","Other: Laboratory Biomarker Analysis|Other: Placebo|Other: Quality-of-Life Assessment|Drug: Temozolomide|Drug: Veliparib","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","440","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","NCI-2014-00616|A071102|CALGB-A071102|P50CA108961|U10CA180821|U10CA031946","May 27, 2014","December 15, 2014","null","May 23, 2017","May 2017","No Study Results Posted","null","June 30, 2022","Overall survival (OS)|Change in quality of life (QOL), measured by the fatigue/uniscale tool|Interaction with Optune device|Objective tumor response, defined as complete response or partial response as specified in the Revised Assessment in Neuro-Oncology criteria|Overall adverse event rates for grade 3 or higher adverse events assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT02152982"
273,"NCT01649830","Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma","Recruiting","No Results Available","Astrocytoma|Oligodendroglioma|Oligodendroastrocytoma","Radiation: Radiotherapy|Drug: Temozolomide","Sun Yat-sen University","All","18 Years to 60 Years   (Adult)","Phase 3","290","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2012012","July 20, 2012","July 2012","August 2022","February 17, 2017","February 2017","No Study Results Posted","null","August 2021","Progression-free survival|Quality of life","https://ClinicalTrials.gov/show/NCT01649830"
274,"NCT01891747","A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma","Active, not recruiting","No Results Available","Malignant Glioma","Drug: Bevacizumab|Drug: Temozolomide|Dietary Supplement: Vitamin C","Vanderbilt-Ingram Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","VICC NEU 1308","June 25, 2013","July 2013","March 2020","March 15, 2017","March 2017","No Study Results Posted","null","February 2020","Maximum Tolerated Dose (Phase I)|Progression-free survival (Phase II)|Objective Response (Phase I)|Number of patients with each worst-grade toxicity. (Phase I)|Overall Survival (Phase II)","https://ClinicalTrials.gov/show/NCT01891747"
275,"NCT00609011","Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma","Completed","No Results Available","Metastatic Melanoma","Drug: MPC-6827 + Temozolomide","Myrexis Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MPC-6827-07-005","January 23, 2008","March 2008","August 2009","August 19, 2010","August 2010","No Study Results Posted","null","August 2009","Safety and Tolerability; Maximum Tolerated Dose|Pharmacokinetics|Antitumor Activity","https://ClinicalTrials.gov/show/NCT00609011"
276,"NCT00498927","Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma","Completed","Has Results","Brain and Central Nervous System Tumors","Drug: temozolomide|Genetic: protein expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: diagnostic laboratory biomarker analysis|Other: immunoenzyme technique","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Weill Medical College of Cornell University|Schering-Plough","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","47","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-064|P30CA008748|MSKCC-07064|SPRI-PO5096","July 10, 2007","June 2007","December 2013","February 1, 2016","February 2016","October 5, 2015","null","December 2013","Progression-free Survival (PFS) Rate at 6 Months|Overall Survival","https://ClinicalTrials.gov/show/NCT00498927"
277,"NCT03128047","HUMC 1612: Optune NovoTTF-200A System","Recruiting","No Results Available","High Grade Glioma","Device: Optune NovoTTF-200A System|Drug: Bevacizumab|Drug: Temozolomide","Hackensack University Medical Center|NovoCure Ltd.","All","1 Year to 17 Years   (Child)","Phase 1","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: No masking|Primary Purpose: Treatment","Pro2016-0583","January 5, 2017","May 2017","February 2019","April 20, 2017","April 2017","No Study Results Posted","null","February 2019","Safety and tolerability of the Optune NovoTTF-200A System when used alone in pediatric patients with recurrent high-grade gliomas.|Safety and tolerability of the Optune NovoTTF-200A System when used in combination with temozolomide and bevacizumab in pediatric patients with newly diagnosed or recurrent high-grade gliomas.|Assess the event-free and overall survival of patients treated on this study protocol to aid in the future development of pediatric phase II/III studies using the Optune NovoTTF-200A System.|Survival of patients with recurrent high-grade glioma receiving treatment with the Optune NovoTTF-200A System.|2-year event-free survival (EFS) and overall survival (OS) of patients with recurrent high-grade glioma treated with the Optune NovoTTF-200A System monotherapy and in combination with temozolomide and bevacizumab|Survival of patients with high-grade glioma receiving treatment with the Optune NovoTTF-200A System in combination with temozolomide and bevacizumab","https://ClinicalTrials.gov/show/NCT03128047"
278,"NCT01543464","Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients","Terminated","No Results Available","Malignant Melanoma","Drug: Chemotherapy: Temozolomide","Inge Marie Svane|Copenhagen University Hospital at Herlev|Herlev Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MM1120","February 8, 2012","May 2012","September 2016","August 17, 2015","August 2015","No Study Results Posted","null","September 2016","Clinical benefit rate (CBR)","https://ClinicalTrials.gov/show/NCT01543464"
279,"NCT00316849","Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma","Other: pharmacological study|Procedure: adjuvant therapy|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy|Drug: temsirolimus|Drug: temozolomide","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","56","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00642|N027D|CDR0000467232|NCCTG-N027D|U10CA025224","April 19, 2006","May 2006","null","April 9, 2013","April 2013","No Study Results Posted","null","November 2010","Maximally tolerated dose (MTD), determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)|Time to treatment related toxicity as assessed by hematologic measures and CTCAE v3.0|Time to treatment related toxicity greater than grade 3, assessed by CTCAE v3.0|Time to progression|Time to treatment failure|Response to therapy associated with patient outcome, as assessed by automated morphological MRI change detector and physiological MRI techniques, including diffusion-weighted imaging, perfusion-weighted imaging, and chemical shift imaging","https://ClinicalTrials.gov/show/NCT00316849"
280,"NCT00875355","Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer","Unknown status","No Results Available","Breast Cancer|Metastatic Cancer","Drug: temozolomide|Radiation: radiation therapy","Institut Curie|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000633496|CLCC-IC-RT-TEMODAL|CLCC-IC-2007-01|INCA-RECF0630|EUDRACT-2007-002531-83|SCHER-CLCC-IC-RT-TEMODAL","April 2, 2009","November 2007","null","August 25, 2009","July 2009","No Study Results Posted","null","November 2009","Response at 6 weeks as assessed by MRI and/or scan","https://ClinicalTrials.gov/show/NCT00875355"
281,"NCT00724841","A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma","Terminated","No Results Available","Metastatic Melanoma","Drug: Obatoclax Mesylate|Drug: Temozolomide","Gemin X|Teva Pharmaceutical Industries","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","1","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEM303","July 28, 2008","June 2008","August 2010","July 20, 2016","July 2016","No Study Results Posted","null","July 2008","Determine the recommended Phase II dose of GMX1777 in combination with temozolomide|Learn more about the side effects of taking GMX1777 in combination with temozolomide|Determine the disease response to treatment with GMX1777 in combination with temozolomide|Learn more about how the body processes GMX1777","https://ClinicalTrials.gov/show/NCT00724841"
282,"NCT00885534","Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma","Completed","Has Results","Melanoma|Skin Cancer","Drug: Cisplatin, Vinblastine, Temozolomide","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-017","April 21, 2009","April 2009","October 2013","April 21, 2015","April 2015","April 7, 2015","null","October 2013","Overall Response to CVT Chemotherapy.","https://ClinicalTrials.gov/show/NCT00885534"
283,"NCT02179086","Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","Recruiting","No Results Available","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma","Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy|Radiation: photon beam radiation therapy|Radiation: intensity-modulated radiation therapy|Radiation: proton beam radiation therapy|Drug: temozolomide|Other: laboratory biomarker analysis","NRG Oncology|National Cancer Institute (NCI)|Radiation Therapy Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","576","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NRG-BN001|NCI-2014-01072|U10CA180868","June 27, 2014","November 2014","null","August 17, 2016","August 2016","No Study Results Posted","null","May 2019","Overall survival (OS) compared between dose-escalated and -intensified photon IMRT or proton beam therapy with concomitant and adjuvant temozolomide and the standard-dose photon irradiation with concomitant and adjuvant temozolomide|OS when compared between dose-escalated and -intensified photon IMRT to dose-escalated and -intensified proton beam therapy|Progression-free survival (PFS)|Incidence of treatment-related toxicity, as measured by the Common Terminology Criteria for Adverse Events version 4|Change in perceived cognitive function, as measured by M.D. Anderson Symptom Inventory Brain Tumor|Change in neurocognitive function, as measured by Hopkins' Verbal Learning Test-Revised, Trail Making Test Parts A and B, and Controlled Oral Word Association Test|Change in CD4 lymphopenia count|Use of magnetic resonance diffusion and perfusion imaging to differentiate between tumor progression and pseudo-progression","https://ClinicalTrials.gov/show/NCT02179086"
284,"NCT00892385","Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors","Active, not recruiting","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: methoxyamine|Drug: temozolomide|Genetic: DNA analysis|Other: laboratory biomarker analysis|Other: pharmacological study","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","66","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE1Y05|P30CA043703|WIRB-20070151|NCI-2009-01286","May 1, 2009","August 2007","April 2017","October 14, 2016","October 2016","No Study Results Posted","null","April 2017","Maximum tolerated dose of methoxyamine|Dose limiting toxicities of the combination of methoxyamine and temozolomide|Pharmacokinetics methoxyamine and temozolomide, when given alone or in combination|Pharmacokinetic profile of methoxyamine after single one-hour IV administration|Biological activity, evidenced by a 40% drop in detectable apurinic/apyrimidinic sites in blood mononuclear cells|DNA strand breaks in blood mononuclear cells as assessed by comet assay","https://ClinicalTrials.gov/show/NCT00892385"
285,"NCT00994071","A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors","Completed","No Results Available","Medulloblastoma|Pontine Glioma|Ependymoma|Astrocytoma|PNET","Drug: Temozolomide|Drug: ABT-888","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","up to 21 Years   (Child, Adult)","Phase 1","9","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","090243|09-C-0243","October 10, 2009","September 22, 2009","March 19, 2013","May 12, 2017","July 16, 2014","No Study Results Posted","null","null","To estimate the maximum tolerated dose (MTD) of ABT-888 in combination with Temozolomide in children with recurrent or refractory CNS tumors|-To study the plasma pharmacokinetics (PK) of ABT-888 and PARPinhibition in peripheral blood mononuclear cells (PBMC) in order torecommend a Phase 2 dose of ABT-888 in combination with temozolomide in children with recurrent or refractory ...|To measure non-homologous end-joining (NHEJ) activity in peripheral blood mononuclear cells (PBMC) prior to and following ABT-888 administration.","https://ClinicalTrials.gov/show/NCT00994071"
286,"NCT00555399","Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)","Active, not recruiting","No Results Available","Glioblastoma Multiforme|Anaplastic Glioma","Drug: Vorinostat|Drug: Isotretinoin|Procedure: Surgical Resection|Drug: Temozolomide","M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","135","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-0709|NCI-2010-00782|4808704|BTTC09-02","November 6, 2007","November 2007","null","September 26, 2016","March 2016","No Study Results Posted","null","November 2017","Maximum Tolerated Dose (MTD)","https://ClinicalTrials.gov/show/NCT00555399"
287,"NCT01835145","Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery","Active, not recruiting","No Results Available","Recurrent Uveal Melanoma|Stage III Uveal Melanoma|Stage IIIA Uveal Melanoma|Stage IIIB Uveal Melanoma|Stage IIIC Uveal Melanoma|Stage IV Uveal Melanoma","Drug: Cabozantinib S-malate|Drug: Dacarbazine|Other: Laboratory Biomarker Analysis|Drug: Temozolomide","National Cancer Institute (NCI)|Exelisis","All","18 Years and older   (Adult, Senior)","Phase 2","69","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2013-00821|CALGB-A091201|A091201|U10CA180821|U10CA031946","April 16, 2013","July 31, 2013","null","May 23, 2017","May 2017","No Study Results Posted","null","November 1, 2017","PFS4|Confirmed response rate as determined by the RECIST criteria (version 1.1)|Maximum grade for each type of adverse event, graded according to the National Cancer Institute CTCAE version 4.0|Overall survival (OS)|PFS","https://ClinicalTrials.gov/show/NCT01835145"
288,"NCT00548938","Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM","Terminated","No Results Available","Glioblastoma Multiforme|High-Grade Glioma","Drug: Gliadel wafer|Drug: Temozolomide|Radiation: External Beam Radiation Therapy","Methodist Healthcare","All","18 Years to 72 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MHIRB #2007-040","October 23, 2007","October 2007","October 2010","September 17, 2009","September 2009","No Study Results Posted","null","October 2009","To determine the efficacy of Gliadel wafer + radiation + temozolomide in patients with newly diagnosed high grade glioma undergoing surgery as determined by time to disease progression.|Median, one year and overall survival rate.","https://ClinicalTrials.gov/show/NCT00548938"
289,"NCT01430351","Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)","Active, not recruiting","No Results Available","Brain Cancer","Drug: Temozolomide|Drug: Memantine|Drug: Mefloquine|Drug: Metformin","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","144","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-0374|NCI-2011-03038","September 6, 2011","September 2011","null","December 19, 2016","December 2016","No Study Results Posted","null","September 2018","Maximum Tolerated Dose (MTD) Levels|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01430351"
290,"NCT00977431","Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform","Active, not recruiting","No Results Available","Glioblastoma","Drug: Temozolomide|Procedure: Radiotherapy|Drug: BIBW2992|Procedure: Radiotherapy|Drug: BIBW2992","Boehringer Ingelheim","All","18 Years to 69 Years   (Adult, Senior)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","1200.38|2008-007284-17","September 14, 2009","September 17, 2009","September 29, 2017","May 8, 2017","May 2017","No Study Results Posted","null","September 29, 2017","MTD of BIBW 2992 when given concomitantly with Temozolomide (TMZ) and radiotherapy|Maximum Tolerated Dose (MTD) of BIBW 2992 when given concomitantly with radiotherapy|Safety of BIBW 2992: Incidence and intensity of AEs according to Common Terminology Criteria (CTCAE v.3.0)|Objective tumour response according to the Macdonald criteria|Pharmacokinetics of BIBW 2992 in combination with radiotherapy (RT) with or without concomitant Temozolomide therapy","https://ClinicalTrials.gov/show/NCT00977431"
291,"NCT00503594","Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine","Unknown status","No Results Available","Lymphoma","Drug: Methotrexate and temozolomide|Drug: Methotrexate , procarbazine ,vincristine ,cytarabine","Assistance Publique - Hôpitaux de Paris|French Innovative Leukemia Organisation","All","60 Years and older   (Adult, Senior)","Phase 2","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P060239","July 18, 2007","July 2007","July 2012","July 27, 2012","July 2007","No Study Results Posted","CNSLymphoma","July 2010","Progression-free survival|Overall survival:median and overall survival|Response rates|Toxicity|Late toxicity","https://ClinicalTrials.gov/show/NCT00503594"
292,"NCT00304031","Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma","Completed","Has Results","Brain and Central Nervous System Tumors","Drug: Concurrent temozolomide|Radiation: Concurrent radiation therapy|Drug: 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle|Drug: 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|European Organisation for Research and Treatment of Cancer - EORTC|NRG Oncology","All","18 Years to 120 Years   (Adult, Senior)","Phase 3","1173","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0525|CDR0000465183|EORTC-26052|EORTC-22053|NCI-2009-00731","March 15, 2006","January 2006","December 2016","December 30, 2016","December 2016","March 28, 2014","null","February 2011","Overall Survival (OS)|Progression-free Survival (PFS)|Comparison of OS and PFS in Patients With Unmethylated MGMT|Comparison of OS and PFS in Patients With Methylated MGMT|Correlation of Tumor MGMT Gene Methylation Status With Treatment Response|Toxicity|Correlation of PFS With OS at 6 Months","https://ClinicalTrials.gov/show/NCT00304031"
293,"NCT01196416","Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma","Completed","No Results Available","Recurrent Melanoma|Stage IV Skin Melanoma","Drug: Cisplatin|Drug: Gamma-Secretase Inhibitor RO4929097|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Temozolomide|Drug: Vinblastine Sulfate","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","14","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02524|CDR0000684220|10-085|8491|N01CM62206|P30CA008748|U01CA069856","September 4, 2010","August 2010","August 2015","August 27, 2015","May 2015","No Study Results Posted","null","August 2015","Maximum-tolerated dose based on the incidence of dose-limiting toxicity as assessed the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase IB)|Overall response rate (complete [CR] or partial response [PR]) according to RECIST version 1.1 (Phase II)|Overall survival (Phase II)|Change in protein levels by immunohistochemistry (Phase Ib)|Pharmacokinetics of gamma-secretase inhibitor RO4929097 in combination with temozolomide (Phase IB)|Presence or absence of markers of pathway inhibition in patient tumors (Phase Ib)|Progression-free survival (Phase II)|Toxicity as assessed by NCI CTCAE v. 4.0","https://ClinicalTrials.gov/show/NCT01196416"
294,"NCT00905060","HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: HSPPC-96","University of California, San Francisco|Agenus Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","081010|C-100-37","May 18, 2009","June 2009","April 2014","November 12, 2014","November 2014","No Study Results Posted","HeatShock","April 2014","To evaluate the safety profile of HSPPC-96 administered concurrently temozolomide in patients with newly diagnosed GBM.|Survival Time|To evaluate the immunologic response to vaccine treatment|Progression Free Survival from date of surgical resection","https://ClinicalTrials.gov/show/NCT00905060"
295,"NCT02052648","Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors","Recruiting","No Results Available","Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor","Drug: Indoximod|Drug: Temozolomide|Drug: Bevacizumab|Radiation: Stereotactic Radiation","NewLink Genetics Corporation","All","16 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","144","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NLG2102","January 29, 2014","March 2014","null","November 2, 2016","November 2016","No Study Results Posted","null","December 2016","Phase 1: Determine Phase 2 Dosing|Phase 2: Efficacy|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Overall Dose of Temozolomide Delivered Versus Historical Control|Pharmacokinetics|Overall response rate","https://ClinicalTrials.gov/show/NCT02052648"
296,"NCT01143402","Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye","Completed","Has Results","Iris Melanoma|Medium/Large Size Posterior Uveal Melanoma|Ocular Melanoma With Extraocular Extension|Recurrent Uveal Melanoma|Small Size Posterior Uveal Melanoma|Stage IV Uveal Melanoma","Drug: Dacarbazine|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Drug: Selumetinib|Drug: Temozolomide","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","120","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-01411|CDR0000674866|10-053|8443|N01CM00070|N01CM00071|N01CM00099|N01CM00100|N01CM62206|N01CM62208|P30CA008748|U01CA132123","June 11, 2010","June 2010","May 2016","April 7, 2017","April 2017","April 7, 2017","null","May 2016","Progression-free Survival (PFS) (Evaluable Randomized Patients)|Median Overall Survival (Evaluable Randomized Patients)","https://ClinicalTrials.gov/show/NCT01143402"
297,"NCT01480479","Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma","Completed","No Results Available","Glioblastoma|Small Cell Glioblastoma|Giant Cell Glioblastoma|Gliosarcoma|Glioblastoma With Oligodendroglial Component","Drug: Rindopepimut (CDX-110) with GM-CSF|Drug: Temozolomide|Drug: KLH","Celldex Therapeutics","All","18 Years and older   (Adult, Senior)","Phase 3","745","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","CDX110-04","November 21, 2011","November 2011","November 2016","April 6, 2017","April 2017","No Study Results Posted","ACT IV","November 2016","Overall Survival|Progression-free survival|Safety and Tolerability","https://ClinicalTrials.gov/show/NCT01480479"
298,"NCT00617539","Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases","Completed","No Results Available","Breast Cancer|Metastatic Cancer","Drug: irinotecan hydrochloride|Drug: temozolomide","University of California, San Francisco|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000583265|UCSF-05751","February 15, 2008","February 2005","January 2014","October 16, 2014","October 2014","No Study Results Posted","null","January 2013","Objective response rate (percentage of patients with complete or partial response) in the CNS at ≥ 16 weeks","https://ClinicalTrials.gov/show/NCT00617539"
299,"NCT00481455","Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)","Completed","No Results Available","Recurrent Glioblastoma Multiforme","Drug: Panzem NCD|Drug: Temozolomide","CASI Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ME-CLN-007","May 30, 2007","April 2007","October 2008","November 24, 2008","November 2008","No Study Results Posted","null","September 2007","6-month progression free survival and median overall survival for patients receiving at least one dose","https://ClinicalTrials.gov/show/NCT00481455"
300,"NCT01767194","Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma","Suspended","No Results Available","Ganglioneuroblastoma|Recurrent Neuroblastoma","Biological: Dinutuximab|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Sargramostim|Drug: Temozolomide|Drug: Temsirolimus","National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","74","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2012-03125|ANBL1221|PANBL1221_A08PAMDREVW01|CDR0000745188|COG-ANBL1221|U10CA180886|U10CA098543","January 9, 2013","February 12, 2013","null","May 24, 2017","May 2017","No Study Results Posted","null","February 28, 2019","Proportion of patients who are responders defined as patients who achieve a >= partial response (PR) per the INRC as their best overall response|Ability to maintain intended treatment with all agents (irinotecan hydrochloride, temozolomide and the experimental agent) without a dose reduction or going off protocol therapy for toxicity|Occurrence of unacceptable toxicities, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Overall response rate (complete response, PR, stable disease, progressive disease) according to the INRC|Overall survival|Progression-free survival, defined as a relapse, progressive disease, or death attributable to tumor or treatment","https://ClinicalTrials.gov/show/NCT01767194"
301,"NCT00817284","Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)","Completed","No Results Available","Glioblastoma Multiforme","Drug: bevacizumab and Irinotecan and radiotherapy|Drug: Bevacizumab and Temozolomide and radiotherapy","Ulrik Lassen|Rigshospitalet, Denmark","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BIBT-01","December 8, 2008","November 2008","November 2011","November 29, 2011","November 2011","No Study Results Posted","null","November 2011","Objective response rate according to McDonald criteria|Progression-free survival","https://ClinicalTrials.gov/show/NCT00817284"
302,"NCT01026493","Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Drug: veliparib","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","240","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0929|CDR0000660545","December 3, 2009","July 2010","null","May 8, 2015","May 2015","No Study Results Posted","null","May 2014","Dose-limiting toxicity (Phase I)|6-month progression-free survival rate (Phase II)|Treatment-related toxicity as measured by the NCI CTCAE version 4.0|Objective response (partial and complete response) rate (Phase II)|Overall survival (Phase II)","https://ClinicalTrials.gov/show/NCT01026493"
303,"NCT01009515","Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma","Terminated","Has Results","Melanoma","Drug: Paclitaxel, carboplatin, temozolomide","New Mexico Cancer Care Alliance","All","18 Years and older   (Adult, Senior)","Phase 2","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INST 0903|NCI-2011-01939","October 14, 2009","August 2009","June 2015","October 5, 2015","October 2015","August 14, 2015","null","September 2013","Objective Response Rate (ORR)|Overall Survival|Safety Profile|Time to Progression","https://ClinicalTrials.gov/show/NCT01009515"
304,"NCT00305864","Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","Completed","Has Results","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma","Radiation: 3-dimensional conformal radiation therapy|Drug: temozolomide|Drug: motexafin gadolinium","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","118","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-01092|CDR0000467802|RTOG 0513|RTOG-0513|U10CA021661","March 21, 2006","February 2006","March 2011","April 29, 2014","October 2011","March 5, 2013","null","February 2011","Maximum Tolerated Dose of MGd (Phase I)|Median Overall Survival (Phase II)|Progression-free Survival (Phase II)","https://ClinicalTrials.gov/show/NCT00305864"
305,"NCT00717210","Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide","Completed","No Results Available","Anaplastic Astrocytoma|Oligodendroglioma|Oligoastrocytoma","Drug: Temozolomide|Radiation: Focal radiotherapy","Neuro-Oncology Working Group of the German Cancer Society|University Hospital Tuebingen|Heinrich-Heine University, Duesseldorf|Heidelberg University|Charite University, Berlin, Germany|University Hospital, Essen|University of Leipzig|University Hospital, Bonn|German Cancer Research Center|University of Zurich","All","18 Years and older   (Adult, Senior)","Phase 3","318","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NOA-04","July 15, 2008","June 1999","March 2008","July 16, 2008","July 2008","No Study Results Posted","NOA-04","February 2005","Time-to-treatment-failure defined as progression after radiotherapy and one chemotherapy in either sequence|Progression-free survival Overall Survival Toxicity Response rates","https://ClinicalTrials.gov/show/NCT00717210"
306,"NCT02029573","Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: Atorvastatin|Drug: Temozolomide|Radiation: Radiotherapy","King Fahad Medical City","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KFMC-CNS-01","January 3, 2014","January 2014","January 2018","March 30, 2015","March 2015","No Study Results Posted","ART","June 2017","Progression free survival at 6 months (PFS-6)|Progression free survival|Overall Survival (OS)|Adverse events","https://ClinicalTrials.gov/show/NCT02029573"
307,"NCT01260103","Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma","Withdrawn","No Results Available","Optic Nerve Glioma","Drug: Temozolomide|Drug: ANP Therapy","Burzynski Research Institute","All","6 Months to 18 Years   (Child, Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BRI-BT-54","December 13, 2010","December 2011","December 2018","December 5, 2016","December 2016","No Study Results Posted","null","December 2016","Progression free survival (PFS)|Safety Analysis","https://ClinicalTrials.gov/show/NCT01260103"
308,"NCT00376103","Radiation Boost for Newly Diagnosed Glioblastoma Multiforme","Terminated","No Results Available","Glioblastoma Multiforme","Drug: temozolomide|Procedure: Brachytherapy|Procedure: External Beam Radiation Therapy","Methodist Healthcare","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MHIRB 2006-032","September 13, 2006","August 2006","null","September 17, 2009","September 2009","No Study Results Posted","null","March 2008","Treatment-related toxicity.|6 month, 1 year and overall survival.|Tumor progression.|Progression-free survival.|Quality of life.","https://ClinicalTrials.gov/show/NCT00376103"
309,"NCT01062425","Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma","Active, not recruiting","Has Results","Adult Glioblastoma|Adult Gliosarcoma","Radiation: Radiation Therapy|Drug: Cediranib|Other: Placebo|Drug: Temozolomide","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","261","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","NCI-2011-02012|CDR0000665163|RTOG 0837|RTOG-0837|U10CA180868|U10CA021661","February 3, 2010","February 2010","null","November 14, 2016","November 2016","July 28, 2016","null","October 2015","6-month Progression-free Survival Rate|Overall Survival (OS)|Progression-free Survival (PFS)|Incidence of Grade 3+ Toxicities","https://ClinicalTrials.gov/show/NCT01062425"
310,"NCT02975882","Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors","Not yet recruiting","No Results Available","Childhood Solid Neoplasm|Recurrent Central Nervous System Neoplasm|Recurrent Solid Neoplasm|Refractory Central Nervous System Neoplasm","Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Nanoparticle Albumin-Bound Rapamycin|Other: Pharmacological Study|Drug: Temozolomide","Children's Oncology Group|National Cancer Institute (NCI)","All","12 Months to 21 Years   (Child, Adult)","Phase 1","51","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ADVL1514|NCI-2016-01412|UM1CA097452","November 15, 2016","September 2017","June 2020","April 26, 2017","April 2017","No Study Results Posted","null","June 2020","Incidence of adverse events according to NCI CTCAE version 4.0|MTD of nanoparticle albumin-bound rapamycin based on incidence of dose limiting toxicity assessed by NCI CTCAE version 4.0|PK for systemic exposure of ABI-009|PK for drug clearance of ABI-009","https://ClinicalTrials.gov/show/NCT02975882"
311,"NCT01055314","Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma","Completed","No Results Available","Adult Rhabdomyosarcoma|Childhood Alveolar Rhabdomyosarcoma|Childhood Embryonal Rhabdomyosarcoma|Metastatic Childhood Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma|Untreated Childhood Rhabdomyosarcoma","Biological: Cixutumumab|Drug: Cyclophosphamide|Biological: Dactinomycin|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Drug: Ifosfamide|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Temozolomide|Drug: Vincristine Sulfate Liposome","National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 2","179","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02005|CDR0000663937|COG-ARST08P1|ARST08P1|U10CA180886|U10CA098543","January 22, 2010","January 2010","September 2014","May 22, 2015","September 2014","No Study Results Posted","null","September 2014","Feasibility of the addition of cixutumumab to chemotherapy determined by patient enrollment|Feasibility of the addition of temozolomide to chemotherapy determined by patient enrollment|Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events version 4.0|Event-free survival|Response rate assessed by Response Evaluation Criteria for Solid Tumors (RECIST)","https://ClinicalTrials.gov/show/NCT01055314"
312,"NCT00276679","Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: temozolomide","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","1 Year to 16 Years   (Child)","Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000454577|CCLG-NAG-2003-02|EU-20591|CCLG-SFOP-NAG-2003-02","January 12, 2006","April 2003","November 2006","September 16, 2013","January 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00276679"
313,"NCT01019434","Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Drug: temsirolimus","European Organisation for Research and Treatment of Cancer - EORTC|Pfizer","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","111","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-26082-22081|EORTC-26082|EORTC-22081|EU-20987|2008-003003-31","November 24, 2009","October 2009","March 2014","October 11, 2016","October 2016","No Study Results Posted","null","December 2013","Overall survival at 1 year|Percentages of worst Adverse Events or Laboratory Event grades as measured by CTCAEs Version 4.0 criteria|Progression-free survival (PFS) probability at 6 months and at 12 months, and overall survival (OS) probability at 2 years|Correlation between biomarkers relevant to temsirolimus and PFS and OS","https://ClinicalTrials.gov/show/NCT01019434"
314,"NCT01845675","Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor","Completed","No Results Available","Advanced Well-differentiated Pancreatic Neuroendocrine Tumor","Drug: temozolomide or dacarbazine-based chemotherapy, endostatin","Peking Union Medical College Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","TEPNET","April 29, 2013","April 2013","March 31, 2017","April 12, 2017","April 2017","No Study Results Posted","null","November 30, 2016","overall response rate|progression free survival|toxicities","https://ClinicalTrials.gov/show/NCT01845675"
315,"NCT01525082","Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors","Active, not recruiting","No Results Available","Gastrinoma|Glucagonoma|Insulinoma|Pancreatic Polypeptide Tumor|Recurrent Islet Cell Carcinoma|Recurrent Pancreatic Cancer|Somatostatinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer","Drug: capecitabine|Drug: temozolomide|Biological: bevacizumab","Stanford University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NET0012|NCI-2011-03497|SU-10282011-8571|END0012","January 10, 2012","December 2012","July 2019","September 21, 2016","September 2016","No Study Results Posted","null","January 2019","RR % determined by RECIST v1.1|Toxicities according to CTCAE v4.0|PFS (median in months)|OS (median in months)|MGMT by central pathology review","https://ClinicalTrials.gov/show/NCT01525082"
316,"NCT00813943","Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status","Completed","Has Results","Glioblastoma","Drug: Cilengitide (2-times weekly)|Drug: cilengitide (5-times weekly)|Drug: Temozolomide|Radiation: Radiotherapy","EMD Serono|Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 2","265","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMD121974-012","December 22, 2008","March 2009","August 2013","January 12, 2017","January 2017","August 29, 2014","CORE","February 2013","Overall Survival (OS) Time|Progression Free Survival (PFS) Time - Investigator and Independent Read|Maximum Observed Plasma Concentration (Cmax)|Time to Maximum Plasma Concentration (Tmax) and Terminal Elimination Half-Life (t1/2)|Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC [0-infinity]) and Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24])|Plasma Concentration at Pre-dose (Cpre) and Plasma Concentration at End of Infusion (CT)|Apparent Terminal Rate Constant|Mean Residence Time From Time 0 to Infinity (MRT [0-infinity])|Plasma Clearance (CL)|Apparent Volume of Distribution During the Terminal Phase (Vz) and Apparent Volume of Distribution at Steady State (Vss)|Number of Participants With Adverse Events (AEs), Serious AEs, Treatment-Related AEs, Treatment-Related Serious AEs, AEs Leading to Death, Treatment-Related AEs Leading to Death, AEs of Grade 3 or 4 and Treatment-Related AEs of Grade 3 or 4|Number of Participants With AEs Belonging to Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs) Thromboembolic Events and Hemorrhage With NCI−CTC Toxicity Grade 3 or 4|Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) and Lab Parameters","https://ClinicalTrials.gov/show/NCT00813943"
317,"NCT00005054","Temozolomide in Treating Women With Advanced Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: temozolomide","The Christie NHS Foundation Trust|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000067649|CHNT-H98-198-50|EU-99047","April 6, 2000","May 1998","null","September 19, 2013","January 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005054"
318,"NCT02831179","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor","Not yet recruiting","No Results Available","Functional Pancreatic Neuroendocrine Tumor|Malignant Somatostatinoma|Merkel Cell Carcinoma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Carcinoid Tumor|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Neuroendocrine Neoplasm|Non-Functional Pancreatic Neuroendocrine Tumor|Pancreatic Glucagonoma|Pancreatic Insulinoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Merkel Cell Carcinoma|Somatostatin-Producing Neuroendocrine Tumor|Stage III Adrenal Cortex Carcinoma|Stage III Thyroid Gland Medullary Carcinoma|Stage IIIA Merkel Cell Carcinoma|Stage IIIB Merkel Cell Carcinoma|Stage IV Adrenal Cortex Carcinoma|Stage IV Merkel Cell Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma|Stage IVB Thyroid Gland Medullary Carcinoma|Stage IVC Thyroid Gland Medullary Carcinoma|Thymic Carcinoid Tumor|VIP-Producing Neuroendocrine Tumor|Well Differentiated Adrenal Cortex Carcinoma|Zollinger Ellison Syndrome","Drug: Capecitabine|Drug: Temozolomide|Drug: Veliparib|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC GI 14134|NCI-2016-01044","July 10, 2016","August 2016","September 2019","July 10, 2016","July 2016","No Study Results Posted","null","September 2018","Maximum tolerated dose determined by dose limiting toxicities defined as any toxicity in the first course evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Response rate measured as complete response, partial response or stable disease according to RECIST 1.1 criteria|Response duration|Progression Free Survival|Overall Survival|Poly-adenosine diphosphate (ADP)-ribosylated (PAR) level","https://ClinicalTrials.gov/show/NCT02831179"
319,"NCT00458601","Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme","Completed","No Results Available","Malignant Glioma","Drug: CDX-110 with GM-CSF|Drug: Temozolomide","Celldex Therapeutics","All","18 Years and older   (Adult, Senior)","Phase 2","82","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDX110-003","April 10, 2007","August 2007","May 2016","August 9, 2016","August 2016","No Study Results Posted","ACT III","November 2010","Progression-free survival status|Safety and tolerability characterized by adverse events (term, grade, frequency).|Safety and tolerability characterized by physical examinations.|Safety and tolerability characterized by hematologic and metabolic panel (including CBC with differential, electrolytes, BUN, Cr, liver associated enzymes).|Safety and tolerability characterized by urinalysis.|Safety and tolerability characterized by vital signs.|Immune response; T-cell response to vaccine.|Immune response; antibody response to vaccine.|Immune response; HLA typing.|Overall survival.","https://ClinicalTrials.gov/show/NCT00458601"
320,"NCT02770378","A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma","Recruiting","No Results Available","Glioblastoma","Drug: Temozolomide|Drug: Aprepitant|Drug: Minocycline|Drug: Disulfiram|Drug: Celecoxib|Drug: Sertraline|Drug: Captopril|Drug: Itraconazole|Drug: Ritonavir|Drug: Auranofin","University of Ulm|Reliable Cancer Therapies|Anticancer Fund, Belgium","All","18 Years and older   (Adult, Senior)","Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CUSP9v3","March 14, 2016","November 2016","null","December 5, 2016","December 2016","No Study Results Posted","null","March 2018","Number of patients experiencing dose-limiting toxicity defined as either any unmanageable grade 3-4 toxicity at the end of the second treatment cycle or inability to receive at least 7 of the 10 drugs, all of them being given at ≥50% of the target doses|Overall survival according to Kaplan-Meier estimates|Progression-free survival according to Kaplan-Meier estimates|Best tumor response according to the Revised Assessment in Neuro-Oncology (RANO) criteria","https://ClinicalTrials.gov/show/NCT02770378"
321,"NCT00038493","Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme","Terminated","No Results Available","Glioblastoma Multiforme","Drug: Temozolomide and SCH66336","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","23","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM01-258","May 31, 2002","September 2001","August 2005","January 20, 2012","January 2012","No Study Results Posted","null","August 2005","","https://ClinicalTrials.gov/show/NCT00038493"
322,"NCT00338130","Randomised Study to Compare the Efficacy of AZD6244 vs TMZ","Completed","No Results Available","Melanoma","Drug: AZD6244|Drug: Temozolomide","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","239","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D1532C00003|EUDRACT No. 2006-001456-12","June 15, 2006","July 2006","July 2013","August 12, 2014","August 2014","No Study Results Posted","null","September 2007","To compare the efficacy of AZD6244 vs temozolomide in patients with unresectable AJCC stage 3 or 4 malignant melanoma by assessing progression free survival (PFS)|Time to death|Objective Response Rate|Duration of response|Assessment of the safety and tolerability of AZD6244|Investigation of the pharmacokinetics of AZD6244|Assessment of the efficacy of AZD6244 versus temozolomide in patients who are BRAF and BRAF and /or NRAS mutation positive","https://ClinicalTrials.gov/show/NCT00338130"
323,"NCT02046187","Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma","Active, not recruiting","No Results Available","Glioblastoma (GBM)","Dietary Supplement: Ketogenic Diet|Radiation: Radiation therapy|Drug: Temozolomide","St. Joseph's Hospital and Medical Center, Phoenix","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","KD-13BN069","January 17, 2014","October 2013","March 2018","April 19, 2017","April 2017","No Study Results Posted","null","October 2017","Number of participants with adverse events|overall survival|time to progression|quality of life","https://ClinicalTrials.gov/show/NCT02046187"
324,"NCT02358356","Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study","Recruiting","No Results Available","Midgut Neuroendocrine Tumours|Pancreatic Neuroendocrine Tumours","Drug: octreotate|Drug: Capecitabine|Drug: Temozolomide","Australasian Gastro-Intestinal Trials Group","All","18 Years and older   (Adult, Senior)","Phase 2","165","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CTC0120 / AG0114NET","November 4, 2014","November 2015","December 2020","September 18, 2016","September 2016","No Study Results Posted","CONTROL NETS","December 2018","Progression Free Survival|Objective tumour response rate (partial or complete response) as per RECIST v1.1 criteria|Overall survival (death from any cause)|Safety (rates of adverse events worst grade according to NCI CTCAE v4.0)|Quality of life (QOL scores determined at beginning, during treatment and until disease progression)|Resource utilisation (use of healthcare resources) and cost-effectiveness (Health utility score determined at beginning, during treatment and until end of follow up, correlated with MBS & PBS data)|Clinical Benefit","https://ClinicalTrials.gov/show/NCT02358356"
325,"NCT02272270","Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)","Recruiting","No Results Available","Newly Diagnosed High Grade Glioma","Drug: Minocycline with chemoradiation (temozolomide and radiation therapy)","University of Utah","All","18 Years and older   (Adult, Senior)","Phase 1","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCI75289","October 20, 2014","October 2014","October 2019","December 28, 2016","December 2016","No Study Results Posted","D-TERMINED","October 2019","Safety and tolerability of minocycline combined with standard radiation and chemotherapy","https://ClinicalTrials.gov/show/NCT02272270"
326,"NCT00003465","Temozolomide in Treating Patients With Anaplastic Oligodendroglioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide","Duke University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Primary Purpose: Treatment","1534|DUMC-1534-00-8R3|DUMC-1372-97-9|DUMC-1403-98-9R1|DUMC-1550-99-9R2|DUMC-97104|NCI-G98-1468|CDR0000066501","November 1, 1999","March 1998","February 2001","June 19, 2013","October 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003465"
327,"NCT00629343","Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide","Unknown status","No Results Available","Soft Tissue Sarcoma|Mesothelioma","Drug: Azacitidine In Combination With Temozolomide","Columbia University|Schering-Plough|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 1","28","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AAAC3255","February 26, 2008","October 2007","August 2014","November 7, 2012","November 2012","No Study Results Posted","null","October 2012","The primary endpoint is dose limiting toxicity.|Clinical response, time to progression and overall survival.","https://ClinicalTrials.gov/show/NCT00629343"
328,"NCT02617589","An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)","Recruiting","No Results Available","Brain Cancer","Drug: Nivolumab|Drug: Temozolomide|Radiation: Radiotherapy","Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd","All","18 Years and older   (Adult, Senior)","Phase 3","550","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CA209-498|2015-003739-37","November 26, 2015","February 2016","October 2019","April 17, 2017","April 2017","No Study Results Posted","CheckMate 498","March 2019","Overall survival (OS)|Progression free survival (PFS)|Overall survival","https://ClinicalTrials.gov/show/NCT02617589"
329,"NCT01085422","A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: ABT-888|Drug: temozolomide","AbbVie (prior sponsor, Abbott)|Prostate Cancer Clinical Trials Consortium|AbbVie","Male","18 Years and older   (Adult, Senior)","Phase 1","35","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M11-070","March 10, 2010","April 2010","June 2011","January 4, 2013","January 2013","No Study Results Posted","null","June 2011","Protein-specific antigen (PSA) test|Assessment of Efficacy|Assessment of Safety","https://ClinicalTrials.gov/show/NCT01085422"
330,"NCT00006025","Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: irinotecan hydrochloride|Drug: temozolomide","North American Brain Tumor Consortium|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068037|NABTC-9907|UCLA-0006095","July 5, 2000","November 2000","null","November 22, 2008","August 2004","No Study Results Posted","null","May 2008","","https://ClinicalTrials.gov/show/NCT00006025"
331,"NCT01364064","Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma","Completed","No Results Available","Glioblastoma","Drug: TMZ","King Faisal Specialist Hospital & Research Center|Radiation Therapy Oncology Group","All","Child, Adult, Senior","Phase 3","1153","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RAC#2081-018","May 31, 2011","January 2007","June 2008","February 24, 2016","September 2013","No Study Results Posted","null","June 2008","safety and efficacy","https://ClinicalTrials.gov/show/NCT01364064"
332,"NCT00257205","CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy","Completed","No Results Available","Melanoma","Drug: dacarbazine|Drug: CP-675,206|Drug: temozolomide","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 3","655","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A3671009","November 18, 2005","March 2006","August 2010","June 25, 2012","June 2012","No Study Results Posted","null","August 2010","overall survival|adverse events|PFS at 6 months|objective tumor response|Durable response|pharmacokinetics endpoints|pharmacogenomic endpoints|HQol|healthcare resource utilization and loss of productivity|human antihuman antibody response for patients in Arm A","https://ClinicalTrials.gov/show/NCT00257205"
333,"NCT01062399","Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: everolimus|Drug: temozolomide|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","279","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG 0913|RTOG-0913|CDR0000664302|NCI-2011-00885","February 3, 2010","December 2010","null","October 11, 2016","October 2016","No Study Results Posted","RTOG 0913","June 2016","Dose-limiting toxicity (phase I)|Progression-free survival (phase II)|Safety profile of RAD001 in combination with radiation and temozolomide (Phase I)|Overall survival (phase II)|The safety profile of RAD001 in combination with radiation and temozolomide (Phase II)|Akt/mTOR axis predicts response to RAD001 (Phase II)|Association between MGMT status and response to RAD001 (Phase II)","https://ClinicalTrials.gov/show/NCT01062399"
334,"NCT01013285","Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Biological: bevacizumab|Drug: temozolomide|Radiation: external beam radiation therapy","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","70","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000628787|P30CA016042|UCLA-0604016|AVF3770s|IRB#06-04-016-03B|GENENTECH-UCLA-0604016","November 11, 2009","June 2006","January 2017","January 19, 2016","January 2016","No Study Results Posted","null","October 2013","Overall survival|Time to disease progression|Progression-free survival at 6 months|Radiographic response (when evaluable)|Correlation of clinical response with VEGF pathway profiling, gene expression microarray, and MGMT methylation","https://ClinicalTrials.gov/show/NCT01013285"
335,"NCT00003718","Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma","Unknown status","No Results Available","Endometrial Cancer|Ovarian Cancer|Sarcoma","Drug: temozolomide","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other","Interventional","Primary Purpose: Treatment","CDR0000066827|CPMC-IRB-8358|NCI-V98-1510","November 1, 1999","September 1998","null","January 3, 2014","August 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003718"
336,"NCT00003731","Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","39","Other","Interventional","Primary Purpose: Treatment","EORTC-26971","November 1, 1999","December 1998","null","September 20, 2012","September 2012","No Study Results Posted","null","January 2001","","https://ClinicalTrials.gov/show/NCT00003731"
337,"NCT00004113","Temozolomide in Treating Patients With Recurrent Malignant Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","99-019|CDR0000067337|NCI-G99-1602","December 10, 1999","June 1999","October 2001","June 18, 2013","June 2013","No Study Results Posted","null","October 2001","","https://ClinicalTrials.gov/show/NCT00004113"
338,"NCT00004204","Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000067449|CPMC-IRB-8622|SPRI-CPMC-IRB-8622","January 21, 2000","February 2000","null","January 3, 2014","April 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004204"
339,"NCT00003304","Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","29","Other","Interventional","Primary Purpose: Treatment","EORTC-26972","November 1, 1999","April 1998","null","March 5, 2012","March 2012","No Study Results Posted","null","March 2000","","https://ClinicalTrials.gov/show/NCT00003304"
340,"NCT00004106","Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome","Terminated","No Results Available","Lymphoma","Drug: temozolomide","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","29","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU FDA97H3|NU-FDA97H3|NCI-G99-1597|STU00010001","December 10, 1999","May 1998","April 2006","May 31, 2012","May 2012","No Study Results Posted","null","April 2006","Response rate","https://ClinicalTrials.gov/show/NCT00004106"
341,"NCT03149575","VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM","Not yet recruiting","No Results Available","Glioblastoma Multiforme|Glioblastoma|Glioma|GBM|Brain Cancer","Drug: VAL-083, Dianhydrogalactitol|Drug: Physician's Choice of Salvage Therapy - temozolomide|Drug: Physician's Choice of Salvage Therapy - lomustine|Drug: Physician's Choice of Salvage Therapy - carboplatin","DelMar Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","DLM-16-002","May 3, 2017","June 2017","August 2019","May 23, 2017","May 2017","No Study Results Posted","STAR-3","June 2019","Overall Survival|Progression Free Survival|Duration of Response|Incidence of Treatment-Emergent Adverse Events (Overall Safety and Toxicity)|Cmax|Tmax|AUClast|AUCinf|CL/F|Mean Residence Time|Vz|Lambda z|T 1/2|Quality of Life","https://ClinicalTrials.gov/show/NCT03149575"
342,"NCT00006877","Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: temozolomide","Case Comprehensive Cancer Center|National Cancer Institute (NCI)|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|NIH|Industry","Interventional","Primary Purpose: Treatment","SCH1500|CWRU-SCH-1500|CWRU-050002|SPRI-P00349|NCI-G00-1876","December 6, 2000","July 2000","September 2003","January 6, 2014","February 2001","No Study Results Posted","null","September 2003","","https://ClinicalTrials.gov/show/NCT00006877"
343,"NCT01957956","Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","Active, not recruiting","No Results Available","Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma","Other: Laboratory Biomarker Analysis|Biological: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Drug: Temozolomide","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MC1272|NCI-2013-01743|P30CA015083","October 4, 2013","November 2013","November 2017","March 17, 2017","May 2016","No Study Results Posted","null","November 2017","Incidence of significant toxicity, defined as grade 3 or higher adverse event that is possibly, probably, or definitely related to treatment measured using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Change in immunologic correlates|Clinical benefit rate|Duration of response|Overall response rate|Time to response","https://ClinicalTrials.gov/show/NCT01957956"
344,"NCT00076856","Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung|Neoplasm Metastasis|Brain Neoplasms","Drug: Temozolomide","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","95","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","P03247","February 4, 2004","March 31, 2004","March 31, 2006","May 8, 2017","May 2017","No Study Results Posted","null","March 31, 2006","Overall Survival|Time to radiological CNS progression","https://ClinicalTrials.gov/show/NCT00076856"
345,"NCT00005951","Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: irinotecan hydrochloride|Drug: temozolomide","Duke University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","1087|DUMC-1087-02-6R3|DUMC-001087-006R1|DUMC-1067-99-6|NCI-G00-1795|DUMC-001087-01-6R2|CDR0000067931","July 5, 2000","August 2000","April 2006","August 20, 2014","February 2013","No Study Results Posted","null","April 2006","","https://ClinicalTrials.gov/show/NCT00005951"
346,"NCT00978458","Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma","Recruiting","No Results Available","Brain and Central Nervous System Tumors|Neurotoxicity","Drug: temozolomide|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","540","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000654697|ECOG-E3F05","September 16, 2009","September 2009","null","December 4, 2012","December 2012","No Study Results Posted","null","May 2026","Progression-free survival (PFS)|Overall survival (OS)|Quality of life as assessed by the FACT-BR questionnaire at baseline, annually until disease progression, and at the time of disease progression|Neurocognitive functioning as assessed at baseline, annually until disease progression, and at the time of disease progression|Correlation of pre-treatment 1p and 19q levels in tumor tissue samples with PFS and OS","https://ClinicalTrials.gov/show/NCT00978458"
347,"NCT00003062","Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: temozolomide","European Organisation for Research and Treatment of Cancer - EORTC","All","up to 69 Years   (Child, Adult, Senior)","Phase 2","70","Other","Interventional","Primary Purpose: Treatment","EORTC-08965","November 1, 1999","July 1997","null","June 29, 2012","June 2012","No Study Results Posted","null","January 2002","","https://ClinicalTrials.gov/show/NCT00003062"
348,"NCT02654106","Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases","Completed","No Results Available","Brain Metastases","Radiation: Fractionated Stereotactic Radiotherapy|Drug: Temozolomide","Chinese Academy of Medical Sciences|Cancer Foundation, China","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","65","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-H&N-003","January 10, 2016","October 2011","November 2015","January 11, 2016","January 2016","No Study Results Posted","SRTRBM","November 2015","Objective response rate|Overall survival rate|progress free survival rate|local control rate|intracranial progress free survival rate|adverse event|causes of death","https://ClinicalTrials.gov/show/NCT02654106"
349,"NCT00138216","Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: irinotecan hydrochloride|Drug: temozolomide|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 1","42","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ADVL0414|COG-ADVL0414|CDR0000440069","August 29, 2005","October 2005","January 2011","February 18, 2014","February 2014","No Study Results Posted","null","June 2009","Determine maximum tolerated dose (MTD) of oral irinotecan|To preliminarily define the antitumor activity","https://ClinicalTrials.gov/show/NCT00138216"
350,"NCT00394628","AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme","Unknown status","No Results Available","Glioblastoma Multiforme","Drug: AQ4N|Drug: Temozolomide|Procedure: Radiotherapy","Novacea","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","021-003","October 31, 2006","October 2006","null","May 29, 2007","May 2007","No Study Results Posted","null","null","Phase 1b: Evaluation of the safety and tolerability of AQ4N in combination with radiation therapy and temozolomide (TEMODAR®)for the treatment of glioblastoma multiforme (GBM). Dose levels for the Phase 2a will be selected.|Phase 2a: Rate of progression-free survival at 6 months.|Phase 2a: Rate of progression-free survival at 12 months|Percent of subjects alive at 12 months|Duration of progression-free survival|Time to progression|Duration of overall survival","https://ClinicalTrials.gov/show/NCT00394628"
351,"NCT00512798","Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma","Terminated","Has Results","Brain and Central Nervous System Tumors|Melanoma|Solid Tumor","Drug: PS-341 (VELCADE)|Drug: temozolomide|Other: immunoenzyme technique|Drug: PS-341 (VELCADE)|Drug: Temozolomide","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","47","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC PHI 0241|VU-VICC-PHI-0241|VU-VICC-IRB-020510","August 6, 2007","June 2003","March 2008","September 19, 2012","September 2012","June 27, 2012","null","July 2006","Optimal Doses of Temozolomide and Bortezomib (Phase I)|Number of Patients With Clinical Anti-tumor Activity Phase II)|Patients With Inhibition in NF-kB Activation (Phase I)|Patients With Clinical Anti-tumor Activity (Phase I)|Patients With Inhibition of NF-kB (Phase II)","https://ClinicalTrials.gov/show/NCT00512798"
352,"NCT00096265","Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer","Terminated","Has Results","Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer|Tumors Metastatic to Brain","Drug: erlotinib hydrochloride|Radiation: 3-dimensional conformal radiation therapy|Radiation: stereotactic radiosurgery|Drug: temozolomide","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","126","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00720|CDR0000389490|RTOG 0320|RTOG-0320|U10CA021661","November 9, 2004","October 2004","April 2012","May 5, 2014","October 2011","March 5, 2013","null","June 2011","Overall Survival|Time to CNS Progression|Quality-adjusted Survival as Measured by EuroQol 5-dimension Instrument|Change in Functional Assessment of Cancer Therapy-Brain Subscale Questionnaire|Change in Performance Status|Change in Steroid Dependence|Cause of Death (Neurologic vs Other)","https://ClinicalTrials.gov/show/NCT00096265"
353,"NCT00027742","Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma","Completed","No Results Available","Intraocular Melanoma|Melanoma (Skin)","Biological: pegylated interferon alfa|Drug: temozolomide","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","01-005|CDR0000069062|NCI-G01-2031","December 7, 2001","May 2001","June 2005","June 4, 2013","June 2013","No Study Results Posted","null","June 2005","","https://ClinicalTrials.gov/show/NCT00027742"
354,"NCT00005955","Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Neuroblastoma","Drug: temozolomide","Duke University|National Cancer Institute (NCI)","All","4 Years to 21 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","0931|DUMC-0931-02-6R3|DUMC-000931-00-5R1|DUMC-0831-99-5|NCI-G00-1799|DUMC-000931-01-6R1|CDR0000067936","July 5, 2000","August 2000","September 2002","June 19, 2013","October 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005955"
355,"NCT01830101","A Phase III Study of Re-Irradiation in Recurrent Glioblastoma","Withdrawn","No Results Available","Recurrent Glioblastoma","Drug: TMZ plus concurrent re-irradiation|Drug: Temozolomide","AHS Cancer Control Alberta","All","18 Years and older   (Adult, Senior)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CCI-Patel-01","March 13, 2013","February 2014","November 2017","March 14, 2016","February 2014","No Study Results Posted","null","May 2015","To determine the overall median survival of the combination of continuous dose-intense temozolomide with or without re-irradiation in patients with recurrent glioblastoma.|To evaluate time to radiographic progression or recurrence of tumour following treatment with continuous dose-intense temozolomide with or without re-irradiation.","https://ClinicalTrials.gov/show/NCT01830101"
356,"NCT00085254","Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","Has Results","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma","Drug: cilengitide|Drug: temozolomide|Radiation: radiation therapy|Other: laboratory biomarker analysis|Other: pharmacological study","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","112","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02932|NABTT 0306|CDR0000368451|U01CA062475","June 10, 2004","April 2005","November 2012","January 28, 2016","October 2015","May 5, 2015","null","November 2012","Dose Limiting Toxicities of EMD + RT and TMZ|Maximum Tolerated or Tolerable Dose (MTD) - 3 Pre-defined Doses|Overall Survival (Phase II)|Overall Survival Based on Dose Level - Phase 2|Frequency of Hematologic and Nonhematologic Adverse Events","https://ClinicalTrials.gov/show/NCT00085254"
357,"NCT00034697","Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)","Terminated","No Results Available","Metastases, Neoplasm|Carcinoma, Non-Small-Cell Lung|Brain Neoplasms","Drug: temozolomide","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (masked roles unspecified)|Primary Purpose: Treatment","P02143","May 1, 2002","June 28, 2001","January 30, 2003","May 22, 2017","May 2017","No Study Results Posted","null","January 30, 2003","","https://ClinicalTrials.gov/show/NCT00034697"
358,"NCT01236560","Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma","Active, not recruiting","No Results Available","Childhood Cerebellar Anaplastic Astrocytoma|Childhood Cerebral Anaplastic Astrocytoma|Childhood Spinal Cord Neoplasm|Untreated Childhood Brain Stem Glioma|Untreated Childhood Cerebral Astrocytoma","Biological: Bevacizumab|Drug: Temozolomide|Drug: Vorinostat","National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2|Phase 3","268","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-02616|CDR0000688443|ACNS0822|U10CA098543","November 5, 2010","November 15, 2010","null","May 23, 2017","May 2017","No Study Results Posted","null","March 31, 2019","Event-free survival of patients in each treatment arm, defined as time to first occurrence of disease progression, relapse, second malignant neoplasm, or death from any cause|Maximum tolerated dose (MTD) of vorinostat when given concurrently with radiation therapy determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) (feasability study)|Overall survival of patients in each treatment arm|Progression-free survival of patients in each treatment arm","https://ClinicalTrials.gov/show/NCT01236560"
359,"NCT01345370","Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients","Completed","No Results Available","Glioblastoma","Drug: Temozolomide|Radiation: Radiation Therapy","Center Eugene Marquis|Rennes University Hospital","All","18 Years to 70 Years   (Adult, Senior)","","300","Other","Observational","Time Perspective: Prospective","ECOM-Glioblastome","April 20, 2011","March 2009","June 2015","January 28, 2016","January 2016","No Study Results Posted","ECOM","April 2015","Survival of patients according to their MGMT status.|Progression-Free Survival","https://ClinicalTrials.gov/show/NCT01345370"
360,"NCT00703859","Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma","Withdrawn","No Results Available","Glioblastoma","Drug: Dichloroacetate (DCA)","AHS Cancer Control Alberta","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CNS-24139","June 23, 2008","July 2008","null","February 18, 2016","September 2011","No Study Results Posted","null","January 2010","Safety and tolerability of DCA in combination with radiotherapy and temozolomide in an adjuvant setting for the treatment of newly diagnosed GBM patients.|To determine if there is a correlation between MGMT promoter methylation status and progression-free survival for newly diagnosed GBM patients undergoing concurrent TMZ, DCA and RT followed by six monthly cycles of TMZ and DCA","https://ClinicalTrials.gov/show/NCT00703859"
361,"NCT00006043","Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin","Completed","No Results Available","Ovarian Cancer|Testicular Germ Cell Tumor","Drug: temozolomide","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","00-010|CDR0000068058|NCI-G00-1817","July 5, 2000","February 2000","November 2001","June 4, 2013","June 2013","No Study Results Posted","null","November 2001","","https://ClinicalTrials.gov/show/NCT00006043"
362,"NCT00272415","A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma","Terminated","No Results Available","Melanoma","Drug: INO-1001|Drug: temozolomide","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","39","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IPC-06-2004|INO4136g","January 3, 2006","October 2005","null","March 9, 2009","November 2007","No Study Results Posted","null","null","Maximum tolerated dose (MTD) or recommended Phase II dose of INO-1001 to be used in combination with TMZ|Pharmacokinetic (PK) profile of intravenous INO-1001|Safety and tolerability of combined therapy with oral temozolomide (TMZ) and intravenous INO-1001|Safety of repeat dosing|Pharmacodynamic (PD) activity of intravenous INO-1001|Response|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00272415"
363,"NCT02343406","Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: ABT-414|Drug: Lomustine|Drug: Temozolomide","AbbVie|European Organisation for Research and Treatment of Cancer - EORTC","All","up to 99 Years   (Child, Adult, Senior)","Phase 2","260","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","M14-483|2014-004438-24|EORTC 1410-BTG","December 22, 2014","February 11, 2015","June 11, 2020","May 1, 2017","May 2017","No Study Results Posted","INTELLANCE 2","December 27, 2019","Adult study: Overall Survival (OS)|Adult study: Progression Free Survival (PFS)|Pediatric study: Safety including toxicities according to CTCAE criteria|Pediatric study: Maximum observed serum concentration (Cmax) for ABT-414|Pediatric study: Half-life (t1/2) observed for ABT-414|Pediatric study: Area Under the Concentration-time Curve (AUC) observed for ABT-414|Pediatric study: Maximum observed plasma concentration (Cmax) for Cys-mcMMAF (toxin, identified as a metabolite of ABT-414)|Pediatric study: t1/2 for Cys-mcMMAF (toxin, identified as a metabolite of ABT-414)|Pediatric study: AUC for Cys-mcMMAF (toxin, identified as a metabolite of ABT-414)|Adult study: Overall Response Rate (ORR)|Adult study: Overall Survival in the subgroup with Epithelial Growth Factor Receptor (EGFRvIII) mutation|Pediatric study: Objective response rate, best response rate and duration of response based on RANO criteria|Pediatric study: Overall survival, Time to progression and Time to progression-free survival|Pediatric study: Changes in neurological status and function (including PedsQL cancer module)","https://ClinicalTrials.gov/show/NCT02343406"
364,"NCT02595424","Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery","Recruiting","No Results Available","Colorectal Large Cell Neuroendocrine Carcinoma|Esophageal Large Cell Neuroendocrine Carcinoma|Gallbladder Large Cell Neuroendocrine Carcinoma|Gastric Large Cell Neuroendocrine Carcinoma|Pancreatic Large Cell Neuroendocrine Carcinoma|Small Intestinal Large Cell Neuroendocrine Carcinoma","Drug: Capecitabine|Drug: Cisplatin|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Temozolomide","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","126","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EA2142|NCI-2015-00547|NCI-2015-00505|U10CA180820","November 2, 2015","November 2015","null","January 5, 2016","January 2016","No Study Results Posted","null","January 2018","PFS|Incidence of toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|OS|Response rate (complete response or partial response) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1","https://ClinicalTrials.gov/show/NCT02595424"
365,"NCT00098436","Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias","Completed","No Results Available","Leukemia","Drug: laromustine|Drug: temozolomide","Vion Pharmaceuticals|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","25","Industry","Interventional","Masking: Open Label|Primary Purpose: Treatment","VION-CLI-036|CDR0000405825|CWRU-050419","December 7, 2004","September 2004","August 2008","July 17, 2013","August 2008","No Study Results Posted","null","October 2006","","https://ClinicalTrials.gov/show/NCT00098436"
366,"NCT00005952","Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Head and Neck Cancer|Kidney Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor","Biological: filgrastim|Drug: temozolomide|Procedure: peripheral blood stem cell transplantation","Duke University|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 1|Phase 2","30","Other|NIH","Interventional","Primary Purpose: Treatment","1735|DUMC-1735-04-9R5|DUMC-1735-02-9R3|DUMC-1735-01-9R2|DUMC-1833-99-10|NCI-G00-1796|CDR0000067932","July 5, 2000","August 2000","November 2005","June 19, 2013","February 2013","No Study Results Posted","null","November 2005","Overall response at 12 months|Disease-free survival at 12 months|Toxicity by NCI Common Toxicity Criteria v. 3.0 at 12 months|Engraftment related to autologous marrow or peripheral blood stem cell transplantation at 12 months","https://ClinicalTrials.gov/show/NCT00005952"
367,"NCT01700569","Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma","Recruiting","No Results Available","Grade IV Astrocytoma|Glioblastoma","Drug: Temozolomide|Drug: folinic acid at pharmacological dose is the escalated drug|Radiation: High voltage radiation therapy (linear accelerator)","Institut Cancerologie de l'Ouest|Centre Antoine Lacassagne","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ICO 2012-02|2012-000774-31","September 12, 2012","January 2013","March 2018","August 30, 2016","August 2016","No Study Results Posted","FOLAGLI","March 2017","Maximal Tolerated Dose|MGMT gene re-methylation","https://ClinicalTrials.gov/show/NCT01700569"
368,"NCT00112502","Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: Celecoxib|Drug: Isotretinoin|Drug: Temozolomide|Drug: Thalidomide","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","178","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2004-0662|MDA-ID-02586|NCI-6636|MDA-2004-0662|CDR0000432954|NCI-2009-00076","June 2, 2005","September 2005","null","September 23, 2014","September 2014","No Study Results Posted","null","September 2014","Progression-free survival at 6 months","https://ClinicalTrials.gov/show/NCT00112502"
369,"NCT00238251","Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases","Completed","No Results Available","Lung Cancer|Metastatic Cancer","Drug: gefitinib|Drug: temozolomide|Radiation: radiation therapy","Swiss Group for Clinical Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 2","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 70/03|EU-20526","October 12, 2005","May 2005","November 2010","June 4, 2012","June 2012","No Study Results Posted","null","April 2009","Overall survival|Time to progression|Time to neurological progression|Time to extracranial disease progression|Adverse events as measured at completion of study treatment","https://ClinicalTrials.gov/show/NCT00238251"
370,"NCT01124240","Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene","Unknown status","No Results Available","Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4","Drug: Cilengitide","Northern Sydney and Central Coast Area Health Service|Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 2","48","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0910259M","May 13, 2010","November 2009","January 2014","July 25, 2011","July 2011","No Study Results Posted","ExCentric","November 2012","12 month progression free survival|Objective response|Toxicity|Peripheral WBC MGMT modulation|biomarker correlation with response","https://ClinicalTrials.gov/show/NCT01124240"
371,"NCT01450826","Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide","Recruiting","No Results Available","Nausea|Vomiting|Glioma","Drug: Aprepitant|Drug: Ondansetron","Katy Peters|Merck Sharp & Dohme Corp.|Duke University","All","18 Years and older   (Adult, Senior)","Phase 2","136","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00031206","October 10, 2011","December 2012","June 2018","July 22, 2016","July 2016","No Study Results Posted","null","June 2017","Proportion of patients achieving an acute and delayed complete response (CR)|Proportion of patients achieving complete control (CC)|Patient's global satisfaction with the antiemetic regimen|Time to treatment failure","https://ClinicalTrials.gov/show/NCT01450826"
372,"NCT00516607","Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: enzastaurin hydrochloride|Drug: temozolomide|Other: pharmacological study","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 1","28","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-26054","August 14, 2007","July 2007","null","February 9, 2015","February 2015","No Study Results Posted","null","November 2008","Recommended phase II dose|Dose-limiting toxicity|Response rate|Progression-free survival|Overall survival|Pharmacokinetics of enzastaurin hydrochloride alone and in combination with temozolomide","https://ClinicalTrials.gov/show/NCT00516607"
373,"NCT00268684","Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC","Unknown status","No Results Available","Carcinoma, Non-Small-Cell Lung|Neoplasm Metastasis","Drug: Erlotinib, Temozolomide","Tel-Aviv Sourasky Medical Center|Radiation Therapy Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 3","381","Other","Interventional","","TASMC-05-FB-05235-CTIL","December 21, 2005","May 2005","null","February 27, 2006","December 2005","No Study Results Posted","null","null","survival","https://ClinicalTrials.gov/show/NCT00268684"
374,"NCT01812616","A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients","Completed","No Results Available","Cancer","Drug: Sativex|Drug: Placebo","GW Research Ltd","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GWCA1208 Part B","March 14, 2013","September 2014","June 2016","August 10, 2016","August 2016","No Study Results Posted","null","June 2016","Incidence of Adverse Events as a Measure of Patient Safety.|The number of patients with Progression Free Survival at six months (PFS6)|Overall Survival","https://ClinicalTrials.gov/show/NCT01812616"
375,"NCT00083096","Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: lonafarnib|Drug: temozolomide","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","EORTC-16027-26023|EORTC-16027|EORTC-26023|SPRI-P03174","May 14, 2004","March 2004","null","February 9, 2015","February 2015","No Study Results Posted","null","June 2009","Dose-limiting toxicity and maximum tolerated dose of lonafarnib determined by CTCAE v3.0|Response (complete [CR] or partial response [PR]) measured by McDonald's criteria at least 4 weeks after first documented response and every 8 weeks until disease progression or until start of another treatment","https://ClinicalTrials.gov/show/NCT00083096"
376,"NCT00006474","Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: O6-benzylguanine|Drug: temozolomide|Procedure: conventional surgery","Duke University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","1388|DUMC-1388-02-8R2|DUMC-1388-00-8|NCI-490|DUMC-1388-01-8R1|CDR0000068301","November 6, 2000","March 2001","August 2004","June 19, 2013","February 2013","No Study Results Posted","null","August 2004","","https://ClinicalTrials.gov/show/NCT00006474"
377,"NCT02490930","A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma","Recruiting","No Results Available","Glioblastoma|Anaplastic Astrocytoma","Drug: Fingolimod","Sidney Kimmel Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","J14168|IRB00055036","July 2, 2015","July 2015","June 2017","August 24, 2016","August 2016","No Study Results Posted","null","June 2017","Incidence of severe infection attributable to fingolimod-induced lymphopenia|Total lymphocyte counts (TLC)","https://ClinicalTrials.gov/show/NCT02490930"
378,"NCT02599090","Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma","Withdrawn","No Results Available","Glioblastoma|Gliosarcoma","Drug: Temozolomide|Radiation: Radiation|Drug: Sorafenib","M.D. Anderson Cancer Center|Bayer","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-0059 Phase II|NCI-2012-01617","November 4, 2015","December 2008","December 2012","November 4, 2015","November 2015","No Study Results Posted","null","December 2012","Time to Progression","https://ClinicalTrials.gov/show/NCT02599090"
379,"NCT00547131","Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Metastatic Cancer","Drug: temozolomide|Other: laboratory biomarker analysis|Other: liquid chromatography|Other: mass spectrometry|Other: pharmacological study|Procedure: conventional surgery|Radiation: stereotactic radiosurgery","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","12","Other|NIH","Interventional","Primary Purpose: Treatment","05117|P30CA033572|CHNMC-05117|CDR0000570280","October 19, 2007","January 2006","May 2009","October 18, 2011","October 2011","No Study Results Posted","null","May 2008","Incidence rate of clinically symptomatic intratumoral hemorrhage|Incidence rate of CNS infection|Incidence rate of catheter malfunction|Systemic and intracerebral pharmacokinetic profile of temozolomide using a microdialysis catheter","https://ClinicalTrials.gov/show/NCT00547131"
380,"NCT00734526","Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma","Completed","No Results Available","Glioblastoma|Gliosarcoma","Drug: Temozolomide|Radiation: Radiation|Drug: Sorafenib","M.D. Anderson Cancer Center|Bayer","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-0059|NCI-2012-01617","August 12, 2008","December 2008","December 2012","November 4, 2015","November 2015","No Study Results Posted","null","December 2012","Phase I: Sorafenib Maximum Tolerated Dose (MTD)|Second MTD|Phase II: Time to Progression","https://ClinicalTrials.gov/show/NCT00734526"
381,"NCT02715609","Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: Disulfiram|Drug: Copper Gluconate|Procedure: Surgery|Radiation: Radiation|Drug: Temozolomide","Washington University School of Medicine|University of Calgary","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201604115","March 9, 2016","June 15, 2016","June 30, 2020","May 18, 2017","May 2017","No Study Results Posted","null","December 31, 2017","Maximum tolerated dose (MTD) of the regimen|Toxicity associated with DSF when given concurrently with radiation therapy and temozolomide as measured by the grade and frequency of adverse events|Intratumoral drug uptake of DSF and its metabolites in resected GBM tissue|Proteasome inhibition of DSF on GBM tissues|Effect of DSF on DNA breaks on GBM tissues|Time to tumor progression (TTP)|Rate of pseudo-progression (PsP)|Progression-free survival (PFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02715609"
382,"NCT00003464","Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Radiation: radiation therapy","Duke University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other|NIH","Interventional","Primary Purpose: Treatment","1171|DUMC-1171-01-6R4|DUMC-1016-97-7|DUMC-1056-98-7R1|DUMC-1058-98-7R1|DUMC-1171-00-6R3|DUMC-1231-99-7R2|DUMC-97081|NCI-G98-1465|CDR0000066498","November 1, 1999","September 1997","August 2003","June 19, 2013","October 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003464"
383,"NCT00568451","Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma","Terminated","Has Results","Melanoma (Skin)","Drug: carboplatin|Drug: paclitaxel|Drug: temozolomide","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","12","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MC057F|P30CA015083|06-002547|NCI-2010-01794","December 5, 2007","June 2006","April 2012","November 25, 2015","March 2014","November 1, 2011","null","May 2009","Number of Participants With an Objective Tumor Status of Either a Complete Response(CR) or Partial Response (PR), According to RECIST (Response Evaluation Criteria in Solid Tumors) Criteria|Time to Disease Progression|Survival Time|Duration of Response for All Evaluable Patients Who Have Achieved an Objective Response|Number of Participants Who Experienced Changes in Immunologic Profile (CD4/CD25+ Cells, CD4/Fox-p3+ T Cells) Within a Treatment|Number of Participants Who Experienced Changes in Immunologic Profile (MART-1, Tyrosinase, and gp100) Within a Treatment|Number of Participants Who Experienced Changes in Immunologic Profile (IFNγ Producing Peptide Specific CTLs) Within a Treatment","https://ClinicalTrials.gov/show/NCT00568451"
384,"NCT00006353","Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC|NCIC Clinical Trials Group","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","575","Other","Interventional","Primary Purpose: Treatment","EORTC-26981-22981|EORTC-26981|CAN-NCIC-CE3|EORTC-22981","October 4, 2000","July 2000","null","September 20, 2012","September 2012","No Study Results Posted","null","March 2002","","https://ClinicalTrials.gov/show/NCT00006353"
385,"NCT02661282","Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients","Recruiting","No Results Available","Glioblastoma|Gliosarcoma","Drug: Temozolomide|Biological: T Cell Infusion|Procedure: Surgery|Behavioral: Phone Calls","M.D. Anderson Cancer Center|Marnie Rose Foundation|Gateway for Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2014-0899|NCI-2016-00183","January 14, 2016","June 2016","June 2020","May 4, 2017","May 2017","No Study Results Posted","null","June 2020","Maximum Tolerated Dose (MTD) of CMV-T Cells|Immunological Effects in Tumor Tissue|Tumor-Mediated Immune Suppression at the Effector Location|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02661282"
386,"NCT00401180","Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: docetaxel|Drug: temozolomide","The Cleveland Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE-CCF-4737|P30CA043703","November 16, 2006","June 2002","July 2008","July 6, 2011","September 2007","No Study Results Posted","null","July 2008","Maximum tolerated dose|Dose-limiting toxicity","https://ClinicalTrials.gov/show/NCT00401180"
387,"NCT01478854","Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide","Active, not recruiting","No Results Available","Glioblastoma Multiforme","Radiation: Radiation|Drug: Chemotherapy","Sidney Kimmel Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J-10100|NA_00042009","November 3, 2011","May 2011","January 2016","November 17, 2015","November 2015","No Study Results Posted","null","January 2016","NPC Sparing|radiation dose sparing assessment|Number of Participants with Cognitive Adverse Events|Oral assessments after treatment","https://ClinicalTrials.gov/show/NCT01478854"
388,"NCT02308527","Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children","Recruiting","No Results Available","Neuroblastoma","Drug: Bevacizumab|Drug: Temozolomide|Drug: Temozolomide|Drug: Irinotecan|Drug: Bevacizumab|Drug: Topotecan|Drug: Temozolomide","University of Birmingham|Cancer Research UK|Roche Pharma AG","All","1 Year to 21 Years   (Child, Adult)","Phase 2","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment","RG_11-087|2012-000072-42","September 10, 2014","July 2013","January 2022","May 5, 2017","May 2017","No Study Results Posted","BEACON","July 2018","Best response (Complete Response or Partial Response) while on trial treatment, within 18 or 24 weeks depending on the arm of the trial participant is randomised to.|To evaluate the toxicity of the regimens|To evaluate the safety of the regimens|To evaluate the overall safety of the regimens","https://ClinicalTrials.gov/show/NCT02308527"
389,"NCT02092038","Preoperative Chemoradiation for Glioblastoma","Completed","No Results Available","Glioblastoma","Drug: Temozolomide|Radiation: partial brain irradiation|Procedure: stereotactic biopsy of brain tumor|Procedure: craniotomy and tumor resection","Tampa General Hospital","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TGH0001","March 11, 2014","November 2014","July 2015","November 7, 2015","November 2015","No Study Results Posted","null","July 2015","toxicity of treatment per Common Toxicity Criteria for Adverse Effects V3.0|Feasibility of measurement of O(6)-Methylguanine-DNA methyltransferase (MGMT) activity on stereotactic samples|progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT02092038"
390,"NCT02343549","A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)","Recruiting","No Results Available","Cancer of Brain and Nervous System","Device: bevacizumab, NovoTTF100A, temozolomide","Ashley Love Sumrall|NovoCure Ltd.|Carolinas Healthcare System","All","22 Years and older   (Adult, Senior)","Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LCI-NEU-NOV-001|00010270","January 16, 2015","January 2015","June 2017","February 3, 2017","February 2017","No Study Results Posted","null","June 2017","Survival at 12 months","https://ClinicalTrials.gov/show/NCT02343549"
391,"NCT00385398","QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC","Withdrawn","No Results Available","Lung Cancer|Metastatic Cancer","Drug: erlotinib hydrochloride|Drug: temozolomide|Radiation: stereotactic radiosurgery","University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Schering-Plough|Genentech, Inc.|Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","030601|P30CA072720|0220060108|CINJ-NJ1506|CDR0000539474","October 5, 2006","July 2008","December 2008","August 29, 2013","August 2013","No Study Results Posted","null","December 2008","Cognitive function|Tumor response|Time to tumor progression in brain|Survival|Quality of life as measured by FACT subscale|Physical functioning as measured by Karnofsky performance status and Katz index of activities of daily living|Frequency of O6-methylguanine-DNA methyltransferase promoter methylation","https://ClinicalTrials.gov/show/NCT00385398"
392,"NCT00602576","Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma","Unknown status","No Results Available","Melanoma (Skin)","Drug: sorafenib tosylate|Drug: temozolomide","University of Pennsylvania|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","167","Other|NIH","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000580808|UPCC-06604|UPCC-802514|SPRI-UPCC-06604","January 25, 2008","January 2005","null","August 12, 2009","August 2009","No Study Results Posted","null","March 2008","Progression-free survival|Response rate|Development of new brain metastasis","https://ClinicalTrials.gov/show/NCT00602576"
393,"NCT00033709","Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma","Unknown status","No Results Available","Sarcoma","Drug: temozolomide|Drug: thalidomide","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069314|CPMC-IRB-14323|NCI-G02-2060","April 9, 2002","March 2002","null","January 3, 2014","May 2005","No Study Results Posted","null","null","Response (complete and partial response)|Time to progression|Overall survival|Clinical benefit","https://ClinicalTrials.gov/show/NCT00033709"
394,"NCT00920595","Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors","Completed","No Results Available","Solid Tumor","Drug: CEP-9722","Cephalon|Teva Pharmaceutical Industries","All","18 Years and older   (Adult, Senior)","Phase 1","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C9722/1065/PK/FR-UK|EudraCT number: 2008-006858-18","June 11, 2009","June 2009","October 2011","August 14, 2012","August 2012","No Study Results Posted","null","October 2011","Determination of Maximum Tolerated Dose (MTD) upon Dose Limiting Toxicities (DLT) data|Pharmacokinetic parameters|Pharmacodynamics assay|Efficacy - will be assessed by the proportion of patients who achieve tumor response during the study","https://ClinicalTrials.gov/show/NCT00920595"
395,"NCT00626405","Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery","Completed","No Results Available","Melanoma (Skin)","Biological: bevacizumab|Drug: carboplatin|Drug: paclitaxel albumin-stabilized nanoparticle formulation|Drug: temozolomide","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","95","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","NCCTG-N0775|NCI-2009-00667|CDR0000587708","February 28, 2008","August 2008","November 2012","August 12, 2016","August 2016","No Study Results Posted","null","July 2010","Progression-free survival at 6 months|Toxicity as measured by NCI CTCAE version 3.0|Tumor response rate|Overall survival|Percent change in number of T, B, NK and dendritic cells from baseline|Percent change in plasma concentrations of IL-1β, IL-1rα, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF, RANTES, TNF-α, and VEGF from baseline","https://ClinicalTrials.gov/show/NCT00626405"
396,"NCT00805961","RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM","Completed","Has Results","Glioblastoma Multiforme","Radiation: Radiation therapy|Drug: Temozolomide|Drug: Bevacizumab|Drug: Bevacizumab|Drug: Everolimus","SCRI Development Innovations, LLC|Genentech, Inc.|Novartis","All","18 Years and older   (Adult, Senior)","Phase 2","68","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI CNS 10","December 9, 2008","January 2009","May 2013","July 1, 2013","August 2012","August 22, 2012","null","October 2009","Progression-free Survival (PFS)|To Assess the Toxicity of This Novel Multimodality Regimen|To Assess the Overall Survival of Patients With Glioblastoma Multiforme Following Treatment With This Novel Multimodality Regimen|To Assess the Complete Response Rate of Patients With Glioblastoma Multiforme Following Treatment With This Novel Multimodality Regimen","https://ClinicalTrials.gov/show/NCT00805961"
397,"NCT01478321","Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas","Active, not recruiting","No Results Available","Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma","Drug: Temozolomide|Radiation: hypofractionated radiation therapy|Biological: bevacizumab|Other: questionnaire administration","Northwestern University","All","18 Years and older   (Adult, Senior)","Phase 2","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NU 11C02|STU00053636|NCI CTRP#","November 17, 2011","November 2011","November 2019","March 28, 2017","March 2017","No Study Results Posted","null","November 2018","OS|Change in neurological status|Safety profile|PFS","https://ClinicalTrials.gov/show/NCT01478321"
398,"NCT02311920","Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma","Recruiting","No Results Available","Gliosarcoma|Supratentorial Glioblastoma","Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Drug: Temozolomide","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","42","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2014-02404|PNRG-BN002_R05PAPP02|NRG-BN002|U10CA180868","December 8, 2014","April 2015","null","April 24, 2017","April 2017","No Study Results Posted","null","July 2017","Immune-related DLTs for the combination of ipilimumab and nivolumab when given with temozolomide|Immune-related DLTs for the single-agent treatment with nivolumab|Immune-related dose-limiting toxicities (DLTs) for the single-agent treatment with ipilimumab|Biomarker analysis of immune cells within tumor samples using standard immunohistochemistry|Incidence of adverse events, graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Number of patients who are alive","https://ClinicalTrials.gov/show/NCT02311920"
399,"NCT02520635","Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients","Recruiting","No Results Available","Glioblastoma","Drug: supra-early TEMODAL® chemotherapy|Drug: standard TEMODAL® chemotherapy|Radiation: Radiotherapy 60Gy","Beijing Tiantan Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","B0008","June 26, 2015","January 2015","December 2017","October 6, 2016","October 2016","No Study Results Posted","null","December 2016","progression free survival|Overall Survival (OS)|Objective Response Rate|Treatment-related adverse event","https://ClinicalTrials.gov/show/NCT02520635"
400,"NCT01220271","A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma","Completed","No Results Available","Glioma","Drug: LY2157299|Drug: Radiation|Drug: Temozolomide","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","11585|H9H-MC-JBAI","October 12, 2010","April 2011","November 2016","February 15, 2017","February 2017","No Study Results Posted","null","August 2015","Phase 1: Recommended dose for Phase 2 portion|Phase 2: Relationship of change in response biomarker to clinical benefit|Phase 1: Pharmacokinetics - Concentration Maximum|Phase 1: Number of patients with a tumor response|Phase 2: Overall Survival at 12 Months|Phase 2: Overall Survival|Phase 2: Progression Free Survival|Phase 2: Proportion of patients achieving an objective response (Response Rate)|Phase 2: Duration of tumor Response|Phase 2: Time to Treatment Failure|Phase 1: Pharmacokinetics - Time to Concentration Maximum|Phase 1: Pharmacokinetics - Area under the Curve|Phase 2: Change from baseline in MD Anderson Symptom Inventory - Brain Tumor","https://ClinicalTrials.gov/show/NCT01220271"
401,"NCT02805179","A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma","Not yet recruiting","No Results Available","Glioma","Radiation: High Dose Radiation|Drug: Temozolomide","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2012.006|HUM00107355","May 12, 2016","September 2016","null","August 11, 2016","August 2016","No Study Results Posted","null","June 2019","Number of patients alive at 12 months|Number of patients alive without progression at 12 months|Radiographic response rate|Calculated difference between tumor volume measured by 11C Methionine Positron Emission Tomography (MET-PET) and diffusion MRI","https://ClinicalTrials.gov/show/NCT02805179"
402,"NCT02943733","Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs","Not yet recruiting","No Results Available","Neuroendocrine Tumors|Neoplasms|Cancer|Tumors","Drug: TAS-102|Drug: Temozolomide","University of Wisconsin, Madison|National Cancer Institute (NCI)|Taiho Pharmaceutical Co., Ltd.","All","18 Years and older   (Adult, Senior)","Phase 1","39","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UW16034|P30CA014520|NCI-2016-01567|2016-0930","October 21, 2016","November 2016","August 2020","October 21, 2016","October 2016","No Study Results Posted","null","August 2019","Part 1: Maximum Tolerated Dose (MTD) of TAS-102|Part 2: Overall Response Rate|Part 2: Progression Free Survival (PFS)|Part 2: Overall Survival|Part 2: Disease Control Rate|Part 2: Duration of Response|Part 2: Safety and Tolerability, Assessed per RECIST Criteria|Part 2: Biochemical Response defined as normalization or >50% reduction in levels of Chromogranin A","https://ClinicalTrials.gov/show/NCT02943733"
403,"NCT00876993","Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors","Completed","No Results Available","Central Nervous System Tumors","Drug: Bevacizumab|Drug: Irinotecan|Drug: Temozolomide","Johns Hopkins All Children's Hospital|V Foundation","All","18 Months to 23 Years   (Child, Adult)","Phase 1","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ACH-CNS-001","April 6, 2009","September 2008","September 2015","May 17, 2017","May 2017","No Study Results Posted","null","September 2015","To conduct a phase I study to evaluate the safety of this combination of chemotherapy agents.|To determine the response of children with recurrent or refractory central nervous system tumors with this combination of chemotherapy agents.|To compare the response and toxicity with historical controls with the same disease.|To estimate the 2 and 5 year survival with children treated with this regimen.|To provide safety and efficacy data for to recommend further larger studies.","https://ClinicalTrials.gov/show/NCT00876993"
404,"NCT00003176","Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: carmustine|Drug: temozolomide","North American Brain Tumor Consortium|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","82","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000065986|NABTC-9701|NCI-T96-0082","November 1, 1999","January 1998","null","December 13, 2008","January 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003176"
405,"NCT00020150","Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Kidney Cancer|Liver Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: O6-benzylguanine|Drug: temozolomide","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 1","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000067880|NCI-00-C-0105I|NCI-237","July 11, 2001","June 2000","null","April 28, 2015","August 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00020150"
406,"NCT00021307","Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme","Withdrawn","No Results Available","Brain and Central Nervous System Tumors","Drug: carboplatin|Drug: temozolomide","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other|NIH","Interventional","Primary Purpose: Treatment","FCCC-01004|CDR0000068768|NCI-G01-1981","July 11, 2001","null","April 2002","July 10, 2013","July 2013","No Study Results Posted","null","April 2002","","https://ClinicalTrials.gov/show/NCT00021307"
407,"NCT00014261","Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Biological: PEG-interferon alfa-2b|Drug: temozolomide","Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068523|P30CA023108|DMS-0010|NCI-G01-1924","April 10, 2001","October 2000","null","March 15, 2013","March 2013","No Study Results Posted","null","November 2002","","https://ClinicalTrials.gov/show/NCT00014261"
408,"NCT00471653","Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy","Unknown status","No Results Available","Brain and Central Nervous System Tumors|Thrombocytopenia","Drug: temozolomide|Genetic: comparative genomic hybridization|Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: pharmacological study|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","150","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000543866|JHOC-J0684|JHOC-NA_00004964","May 8, 2007","November 2006","null","November 6, 2009","July 2009","No Study Results Posted","null","December 2008","Correlation of pharmacokinetics with incidence of dose-limiting toxicities|Maximum concentration of temozolomide|Polymorphisms in the MGMT repair gene","https://ClinicalTrials.gov/show/NCT00471653"
409,"NCT02137759","MRSI to Predict Response to RT/TMZ ± Belinostat in GBM","Recruiting","No Results Available","Glioblastoma Multiforme of Brain","Radiation: Standard Radiation Therapy|Drug: Standard Temozolomide|Drug: Belinostat","Emory University|Johns Hopkins University|Spectrum Pharmaceuticals, Inc|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","87","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IRB00065425|Winship2434-13|U01CA172027|F30CA206291","May 9, 2014","May 2014","June 2019","April 25, 2017","April 2017","No Study Results Posted","null","May 2018","Progression Free Survival (PFS) (Cohort 1)|Maximum Tolerated Dose of Belinostat (Cohort 2a)|Progression Free Survival (PFS) (Cohort 2b)|Overall Survival|Progression Free Survival|IDS-SR score change","https://ClinicalTrials.gov/show/NCT02137759"
410,"NCT00006358","Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Drug: thalidomide","North American Brain Tumor Consortium|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068227|NABTC-9904","October 4, 2000","May 2000","null","July 23, 2008","October 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006358"
411,"NCT00884741","Temozolomide (TMZ) and Radiation Therapy (RT) With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)","Active, not recruiting","Has Results","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Cognitive Side Effects of Cancer Therapy","Radiation: Radiation therapy pre-randomization|Biological: Bevacizumab|Drug: Placebo|Drug: Temozolomide pre-randomization|Drug: Temozolomide post-randomization|Radiation: Radiation therapy post-randomization","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","637","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NCI-2009-01670|RTOG-0825|CDR0000640428|RTOG 0825|U10CA180868|U10CA021661","April 18, 2009","April 2009","null","November 14, 2016","November 2016","December 18, 2015","null","March 2013","Overall Survival (OS)|Progression-free Survival (PFS)|Incidence of Grade 3 and Higher Treatment-related Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 3.0","https://ClinicalTrials.gov/show/NCT00884741"
412,"NCT00027625","Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: gefitinib|Drug: temozolomide","North American Brain Tumor Consortium|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069049|NABTC-0102","December 7, 2001","January 2002","null","December 13, 2008","September 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00027625"
413,"NCT03139331","PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma","Not yet recruiting","No Results Available","Sarcoma","Drug: Pazopanib|Drug: Irinotecan|Drug: Temozolomide","University of California, San Francisco|Children's Hospital & Research Center Oakland|Dana-Farber Cancer Institute","All","6 Years to 30 Years   (Child, Adult)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CC#160821","April 28, 2017","May 2017","November 30, 2019","May 2, 2017","May 2017","No Study Results Posted","null","November 30, 2018","Maximum Tolerated Dose|Describing toxicities of PAZIT drug combination using the NCI CTCAE Version 4.0","https://ClinicalTrials.gov/show/NCT03139331"
414,"NCT00412503","Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents","Completed","No Results Available","Refractory Tumors|Malignant Tumors","Drug: Topotecan, Temozolomide","Gustave Roussy, Cancer Campus, Grand Paris","All","6 Months to 21 Years   (Child, Adult)","Phase 1","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CSET 1197","December 15, 2006","null","null","August 6, 2009","August 2009","No Study Results Posted","null","null","- To determine MTD and DLT of each drug|To assess safety profile|To evaluate Pharmacokinetic of Temozolomide and Topotecan when associated|To assess the efficacy of the association","https://ClinicalTrials.gov/show/NCT00412503"
415,"NCT03082846","Treatment of High-grade Gliomas Using Hypofractionated Radiation Therapy -a Phase I Clinical Trial","Completed","No Results Available","Glioma|Radiotherapy, Intensity-Modulated|Maximum Tolerated Dose","Radiation: hypofractionated radiation|Drug: Temozolomide chemotherapy","Xue Xiaoying|The Second Hospital of Hebei Medical University","All","18 Years to 70 Years   (Adult, Senior)","","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","phase I clinical trial-gliomas","February 22, 2017","January 1, 2014","December 3, 2016","March 17, 2017","March 2017","No Study Results Posted","null","November 7, 2016","the maximum tolerated dose(MTD)|Progression free survival","https://ClinicalTrials.gov/show/NCT03082846"
416,"NCT00003747","Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma","Unknown status","No Results Available","Melanoma (Skin)","Drug: carboplatin|Drug: temozolomide","Mount Vernon Cancer Centre at Mount Vernon Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Primary Purpose: Treatment","CDR0000066867|MTVERNHOSP-OCT1998|EU-98069","November 1, 1999","October 1998","null","September 19, 2013","March 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003747"
417,"NCT00006024","Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma","Completed","No Results Available","Brain Tumor|Central Nervous System Tumor","Drug: lomustine|Drug: temozolomide","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 1","32","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ADVL0011|COG-ADVL0011|CCG-ADVL0011|CCG-A0993|CDR0000068036","July 5, 2000","November 2000","September 2006","February 11, 2014","February 2014","No Study Results Posted","null","January 2005","Progression Free Survival","https://ClinicalTrials.gov/show/NCT00006024"
418,"NCT01149850","Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma","Active, not recruiting","No Results Available","Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma","Biological: bevacizumab|Drug: temozolomide|Other: laboratory biomarker analysis|Other: immunohistochemistry staining method|Genetic: microarray analysis|Genetic: DNA methylation analysis","Jonsson Comprehensive Cancer Center|Genentech, Inc.","All","70 Years and older   (Senior)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AVF4535s|09-06-032","June 22, 2010","April 2010","July 2018","March 10, 2017","March 2017","No Study Results Posted","null","July 2017","Overall survival|Time to progression|progression free survival","https://ClinicalTrials.gov/show/NCT01149850"
419,"NCT01328535","Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery","Active, not recruiting","No Results Available","Recurrent Melanoma|Stage IV Melanoma","Drug: temozolomide|Other: flow cytometry|Other: staining method|Procedure: biopsy|Other: laboratory biomarker analysis","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MC1076|NCI-2011-00449|10-008497","March 30, 2011","January 2011","December 2017","March 21, 2017","March 2017","No Study Results Posted","null","December 2017","To assess the clinical activity of timed administration of TMZ therapy in patients with stage IV melanoma|To evaluate the parameters of immune homeostasis that are associated with the anti-tumor immune biorhythm in order to gain insight into the mechanism of the observed clinical and immunological effect of timed TMZ chemotherapy|To assess the toxicity profile of timed administration of TMZ therapy in patients with stage IV melanoma who have or have not received prior chemotherapy for their metastatic disease|To evaluate the impact of timed TMZ chemotherapy on immune biomarkers and the anti-tumor immune biorhythms.","https://ClinicalTrials.gov/show/NCT01328535"
420,"NCT01115491","A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme","Completed","Has Results","Glioblastoma Multiforme","Drug: bevacizumab [Avastin]|Drug: temozolomide","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML25152|2010-019051-21","April 30, 2010","June 2010","July 2012","December 3, 2014","December 2014","May 28, 2014","null","July 2012","Progression-Free Survival (PFS) - Percentage of Participants With an Event|PFS - Time to Event|PFS: Probability of Remaining Progression Free at 24 Weeks After Beginning the Study|Overall Survival - Percentage of Participants With an Event|Overall Survival - Time to Event|Percentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR)","https://ClinicalTrials.gov/show/NCT01115491"
421,"NCT00601614","Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery","Withdrawn","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: temozolomide|Drug: vandetanib|Other: immunoenzyme technique|Other: laboratory biomarker analysis","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other|NIH","Interventional","Primary Purpose: Treatment","MC0615|MAYO-MC0615|MAYO-07-004966","January 24, 2008","January 2008","null","March 6, 2014","March 2014","No Study Results Posted","null","January 2010","Maximum tolerated dose of vandetanib and temozolomide|Adverse events profile|Toxicity profile|Response profile|Time until any treatment-related toxicity|Time until treatment-related grade 3+ toxicity|Time until hematologic nadirs|Time to progression|Time to treatment failure|Correlation of changes in VEGF levels, serum angiogenesis, and circulating endothelial cells with response and dose levels","https://ClinicalTrials.gov/show/NCT00601614"
422,"NCT01164189","Bevacizumab in Recurrent Grade II and III Glioma","Active, not recruiting","No Results Available","Central Nervous System Tumors","Biological: Bevacizumab|Drug: Temozolomide","European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","144","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-26091|2009-017422-39","July 15, 2010","February 2011","null","October 11, 2016","October 2016","No Study Results Posted","TAVAREC","June 2017","Probability of survival at 1 year|Objective response rate and duration of response|Progression-free survival|Overall survival and survival at 24 months|Safety|Clinical/neurological deterioration-free survival|Steroid use|Quality of life of patients and caregivers/relatives|Cognitive deterioration","https://ClinicalTrials.gov/show/NCT01164189"
423,"NCT00626990","Phase III Trial of Anaplastic Glioma Without 1p/19q LOH","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Genetic: DNA methylation analysis|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: quality-of-life assessment|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC|NCIC Clinical Trials Group|Radiation Therapy Oncology Group|Medical Research Council|Cooperative Trials Group for Neuro-Oncology|Merck Sharp & Dohme Corp.","All","18 Years to 120 Years   (Adult, Senior)","Phase 3","751","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-26053-22054|NCIC CTG CEC.1|RTOG-0834|2006-001533-17|P04839|MRC BR14","February 28, 2008","December 2007","null","February 9, 2016","February 2016","No Study Results Posted","CATNON","January 2020","Overall survival as measured from the day of randomization|Progression-free survival|Neurological deterioration-free survival|Quality of life as assessed by the EORTC Quality of Life Questionnaire (QLQ-C30) version 3 and the Brain Cancer Module-20|Toxicity as measured by CTEP Active Version of CTCAE|Development of cognitive deterioration as measured by the Mini Mental Status Exam","https://ClinicalTrials.gov/show/NCT00626990"
424,"NCT00004200","Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: prinomastat|Drug: temozolomide","Pfizer","All","16 Years and older   (Child, Adult, Senior)","Phase 2","null","Industry","Interventional","Allocation: Randomized|Primary Purpose: Treatment","AG-3340-019|CDR0000067443|MCC-12151|MDA-DM-99254|MSKCC-99116","January 21, 2000","October 1999","null","August 7, 2012","August 2012","No Study Results Posted","null","January 2002","","https://ClinicalTrials.gov/show/NCT00004200"
425,"NCT01355445","Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma : International Randomized Trial","Unknown status","No Results Available","RHABDOMYOSARCOMA","Drug: Vincristine, Irinotecan|Drug: Vincristine-Irinotecan-Temozolomide","Centre Oscar Lambret|SFCE","All","6 Months to 50 Years   (Child, Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","VIT-0910|2010-023135-42","May 16, 2011","January 2012","June 2015","June 20, 2014","June 2014","No Study Results Posted","VIT-0910","June 2014","Objective tumour response and progression in each treatment arm.|To assess the duration of tumor response in each treatment arm|To determine the time to tumor progression in each treatment arm|To assess the time to treatment failure in each treatment arm|To assess the overall survival in each treament arm|To assess the safety profile and tolerability in each treatment arm","https://ClinicalTrials.gov/show/NCT01355445"
426,"NCT00354068","Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: imatinib mesylate|Drug: temozolomide|Other: pharmacological study","Duke University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","65","Other|NIH","Interventional","Primary Purpose: Treatment","Pro00004364|DUMC-5514-06-1R2|NOVARTIS-DUMC-5514-06-1R2|CDR0000483760","July 19, 2006","July 2004","November 2008","March 26, 2013","March 2013","No Study Results Posted","null","November 2008","Maximum tolerated dose|Dose-limiting toxicity|Safety and tolerability|Pharmacokinetics|Anti-tumor activity","https://ClinicalTrials.gov/show/NCT00354068"
427,"NCT01777919","Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform","Not yet recruiting","No Results Available","Glioblastoma Multiforme","Drug: Temozolomide|Drug: Disulfiram|Drug: Copper","Olympion Medical Center|University of Ioannina|University of Eastern Finland|University of Ulm","All","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PK-18081973","January 24, 2013","January 2017","January 2020","October 14, 2016","October 2016","No Study Results Posted","GLIODIS","January 2019","Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01777919"
428,"NCT00639262","Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors","Completed","No Results Available","Brain Metastases|Primary Brain Tumors","Drug: Sorafenib|Drug: Temozolomide|Radiation: Radiotherapy","Sidney Kimmel Cancer Center at Thomas Jefferson University|Bayer|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 1","35","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","07P.381|2006-58","March 13, 2008","March 2008","September 2012","October 19, 2016","October 2016","No Study Results Posted","null","September 2012","Maximum Tolerated Dose of Sorafenib|Response Rate|Prediction of 1-year Recurrence|Safety and Toxicity of Sorafenib","https://ClinicalTrials.gov/show/NCT00639262"
429,"NCT00072345","Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma","Completed","No Results Available","Intraocular Melanoma|Melanoma (Skin)","Drug: lomustine|Drug: temozolomide|Drug: thalidomide","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","03-084|P30CA008748|MSKCC-03084","November 4, 2003","July 2003","null","January 17, 2013","January 2013","No Study Results Posted","null","August 2004","","https://ClinicalTrials.gov/show/NCT00072345"
430,"NCT02780024","Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: Metformin","McGill University Health Center","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MUHC ID: 4315","May 20, 2015","March 2015","December 2021","November 1, 2016","November 2016","No Study Results Posted","null","December 2019","Number of patients completing the study treatment|To assess toxicity of the regimen","https://ClinicalTrials.gov/show/NCT02780024"
431,"NCT01390571","Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma","Recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: olaparib|Drug: temozolomide|Genetic: gene expression analysis|Genetic: protein expression analysis|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: diffusion-weighted magnetic resonance imaging|Procedure: dynamic contrast-enhanced magnetic resonance imaging|Procedure: therapeutic conventional surgery","Cancer Research UK","All","18 Years and older   (Adult, Senior)","Phase 1","34","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000702605|CRUK-CR0901-11|EUDRACT-2010-018615-15","July 7, 2011","July 2011","null","April 13, 2016","April 2016","No Study Results Posted","null","May 2017","Detection of olaparib in tumor tissue using liquid chromatography mass spectrometry (LC-MS) seen in at least 1 out of the 6 patients treated in stage 1 of the study|Maximum-tolerated dose of olaparib in combination with temozolomide (stage 2)|Toxicity profile and dose-limiting toxicity as assessed by NCI CTCAE Version 4.02 (stage 2)|Measurement of blood-brain barrier (BBB) disruption and permeability biomarkers by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) (stage 1 and stage 2 MTD expansion cohort)|Progression-free survival at 6 months post-surgery as assessed by the Response Assessment in Neuro-Oncology Working Group (RANO) criteria from conventional MRI and clinical assessment (stage 2)","https://ClinicalTrials.gov/show/NCT01390571"
432,"NCT03150810","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors","Not yet recruiting","No Results Available","Locally Advanced or Metastatic Solid Tumors","Drug: BGB-290|Drug: Temozolomide|Drug: BGB-290|Drug: Temozolomide","BeiGene USA, Inc.|Myriad Genetics, Inc.|BeiGene","All","18 Years to 99 Years   (Adult, Senior)","Phase 1|Phase 2","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BGB-290-103","May 8, 2017","June 30, 2017","August 1, 2020","May 10, 2017","May 2017","No Study Results Posted","null","July 1, 2020","Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE.|Incidence, nature and severity of adverse events as assessed by CTCAE.|Pharmacokinetic (PK) parameters (Cmax) of BGB-290 and TMZ.|Pharmacokinetic (PK) parameters (Tmax) of BGB-290 and TMZ.|Objective response rate (ORR) as assessed using RECIST.|Duration of response (DOR).|Disease control rate (DCR)|Progression free survival (PFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT03150810"
433,"NCT02836028","A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer","Withdrawn","No Results Available","Ovarian Cancer","Drug: Talazoparib|Drug: Temozolomide","Medivation, Inc.|Myriad Genetic Laboratories, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MDV3800-11","July 14, 2016","October 2016","null","May 23, 2017","December 2016","No Study Results Posted","null","June 2020","Determine Objective Response Rate (ORR)|Progression-free survival (PFS)|PFS at 24 weeks|Gynecologic Cancer Intergroup (GCIG) CA125 response rate|Clinical benefit rate at 24 weeks|Duration of response (DOR)|Time to response|Overall survival|Safety as assessed by percentage of patients with any Adverse Event (AE), AE leading to Study Drug Discontinuation, AE leading to death, SAE, AE related to study drug, SAE related to study drug.|Pharmacokinetics of talazoparib as assessed by trough plasma concentrations","https://ClinicalTrials.gov/show/NCT02836028"
434,"NCT02378532","The Addition of Chloroquine to Chemoradiation for Glioblastoma","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: Chloroquine|Radiation: Radiotherapy|Drug: Temozolomide","Maastricht Radiation Oncology","All","18 Years and older   (Adult, Senior)","Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CHLOROBRAIN","February 12, 2015","August 2016","August 2018","August 1, 2016","August 2016","No Study Results Posted","CHLOROBRAIN","July 2018","Toxicity (CTC AE 4.0|Pharmacokinetics of chloroquine, desethylchloroquine, bisdesethylchloroquine. Profile parameters will include trough level (Cmin), AUC and elimination half-life.|Presence of autophagic markers (LC3 and autophagic vesicles)|Evaluation of EGFRvIII status in histopathological material","https://ClinicalTrials.gov/show/NCT02378532"
435,"NCT01851369","TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas","Recruiting","No Results Available","Lymphomas|Solid Tumors|NSCLC|Metastatic Colon Carcinoma|Granulosa Cell Ovarian Cancer","Drug: TRC 102","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","65","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","130118|13-C-0118","May 8, 2013","April 9, 2013","December 24, 2019","May 12, 2017","September 27, 2016","No Study Results Posted","null","December 24, 2019","Establish safety, tolerability, and maximum tolerated dose of oral TRC102 in combination with oral TMZ in patients with refractory solid tumors.|To explore the response rate of this combination in patients with colon cancer, NSCLC, and granulosa cell ovarian cancer|Evaluate the pharmacokinetic (PK) profile of oral TRC102 when administered in combination with TMZ|To explore the progression free survival rate of this combination in patients with colon cancer, NSCLC, and granulosa cell ovarian cancer","https://ClinicalTrials.gov/show/NCT01851369"
436,"NCT00601289","Temozolomide in Treating Patients With Invasive Pituitary Tumors","Withdrawn","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Genetic: DNA methylation analysis|Genetic: microarray analysis|Genetic: protein expression analysis|Genetic: proteomic profiling|Other: laboratory biomarker analysis","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000577534|P30CA016042|07-05-077-01","January 25, 2008","December 2009","null","July 27, 2012","July 2012","No Study Results Posted","null","October 2010","Change from baseline of pituitary tumor control as assessed by MRI at 3, 6, 9, and 12 months|Change in Tumor response rate (complete response or partial response) from baseline as assessed by RECIST criteria at 3, 6, 9, and 12 months|Rebound tumor growth as assessed by MRI at 6 months after completion of treatment|Biochemical control as assessed by measurement of hormones secreted in excess by the pituitary tumor at baseline, at 3, 6, 9, and 12 months during treatment, and then at 2 months after completion of treatment|Pituitary function as assessed by standard pituitary function tests at baseline and at 6 months and 12 months|Safety and tolerability of temozolomide as assessed by NCI CTC v2.0 at screening, baseline, and then monthly until study completion|Overall quality of life as assessed by Karnofsky performance status questionnaire periodically during study","https://ClinicalTrials.gov/show/NCT00601289"
437,"NCT00650923","Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma","Completed","No Results Available","Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Recurrent Adult Brain Tumor","Drug: ziv-aflibercept|Procedure: radiation therapy|Drug: temozolomide|Procedure: pharmacological study|Procedure: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","61","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00678|CDR0000590174|NABTC-07-01|NABTC07-01|U01CA137443","April 1, 2008","July 2008","December 2013","May 29, 2014","April 2014","No Study Results Posted","null","June 2013","Maximum tolerated dose of aflibercept defined as the dose at which fewer than one-third of patients experience DLT based on the CTC severity grading|Efficacy in terms of antitumor activity based on clinical, radiographic, and biologic assessments|Plasma aflibercept (VEGF Trap) concentrations and PK parameters such as Cmax, Tmax, area under the plasma concentration-time curve (AUCo-t and AUC), clearance (CL), apparent volume of distribution at steady state (Vdss), and terminal half-life (t1/2)","https://ClinicalTrials.gov/show/NCT00650923"
438,"NCT02871843","Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas","Not yet recruiting","No Results Available","Glioblastoma|Oligodendroglioma|Anaplastic Oligodendroglioma","Drug: RRx-001 dose escalation with TMZ + RT|Radiation: Radiation|Drug: Fixed dose Temozolomide (75 mg/m2)|Drug: Fixed RRx-001 weekly|Drug: Staged TMZ and RRx-001 escalation in maintenance stage|Drug: TMZ Maintenance","EpicentRx, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","39","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","RRx001-17-02","August 11, 2016","August 2016","August 2018","February 3, 2017","February 2017","No Study Results Posted","G-FORCE-1","August 2018","Number, frequency and type of adverse events|Objective Response Rate (ORR)|Clinical Benefit Rate (CBR)|Intracranial Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02871843"
439,"NCT00943826","A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma","Completed","Has Results","Glioblastoma","Drug: bevacizumab [Avastin®]|Drug: Placebo|Drug: temozolomide|Radiation: Radiation therapy","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","921","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","BO21990|2008-006146-26","July 17, 2009","June 2009","September 2015","September 25, 2015","September 2015","March 29, 2013","null","March 2012","Co-Primary: Progression-free Survival (PFS) as Assessed by Investigator|Co-Primary: Overall Survival (OS)|Progression-free Survival (PFS) as Assessed by an Independent Review Facility|Percentage of Participants With One-Year Survival|Percentage of Participants With Two-year Survival|Duration of Stable/Improved Health Related Quality of Life (HRQoL) Using the European Organisation for Research and Treatment of Cancer Scales (EORTC) QLQ-C30 and BN20|Number of Participants With Adverse Events, Serious Adverse Events and Death","https://ClinicalTrials.gov/show/NCT00943826"
440,"NCT00869401","Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Active, not recruiting","Has Results","Brain and Central Nervous System Tumors","Drug: dasatinib|Drug: temozolomide|Other: placebo|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","217","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","NCCTG-N0877|NCI-2009-01179|CDR0000637854|U10CA025224","March 25, 2009","June 2009","null","March 28, 2017","March 2017","December 12, 2016","null","October 2014","Overall Survival|The Number of Dose Limiting Toxicities(DLT) in Order to Determine Maximum Tolerable Dose(MTD) of Dasatinib Combined With Radiation and Temozolomide in This Patient Population.|Progression-free Survival|Objective Response","https://ClinicalTrials.gov/show/NCT00869401"
441,"NCT01022918","Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma","Completed","No Results Available","Naive Unresectable Glioblastoma","Drug: Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|Drug: Temodal/radiotherapy","Centre Georges Francois Leclerc|National Cancer Institute, France|Association de Neuro-Oncologues d’Expression Francaise|UNICANCER|Hoffmann-La Roche|Pfizer","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","134","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TemAvIr","November 26, 2009","January 2009","January 2011","September 24, 2012","September 2012","No Study Results Posted","TemAvIr","July 2010","To determine the rate of non-progressive disease at 6 months after inclusion in each arms|To determine if bevacizumab-based regimen increases the overall survival in comparison of the Stupp regimen|To evaluate if any bevacizumab-based regimen increases the survival without neurologic degradation and the quality of life according to the QLC-C30 and the specific Brain Cancer Module QLQ-BN20 scales.|To evaluate the tolerance of the bevacizumab-based regimens according to the NCI-CTCAE, version 3.0 scale. To record the rate of serious adverse events (mainly the theoretical risk of brain hemorrhage with bevacizumab)","https://ClinicalTrials.gov/show/NCT01022918"
442,"NCT00049361","Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases","Completed","No Results Available","Brain and Central Nervous System Tumors|Unspecified Adult Solid Tumor, Protocol Specific","Drug: temozolomide|Drug: thalidomide|Radiation: radiation therapy","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: No masking|Primary Purpose: Treatment","REBACDR0000258057|CCCWFU-91102|NCI-5883","November 12, 2002","January 2004","December 7, 2004","April 17, 2017","April 2017","No Study Results Posted","null","December 7, 2004","Overall median survival|Radiographic response rate as assessed by MRI and RECIST one-dimensional criterion at 1 month, 3 months, and every 3 months thereafter|Median time to tumor progression|Median time to neurologic response and progression|Cause of death at median time|Quality of life as assessed by FACT-BT, FACT-F, and Beck Depression Inventory at 1 month, 3 months, and every 3 months thereafter|Toxicity as assessed by NCI Common Toxicity Criteria (CTC) version 2.0 for up to 90 days","https://ClinicalTrials.gov/show/NCT00049361"
443,"NCT00086879","Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: carmustine|Drug: erlotinib hydrochloride|Drug: temozolomide","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 2","110","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-26034-16031","July 8, 2004","May 2004","null","September 20, 2012","September 2012","No Study Results Posted","null","March 2006","Progression-free survival at 6 months|Response (complete [CR] or partial response [PR]) measured by McDonald's criteria at least 4 weeks after first documented response and every 8 weeks until disease progression or until start of another treatment|Severe toxic events assessed by CTCAE v3.0 at the end of each course|Progression-free survival at 1 year|Overall survival at 6 months and 1 year","https://ClinicalTrials.gov/show/NCT00086879"
444,"NCT01864109","Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma","Recruiting","No Results Available","Newly Diagnosed Ewing Sarcoma","Drug: Cyclophosphamide|Device: Doxorubicin|Drug: Vincristine|Device: Ifosfamide|Drug: Etoposide|Procedure: Surgery|Radiation: Radiation Therapy*|Drug: Temozolomide|Drug: Irinotecan","Memorial Sloan Kettering Cancer Center","All","1 Year to 40 Years   (Child, Adult)","Phase 2","83","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","13-068","May 23, 2013","May 2013","May 2019","May 19, 2017","May 2017","No Study Results Posted","null","May 2019","event free survival of patients with localized disease|event free survival of patients with metastatic disease|adverse event profile","https://ClinicalTrials.gov/show/NCT01864109"
445,"NCT00887146","Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma","Recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: concomitant temozolomide (TMZ)|Radiation: radiotherapy|Drug: procarbazine|Drug: adjuvant temozolomide (TMZ)|Drug: CCNU|Drug: vincristine","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|European Organisation for Research and Treatment Center (EORTC)|NCIC Clinical Trials Group","All","18 Years and older   (Adult, Senior)","Phase 3","360","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","N0577|NCI-2011-01915|EORTC-26081-22086|EudraCT-2008-007295-14|CDR0000640442","April 22, 2009","September 2009","null","May 23, 2017","May 2017","No Study Results Posted","null","December 2018","Progression-free survival|Overall survival|Objective tumor response|Treatment-related adverse event as per the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Time to progression (eg, clinical progression, radiographic progression or neurocognitive progression)","https://ClinicalTrials.gov/show/NCT00887146"
446,"NCT00283543","Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma","Unknown status","No Results Available","Newly Diagnosed Supratentorial Malignant Glioma","Drug: Gliadel Wafer|Drug: Temozolomide|Procedure: Limited field radiation","Kentuckiana Cancer Institute|Eisai Inc.","All","18 Years to 72 Years   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1068016|128-02","January 26, 2006","September 2002","April 2008","October 30, 2007","October 2007","No Study Results Posted","null","null","To determine the safety and efficacy of Gliadel 3.85% wafers","https://ClinicalTrials.gov/show/NCT00283543"
447,"NCT02455557","SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","Recruiting","No Results Available","Glioblastoma|Gliosarcoma","Other: Laboratory Biomarker Analysis|Drug: Montanide ISA 51 VG|Biological: Sargramostim|Biological: SVN53-67/M57-KLH Peptide Vaccine|Drug: Temozolomide","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","I 259614|NCI-2015-00694|P30CA016056","May 22, 2015","May 4, 2015","April 2, 2019","April 6, 2017","April 2017","No Study Results Posted","null","April 2, 2018","Progression-free survival (PFS)|Immune responses to SurVaxM and predictors of response|Incidence of grade 3 or 4 toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events version 4|Overall survival","https://ClinicalTrials.gov/show/NCT02455557"
448,"NCT03008148","Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM","Not yet recruiting","No Results Available","Glioblastoma","Radiation: CCRT|Drug: Temozolomide|Drug: Siroquine","Johnpro Biotech, Inc.","All","20 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","264","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JP001-GM-001","December 23, 2016","April 2017","October 2023","January 2, 2017","January 2017","No Study Results Posted","null","October 2023","Overall survival time.|Progression-free survival time|OS rate at 1 year.|PFS rate at 1 year.|The time and rate of OS in different RPA class.|The time and rate of PFS in different RPA class.|Objective response rate.|Changes in score of EORTC QLQ-C30|Changes in score of EORTC QLQ-BN20.|Changes in grade of ECOG performance status.","https://ClinicalTrials.gov/show/NCT03008148"
449,"NCT00089427","IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma","Completed","No Results Available","Glioblastoma Multiforme|Anaplastic Astrocytoma|Oligoastrocytoma","Drug: IL13-PE38QQR|Procedure: Surgery for placement|Procedure: Radiation therapy|Drug: Temozolomide with radiation therapy","INSYS Therapeutics Inc","All","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IL13PEI-106-R01","August 5, 2004","July 2004","null","June 30, 2011","April 2011","No Study Results Posted","null","July 2007","","https://ClinicalTrials.gov/show/NCT00089427"
450,"NCT00763750","BrUOG-Brain-223:A Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103)","Completed","Has Results","Brain Tumor","Drug: PPX +TMZ+XRT","howard safran|Rhode Island Hospital|Maine Medical Center Research Institute|Brown University","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG-Brain-223","September 30, 2008","October 2008","July 2012","June 18, 2014","June 2014","May 9, 2013","null","June 2011","Number of Patients Assessed for Toxicity According to CTC Version 3.0","https://ClinicalTrials.gov/show/NCT00763750"
451,"NCT01313884","Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma","Terminated","Has Results","Bone Cancer|Ewing's Sarcoma","Drug: Irinotecan|Drug: Vincristine|Drug: Temozolomide|Drug: Doxorubicin|Drug: Cytoxan|Drug: Pegfilgrastim|Drug: Mesna","Stanford University|Amgen","All","13 Years and older   (Child, Adult, Senior)","Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB-20323|SU-03082011-7559|SARCOMA0007","March 10, 2011","May 2011","July 2014","December 7, 2016","December 2016","December 7, 2016","null","July 2014","Overall Response Rate (Partial and Complete Response)|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01313884"
452,"NCT00993044","A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin","Completed","Has Results","Refractory Solid Tumors in Children","Drug: Irinotecan|Drug: Vincristine|Drug: Temozolomide|Drug: Bevacizumab","Children's Hospital Los Angeles","All","12 Months to 20 Years   (Child, Adult)","Phase 1","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-00214","October 8, 2009","September 2009","February 2013","July 22, 2014","July 2014","January 3, 2014","VIT-B","February 2013","Dose Limiting Toxicity","https://ClinicalTrials.gov/show/NCT00993044"
453,"NCT01217398","Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye","Unknown status","No Results Available","Intraocular Melanoma","Biological: bevacizumab|Drug: temozolomide|Genetic: polymorphism analysis|Other: pharmacogenomic studies","Institut Curie|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000683852|CLCC-IC-2009-01|EUDRACT-2009-011751-46|EU-21063","October 7, 2010","October 2009","null","August 23, 2013","August 2012","No Study Results Posted","null","October 2012","Disease control rate, in terms of objective response rate and the stable disease rate determined according to RECIST criteria at 6 months|Response rate|Duration of response|Progression-free survival|Overall survival|Safety of this regimen in these patients|Functional imaging of response by CT perfusion imaging","https://ClinicalTrials.gov/show/NCT01217398"
454,"NCT00248534","Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: methylprednisolone|Drug: temozolomide","North American Brain Tumor Consortium|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000445289|NABTC-05-01","November 3, 2005","September 2005","null","October 11, 2012","October 2008","No Study Results Posted","null","September 2012","Response rate assessed by MRI every 2 months|Overall survival|Progression-free survival at 6 months","https://ClinicalTrials.gov/show/NCT00248534"
455,"NCT00128700","Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Drug: vatalanib|Procedure: adjuvant therapy|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 69 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-26041-22041|EORTC-26041|EORTC-22041|EUDRACT-2004-003896-35","August 8, 2005","June 2005","null","September 20, 2012","September 2012","No Study Results Posted","null","November 2007","Dose-limiting toxicity and maximum tolerated dose of vatalanib as determined by CTCAE v3.0 during phase I|Progression-free survival at 6 months during phase II|Severe toxic events as assessed by CTCAE v3.0 at weeks 3 and 6 (concomitant treatment), weeks 2 and 4 after radiotherapy, before each course of adjuvant treatment, monthly during maintenance treatment, and every 3 months during follow-up in phase II|Overall survival at 1 year during phase II|Correlation of angiogenesis and hypoxia markers expression and O-6-methylguanine DNA methyltransferase (MGMT) methylation status with clinical outcome during phase II","https://ClinicalTrials.gov/show/NCT00128700"
456,"NCT02976441","Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas","Withdrawn","No Results Available","Astrocytoma|Brainstem Glioma|Ependymoma|Mixed Glioma|Oligodendroglioma|Optic Nerve Glioma","Radiation: Radiation therapy|Drug: Temozolomide|Procedure: Stem cell collection|Procedure: Stem cell infusion","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","15-x135","November 23, 2016","January 2017","February 2018","February 16, 2017","February 2017","No Study Results Posted","null","February 2018","Efficacy of lymphocyte stem cell harvesting and reinfusion in patients as measured by the number of patients from whom 1-5x10e6 lymphocyte stem cells are collected and successfully reinfused without an adverse event|Number of lymphocyte stem cells that can be harvested from this patient population|Proportion of patients who have an increase in lymphocyte of ≥300 cells/mm^3 after autologous stem cell reinfusion.|Duration of lymphocyte rise following stem cell reinfusion|Changes in lymphocyte subtypes following collection and reinfusion|Changes in series of cytokine levels following collection and reinfusion|Safety and toxicities with stem cell collection and reinfusion as measured by grade and frequency of adverse events","https://ClinicalTrials.gov/show/NCT02976441"
457,"NCT00238277","Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme","Terminated","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Procedure: adjuvant therapy|Procedure: chemotherapy|Procedure: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","72","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000445270|JHOC-J0498|JHOC-04121603","October 12, 2005","March 2005","null","January 30, 2008","December 2007","No Study Results Posted","null","December 2007","Death","https://ClinicalTrials.gov/show/NCT00238277"
458,"NCT01127178","Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors","Completed","No Results Available","Solid Tumors","Drug: E7016 + TMZ","Eisai Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E7016-A001-101","May 10, 2010","May 2012","February 2014","January 27, 2016","December 2015","No Study Results Posted","null","August 2013","Determine dose-limiting toxicities (DLTs) for E7016 in combination with temozolomide (TMZ) in subjects with advanced solid tumors and gliomas.|Determine alternative dose of interest (ADI) for E7016 in combination with temozolomide (TMZ) in subjects with advanced solid tumors and gliomas.|Determine the maximum tolerated dose (MTD) for E7016 in combination with temozolomide (TMZ) in subjects with advanced solid tumors and gliomas.|Evaluate the overall safety and tolerability of E7016 in combination with TMZ.|Determine the plasma pharmacokinetics (PK) of E7016 and of TMZ.|Assess the pharmacodynamic (PD) activity of E7016, including inhibition of poly(ADP-ribose) polymerase (PARP)","https://ClinicalTrials.gov/show/NCT01127178"
459,"NCT02049593","PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors","Active, not recruiting","No Results Available","Metastatic Cancer|Unspecified Adult Solid Tumor","Drug: PARP inhibitor BMN-673|Drug: temozolomide|Drug: irinotecan hydrochloride|Other: pharmacological study|Other: laboratory biomarker analysis","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","41","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TRIO-US GI-07|NCI-2014-00048|P30CA016042","January 27, 2014","June 2014","April 2018","January 18, 2017","January 2016","No Study Results Posted","null","April 2017","Dose Limiting Toxicity graded using the NCI CTCAE v. 4.03|Incidence of adverse events graded by NCI CTCAE v. 4.03|Levels of PARP inhibitory BMN 673|levels of temozolomide|Levels of irinotecan hydrochloride|Biomarker levels in blood and tumor tissue|Incidence of laboratory abnormalities graded by NCI CTCAE v. 4.03|Objective tumor response assessed using RECIST v. 1.1|Duration of response|Progression-free survival|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02049593"
460,"NCT03119064","BrUOG 329 GBM Onyvide With TMZ","Not yet recruiting","No Results Available","Glioblastoma Multiforme|Glioblastoma|GBM","Drug: Nanoliposomal Irinotecan|Drug: Temozolomide","Heinrich Elinzano, MD|Merrimack Pharmaceuticals|Rhode Island Hospital|Brown University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: No masking|Primary Purpose: Treatment","BrUOG 329","April 6, 2017","July 2017","July 2020","April 13, 2017","April 2017","No Study Results Posted","329","July 2019","MTD|Response|PFS|Safety","https://ClinicalTrials.gov/show/NCT03119064"
461,"NCT02663440","Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma Multiforme","Radiation: Hypofractionated IMRT|Biological: Granulocyte-macrophage Colony-stimulating Factor|Drug: Temozolomide","Zhejiang Cancer Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZJZLYY-HN-2016-01","January 18, 2016","January 2016","null","January 21, 2016","January 2016","No Study Results Posted","null","December 2017","PFS","https://ClinicalTrials.gov/show/NCT02663440"
462,"NCT00093353","N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma","Completed","No Results Available","Diarrhea|Drug/Agent Toxicity by Tissue/Organ|Neuroblastoma","Drug: cefixime|Drug: irinotecan hydrochloride|Drug: temozolomide","Children's Hospital Los Angeles|National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","Phase 1","30","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000373759|P01CA081403|N2003-01","October 6, 2004","May 2004","null","October 14, 2010","May 2009","No Study Results Posted","null","July 2006","","https://ClinicalTrials.gov/show/NCT00093353"
463,"NCT00387400","Temozolomide and Everolimus in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: everolimus|Drug: temozolomide|Genetic: microarray analysis|Other: immunohistochemistry staining method","NCIC Clinical Trials Group|Canadian Cancer Trials Group","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I162|CAN-NCIC-IND162|CDR0000507616","October 12, 2006","July 2006","January 2012","November 25, 2016","January 2012","No Study Results Posted","null","January 2012","Safety and tolerability of everolimus as measured by NCI CTCAE v3.0|Response as measured by CT scan and/or brain MRI at baseline and after every other course and clinical neurologic assessment at baseline and after every course|Correlation of clinical outcome with pretreatment tumor tissue molecular markers as measured by molecular studies of paraffin-embedded tumor samples|Pharmacokinetics of everolimus during course 1","https://ClinicalTrials.gov/show/NCT00387400"
464,"NCT02270034","Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma","Recruiting","No Results Available","Glioblastoma Multiforme (Grade IV) of Cerebellum","Drug: Crizotinib","Grupo Español de Investigación en Neurooncología|Pfizer","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEINO 1402","October 14, 2014","November 2014","December 2016","August 10, 2016","August 2016","No Study Results Posted","null","October 2016","Number of participants with adverse events as a measure of safety and tolerability|Cmax|Anti-tumor activity|Overall Survival","https://ClinicalTrials.gov/show/NCT02270034"
465,"NCT00915694","Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: nelfinavir mesylate|Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy","Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","23","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000644278|UPCC-01309|IRB#809463","June 5, 2009","April 2009","null","February 9, 2016","February 2016","No Study Results Posted","null","July 2011","Maximum tolerated dose of nelfinavir mesylate|Dose-limiting toxicities as assessed by NCI CTC v3.0|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00915694"
466,"NCT00303940","Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Kidney Cancer|Liver Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: carboplatin|Drug: talabostat mesylate|Drug: temozolomide|Other: pharmacological study","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","2 Years to 18 Years   (Child, Adult)","Phase 1","26","NIH","Interventional","Primary Purpose: Treatment","050239|05-C-0239|NCI-P6672|CDR0000462620","March 15, 2006","December 2005","February 2010","March 14, 2012","March 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00303940"
467,"NCT01119599","RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma","Completed","No Results Available","Acoustic Schwannoma|Adult Anaplastic (Malignant) Meningioma|Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Brain Stem Glioma|Adult Choroid Plexus Neoplasm|Adult Craniopharyngioma|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Grade I Meningioma|Adult Grade II Meningioma|Adult Medulloblastoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Papillary Meningioma|Adult Pilocytic Astrocytoma|Adult Pineal Gland Astrocytoma|Adult Pineoblastoma|Adult Pineocytoma|Adult Primary Melanocytic Lesion of Meninges|Adult Subependymal Giant Cell Astrocytoma|Adult Subependymoma|Adult Supratentorial Primitive Neuroectodermal Tumor|Malignant Adult Intracranial Hemangiopericytoma","Radiation: 3-Dimensional Conformal Radiation Therapy|Drug: Gamma-Secretase Inhibitor RO4929097|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Temozolomide|Procedure: Therapeutic Conventional Surgery","National Cancer Institute (NCI)","All","19 Years and older   (Adult, Senior)","Phase 1","22","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-01410|CDR0000672641|09-177|8556|P30CA008748|U01CA069856","May 6, 2010","May 2010","null","September 28, 2015","June 2015","No Study Results Posted","null","June 2013","Maximum-tolerated dose defined as the highest dose studied for which the incidence of dose limiting toxicity is less than 33% using National Cancer Institute Common Toxicity Criteria|Changes in MRI parameters|Percent changes in serum YKL-40 levels and hair follicle HES1 levels|Pharmacokinetic (PK) parameters of gamma-secretase/Notch signalling pathway inhibitor RO4929097","https://ClinicalTrials.gov/show/NCT01119599"
468,"NCT00006263","Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma","Withdrawn","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: carboplatin|Drug: temozolomide","New York University School of Medicine|National Cancer Institute (NCI)","All","up to 64 Years   (Child, Adult)","Phase 2","0","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068203|NYU-0004H|NYU-0029H|NCI-G00-1856","September 11, 2000","November 1997","null","August 3, 2015","August 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006263"
469,"NCT00514397","Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: motexafin gadolinium|Drug: temozolomide|Procedure: adjuvant therapy|Procedure: quality-of-life assessment|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","2 Years to 21 Years   (Child, Adult)","Phase 2","43","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CCLG-CNS-2007-04|CDR0000560114|EU-20746|EUDRACT-2007-001768-60","August 8, 2007","January 2008","null","August 9, 2013","June 2009","No Study Results Posted","null","null","Overall survival|Quality of life including health status, behavior, and the subjective experience using HUI and SDQ methods|Toxicity, steroid usage, and radiological response|Adverse events, including abnormal laboratory parameters, as assessed by CTC criteria","https://ClinicalTrials.gov/show/NCT00514397"
470,"NCT00047294","Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: celecoxib|Drug: temozolomide|Drug: thalidomide|Procedure: adjuvant therapy","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000257587|DFCI-00302|NCI-G02-2118|CELGENE-2000-P-002521/1","October 3, 2002","April 2002","null","February 6, 2009","May 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00047294"
471,"NCT00807027","Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea","Completed","No Results Available","Glioblastoma","Drug: Activated T lymphocyte(Immuncell-LC)","Green Cross Cell Corporation","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IcmLCBT_301","December 10, 2008","December 2008","October 2012","October 24, 2012","October 2012","No Study Results Posted","null","October 2012","MRI|Overall survival, therapy reaction, EORTC QLQ-C30, and Karnofsky Performance Status (KPS)","https://ClinicalTrials.gov/show/NCT00807027"
472,"NCT00715793","Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma","Completed","No Results Available","Malignant Melanoma","Drug: Decitabine|Drug: Temozolomide|Procedure: biopsy","University of Pittsburgh|Eisai Inc.|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","39","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCI 07-008","June 27, 2008","June 2008","August 2015","August 12, 2015","August 2015","No Study Results Posted","UPCI-07-008","May 2015","Phase I: Safety, tolerability and Phase II recommended dose of the combination of TMZ + DAC. Phase II: Objective response rate|Phase I: Pharmacokinetics of TMZ and DAC when administered in combination|Phase II: -Progression-free survival -safety -pharmacodynamic effects of the combination in PBMC and tumor tissues.","https://ClinicalTrials.gov/show/NCT00715793"
473,"NCT02329795","Image-derived Prediction of Response to Chemo-radiation in Glioblastoma","Terminated","No Results Available","Glioblastoma","Radiation: Radiotherapy|Drug: Temozolomide","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Senior)","","16","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","192/13","December 16, 2014","October 2014","September 2017","April 23, 2017","April 2017","No Study Results Posted","IDEPREG","May 2017","Sensitivity and specificity of predicted response|DICE-similarity coefficient and percentage overlap of 64Cu-ATSM and contrast-enhanced T1-weighted MRI|Correlation (volume and maximum values) between lactate and hypoxia","https://ClinicalTrials.gov/show/NCT02329795"
474,"NCT00099125","Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: irinotecan hydrochloride|Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","170","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0420|CDR0000389229","December 8, 2004","November 2004","November 2013","January 23, 2014","January 2014","No Study Results Posted","null","October 2006","Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT00099125"
475,"NCT02903069","Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer","Recruiting","No Results Available","Glioblastoma|Malignant Glioma","Drug: MRZ|Drug: TMZ|Radiation: RT","Triphase Research and Development I Corporation","All","18 Years and older   (Adult, Senior)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MRZ-112","September 7, 2016","August 2016","December 2018","October 11, 2016","October 2016","No Study Results Posted","null","December 2017","Determine MRZ maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for both concomitant treatment (MRZ + TMZ + RT) and adjuvant treatment (MRZ + TMZ)|To confirm the MRZ RP2D for concomitant and adjuvant treatment in an expanded group of patients|Assess adverse events during concomitant and adjuvant treatment|Evaluate the activity (overall survival [OS]) of MRZ + TMZ + RT|Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + RT|MRZ pharmacokinetics - Maximum Serum Concentration (Cmax)|MRZ pharmacokinetics - Elimination Half-Life (t1/2)|MRZ pharmacokinetics - Area Under the Blood Concentration-Time Curve (AUC0-t, AUC0-inf)|MRZ pharmacokinetics - Clearance (CL)|MRZ pharmacokinetics - Volume of Distribution (Vd)|TMZ serum concentration|Assess neurological coordination using the Scale for the Assessment and Rating for Ataxia (SARA)","https://ClinicalTrials.gov/show/NCT02903069"
476,"NCT00020839","Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain","Terminated","No Results Available","Melanoma (Skin)|Metastatic Cancer","Drug: temozolomide|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 3","23","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-18981","July 11, 2001","April 2001","null","September 20, 2012","September 2012","No Study Results Posted","null","May 2003","","https://ClinicalTrials.gov/show/NCT00020839"
477,"NCT00068952","Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme","Completed","No Results Available","Glioblastoma","Drug: Edotecarin|Drug: Temozolomide|Drug: Carmustine (BCNU)|Drug: Lomustine (CCNU)","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 3","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EDOAGL-8725-001|A5921009","September 12, 2003","August 2003","March 2006","March 27, 2008","March 2008","No Study Results Posted","null","null","To compare the overall survival associated with edotecarin versus that associated with temozolomide or BCNU or CCNU for the treatment of patients with GBM at first relapse previously treated with alkylator-based (neo)adjuvant therapy|To assess measures of tumor control To evaluate measures of clinical benefit To assess the safety profile of edotecarin To assess the PK profile of edotecarin and the potential for drug interactions between anticonvulsants and edotecarin","https://ClinicalTrials.gov/show/NCT00068952"
478,"NCT01342757","Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma","Completed","Has Results","Adult Glioblastoma|Depression|Recurrent Adult Brain Tumor","Drug: vorinostat|Drug: temozolomide|Procedure: magnetic resonance spectroscopic imaging|Other: survey administration","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","12","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","NCI-2011-02569|EMORY IRB #00044064|WCI-44064|R21CA141836","April 26, 2011","December 2010","May 2012","April 14, 2015","June 2014","May 3, 2013","null","May 2012","Proportion of Patients With Magnetic Resonance Spectroscopy Response to Initial Vorinostat by MRI and MRS Scans as Determined by Spectroscopic Index|Proportion of Patients Who Experience Metabolic Restoration Between the Responders and Non-responder Groups by MRS Scans|Measurable Change on Magnetic Resonance Spectroscopy Imaging After Vorinostat Administration|Mean (or Median) Change in Metabolite Levels","https://ClinicalTrials.gov/show/NCT01342757"
479,"NCT02681705","Radiation Therapy and Combination Chemotherapy for Medulloblastoma","Recruiting","No Results Available","Medulloblastoma","Drug: Temozolomide|Radiation: Craniospinal Radiation","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","3 Years to 12 Years   (Child)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","sanghaixinhua-003","February 10, 2016","January 2010","December 2016","August 16, 2016","August 2016","No Study Results Posted","null","December 2016","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Progression free survival(PFS)|Overall survival (OS)|Evaluate Rate of Late Neurotoxic Effects","https://ClinicalTrials.gov/show/NCT02681705"
480,"NCT02772107","Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer","Recruiting","No Results Available","Extensive-stage Small Cell Lung Cancer","Drug: Temozolomide|Drug: first-line chemotherapy|Radiation: Prophylactic cranial irradiation|Radiation: thoracic radiotherapy","Chinese PLA General Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","301PLAGH","May 7, 2016","December 2015","January 2018","May 15, 2016","May 2016","No Study Results Posted","null","June 2017","PFS of the maintenance therapy|PFS|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02772107"
481,"NCT01480050","Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Other: 3'-deoxy-3'-[18F]fluorothymidine|Other: pharmacological study|Drug: Mibefradil","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)|Cavion LLC","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","28","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ABTC-1101 CDR0000716313|ABTC-1101","November 23, 2011","April 2012","null","October 12, 2016","October 2016","No Study Results Posted","null","August 2015","Maximum-tolerated dose of mibefradil dihydrochloride|Dose-limiting toxicity|Toxicity and adverse events according to CTCAE v. 4.0|Biological activity of treatment determined by radiographic response|Pharmacokinetics of mibefradil dihydrochloride|Potential effect of mibefradil dihydrochloride on tumor metabolism as determined by [F-18]FLT PET scans in the dose-expansion cohort","https://ClinicalTrials.gov/show/NCT01480050"
482,"NCT01729260","Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide","Completed","No Results Available","Newly Diagnosed High-Grade Glioma","Drug: Mebendazole","Sidney Kimmel Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J1194|NA_00049848","November 13, 2012","November 2012","null","November 10, 2016","November 2016","No Study Results Posted","Mebendazole","September 2016","maximum tolerated dose (MTD) of mebendazole","https://ClinicalTrials.gov/show/NCT01729260"
483,"NCT00720564","Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: arsenic trioxide|Drug: temozolomide|Procedure: adjuvant therapy|Radiation: intensity-modulated radiation therapy|Radiation: radiation therapy","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000600335|P30CA033572|CHNMC-07058|CEPHALON-CHNMC-07058","July 19, 2008","April 2008","February 2009","August 9, 2010","August 2010","No Study Results Posted","null","February 2009","Maximum tolerated dose of arsenic trioxide|Dose-limiting toxicities as measured by CTCAE version 3.0","https://ClinicalTrials.gov/show/NCT00720564"
484,"NCT00504660","6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients","Completed","Has Results","Anaplastic Glioma of Brain|Glioblastoma Multiforme|Brain Cancer","Drug: Capecitabine|Drug: Celecoxib (Celebrex)|Drug: Temozolomide|Drug: Lomustine|Drug: 6-Thioguanine","M.D. Anderson Cancer Center","All","12 Years and older   (Child, Adult, Senior)","Phase 2","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0600","July 18, 2007","September 2003","August 2010","December 6, 2011","December 2011","December 6, 2011","null","August 2010","12 Month-progression-free Survival for Participants With Anaplastic Tumors|6 Month Progression-free Survival for Participants With Glioblastoma","https://ClinicalTrials.gov/show/NCT00504660"
485,"NCT01587144","Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)","Terminated","No Results Available","Glioblastoma Multiforme","Drug: Lucanthone|Drug: Temozolomide (TMZ)|Radiation: Radiation|Drug: Placebo","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Senior)","Phase 2","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","SPI-LUC-11-01","April 11, 2012","March 2012","March 2015","July 20, 2016","July 2016","No Study Results Posted","null","March 2015","Progression Free Survival|Objective response rate (ORR)|Overall Survival|Safety Profile of Lucanthone","https://ClinicalTrials.gov/show/NCT01587144"
486,"NCT00936052","Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma","Unknown status","No Results Available","Glioblastomas|Gliosarcoma","Other: Hyperbaric Oxygen Therapy","Neurological Surgery, P.C.","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LIBTC-2008-2","July 7, 2009","December 2008","December 2010","July 15, 2010","July 2010","No Study Results Posted","HBO","December 2010","to generate preliminary data of the anti-tumor efficacy of hyperbaric oxygenation in conjunction with radiotherapy and chemotherapy,to determine median progression-free survival, to determine median survival and to determine median 2 year survival.|to determine the health related quality of life of this treatment regimen and its influence upon subjects'' perceived level of traumatic stress throughout the course of treatment.","https://ClinicalTrials.gov/show/NCT00936052"
487,"NCT00673361","Pilot Trial of ""Chemo-Switch"" Regimen to Treat Advanced Melanoma","Terminated","Has Results","Melanoma","Drug: Concurrent decrescendo biochemotherapy regimen|Drug: Low-dose Temozolomide plus Sorafenib","Duke University|Bayer","All","18 Years and older   (Adult, Senior)","Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9361|SR05-888","May 4, 2008","March 2007","January 2009","January 11, 2016","December 2012","March 20, 2013","null","January 2009","Progression Free Survival (PFS)|Response Rate as Determined by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria","https://ClinicalTrials.gov/show/NCT00673361"
488,"NCT00492687","Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: carboplatin|Drug: tamoxifen citrate|Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy","San Diego Pacific Oncology & Hematology Associates|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000551555|POHA-0601","June 25, 2007","December 2006","null","January 9, 2014","July 2009","No Study Results Posted","null","July 2009","Progression-free survival|Overall survival|Toxicity|Tumor response","https://ClinicalTrials.gov/show/NCT00492687"
489,"NCT00402116","Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients","Completed","No Results Available","Glioblastoma|Glioblastoma Multiforme|Gliosarcoma","Drug: enzastaurin|Drug: temozolomide|Radiation: radiation","Eli Lilly and Company|University of California, San Francisco","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","72","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9815|H6Q-MC-S008","November 17, 2006","September 2006","December 2009","October 25, 2010","October 2010","No Study Results Posted","null","December 2009","Phase 1 - To determine the maximum tolerated dose (MTD) of enzastaurin in patients with newly diagnosed GBM or GS|Phase 2 - To determine the efficacy of enzastaurin in combination with radiation therapy and temozolomide in patients with newly diagnosed GBM or GS as measured by overall survival (OS)|Phase 1 - To characterize the safety of enzastaurin when combined with temozolomide and radiation therapy in this setting|Phase 1 - To characterize the pharmacokinetics of enzastaurin when administered in combination with temozolomide and radiation therapy|Phase 1 - To assess biomarkers relevant to enzastaurin and disease state, and their correlation to clinical outcome|Phase 1 - To assess for evidence of antitumor activity in this patient population|Phase 2 - To evaluate progression free survival (PFS)|Phase 2 - To evaluate the safety profile of enzastaurin in combination with temozolomide and radiation therapy in this patient population|Phase 2 - To assess biomarkers relevant to enzastaurin and disease state and their correlation to clinical outcome|Phase 2 - To explore the utility of magnetic resonance perfusion techniques to assess treatment with enzastaurin when possible|Phase 2 - To assess changes in health-related quality of life and symptoms in this patient population","https://ClinicalTrials.gov/show/NCT00402116"
490,"NCT03018288","Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)","Recruiting","No Results Available","Glioblastoma","Drug: Pembrolizumab|Biological: HSPPC-96|Drug: Temozolomide|Other: Placebo|Radiation: radiation treatment","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","108","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","170034|17-C-0034","January 11, 2017","January 3, 2017","May 1, 2019","April 20, 2017","March 21, 2017","No Study Results Posted","null","May 1, 2018","To determine whether the one-year overall survival (OS) is improved in newly diagnosed MGMT unmethylated GBM patients treated with RT + TMZ + Pembrolizumab followed by Pembrolizumab + TMZ +/- HSPPC-96 x 6 cycles (1 cycle is 9 weeks) months.|Progression Free Survival-6 ((PFS-6) (percentage of patients alive and progression-free at 6 months post registration) will be defined from the time of registration to the time of confirmed progression in cases where this might be unclear, patie...|Overall Survival (OS) OS-6, 12 and 24 (percentage of patients alive at 6, 12 and 24 months respectively). These quantities will be determined from the level of the Kaplan-Meier curves at these time points.|Response will be determined by tables below using RANO as main criteria but also assess by iRANO. If a lesion is 25% larger but there remains a question as to disease progression or pseudoprogression due to treatment, the patient can remain on t...","https://ClinicalTrials.gov/show/NCT03018288"
491,"NCT02942264","TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma","Recruiting","No Results Available","Brain Tumor|Astrocytoma|Astroglioma|Glioblastoma|Gliosarcoma","Drug: TG02|Drug: TMZ","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1|Phase 2","152","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","170009|17-C-0009","October 21, 2016","October 17, 2016","August 2, 2022","May 12, 2017","November 30, 2016","No Study Results Posted","null","August 2, 2021","Phase I: maximum tolerated dose (MTD) of TG02 plus TMZ using both the dd and mn TMZ schedules in adult patients with recurrent anaplastic astrocytoma or glioblastoma/gliosarcoma.|Phase II: progression free survival in subjects taking TG02 plus TMZ versus TMZ alone in patients with recurrent WHO grade III or IV astrocytoma.|The treatment regimen with better PFS4 between TG02 plus dd TMZ or mn TMZ at each of the MTDs following cohort expansion.|Objective response rate, PFS at 6 months (PFS6) and overall survival(OS) in the treatment arms.|Relationship between symptoms and disease progression and treatment tolerance","https://ClinicalTrials.gov/show/NCT02942264"
492,"NCT00811759","Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma","Unknown status","No Results Available","Melanoma (Skin)","Drug: sorafenib tosylate|Drug: temozolomide|Genetic: gene expression analysis|Genetic: mutation analysis|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: biopsy","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","58","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000626803|IGR-CSET-2006/1261|IGR-SORAF-TEM ST1|INCA-RECF0818|EUDRACT-2007-00527-18|SCHER-IGR-CSET-2006/1261|BAYER-IGR-CSET-2006/1261","December 18, 2008","June 2007","null","October 6, 2010","July 2009","No Study Results Posted","null","May 2009","Maximum tolerated dose (Phase I)|Progression-free survival at 12 weeks (Phase II)","https://ClinicalTrials.gov/show/NCT00811759"
493,"NCT00360945","Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: cisplatin|Drug: temozolomide|Genetic: fluorescence in situ hybridization|Genetic: loss of heterozygosity analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","4 Years to 20 Years   (Child, Adult)","Phase 2","87","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000482280|CCLG-CNS-2004-02|EU-20622","August 3, 2006","April 2004","null","September 16, 2013","November 2006","No Study Results Posted","null","null","Response rate after 2 courses|Relapse-free survival|Best response in patients receiving more than 2 courses|Rate of progression at 6 months and 1 and 2 years|Overall survival","https://ClinicalTrials.gov/show/NCT00360945"
494,"NCT00052455","Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: lomustine|Drug: procarbazine hydrochloride|Drug: temozolomide|Drug: vincristine sulfate","Institute of Cancer Research, United Kingdom|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","500","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000258428|MRC-BR12|EU-20114|ISRCTN83176944","January 24, 2003","October 2002","September 2010","December 17, 2013","May 2007","No Study Results Posted","null","null","Overall survival|Progression-free survival at 12 weeks (Arm II)|Toxicity|Quality of life as measured by EORTC QLQ-C30 and BTM|Cost effectiveness","https://ClinicalTrials.gov/show/NCT00052455"
495,"NCT00770471","ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Drug: veliparib|Genetic: DNA methylation analysis|Genetic: gene expression analysis|Genetic: mutation analysis|Genetic: proteomic profiling|Other: high performance liquid chromatography|Other: immunoenzyme technique|Other: laboratory biomarker analysis|Other: mass spectrometry|Other: pharmacogenomic studies|Other: pharmacological study|Procedure: adjuvant therapy|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NABTT-0801 CDR0000616542|U01CA062475|ABTC-0801|NABTT-0801|ABBOTT-M10-190","October 9, 2008","June 2009","March 2012","May 1, 2012","May 2012","No Study Results Posted","null","March 2012","Maximum tolerated dose of ABT-888 (Phase I)|Overall survival (Phase II)|Toxicity (Phase I)|Pharmacokinetics of ABT-888 (Phase I)|Frequency of toxicity (Phase II)","https://ClinicalTrials.gov/show/NCT00770471"
496,"NCT00714181","Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: hydroxychloroquine|Drug: temozolomide|Genetic: TdT-mediated dUTP nick end labeling assay|Genetic: western blotting|Other: electron microscopy|Other: high performance liquid chromatography|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: mass spectrometry|Other: pharmacological study","Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","38","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000600329|UPCC-12907","July 11, 2008","June 2008","June 2013","February 17, 2016","February 2016","No Study Results Posted","null","July 2011","Maximum tolerated dose of hydroxychloroquine|Toxicity rates|Pharmacodynamic and pharmacokinetic correlative endpoints","https://ClinicalTrials.gov/show/NCT00714181"
497,"NCT02880410","Feasibility Study on LITT for Newly Diagnosed Glioblastoma","Recruiting","No Results Available","Glioblastoma","Device: NeuroBlate System|Drug: Radiation therapy and temozolomide","Monteris Medical","All","18 Years and older   (Adult, Senior)","Phase 1","45","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","FLAG","August 18, 2016","June 2017","December 2020","May 16, 2017","May 2017","No Study Results Posted","FLAG","May 2019","Adverse Events|Progression-Free Survival Rate|Overall Survival|Changes in Quality of Life","https://ClinicalTrials.gov/show/NCT02880410"
498,"NCT01269424","O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma","Suspended","No Results Available","Glioblastoma Multiforme","Biological: MGMTP140K-encoding retroviral vector|Drug: O6-benzylguanine|Drug: temozolomide|Other: laboratory biomarker analysis|Procedure: autologous hematopoietic stem cell transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation|Radiation: radiation therapy","Stanton Gerson MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","14","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE6307|NCI-2011-02566|8274|U01CA062502","December 31, 2010","December 2010","June 2018","December 20, 2016","December 2016","No Study Results Posted","null","June 2017","Feasibility and safety of infusing autologous P140K MGMT-transduced hematopoietic progenitors into patients with GBM|Successful transduction rate|To evaluate the in vivo enrichment of P140K expressing hematopoietic cells by repeated treatments of BG and TMZ|Progression-free|Number of patients with radiological progression|Overall Survival","https://ClinicalTrials.gov/show/NCT01269424"
499,"NCT00004068","Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: irinotecan hydrochloride|Drug: temozolomide|Procedure: conventional surgery|Radiation: radiation therapy","St. Jude Children's Research Hospital|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","53","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067271|P30CA021765|SJCRH: SJHG98|SPRI-P-00112|NCI-G99-1577","December 10, 1999","March 1999","April 2003","October 3, 2011","October 2011","No Study Results Posted","null","April 2003","","https://ClinicalTrials.gov/show/NCT00004068"
500,"NCT00486603","Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: hydroxychloroquine|Drug: temozolomide|Genetic: mutation analysis|Genetic: polymerase chain reaction|Other: immunologic technique|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: adjuvant therapy|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","94","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NABTT-0603 CDR0000549734|U01CA062475|ABTC-0603|NABTT-0603","June 13, 2007","October 2007","null","May 1, 2012","May 2012","No Study Results Posted","null","January 2013","Maximum tolerated dose of hydroxychloroquine (Phase I)|Safety|Overall survival|Death|Toxicity and tolerability (Phase I)|Frequency of toxicity (Phase II)|Pharmacokinetics and pharmacodynamics of hydroxychloroquine|Correlation of the presence of TP53 and PTEN genes and BECN1 with toxicity and clinical outcomes|Correlation of the average change in autophagic vesicles from baseline with genotype, toxicity, and clinical outcomes","https://ClinicalTrials.gov/show/NCT00486603"
501,"NCT01402063","PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation","Completed","Has Results","Glioblastoma Multiforme","Drug: PPX (CT2103)|Drug: Temozolomide","Brown University|Rhode Island Hospital|Milton S. Hershey Medical Center|University of Washington|University of Massachusetts, Worcester|Maine Medical Center|University of California, San Diego|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG 244","July 8, 2011","September 2011","June 2015","July 8, 2015","July 2015","April 30, 2015","null","April 2014","Progression Free Survival PPX/RT Versus TMZ/RT for Patients With GBM Without Methylation","https://ClinicalTrials.gov/show/NCT01402063"
502,"NCT02672241","Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children","Recruiting","No Results Available","Childhood Brain Stem Neoplasm","Drug: Nimotuzumab|Drug: Temozolomide","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","3 Years to 12 Years   (Child)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","sanghaixinhua-002","January 31, 2016","January 2016","August 2017","September 11, 2016","September 2016","No Study Results Posted","null","January 2017","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Progression free survival(PFS)|Overall survival (OS)|Objective response rate (ORR)","https://ClinicalTrials.gov/show/NCT02672241"
503,"NCT01247623","Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma","Completed","No Results Available","Malignant Melanoma","Biological: GV1001","Oslo University Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","null","Other","Interventional","","P03700","November 23, 2010","January 2005","September 2012","November 4, 2014","November 2014","No Study Results Posted","null","September 2011","","https://ClinicalTrials.gov/show/NCT01247623"
504,"NCT00662506","Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma","Completed","No Results Available","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma","Drug: Cediranib Maleate|Procedure: Diffusion Tensor Imaging|Procedure: Diffusion Weighted Imaging|Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Radiation: Fludeoxyglucose F-18|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Procedure: Perfusion Magnetic Resonance Imaging|Procedure: Positron Emission Tomography|Drug: Temozolomide","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","46","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2009-00267|MGH-07-344|R01CA129371|PHS 398/2590|CDR0000593717|8030|P30CA006516","April 18, 2008","April 2008","April 2014","April 27, 2017","April 2017","No Study Results Posted","null","April 2014","Progression-free survival (Phase II)|Safety profile and optimal dose of cediranib during chemoradiotherapy (Phase I)|Blood biomarkers (Phase II)|MRI parameters (Phase II)|Tumor biomarkers (Phase II)","https://ClinicalTrials.gov/show/NCT00662506"
505,"NCT00499798","Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Chemotherapeutic Agent Toxicity|Infertility","","Wake Forest University Health Sciences|National Cancer Institute (NCI)","Male","18 Years to 60 Years   (Adult)","","16","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDR0000553297|CCCWFU-97404|CCCWFU-BG04-308","July 10, 2007","August 2004","September 2014","January 17, 2017","July 2013","No Study Results Posted","null","June 2009","assess any changes in standard semen/sperm analysis parameters","https://ClinicalTrials.gov/show/NCT00499798"
506,"NCT00943462","Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM","Withdrawn","No Results Available","Astrocytoma, Grade IV|Giant Cell Glioblastoma|Glioblastoma Multiforme","Radiation: External-beam radiation therapy|Drug: Temozolomide","Centre hospitalier de l'Université de Montréal (CHUM)|Schering-Plough","All","18 Years to 70 Years   (Adult, Senior)","","20","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CE-08-234|Schering-P06046","July 20, 2009","June 2009","June 2011","April 26, 2011","April 2011","No Study Results Posted","null","June 2011","","https://ClinicalTrials.gov/show/NCT00943462"
507,"NCT00734864","Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma","Withdrawn","No Results Available","Glioblastoma Multiforme|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Glioma","Drug: enzyme-inducing anti-epileptic drugs|Drug: enzyme-inducing anti-epileptic drugs","Annick Desjardins|Bristol-Myers Squibb|Duke University","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00007909|BMS Protocol #CA180-108","May 4, 2008","June 2009","June 2012","November 20, 2012","November 2012","No Study Results Posted","null","June 2010","Toxicity assessed using CTCAE v.3.0|Progression free and overall survival|Radiographic response (modified MacDonald Criteria)","https://ClinicalTrials.gov/show/NCT00734864"
508,"NCT02977780","INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)","Recruiting","No Results Available","Glioblastoma","Drug: Temozolomide|Drug: Neratinib|Drug: CC-115|Drug: Abemaciclib","Dana-Farber Cancer Institute|Eli Lilly and Company|Celgene|Puma Biotechnology, Inc.|Accelerate Brain Cancer Cure","All","18 Years and older   (Adult, Senior)","Phase 2","280","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","16-443","November 18, 2016","February 9, 2017","May 2021","April 12, 2017","April 2017","No Study Results Posted","null","May 2019","Overall Survival in Experimental Arms Compared with Standard Therapy|Incidence of Treatment-Emergent Adverse Events|Progression Free Survival Among Experimental Arms And Biomarker Groups|Overall Survival Among Experimental Arms And Biomarker Groups|Association Between Progression Free Survival and Overall Survival Effects Of Experimental Agents","https://ClinicalTrials.gov/show/NCT02977780"
509,"NCT01528046","Metformin in Children With Relapsed or Refractory Solid Tumors","Recruiting","No Results Available","Solid Tumors|Primary Brain Tumors","Drug: Vincristine|Drug: Irinotecan|Drug: Temozolomide|Drug: Metformin","H. Lee Moffitt Cancer Center and Research Institute|Pediatric Cancer Foundation","All","1 Year to 18 Years   (Child, Adult)","Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-16962|SP003","February 3, 2012","April 25, 2012","February 2018","May 18, 2017","May 2017","No Study Results Posted","null","February 2018","Maximum Tolerated Dose (MTD)|Number of Participants with Antitumor Activity|Pharmacokinetics|Pharmacodynamics|Metformin Concentrations","https://ClinicalTrials.gov/show/NCT01528046"
510,"NCT02659800","IL-7 in Increasing Low CD4 Counts After Concurrent Radiation and Temozolomide Treatment in Patients With High Grade Gliomas","Recruiting","No Results Available","Lymphopenia|Malignant Glioma","Other: Laboratory Biomarker Analysis|Biological: Glycosylated Recombinant Human Interleukin-7|Other: Placebo","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)|Revimmune","All","18 Years and older   (Adult, Senior)","","50","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider)|Primary Purpose: Supportive Care","ABTC 1403|UM1CA137443|IRB00073777","January 15, 2016","November 2015","August 2018","December 8, 2016","December 2016","No Study Results Posted","null","November 2017","Absolute total CD4 cell counts|Optimal dose of glycosylated recombinant human interleukin-7 determined by dose-limiting toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0","https://ClinicalTrials.gov/show/NCT02659800"
511,"NCT00004259","Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: Nitrosourea (BCNU or CCNU)|Drug: temozolomide|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group|Eastern Cooperative Oncology Group|NRG Oncology","All","18 Years to 120 Years   (Adult, Senior)","Phase 3","230","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-9813|CDR0000067512|ECOG-R9813|NCCTG-RTOG-9813","January 28, 2000","June 2000","null","September 28, 2016","September 2016","No Study Results Posted","null","March 2020","Overall survival (OS)|Time to tumor progression (TTP)|Toxicity|Correlation of molecular analyses with OS and TTP","https://ClinicalTrials.gov/show/NCT00004259"
512,"NCT02991456","Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide","Not yet recruiting","No Results Available","Chemo-radiation Induced Nausea and Vomiting","Drug: Rolapitant|Drug: Ondansetron","Duke University|Tesaro, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: No masking|Primary Purpose: Supportive Care","Pro00076418","December 9, 2016","June 15, 2017","December 27, 2020","April 27, 2017","April 2017","No Study Results Posted","null","November 15, 2020","Complete response (CR) rate|Percentage of patients preferring rolapitant in combination with ondansetron versus ondansetron alone|Ondansetron monotherapy patient satisfaction: Effectiveness|Ondansetron + rolapitant patient satisfaction: Effectiveness|Ondansetron monotherapy patient satisfaction: Convenience|Ondansetron + rolapitant patient satisfaction: Convenience|Ondansetron monotherapy patient satisfaction: Global satisfaction|Ondansetron + rolapitant patient satisfaction: Global satisfaction|Chemotherapy-induced nausea (CIN) CR Rate for ondansetron monotherapy|Chemotherapy-induced nausea (CIN) CR Rate for ondansetron + rolapitant|Chemotherapy-induced vomiting (CIV) CR Rate for ondansetron monotherapy|Chemotherapy-induced vomiting (CIV) CR Rate for ondansetron + rolapitant|Ondansetron monotherapy medication compliance|Ondansetron + rolapitant medication compliance|Percentage of participants with grade 3, 4 or 5 treatment-related adverse events","https://ClinicalTrials.gov/show/NCT02991456"
513,"NCT01213407","Dendritic Cell Cancer Vaccine for High-grade Glioma","Completed","No Results Available","Glioblastoma Multiforme","Drug: Trivax, Temozolomide, Surgery, Radiotherapy|Drug: Temozolomide, Surgery, Radiotherapy","Activartis Biotech","All","3 Years to 70 Years   (Child, Adult, Senior)","Phase 2","87","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GBM-Vax-TRX2","May 28, 2010","April 2010","November 2015","May 18, 2016","May 2016","No Study Results Posted","GBM-Vax","June 2015","Progression free survival|Quality of Life|Progression free survival at 18 and 24 months|Overall survival","https://ClinicalTrials.gov/show/NCT01213407"
514,"NCT00687765","Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma","Completed","No Results Available","Glioblastoma","Drug: bsi-201 plus temozolomide","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","126","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TCD11616|20070104","May 28, 2008","July 2008","June 2015","July 10, 2015","July 2015","No Study Results Posted","null","June 2015","To determine the Maximum Tolerated Dose (MTD) of BSI-201, administered as an IV infusion in patients with newly diagnosed malignant glioma when given with temozolomide (TMZ) after the completion of standard radiation therapy and concomitant TMZ","https://ClinicalTrials.gov/show/NCT00687765"
515,"NCT00390403","Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: R-(-)-gossypol acetic acid|Drug: temozolomide|Genetic: gene expression analysis|Genetic: mutation analysis|Genetic: protein expression analysis|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: adjuvant therapy|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","50","Other|NIH","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","NABTT-0602 CDR0000507451|U01CA062475|NABTT-0602","October 18, 2006","February 2007","null","May 1, 2012","May 2012","No Study Results Posted","null","June 2009","Maximum tolerated dose|Toxicity|Pharmacokinetic profile of gossypol|Therapeutic activity|Cellular and molecular outcomes (intratumoral expression levels of biomarkers, including Bcl-2 family protein expression [e.g., Bcl-2, Bcl-xL, MCl-1, Bax, Bak, BH3 domain], MGMT gene methylation status, and gene expression array)","https://ClinicalTrials.gov/show/NCT00390403"
516,"NCT02331498","Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: Pazopanib","Centre Antoine Lacassagne|GlaxoSmithKline","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","51","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2012/49","November 10, 2014","June 2015","December 2018","February 21, 2017","February 2016","No Study Results Posted","PAZOGLIO","August 2018","Recommended Phase 2 Dose (RP2D) of pazopanib in oral route in addition to the maintenance phase of the Stupp protocol, according the rate (33 %) of tolerate toxicities|overall tolerance of pazopanib : number of biological toxicities, blood pressure and hemorragic events|antitumor activity of the adjunction of daily dose of pazopanib to the maintenance phase of the Stupp protocol|determine the median Progression-Free-Survival|determine the median Overall Survival (mOS)|pharmacokinetics profile: area under curve regarding plasma concentration /time between 0 and 8 h (AUC0-8 hours) from 0 to 24 h (AUC 0-24 hours), maximum plasma concentration (Cmax), time to the concentration maximum (Tmax) and plasma half-life (t1/2)|determine the pharmacokinetics (PK) profile of TMZ","https://ClinicalTrials.gov/show/NCT02331498"
517,"NCT03150862","A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma","Not yet recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: BGB-290|Drug: TMZ|Radiation: Radiation","BeiGene USA, Inc.|BeiGene","All","18 Years to 99 Years   (Adult, Senior)","Phase 1|Phase 2","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BGB-290-104","May 8, 2017","June 30, 2017","October 31, 2021","May 10, 2017","May 2017","No Study Results Posted","null","June 30, 2021","Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE|Incidence, nature and severity of adverse events as assessed by CTCAE|Number of treatment cycles, dose intensity of components of each treatment regimen, and changes in vital signs and clinical laboratory tests during and following treatment|Phase 2: Arm A [BGB-290 + RT] and Arm B [BGB-290 + RT + TMZ]|Phase 2 Arm C [BGB-290 + TMZ]|Pharmacokinetic (PK) parameters of BGB-290 of steady state Ctrough|Modified disease control rate (DCR). (Arms A and B)|Disease control rate (Arm C)|Objective response rate (ORR)|Clinical benefit rate (CBR).|Duration of response (DOR).|Progression free survival (PFS).|Overall survival (OS)|Objective response rate (ORR).|Clinical benefit rate (CBR)|Duration of response (DOR)|Progression free survival (PFS)|PK parameter of BGB-290 of steady state Ctrough|PK parameter of BGB-290 (Cmax)|Disease control rate (DCR).","https://ClinicalTrials.gov/show/NCT03150862"
518,"NCT00974987","Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Radiation: BNCT(boron neutron capture therapy)|Radiation: XRT(X-ray radiation treatment)|Drug: TMZ(temozolomide)","Translational Research Informatics Center, Kobe, Hyogo, Japan|Department of Nuerosurgery, Osaka Medical College","All","15 Years to 75 Years   (Child, Adult, Senior)","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSAKA-TRIBRAIN0902|CDR0000650829|UMIN000002385","September 10, 2009","September 2009","null","November 7, 2016","November 2016","No Study Results Posted","null","December 2016","Overall survival (OS)|Tumor response（RECIST）|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Adverse event","https://ClinicalTrials.gov/show/NCT00974987"
519,"NCT00267592","Safety and Efficacy of Talampanel in Glioblastoma Multiforme","Completed","No Results Available","Glioblastoma Multiforme","Drug: Talampanel|Radiation: Radiation Therapy (RT) 5 days a week +|Drug: temozolomide(TMZ) 75mg|Drug: adjuvant TMZ 200mg","Teva Pharmaceutical Industries","All","18 Years and older   (Adult, Senior)","Phase 2","72","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IXR-207-21-189 / NABTT 0304","December 19, 2005","December 2005","February 2011","April 20, 2016","April 2016","No Study Results Posted","null","September 2008","Overall Survival|Talampanel-related toxicity","https://ClinicalTrials.gov/show/NCT00267592"
520,"NCT00991250","SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma","Unknown status","No Results Available","Malignant Melanoma","Biological: SentoClone®|Drug: Temodal® or Dacarbazine Medac®","SentoClone AB","All","Child, Adult, Senior","Phase 2","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Mel-Swe-01 2009-12-17|EudraCT No: 2008-007515-33","October 5, 2009","October 2009","September 2011","February 4, 2010","February 2010","No Study Results Posted","null","September 2011","Tumour response rate, defined as complete response (CR) or partial response (PR) (i.e. at least partial response) measured using the RECIST (Response Evaluation Criteria in Solid Tumours) criteria.|Progression-free survival|Overall survival|Time to tumour progression|Disease-free survival|Time to treatment failure|Duration of response|Correlation between tumour response and tumour marker S100|Proportion of patients showing toxic symptoms according to CTCAE criteria|Quality of life (EQ-5D and QLQ-C30)|Adverse Events (AEs) classified according to seriousness, causality, and intensity, clinically significant deviations in vital signs, clinical chemistry, and haematology","https://ClinicalTrials.gov/show/NCT00991250"
521,"NCT00473408","The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas","Terminated","No Results Available","Anaplastic Astrocytoma|Glioblastoma Multiforme|Tumor Angiogenesis","Device: Functional MRI (DCE-MRI)|Procedure: Blood sample|Procedure: Tumor sample","Haukeland University Hospital|University of Bergen","All","18 Years and older   (Adult, Senior)","","1","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15437|REK ID: 202.06","May 14, 2007","March 2007","November 2011","December 5, 2016","December 2016","No Study Results Posted","Gliomstudien","May 2007","","https://ClinicalTrials.gov/show/NCT00473408"
522,"NCT00068250","Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma","Completed","No Results Available","Brain and Central Nervous System Tumors|Lymphoma","Biological: rituximab|Drug: methotrexate|Drug: temozolomide|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0227|CDR0000301563","September 10, 2003","July 2003","December 2016","December 30, 2016","December 2016","No Study Results Posted","null","December 2016","Toxicity rate (Phase I)|Overall survival rate at 2 years (Phase ll)|Pre-irradiation chemotherapy tumor response rate (Phase II)|Progression-free survival (Phase II)","https://ClinicalTrials.gov/show/NCT00068250"
523,"NCT00154375","Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma","Completed","Has Results","Glioblastoma Multiforme|Astrocytoma","Drug: Imatinib mesylate|Drug: Hydroxyurea","Novartis Pharmaceuticals|Novartis","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSTI571BDE40","September 9, 2005","October 2004","null","April 19, 2011","April 2011","January 13, 2011","null","August 2008","Percentage of Participants With Progression Free Survival (PFS) During the Study Duration|Number of Participants With Death, Other Serious or Clinically Significant Adverse Events (AEs) or Related Discontinuations","https://ClinicalTrials.gov/show/NCT00154375"
524,"NCT00884416","Sorafenib in Newly Diagnosed High Grade Glioma","Completed","No Results Available","Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma","Drug: Sorafenib dose escalation","University Hospital, Geneva|Bayer","All","18 Years and older   (Adult, Senior)","Phase 1","17","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-122|2009DR1029|13031","April 17, 2009","March 2009","March 2012","October 31, 2014","October 2014","No Study Results Posted","null","December 2011","Safety and tolerability of sorafenib in combination with radiation and temozolomide chemotherapy|Maximum Observed Plasma Concentration (Cmax) and Area under the curve (AUC) of sorafenib and temozolomide|Response rate|Time to treatment failure|6 month progression-free survival|Event free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00884416"
525,"NCT01020292","A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma","Active, not recruiting","No Results Available","Glioma","Drug: Nelfinavir","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Phase 1","31","Other","Interventional","","UPCC 01309","November 23, 2009","April 2009","null","January 24, 2017","January 2017","No Study Results Posted","null","December 2017","To determine the safety, dose-limiting toxicities, and maximally tolerated dose of NFV concurrently with radiation and temozolomide.|To determine the progression free survival (PFS) and overall survival (OS) with an exploratory analysis to compare the observed median value obtained in this study to the historical median values of 6.9 months and 14.6 months respectively.","https://ClinicalTrials.gov/show/NCT01020292"
526,"NCT02193347","IDH1 Peptide Vaccine for Recurrent Grade II Glioma","Recruiting","No Results Available","Brain Cancer|Brain Neoplasm, Primary|Brain Neoplasms, Recurrent|Brain Tumor|Cancer of the Brain","Biological: PEPIDH1M vaccine|Biological: Tetanus-Diphtheria Toxoid (Td)|Drug: Temozolomide","Duke University","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Pro00054746","July 2, 2014","December 2015","June 2019","April 10, 2017","April 2017","No Study Results Posted","RESIST","June 2019","The percentage of patients with an unacceptable toxicity will be estimated.|IFNγ ELIspot Measurements","https://ClinicalTrials.gov/show/NCT02193347"
527,"NCT00667953","Study of Temzolomide and Gleevec in Advanced Melanoma","Active, not recruiting","No Results Available","Melanoma|Advanced Melanoma","Drug: Gleevec + Temozolomide","Abramson Cancer Center of the University of Pennsylvania|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","56","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCC 02602","April 24, 2008","January 2003","null","September 23, 2016","September 2016","No Study Results Posted","null","March 2011","To determine the safety and efficacy of combination therapy with Gleevec and Temzolomide in patients with advanced melanoma.|To evaluate the secondary endpoints of time to disease progression, duration of response, and overall survival of patients receiving Gleevec + Temozolomide","https://ClinicalTrials.gov/show/NCT00667953"
528,"NCT00080054","A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas","Completed","No Results Available","Glioma|Glioblastoma|Astrocytoma|Oligodendroglioma|Brain Neoplasm","Drug: Motexafin Gadolinium Injection","Pharmacyclics LLC.","All","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PCYC-0218","March 22, 2004","null","null","April 2, 2009","January 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00080054"
529,"NCT00369590","VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide","Completed","Has Results","Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor","Biological: ziv-aflibercept|Other: pharmacological study|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","58","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00677|CDR0000495275|NABTC06-01|NABTC-06-01|U01CA062399","August 24, 2006","August 2006","October 2012","August 31, 2015","August 2015","June 3, 2015","null","December 2011","Progression-free Survival (PFS) at 6 Months|Safety Profile - Toxicities|Safety Profile - Events That Discontinued Treatment|Response Rate Associated With VEGF Trap Therapy Defined as Proportions of Patients Experiencing Complete or Partial Response|Progression Free Survival (PFS) Rate for Subjects With Radiographic Response|Overall Survival","https://ClinicalTrials.gov/show/NCT00369590"
530,"NCT01866449","Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme","Active, not recruiting","No Results Available","Glioblastoma Multiforme (GBM) WHO Grade IV","Drug: Cabazitaxel","University of Ulm","All","18 Years and older   (Adult, Senior)","Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","C-GBM (XRP6258)","May 22, 2013","October 2013","December 2017","February 23, 2017","February 2017","No Study Results Posted","null","December 2016","Response including SD, PR or CR determined by MRI (modified RANO criteria)|Overall and progression-free survival|Safety and tolerability|Pharmacokinetics data concerning drug interactions (i.e. CYP3A induction)|Quality of life and neurocognitive functioning","https://ClinicalTrials.gov/show/NCT01866449"
531,"NCT00539591","Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","Completed","Has Results","Malignant Melanoma","Drug: Peginterferon alfa-2b|Drug: Temozolomide|Drug: Recombinant interferon alfa-2b","St. Jude Children's Research Hospital|Schering-Plough","All","up to 21 Years   (Child, Adult)","Phase 2","29","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MEL06|NCI-2011-01192","October 2, 2007","October 2007","October 2015","February 20, 2017","August 2016","September 10, 2013","null","June 2015","Tumor Response Rate|Number of Patients Who Experience Toxicity at or Above the Target Toxicity for Strata B1 and B2|Number of Patients Who Experience Toxicity at or Above the Target Toxicity for Stratum A Patients|Probability of Event-free Survival (EFS) of Stratum A Participants","https://ClinicalTrials.gov/show/NCT00539591"
532,"NCT00311857","Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)","Unknown status","No Results Available","Glioblastoma Multiforme","Drug: Cetuximab|Drug: Temozolomide|Procedure: Radiation therapy","Heidelberg University|Merck KGaA","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","46","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Eudract-2005-003911-63|PEI 119/01","April 5, 2006","February 2006","null","September 7, 2006","September 2006","No Study Results Posted","null","null","Toxicity|Overall survival","https://ClinicalTrials.gov/show/NCT00311857"
533,"NCT00016055","Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma","Unknown status","No Results Available","Melanoma (Skin)","Biological: lymphokine-activated killer cells|Drug: temozolomide","St. Luke's Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other","Interventional","Primary Purpose: Treatment","CDR0000068590|STLMC-IMM-0002|NCI-V01-1657","May 6, 2001","November 2000","null","September 19, 2013","November 2006","No Study Results Posted","null","null","Maximum tolerated dose at completion of study|Safety as measured by NCI common toxicity table at completion of study","https://ClinicalTrials.gov/show/NCT00016055"
534,"NCT00005815","Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma","Completed","No Results Available","Intraocular Melanoma|Melanoma (Skin)","Drug: temozolomide|Drug: thalidomide","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","99-103|CDR0000067818|NCI-G00-1786","June 2, 2000","December 1999","August 2004","June 17, 2013","June 2013","No Study Results Posted","null","August 2004","","https://ClinicalTrials.gov/show/NCT00005815"
535,"NCT01465347","Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) With Concomitant Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM)","Active, not recruiting","No Results Available","Glioblastoma|GBM|Glioma|High Grade Glioma","Drug: Trans Sodium Crocetinate (TSC)","Diffusion Pharmaceuticals LLC","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","59","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DP100-202","November 2, 2011","February 2012","September 2016","August 3, 2015","August 2015","No Study Results Posted","null","September 2015","Overall Survival|Quality of Life (QoL)","https://ClinicalTrials.gov/show/NCT01465347"
536,"NCT00626483","Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia","Active, not recruiting","No Results Available","Malignant Neoplasms Brain","Biological: RNA-loaded dendritic cell vaccine|Drug: basiliximab","John Sampson|National Cancer Institute (NCI)|Duke University","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","18","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Pro00000581|P50CA108786|P30CA014236|SPORE Project 3|CDR0000579683","February 28, 2008","March 2007","June 2018","May 22, 2017","May 2017","No Study Results Posted","REGULATe","December 2017","Functional capacity of CD4+,CD25+, CD127- T-regulatory cells|Safety","https://ClinicalTrials.gov/show/NCT00626483"
537,"NCT00222443","Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy","Completed","No Results Available","Lymphomas|Tumors","Drug: Irinotecan","University of Oklahoma","All","1 Year to 21 Years   (Child, Adult)","Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","JEC Toca One","September 20, 2005","September 2004","December 2007","September 19, 2008","September 2008","No Study Results Posted","null","December 2007","Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan.|Evaluate feasibility of repetitive cycles of this combination .|Estimate response rate in children and adolescents with recurrent solid tumors and lymphomas.","https://ClinicalTrials.gov/show/NCT00222443"
538,"NCT00121680","A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma","Completed","No Results Available","Metastatic Melanoma","Drug: E7080","Eisai Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","115","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E7080-A001-102","July 15, 2005","July 2005","May 2015","December 9, 2015","November 2015","No Study Results Posted","null","September 2011","To determine the maximum tolerated dose (MTD) of E7080 for two different schedules incorporating dose interruptions.|Identify the dose limiting toxicities (DLT); explore safety and tolerability; determine pharmacokinetic profile; explore anti-tumor efficacy.","https://ClinicalTrials.gov/show/NCT00121680"
539,"NCT00944801","Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma","Completed","No Results Available","Glioblastoma","Drug: Pegylated Liposomal Doxorubicine","University of Regensburg|Essex Pharma (Schering-Plough) Germany","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RNOP-09","July 17, 2009","July 2002","May 2009","July 21, 2009","July 2009","No Study Results Posted","null","May 2009","progression free survival probability at 12 months to detect an improvement of the PFS-12 of 15.6% as compared to EORTC26981/NCIC-CE.3 combination arm (PFS-12: 26.9%)|PFS-24, mOS, OS-12, OS-24, mTTP, response rate, rate of stabilizations , and toxicity profile","https://ClinicalTrials.gov/show/NCT00944801"
540,"NCT01702610","Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Glioblastoma Mutliforme","Radiation: IMRT Technique|Radiation: IMRT and accelerated hypofractionation technique|Radiation: neo-adjuvant TMZ followed by accelerated hypofractionated EBRT|Drug: Temozolomide and Accelerated Hypofractionation RT","McGill University Health Center","All","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEN-08-013|MGRT01:TMZ/GBM","August 22, 2012","December 2008","December 2014","September 26, 2016","September 2016","No Study Results Posted","null","December 2014","Percent of patients completing the study treatment|To assess toxicity of the regimen","https://ClinicalTrials.gov/show/NCT01702610"
541,"NCT01605162","Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma","Terminated","No Results Available","Wild Type BRAF Stage IV Melanoma|Unresectable Stage III Melanoma","Drug: TMZ|Drug: E7016","Eisai Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E7016-A001-201","May 22, 2012","May 2012","February 2014","July 25, 2016","July 2016","No Study Results Posted","null","February 2014","The Progression Free Survival-6m rate defined as the proportion of subjects that are alive and progression-free at 6-months from the date of first dosing based on RECIST 1.1.","https://ClinicalTrials.gov/show/NCT01605162"
542,"NCT01044225","Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma","Terminated","No Results Available","Glioblastoma","Drug: Cetuximab|Drug: Cilengitide EMD 121974","Bart Neyns|Universitair Ziekenhuis Brussel","All","18 Years and older   (Adult, Senior)","Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-012324-83","January 6, 2010","September 2009","September 2011","March 21, 2012","March 2012","No Study Results Posted","null","September 2011","the 1 year overall survival","https://ClinicalTrials.gov/show/NCT01044225"
543,"NCT02203526","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma","Suspended","No Results Available","Primary Central Nervious System Lymphoma","Drug: TEDDI|Biological: Rituximab|Drug: Cytarabine|Drug: TEDD|Drug: Ibrutinib","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","Phase 1","18","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","140157|14-C-0157","July 29, 2014","July 24, 2014","June 15, 2023","May 12, 2017","April 14, 2017","No Study Results Posted","null","June 15, 2022","MTD of ibrutinib when given with TEDD-R","https://ClinicalTrials.gov/show/NCT02203526"
544,"NCT02970448","Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas","Not yet recruiting","No Results Available","High Grade Glioma","Procedure: LITT|Radiation: Radiation therapy|Drug: Temozolomide","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Early Phase 1","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE4316","November 18, 2016","December 2016","January 2020","November 21, 2016","November 2016","No Study Results Posted","null","January 2020","Study safety as determined by the number of patients who experience pre-specified adverse events|Number of patients with adjustments to radiation plan to account for post-LITT tissue distortion","https://ClinicalTrials.gov/show/NCT02970448"
545,"NCT02065466","Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases","Withdrawn","No Results Available","Metastatic Melanoma|Brain Metastases","Drug: nab-paclitaxel|Drug: Temozolomide|Drug: Bevacizumab","University of Arizona","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1312169092","February 6, 2014","July 2014","August 2015","April 20, 2016","April 2016","No Study Results Posted","null","February 2015","Maximum Tolerance Dose|Progression Free Survival|Response Rate","https://ClinicalTrials.gov/show/NCT02065466"
546,"NCT00720356","Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: bevacizumab|Drug: erlotinib hydrochloride","Northwestern University|M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU 07C3|BTTC08-01|STU00002792","July 19, 2008","March 2009","March 2019","May 31, 2016","May 2016","No Study Results Posted","null","March 2018","Overall survival|Progression-free survival at 12 and 18 months|Radiographic response rates|Safety of the combination of erlotinib and bevacizumab in this patient population","https://ClinicalTrials.gov/show/NCT00720356"
547,"NCT01502241","Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly","Completed","No Results Available","Glioblastoma|Anaplastic Astrocytoma","Drug: Temozolomide|Radiation: Radiotherapy of the partial brain.","Heidelberg University","All","65 Years and older   (Adult, Senior)","Phase 3","412","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","NOA-08|05-01","December 24, 2011","January 2005","November 2011","December 29, 2011","December 2011","No Study Results Posted","Methusalem","November 2010","Overall survival|Event-free survival|Best response|Molecular prognostic or predictive biomarkers","https://ClinicalTrials.gov/show/NCT01502241"
548,"NCT02227576","Prevention of Thrombocytopenia in Glioblastoma Patients","Recruiting","No Results Available","Thrombocytopenia|Glioblastoma","Drug: Romiplostim","University Hospital, Lille","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2011_29|2012-001751-38","August 26, 2014","July 10, 2014","December 2017","May 17, 2017","May 2017","No Study Results Posted","PLATUM","December 2017","Proportion of patients receiving 100% of the planned TMZ dosage in the whole Stupp protocol. The primary endpoint will consider dose reduction and dose delay.|Incidence of serious adverse events according to CTCAE 4.0 criteria.|Incidence of delayed chemotherapy cycles and the incidence of chemotherapy cycles with dose reduction due to severe TP|Number and percentage of patients with TP of grade 3 or grade 4 after receiving Romiplostim.|Number and percentage of patients receiving platelets transfusion for TP|Incidence and type of adverse events linked to TP episodes during Romiplostim and Temozolomide combined treatment.|6 months Progression Free Survival:","https://ClinicalTrials.gov/show/NCT02227576"
549,"NCT00786669","A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors","Completed","No Results Available","Solid Tumor","Drug: Bevacizumab|Drug: Temozolomide|Drug: Vincristine|Drug: Irinotecan|Drug: Cefixime","Children's Hospital Medical Center, Cincinnati","All","1 Year to 30 Years   (Child, Adult)","Phase 1","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VITAC","November 5, 2008","October 2008","November 2012","February 24, 2015","February 2015","No Study Results Posted","VITAC","November 2012","Define the toxicities of adding bevacizumab to the established VOIT regimen using cefixime to reduce irinotecan-associated diarrhea.|Preliminarily define the antitumor activity of this drug combination within the confines of a small pilot trial.|To assess the feasibility of collecting and analyzing serum DNA for methylation of the MGMT promotor.|Compare free and total levels of VEGF in serum following treatment with bevacizumab.","https://ClinicalTrials.gov/show/NCT00786669"
550,"NCT02799238","Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma","Recruiting","No Results Available","Glioblastoma","Biological: ALECSAT|Radiation: radiotherapy|Drug: Temozolomide","CytoVac A/S","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","87","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CV-006","June 6, 2016","March 2016","January 2022","June 20, 2016","June 2016","No Study Results Posted","ALECSAT","January 2020","Overall Survival|Proportion of patients alive at 12, 24 and 36 months|Progression Free Survival|Frequency and Severity of treatment related Adverse Events","https://ClinicalTrials.gov/show/NCT02799238"
551,"NCT00890786","A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas","Active, not recruiting","No Results Available","Newly Diagnosed High-Grade Gliomas|Diffuse Intrinsic Pontine Glioma","Drug: Temozolomide|Drug: Bevacizumab|Drug: Irinotecan","Children's Hospital Medical Center, Cincinnati|Genentech, Inc.","All","3 Years to 30 Years   (Child, Adult)","Early Phase 1","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HGG","April 29, 2009","May 2009","June 2018","February 28, 2017","February 2017","No Study Results Posted","null","October 2014","To determine the toxicities and feasibility of the proposed treatment regimen in patients with high-grade glioma and diffuse intrinsic brainstem glioma|To determine 1-year EFS, median PFS and median OS in newly diagnosed patients with high-grade glioma treated with radiotherapy and concurrent temozolomide, bevacizumab followed by bevacizumab, irinotecan and temozolomide for 12 courses|To determine the 1-year EFS, median PFS and median OS in newly diagnosed patients with diffuse intrinsic brainstem glioma treated with radiotherapy and concurrent bevacizumab followed by bevacizumab and irinotecan for 12 courses|To estimate blood levels of VEGF in circulating endothelial cells in patients at different time points|To document changes in MR perfusion and diffusion within 24-48 hours after the 2nd dose of bevacizumab during radiotherapy|To correlate functional changes in tumor with responses to treatment using MR diffusion/perfusion imaging|To correlate the results of the biology studies in serum or tumor with PFS|To conduct gene expression profiling, CGH and SNP arrays in patients with high-grade gliomas|To assess telomerase activity, hTert expression, and telomere length in patients with high-grade gliomas|To assess the health-related quality of life of patients by parent report, and when possible, patient report at key points in therapy|To assess functional abilities and level of independence of patients during and following treatment","https://ClinicalTrials.gov/show/NCT00890786"
552,"NCT02815410","Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients","Not yet recruiting","No Results Available","Glioblastoma Multiforme","Drug: levetiracetam","Seoul National University Hospital","All","20 Years to 76 Years   (Adult, Senior)","Phase 2","73","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","cykim","June 14, 2016","July 2016","June 2022","June 23, 2016","June 2016","No Study Results Posted","null","June 2019","6 months Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02815410"
553,"NCT00250211","Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide","Completed","No Results Available","Glioblastoma|Glioma","Procedure: Functional MRI imaging and tomotherapy","AHS Cancer Control Alberta|Cross Cancer Institute","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CNS-09-0027 / ethics 21780","November 4, 2005","March 2005","April 2011","February 23, 2016","October 2011","No Study Results Posted","null","March 2011","determine tumor response and pattern of failure using functional MRI imaging|time to disease progression|distinguish residual tumor from treatment-related necrosis|survival|acute late toxicity of tomotherapy and hypofractionation","https://ClinicalTrials.gov/show/NCT00250211"
554,"NCT02375334","Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy","Suspended","No Results Available","Malignant Glioma|Myelosuppression","Other: Medical Chart Review","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","Child, Adult, Senior","","50","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCCWFU # 99115|NCI-2015-00113|CCCWFU 99115|P30CA012197","February 11, 2015","February 2015","null","March 13, 2017","March 2017","No Study Results Posted","null","February 2017","Development of a new adherence monitoring system within Epic that is functionally equivalent to the previously designed and validated system in the Cancer Center ORIS|Frequency and timing of flags (laboratory date flags, visit date flags and in-patient status flags) generated with the new system|Non-adherent days generated with the new system|Expansion of both systems to other therapies that require compliance monitoring","https://ClinicalTrials.gov/show/NCT02375334"
555,"NCT00967330","A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma","Completed","Has Results","Glioblastoma Multiforme","Drug: bevacizumab [Avastin]|Drug: irinotecan|Drug: temozolomide","Hoffmann-La Roche","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21965|2009-010390-21","June 16, 2009","June 2010","September 2014","October 20, 2015","October 2015","October 20, 2015","null","September 2014","Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months|Progression-Free Survival (PFS)|Overall Survival (OS)|Percentage of Participants Who Discontinued|Number of Participants With A Best Overall Response (BOR) of Complete Response (CR) and With A BOR of CR or Partial Response (PR)|Percentage of Participants With Response on FLAIR Imaging|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ - C30) at Baseline, Post-Baseline (up to Month 30)|Change From Baseline for EORTC QLQ Brain Neoplasm 20 (BN20) at Baseline, Post-Baseline (up to Month 30)|Change From Baseline for Mini-Mental Status Examination (MMSE) at Baseline, Post-Baseline (up to Month 30)|Change From Baseline for Karnofsky Performance Status (KPS) Score at Baseline, Post-Baseline (up to Month 30)|Percentage of Participants Who Received Corticosteroid for Glioblastoma|Time to Treatment Failure","https://ClinicalTrials.gov/show/NCT00967330"
556,"NCT00005637","Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: carmustine|Drug: temozolomide","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067793|MSKCC-99114|NCI-G00-1765","May 2, 2000","December 1999","December 2009","April 2, 2013","March 2003","No Study Results Posted","null","June 2003","","https://ClinicalTrials.gov/show/NCT00005637"
557,"NCT01182350","Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)","Active, not recruiting","No Results Available","Diffuse Intrinsic Pontine Glioma","Drug: Bevacizumab|Drug: Erlotinib|Drug: Temozolomide|Radiation: Irradiation","Dana-Farber Cancer Institute|Children's Hospital Colorado|University of California, San Francisco|Ann & Robert H Lurie Children's Hospital of Chicago|Children's Healthcare of Atlanta|Children's Hospital Los Angeles|Children's Hospital of Michigan|Children's Hospitals and Clinics of Minnesota|Cook Children's Medical Center|Doernbecher Children's Hospital|Duke University|Johns Hopkins University|Nicklaus Children's Hospital f/k/a Miami Children's Hospital|Nemours Children's Clinic Jacksonville|New York University|Milton S. Hershey Medical Center|Seattle Children's|Lucile Packard Children's Hospital|University of Louisville|UT Southwestern Medical Center|Washington University School of Medicine|Phoenix Children's Hospital|Medical University of South Carolina","All","3 Years to 18 Years   (Child, Adult)","Phase 2","53","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","DFCI 10-321","August 12, 2010","September 2011","null","February 6, 2017","February 2017","No Study Results Posted","null","March 2017","Overall survival of children and young adults with diffuse intrinsic pontine glioma treated with a molecularly based treatment strategy, compared to historical controls (COG ACNS0126)|Safety and feasibility of performing biopsy and obtaining tissue useful for histologic diagnosis, immunohistochemistry and DNA analyses in newly diagnosed DIPG patients|Toxicity profiles of the 4 treatment strata|Progression free survival of children and young adults with diffuse intrinsic pontine glioma treated with a molecularly based treatment strategy, compared to historical controls (COG ACNS0126).|Molecular pathology analyses|Correlation of imaging including perfusion/diffusion, diffusion tensor imaging (DTI) and magnetic resonance imaging (MRS) scan with patient response and outcome","https://ClinicalTrials.gov/show/NCT01182350"
558,"NCT02832635","A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases","Not yet recruiting","No Results Available","Brain Metastasis|Radiation Therapy Complication","Drug: TMZ|Radiation: WBRT with avoidance of hippocampus|Radiation: WBRT without avoidance of hippocampus","Sun Yat-sen University|Fifth Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","256","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","B2016-005-01","June 14, 2016","July 2016","December 2017","July 11, 2016","June 2016","No Study Results Posted","null","June 2017","Change of neurocognitive function between baseline and 4 months after radiotherapy|Effect on response rate|The tolerance of radiotherapy with TMZ concurrent chemotherapy","https://ClinicalTrials.gov/show/NCT02832635"
559,"NCT02082119","Hypofractionated IMRT With Temozolomide for HGG","Completed","No Results Available","Glioma","Radiation: Hypofractionated IMRT","Istituto Clinico Humanitas","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","82","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","1138","December 13, 2013","July 2013","May 2016","May 19, 2016","May 2016","No Study Results Posted","null","May 2016","Progression free survival (PFS), Overall Survival (OS) and Toxicity|Quality of life (QoL) of patients after surgery, concomitant chemo-radiotherapy and adjuvant chemotherapy","https://ClinicalTrials.gov/show/NCT02082119"
560,"NCT00395070","A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma","Completed","No Results Available","Metastatic Melanoma","Biological: Allovectin-7®|Drug: Dacarbazine (DTIC)|Drug: Temozolomide (TMZ)","Vical","All","18 Years and older   (Adult, Senior)","Phase 3","390","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","LX01-315","October 31, 2006","October 2006","July 2013","September 11, 2013","September 2013","No Study Results Posted","null","March 2012","To compare the overall response rate at ≥24 weeks after randomization in the Allovectin-7® arm versus the control (DTIC/TMZ) arm.|To investigate the safety/tolerability of Allovectin-7® in comparison to DTIC/TMZ.|To investigate the effect of Allovectin-7® in comparison to DTIC-TMZ on overall survival.","https://ClinicalTrials.gov/show/NCT00395070"
561,"NCT01310868","Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma","Active, not recruiting","No Results Available","Glioblastoma","Drug: 5-ALA|Drug: Gliadel wafers","University College, London","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000696316|CRUK-UCL-09-0398|2010-022496-66|09/0398|10/H0304/100","March 5, 2011","May 2011","null","December 7, 2015","December 2015","No Study Results Posted","null","February 2016","Safety, tolerability, and feasibility of combination intra-operative 5-ALA and Gliadel wafers prior to adjuvant radiotherapy plus temozolomide|Time to clinical progression|Survival at 24 months","https://ClinicalTrials.gov/show/NCT01310868"
562,"NCT02510950","Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma","Recruiting","No Results Available","Glioblastoma Multiforme|Astrocytoma, Grade IV","Biological: Personalized peptide vaccine|Drug: Poly-ICLC|Drug: Temozolomide","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201510022","July 27, 2015","December 3, 2015","June 30, 2019","February 16, 2017","February 2017","No Study Results Posted","null","August 31, 2017","Safety and tolerability of adjuvant personalized neoantigen peptide vaccine with poly-ICLC as measured by grade 3 and 4 adverse events as defined by CTCAE v. 4.03|Feasibility of the peptide vaccine with poly-ICLC as measured by the ability to identify patient tumor-derived candidate neoantigens and generate a tumor-specific vaccine from time of initial diagnosis to time of proposed administration of the vaccine|Progression-free survival (PFS) rate|Overall survival (OS) rate|Number of neoantigens present in patients with newly diagnosed GBM","https://ClinicalTrials.gov/show/NCT02510950"
563,"NCT02850744","Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients","Active, not recruiting","No Results Available","Glioblastoma Multiforme","Drug: PQR309","PIQUR Therapeutics AG|University Hospital, Basel, Switzerland|University Hospital Inselspital, Berne|University Hospital, Zürich","All","18 Years and older   (Adult, Senior)","Phase 2","35","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","PQR309-004","March 24, 2016","December 2015","January 2018","April 10, 2017","April 2017","No Study Results Posted","null","October 2017","Progression-free survival rate at 6 months (PFS6) based on RANO criteria [30]glioblastoma, using progression-free survival rate at 6 months (PFS6) based on RANO criteria [30]|Number of Adverse Events and Serious Adverse Events as related to the study medication|Changes in pulse rate|Changes in blood pressure|Changes in body weight|Changes in temperature|Changes in ECG|Physical examination according to Karnofsky Performance Status|Depression Test (PHQ-9)|Depression test PHQ-9|Generalized Anxiety Disorder mood scale score (GAD7)|Generalized Anxiety Disorder mood scale score (GAD)|Changes in routine blood chemistry|Changes in hematology|Changes of urinalysis|Change of Insulin/Glucose/C-Peptide|Change of Haemostasis|Determination of cmax|Determination of AUC0-24|Determination of tmax|Determination of AUClast|Determination of AUC0-∞|Determination of t½|Assessment of tumor concentration,|Assessment of PQR309 concentration in cerebrospinal fluid Day 3,pre-dose,0.5h, 1h, 2h, 4h, 6h, 8h post-dose Day 4 24h after the last dose given|Assessment of PQR309 Skin concentration|Overall Response Rate (ORR) including complete and partial Response based on RANO criteria|Duration of response (DOR) based on RANO criteria|Progression-free survival at 3 months (PFS3) based on RANO criteria","https://ClinicalTrials.gov/show/NCT02850744"
564,"NCT00588523","Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma","Active, not recruiting","No Results Available","CNS Cancer|CNS BRAIN","Drug: temozolomide followed by high dose busulfan and thiotepa","Memorial Sloan Kettering Cancer Center|University of Calgary|Northwestern University|Northwestern Memorial Hospital|Massachusetts General Hospital|Schering-Plough","All","Child, Adult, Senior","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","02-089","December 22, 2007","September 2002","September 2018","March 8, 2017","March 2017","No Study Results Posted","null","September 2018","To determine the duration of disease control of newly diagnosed pure and mixed anaplastic oligodendrogliomas treated with dose-intensive chemotherapy requiring hematopoietic stem cell support.|To determine the neurological and systemic toxicities of such treatment.","https://ClinicalTrials.gov/show/NCT00588523"
565,"NCT02758366","Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma","Recruiting","No Results Available","Glioblastoma (GBM)|DIPG","Drug: Doxorubicin","Meyer Children's Hospital","All","3 Years to 30 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GBMTMZ/DOX2015|2015-002307-28","April 27, 2016","February 2016","July 2020","April 28, 2016","April 2016","No Study Results Posted","null","July 2020","Time to early discontinuation of the study drug (doxorubicin)|Number of participants with treatment-related serious adverse events (SAE) as assessed by CTCAE v4.0|Number of patients who died for SAE as assessed by CTCAE v4.0|Number of patients who undergone to withdrawal of doxorubicin|Event free survival|Overall survival|Progression free survival|Rate of treatment response","https://ClinicalTrials.gov/show/NCT02758366"
566,"NCT00961844","Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma","Terminated","No Results Available","Metastatic Malignant Melanoma","Biological: Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|Drug: Temozolomide","Oslo University Hospital","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DC-004|2008-006253-41","August 12, 2009","August 2009","June 2012","August 22, 2014","August 2014","No Study Results Posted","null","June 2012","Safety and toxicity of vaccination with DC transfected h-TERT mRNA, survivin mRNA and tumor cell mRNA, lymphodepletion treatment and T cell expansion and reinfusion in patients with metastatic malignant melanoma.|Evaluation of immunological responses, time to disease progression and survival time.","https://ClinicalTrials.gov/show/NCT00961844"
567,"NCT01467986","Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma","Recruiting","No Results Available","Neuroblastoma Recurrent","Drug: Dasatinib|Drug: Rapamycin|Drug: Irinotecan|Drug: Temozolomide|Drug: Irinotecan|Drug: Temozolomide","University of Regensburg","All","up to 25 Years   (Child, Adult)","Phase 2","114","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","RIST-rNB-2011","October 27, 2011","August 2013","December 2018","December 29, 2016","December 2016","No Study Results Posted","RIST-rNB-2011","September 2018","The primary endpoint is progression-free survival (PFS)|Overall survival (OS)|Response to the investigational treatment after 4 and 8 courses of I/T and 1-year-follow-up in the RIST treatment arm|Duration until adequate response to this treatment regimen|Assessment of quality of life (Lansky and Karnofsky Scores)|Toxicity of this combination of drugs in children, adolescents and young adults with rNB|Safety and tolerability of the investigational treatment|Assessment of the prognostic relevance of International Neuroblastoma Risk Group (INRG) classification system on the event free survival|Prognostic relevance of defined factors on the event free survival in this patient population (i.e. response assessment of HVA, VMA, NSE)","https://ClinicalTrials.gov/show/NCT01467986"
568,"NCT00455286","a Phase II Study in Primary Central Nervous System Lymphoma","Unknown status","No Results Available","Primary Central Nervous System Lymphoma","Drug: Methotrexate|Drug: Methylprednisolone|Drug: Temozolomide","National Health Research Institutes, Taiwan|National Taiwan University Hospital|Mackay Memorial Hospital|China Medical University Hospital|National Cheng-Kung University Hospital|Chi Mei Medical Hospital|Taichung Veterans General Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","T1406","April 2, 2007","November 2006","November 2011","April 3, 2007","April 2007","No Study Results Posted","null","null","Primary : To evaluate objective tumor response rate||Secondary : To assess toxicity profile|To assess time to disease progression","https://ClinicalTrials.gov/show/NCT00455286"
569,"NCT01409174","IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma","Drug: Ipilimumab|Drug: Temozolomide|Drug: Cisplatin|Drug: Interferon Alfa-2b|Drug: Interleukin-2","M.D. Anderson Cancer Center|Bristol-Myers Squibb","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-0073|NCI-2011-02768","August 2, 2011","February 2013","May 2016","May 10, 2016","May 2016","No Study Results Posted","null","May 2016","Tumor Response by Participant using immune-related response criteria (irRC)","https://ClinicalTrials.gov/show/NCT01409174"
570,"NCT02573324","A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification","Recruiting","No Results Available","Glioblastoma|Gliosarcoma","Drug: ABT-414|Radiation: Radiation|Drug: Temozolomide|Drug: Placebo for ABT-414","AbbVie|Radiation Therapy Oncology Group","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","720","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","M13-813|2015-001166-26","September 28, 2015","December 22, 2015","April 17, 2020","May 2, 2017","May 2017","No Study Results Posted","Intellance1","March 18, 2020","Progression Free Survival (PFS) for Phase 2b|Overall Survival (OS) for Phase 3|Progression Free Survival (PFS) for Phase 3|Overall Survival (OS) for Phase 2b|OS for the EGFRvIII-mutated tumor subgroup|PFS for EGFRvIII-mutated tumor subgroup|Number of days to deterioration in verbal memory (HVLT-R)|Number of days to deterioration in symptom severity score M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)|Number of days to deterioration in symptom interference score (MDASI-BT)","https://ClinicalTrials.gov/show/NCT02573324"
571,"NCT01670890","Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas","Unknown status","No Results Available","Malignant Gliomas","Drug: TMZ|Drug: TMZ plus CDDP","Peking Union Medical College Hospital|Beijing Tiantan Hospital|Tianjin Medical University General Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","pumch-neurosurgery-01","August 19, 2012","August 2012","null","August 21, 2012","August 2012","No Study Results Posted","null","August 2014","over all survival|progression free survival","https://ClinicalTrials.gov/show/NCT01670890"
572,"NCT00643097","Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","Has Results","Malignant Neoplasms of Brain","Biological: PEP-3 vaccine|Biological: sargramostim|Drug: Temozolomide","John Sampson|National Institute of Neurological Disorders and Stroke (NINDS)|Duke University","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00004040|P50NS020023|CDR0000589632|DUMC-5421","March 25, 2008","September 2007","November 2016","December 2, 2016","December 2016","January 6, 2014","ACTIVATe","January 2012","Humoral and Cellular Immune Response|Clinical Efficacy of Vaccination, in Terms of Progression-free Survival (PFS)|Response to Vaccination|Toxicity to PEP-3 Vaccine Immunization","https://ClinicalTrials.gov/show/NCT00643097"
573,"NCT00660543","MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy","Completed","Has Results","Adult Brain Glioblastoma","Drug: Gadolinium|Drug: Ferumoxytol Non-Stoichiometric Magnetite|Other: Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Other: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Other: Diffusion Weighted Imaging|Other: MRI-Based Angiogram","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","14","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Diagnostic","IRB00002753|NCI-2015-00224|SOL-06062-LX|813|NCI-2015-00204|8097|2753|P30CA069533","April 10, 2008","December 2006","June 2014","April 19, 2017","April 2017","February 12, 2016","null","June 2014","Mean Cerebral Blood Volume (CBV)|Tumor Progression on Conventional MR","https://ClinicalTrials.gov/show/NCT00660543"
574,"NCT01837862","A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas","Recruiting","No Results Available","Pilomyxoid Astrocytoma|Pilocytic Astrocytoma|Glioma, Astrocytic|Optic Nerve Glioma|Pleomorphic Xanthoastrocytoma|Glioblastoma Multiforme|Anaplastic Astrocytoma|Gliosarcoma|Diffuse Intrinsic Pontine Glioma|DIPG|Low-grade Glioma|Brainstem Glioma","Drug: Mebendazole|Drug: Vincristine|Drug: Carboplatin|Drug: Temozolomide|Drug: Bevacizumab|Drug: Irinotecan","Mark Atlas|Janssen Pharmaceuticals|Northwell Health","All","1 Year to 21 Years   (Child, Adult)","Phase 1|Phase 2","36","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CCMC1411","April 16, 2013","April 2015","April 2020","January 30, 2017","January 2017","No Study Results Posted","null","April 2018","Maximally tolerated dose of mebendazole in combination with vincristine, carboplatin, and temozolomide|Maximally tolerated dose of mebendazole in combination with bevacizumab and irinotecan.|Survival of patients with low-grade gliomas|Survival of patients with high-grade gliomas|Frequency of cerebrospinal fluid (CSF) dissemination in pilomyxoid astrocytoma|Partial or complete response rate on MRI of patients with high-grade gliomas/pontine gliomas|Partial or complete response rate on MRI of patients with low-grade gliomas","https://ClinicalTrials.gov/show/NCT01837862"
575,"NCT01222221","Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: glioblastoma multiforme multipeptide vaccine IMA950|Biological: sargramostim|Drug: temozolomide|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: adjuvant therapy|Radiation: radiation therapy","Cancer Research UK|immatics Biotechnologies GmbH","All","18 Years and older   (Adult, Senior)","Phase 1","45","Other|Industry","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000686559|CRUK-CR0902-11|EUDRACT-2009-015971-28","October 14, 2010","July 2010","February 2015","October 13, 2015","October 2015","No Study Results Posted","null","February 2015","Causality of each adverse event (AE) to glioblastoma multiform multi-antigen vaccine IMA950 and GM-CSF and AE severity according to NCI CTCAE Version 4.0|Total number of patients showing patient-individual T-cell responses against a single or multiple tumor-associated peptides (TUMAP) contained in the study vaccine IMA950 at one or more post-vaccination time points by HLA multimer analysis|Progression-free survival (PSF) at 6 and 9 months post-surgery as assessed by the Macdonald criteria from conventional gadolinium-enhanced MRI and clinical assessment|Correlation between steroid levels and observed T-cell responses|Correlation between O6-methyl-DNA-methyltransferase (MGMT) promoter methylation status in tumor tissue using methylation-specific polymerase chain reaction and clinical benefit (PFS at 6 months and 9 months)|Kinetics of vaccine-induced TUMAP responses including summary descriptions of the time of onset, sustainability, and magnitude of the observed response","https://ClinicalTrials.gov/show/NCT01222221"
576,"NCT01860638","A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma","Active, not recruiting","No Results Available","Glioblastoma","Drug: Bevacizumab|Drug: Lomustine|Drug: Placebo|Radiation: Radiotherapy|Drug: SOC|Drug: Temozolomide","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","299","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","MO28347|2012-003138-17","May 21, 2013","August 2013","December 2016","November 1, 2016","November 2016","No Study Results Posted","null","December 2016","Overall survival, defined as time from randomization (at PD1) to death from any cause|Health-related quality of life: EORTC QLQ-BN20|Resource utilization (EQ-5D)|Second-line progression-free survival|Third-line progression-free survival|Response rates: Proportion of participants with a best overall response of complete response (CR) or partial response (PR)|Disease control rates: Proportion of participants with a best overall response of CR, PR or stable disease|Duration of response|Incidence, nature and severity of adverse events|Health-related quality of life: European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ)-C30 and BN20|Neurocognitive function tests|Resource utilization (hospitalizations, EQ-5D)","https://ClinicalTrials.gov/show/NCT01860638"
577,"NCT02364206","Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma","Recruiting","No Results Available","Adult Glioblastoma","Drug: LY2228820|Drug: Temozolomide|Radiation: radiotherapy","Centre Jean Perrin|National Cancer Institute, France|ARC Foundation for Cancer Research","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-005442-11","February 4, 2015","June 2015","February 2019","June 10, 2016","June 2016","No Study Results Posted","GLYRad","June 2018","maximum tolerated dose (MTD) (phase I) of LY2228820 in combination with TMZ and radiotherapy during chemoradiotherapy period|6-month Progression Free Survival (PFS) rate (phase II) defined as the rate of patients who not presented a progression at 6 months from the first dose of LY2228820|Safety profile according to NCI Common Toxicity Criteria for Adverse Effect (CTCAE) criteria version 4.03.|PFS|Overall Survival|12-month PFS rate defined as the rate of patients who not presented a progression at 12 months from the first dose of LY2228820|Objective response rate according to RANO criteria for patients with incomplete resection or only biopsy|The neurologic status evaluated by clinical assessment and Mini-Mental State Examination (MMSE) and evaluation of corticosteroid dosage|Pharmacokinetic of LY2228820 and TMZ (AUC0-12h)|MAPKAPK-2 activation|Validated biomarker of glioblastoma (MGMT, IDH1 (isocitrate dehydrogenase 1), pTEN (phosphatase and tensin homolog), p53)","https://ClinicalTrials.gov/show/NCT02364206"
578,"NCT01920191","Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma","Completed","No Results Available","CNS Tumor, Adult","Biological: IMA 950|Biological: Poly ICLC|Other: Immunomonitoring","University Hospital, Geneva|immatics Biotechnologies GmbH|Oncovir, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMA950 Poly ICLC","July 31, 2013","August 2013","March 2016","April 19, 2016","April 2016","No Study Results Posted","null","March 2016","Tolerability and safety of IMA950 adjuvanted with Poly-ICLC when given together with temozolomide, using CTCAE V 4.0|6, 9 month progression free survival (PFS) using gadolinium enhanced MRI and clinical assessment according to revised RANO criteria|Overall survival (OS)|Immunologic endpoints","https://ClinicalTrials.gov/show/NCT01920191"
579,"NCT00014105","Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: carboplatin|Drug: temozolomide","Atlantic Health System|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068432|NYU-9948|SPRI-NYU-9948|NCI-G00-1907|NCI-V01-1650","April 10, 2001","December 2000","null","December 3, 2013","May 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00014105"
580,"NCT02546102","Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma","Recruiting","No Results Available","Glioblastoma Multiforme","Biological: ICT-107|Biological: Placebo","ImmunoCellular Therapeutics, Ltd.|Novella Clinical","All","18 Years and older   (Adult, Senior)","Phase 3","414","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","ICT-107-301","September 7, 2015","December 2015","December 2021","May 24, 2017","May 2017","No Study Results Posted","null","December 2019","Overall survival|Overall survival in patients with unmethylated MGMT tumors|Overall survival in patients with methylated MGMT (O6-methylguanine-DNA methyltransferase) tumors|Progression-free survival|Type and frequency of treatment emergent adverse events","https://ClinicalTrials.gov/show/NCT02546102"
581,"NCT02010606","Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma","Recruiting","No Results Available","Glioblastoma|Glioblastoma Multiforme|Glioma|Astrocytoma|Brain Tumor","Biological: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Biological: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab","Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Senior)","Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","33203","December 2, 2013","December 2013","null","March 29, 2016","March 2016","No Study Results Posted","null","October 2018","Assess safety and tolerability according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAEs) Version 4.03|Assess the number of serious adverse events|Assess treatment-related toxicities|Evaluate Overall Survival (OS) and Progression-Free Survival (PFS)|Evaluate health-related quality of life parameters|Assess the overall response rate, defined as the percentage of patients showing either partial response or complete response, in patients with subtotal resection|Evaluate immune response by assessing cytotoxic T cell activity in vitro pre- vs post-vaccination|Assess tumor stem cell antigen expression","https://ClinicalTrials.gov/show/NCT02010606"
582,"NCT02414165","P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA","Active, not recruiting","No Results Available","Glioblastoma Multiforme|Anaplastic Astrocytoma","Biological: Toca 511|Drug: Toca FC|Drug: Lomustine|Drug: Temozolomide|Biological: Bevacizumab","Tocagen Inc.","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","187","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","Tg 511-15-01","April 3, 2015","November 2015","September 2019","February 8, 2017","November 2016","No Study Results Posted","Toca5","November 2017","Compare overall survival between two arms (requires 116 events)","https://ClinicalTrials.gov/show/NCT02414165"
583,"NCT01507506","Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma","Recruiting","No Results Available","Glioblastoma","Radiation: Radiotherapy|Radiation: Experimental arm","Institut Claudius Regaud","All","18 Years and older   (Adult, Senior)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","08 TETE 01","December 20, 2011","March 2011","March 2019","May 26, 2015","September 2014","No Study Results Posted","SPECTRO GLIO","March 2016","Overall survival defined as the time from randomization to the date of death or date of last follow-up news (censured data)|Progression-free survival, defined as the time from randomization to the date of progression or death|Safety evaluated according to the classification of NCI CTCAE (Common Terminology Criteria for Adverse Events)V3.0","https://ClinicalTrials.gov/show/NCT01507506"
584,"NCT00014092","Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery","Completed","No Results Available","Melanoma (Skin)","Biological: aldesleukin|Biological: recombinant interferon alfa|Biological: sargramostim|Drug: temozolomide","Saint Francis Memorial Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000067958|SFMH-BB-IND-5301|NCI-V00-1591","April 10, 2001","December 1999","December 2003","March 25, 2013","March 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00014092"
585,"NCT01618136","An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors","Completed","No Results Available","Malignant Solid Tumour|Ovarian Cancer|Triple Negative Breast Cancer|Advanced Melanoma|B-cell Malignancy, Low-grade","Drug: E7449 alone|Drug: E7449 plus TMZ|Drug: E7449 plus carboplatin and paclitaxel","Eisai Limited|Eisai Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E7449-E044-101","May 14, 2012","January 2012","July 2015","November 15, 2016","October 2016","No Study Results Posted","null","July 2015","Phase 1 To determine the maximum tolerated dose of E7449 as a single agent|Phase 1 To determine the maximum tolerated dose of E7449 and in combination with TMZ|Phase 1 To determine the maximum tolerated dose of E7449 and in combination with carboplatin and paclitaxel|Phase 2 to assess the objective response rate of E7449 as a single agent in subjects with platinum sensitive recurrent high-grade serious ovarian cancer and subjects with relapsed and/or refractory ATM- deficient B-cell malignancies|Phase 2 to assess the objective response rate of E7447 in combination with TMZ in subjects with advanced melanoma|Phase 2 to assess the objective response rate of E7449 in combination with carboplatin and paclitaxel in subjects with metastatic triple negative breast cancer","https://ClinicalTrials.gov/show/NCT01618136"
586,"NCT01752491","A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme","Active, not recruiting","No Results Available","Glioblastoma|GBM|Glioblastoma Multiforme","Drug: Ascorbate|Drug: Temozolomide|Radiation: Radiation therapy","University of Iowa|National Institutes of Health (NIH)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","13","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201211713|P30CA086862|U01CA140206","December 14, 2012","April 2013","March 2018","April 20, 2017","April 2017","No Study Results Posted","null","November 2015","Number of grade 3, 4, & 5 adverse events|Time to progression|Overall survival","https://ClinicalTrials.gov/show/NCT01752491"
587,"NCT00253487","Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: O6-benzylguanine|Drug: busulfan|Drug: temozolomide|Procedure: adjuvant therapy|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Hospital Medical Center, Cincinnati|National Cancer Institute (NCI)","All","5 Years to 55 Years   (Child, Adult)","","null","Other|NIH","Interventional","Primary Purpose: Treatment","CCHMC-04660|CDR0000446082|NCI-7036","November 11, 2005","August 2005","August 2012","January 3, 2014","January 2006","No Study Results Posted","null","August 2012","","https://ClinicalTrials.gov/show/NCT00253487"
588,"NCT00028795","Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","170","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACNS0126|COG-ACNS0126|CDR0000069135","January 4, 2002","December 2002","March 2012","February 19, 2014","February 2014","No Study Results Posted","null","September 2007","Improved outcome|Toxicity as assessed by NCI CTCAE v. 2.0","https://ClinicalTrials.gov/show/NCT00028795"
589,"NCT00897377","Treatment Strategy for Low-grade Gliomas","Terminated","No Results Available","Astrocytomas|Oligodendrogliomas|Oligoastrocytoma","Radiation: Radiation therapy|Drug: Temozolomide","Sun Yat-sen University","All","18 Years to 60 Years   (Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","YP2008009","May 8, 2009","December 2007","null","August 4, 2014","May 2009","No Study Results Posted","null","null","Efficacy of early radiation therapy in MRI-determined total resected LGGs: evaluated as 5-year progression-free survival.|Efficacy of early radiation therapy vs. initial chemotherapy with temozolomide in LGGs without total resection: evaluated as 5-year progression-free survival.","https://ClinicalTrials.gov/show/NCT00897377"
590,"NCT02288897","PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma","Recruiting","No Results Available","Melanoma Recurrent","Drug: PV-10 (10% rose bengal disodium)|Drug: Dacarbazine, temozolomide or talimogene laherparepvec","Provectus Biopharmaceuticals, Inc.|Provectus Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 3","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PV-10-MM-31","November 4, 2014","April 2015","October 2018","May 19, 2017","May 2017","No Study Results Posted","null","September 2018","Progression-free survival (PFS)|Complete response rate (CRR)|Duration of complete response|Overall survival (OS)|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT02288897"
591,"NCT01458730","Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","Active, not recruiting","No Results Available","Central Nervous System Lymphoma","Drug: Immunochemotherapy","University of Aarhus|Nordic Cancer Union|Roche Pharma AG|Mundipharma Pte Ltd.|Schering-Plough","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","66","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT No 2006-004772-12","September 15, 2011","May 2007","October 2020","November 15, 2012","November 2012","No Study Results Posted","null","October 2010","Overall survival|response rate|neurotoxicity","https://ClinicalTrials.gov/show/NCT01458730"
592,"NCT02254954","Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma","Completed","No Results Available","Glioblastoma","Drug: Macitentan in combination with RT and TMZ","Actelion","All","18 Years and older   (Adult, Senior)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AC-055-118","September 23, 2014","October 2014","September 2016","November 1, 2016","November 2016","No Study Results Posted","null","September 2016","Number of subjects with dose-limiting toxicities observed during the first 10 weeks of study treatment (i.e., 6 weeks of concurrent therapy with macitentan, RT and TMZ and 4 weeks of monotherapy with macitentan).|Plasma concentrations of endothelin-1|Plasma concentrations of macitentan and its metabolite|Area under the plasma concentration-time curve (AUCτ) for macitentan during one dosing interval for subjects treated with doses of macitentan 150 mg or higher|Peak plasma concentration (Cmax) of macitentan during one dosing interval for subjects treated with doses of macitentan 150 mg or higher|Time to reach peak plasma concentration (Tmax) of macitentan during one dosing interval for subjects treated with doses of macitentan 150 mg or higher|Number of adverse events (per Common Terminology Criteria for Adverse Events [CTCAE] criteria, version 4.03]) leading to premature discontinuation of study treatment|Number of subjects with marked laboratory abnormalities or abnormal electrocardiogram (ECG) findings|Change from baseline in pulse rate, systolic & diastolic blood pressure|Exploratory efficacy endpoint of proportion of subjects with progression free survival (PFS) at 6 and 12 months|Number of adverse events (per CTCAE] criteria, version 4.03]) as a measure of safety and tolerability.","https://ClinicalTrials.gov/show/NCT02254954"
593,"NCT00025558","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: carboplatin|Drug: temozolomide|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","New York University School of Medicine|National Cancer Institute (NCI)","All","1 Year to 49 Years   (Child, Adult)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068973|P30CA016087|NYU-0006H|NCI-G01-2022","October 11, 2001","October 2000","null","March 25, 2011","March 2011","No Study Results Posted","null","May 2007","","https://ClinicalTrials.gov/show/NCT00025558"
594,"NCT01939574","A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma","Active, not recruiting","No Results Available","Glioblastoma","Other: Chemoradiation Therapy|Other: Adjuvant Therapy","Shandong Cancer Hospital and Institute","All","18 Years and older   (Adult, Senior)","","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML28676","September 2, 2013","August 2013","September 2016","January 20, 2016","January 2016","No Study Results Posted","null","June 2016","Correlation between image biomarker change and PFS|To assess overall survival(OS)|To evaluate the overall response rate (ORR)|To evaluate health-related quality of life|To assess the safety profile","https://ClinicalTrials.gov/show/NCT01939574"
595,"NCT01390948","A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma","Active, not recruiting","No Results Available","High Grade Glioma","Drug: Bevacizumab|Radiation: Radiotherapy|Drug: Temozolomide (TMZ)","Hoffmann-La Roche","All","6 Months to 18 Years   (Child, Adult)","Phase 2","123","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BO25041|2010-022189-28|ITCC-019|HGG-01","July 7, 2011","October 2011","March 2020","April 27, 2016","April 2016","No Study Results Posted","null","March 2020","Event-Free Survival Defined as the Earliest Occurrence of Any One of the Following: Tumor progression, Tumor recurrence, Second Primary non- HGG Malignancy or Death Attributable to Any Cause as Determined by the Central Radiology Review Committee (CRRC)|Overall Survival|1-Year Overall Survival|6-Months EFS Defined as the Earliest Occurrence of Any One of the Following: Tumor Progression, Tumor Recurrence, Second Primary Non-HGG Malignancy or Death Attributable to Any Cause as Determined by the CRRC|1-year EFS Defined as the Earliest Occurrence of Any One of the Following: Tumor Progression, Tumor Recurrence, Second Primary Non-HGG Malignancy or Death Attributable to Any Cause as Determined by the CRRC|EFS Defined as the Earliest Occurrence of Any One of the Following: Tumor Progression, Tumor Recurrence, Second Primary Non-HGG Malignancy or Death Attributable to Any Cause Determined by the Investigator|Neurological Psychological Function as Measured by the Wechsler Scale Between the Treatment Arms|Percentage of Participants with Adverse Events|Percentage of Participants with Overall Response as Determined by the CRRC based on Response Assessment in Neuro-Oncology (RANO) Criteria|Functional Changes in Tumor Assessed by MRI|Health Status as Measured by the Health Utility Index (HUI) Between the Treatment Arms (for Participants Aged 5 Years and Older)","https://ClinicalTrials.gov/show/NCT01390948"
596,"NCT02206230","Trial of Hypofractionated Radiation Therapy for Glioblastoma","Recruiting","No Results Available","Glioblastoma","Radiation: Hypofractionated radiation therapy|Radiation: Standard radiation therapy","AHS Cancer Control Alberta|Cross Cancer Institute","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BR-02-1401","July 24, 2014","August 2014","August 2020","December 31, 2015","December 2015","No Study Results Posted","null","August 2019","Overall survival|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT02206230"
597,"NCT00416819","Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma","Completed","No Results Available","Brain and Central Nervous System Tumors|Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cytarabine|Drug: etoposide phosphate|Drug: leucovorin calcium|Drug: methotrexate|Drug: temozolomide","University of California, San Francisco|National Cancer Institute (NCI)","All","Child, Adult, Senior","","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000458052|UCSF-03301|UCSF-H9414-23160-02A","December 27, 2006","September 2003","February 2012","August 18, 2015","August 2015","No Study Results Posted","null","December 2005","rate of toxicity in patients with untreated primary CNS lymphoma|Efficacy in patients with untreated primary CNS lymphoma treated with induction therapy comprising high-dose methotrexate, leucovorin calcium, rituximab, and temozolomide followed by consolidation therapy comprising cytarabine and etoposide phosphate.","https://ClinicalTrials.gov/show/NCT00416819"
598,"NCT01284335","A Safety Study in Patients With Advanced Solid Tumors","Completed","No Results Available","Advanced Solid Tumors","Drug: Gemcitabine|Drug: Docetaxel|Drug: Temozolomide|Drug: Cisplatin|Drug: Erlotinib|Drug: LY573636","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1","234","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12267|H8K-MC-JZAK","January 19, 2011","July 2008","May 2016","August 25, 2016","August 2016","No Study Results Posted","null","October 2012","Recommended Phase 2 dose|Pharmacokinetic, concentration maximum (Cmax)|Number of patients with a tumor response|Number of participants with a clinically significant effects|Pharmacokinetic, area under the curve (AUC)","https://ClinicalTrials.gov/show/NCT01284335"
599,"NCT00820963","Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Radiation: hypofractionated radiation therapy|Radiation: radiation therapy","Centre Leon Berard|National Cancer Institute (NCI)","All","60 Years and older   (Adult, Senior)","Phase 3","70","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000626713|LEONB-ET2005-006|LEONB-Nordic Glioma Adulte|INCA-RECF0031|EUDRACT-2006-003606-25|SPRI-LEONB-ET2005-006","January 9, 2009","July 2006","null","May 11, 2011","July 2009","No Study Results Posted","null","May 2011","Duration of survival","https://ClinicalTrials.gov/show/NCT00820963"
600,"NCT00761280","Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma","Terminated","Has Results","Anaplastic Astrocytoma|Glioblastoma","Drug: trabedersen|Drug: temozolomide|Device: Drug delivery system for administration of AP 12009|Procedure: Placement of Drug Delivery System|Drug: carmustine|Drug: lomustine","Isarna Therapeutics GmbH","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AP 12009-G005","September 26, 2008","December 2008","June 2012","November 4, 2014","November 2014","August 7, 2014","SAPPHIRE","February 2012","Survival Rate at 24 Months in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Survival at 24 Months in the Intent-to-treat Population - Number of Participants|Survival Rate at 12, 18, and 21 Months in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Survival at 12, 18, and 21 Months in the Intent-to-treat Population - Number of Participants|Median Overall Survival (Days) From Randomization in the Intent-to-treat Population (Descriptive Analysis, Only)|Response Category by Independent Review in the Intent-to-treat Population - Number of Participants|Overall Response Rate (CR+PR) by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Tumor Control Rate (CR+PR+SD) by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Median Duration of Response (Days) by Independent Review (Descriptive Analysis, Only)|Disease Progression at 10, 12, 14, 16, 18, 21, and 24 Months by Independent Review in the Intent-to-treat Population - Number of Participants|Disease Progression Rate at 10, 12, 14, 16, 18, 21, and 24 Months by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Median Time to Progression (Days) by Independent Review for the Intent-to-treat Population (Descriptive Analysis, Only)","https://ClinicalTrials.gov/show/NCT00761280"
601,"NCT00431561","Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma","Completed","No Results Available","Glioblastoma|Anaplastic Astrocytoma","Drug: AP 12009 10 µM|Drug: AP 12009 80 µM|Drug: temozolomide or PCV|Device: Drug delivery system for administration of AP 12009|Procedure: Placement of Drug Delivery System","Isarna Therapeutics GmbH","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","141","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AP 12009-G004","February 5, 2007","April 2003","March 2009","December 2, 2013","December 2013","No Study Results Posted","null","March 2009","Overall response rate of two AP 12009 dose groups and control group assessed by the evaluation of tumor size on brain MRI scans|Overall survival|Response rates|Progression-free survival|Time to progression|Time to response|Best of all response rates assessed by survival status and variation of tumor size on brain MRI|Change of quality of life and Karnofsky Performance Status (KPS)|Best of all response rates|Safety and tolerability","https://ClinicalTrials.gov/show/NCT00431561"
602,"NCT02313389","Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma","Recruiting","No Results Available","Primary Central Nervous System Lymphoma","Drug: Rituximab, Methotrexate, Temozolomide","Assistance Publique - Hôpitaux de Paris","All","60 Years and older   (Adult, Senior)","Phase 3","295","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P130950|2014-002597-37","December 5, 2014","September 2015","June 2021","November 4, 2016","November 2016","No Study Results Posted","BLOCAGE-01","June 2019","progression free survival|overall survival|Toxicity graded according to the NCI-CTCAE|Cognitive functions evaluated by a standardized and validated test battery exploring 5 cognitive domains|Quality of life","https://ClinicalTrials.gov/show/NCT02313389"
603,"NCT01014767","Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors","Suspended","No Results Available","Brain Cancer|Choroid Plexus Tumors","Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Dactinomycin|Drug: Doxorubicin|Drug: Etoposide|Drug: Irinotecan|Drug: Leucovorin|Drug: Methotrexate|Drug: Temozolomide|Drug: Vincristine","Tufts Medical Center","All","Child, Adult, Senior","Phase 3","190","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CPT-SIOP-2009","November 13, 2009","November 2009","null","July 21, 2016","July 2016","No Study Results Posted","null","October 2013","Time to Disease Progression|Toxicity during first 4 months of therapy","https://ClinicalTrials.gov/show/NCT01014767"
604,"NCT03137888","Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma","Not yet recruiting","No Results Available","Glioblastoma|Gliosarcoma","Radiation: Dose-Escalated Radiation Therapy|Procedure: Spectroscopic Magnetic Resonance Imaging|Drug: Temozolomide","Emory University|Johns Hopkins University|University of Miami","All","18 Years and older   (Adult, Senior)","Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IRB00094188|NCI-2017-00424|RAD3383-17","April 25, 2017","October 2017","October 2019","April 30, 2017","April 2017","No Study Results Posted","null","October 2019","Feasibility as assessed by successful co-registration of sMRI-based treatment volumes with clinical images into the radiation treatment execution platform|Incidence of adverse event assessed by Common Terminology Criteria for Adverse Events version 4.0|Progression free survival (PFS)","https://ClinicalTrials.gov/show/NCT03137888"
605,"NCT02189109","The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma","Active, not recruiting","No Results Available","Glioblastoma Multiforme","Drug: NVX-108","NuvOx Pharma Pty Ltd|The Alfred","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","25","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NVX108-GBM1B","May 19, 2014","May 2014","December 2017","September 22, 2016","September 2016","No Study Results Posted","GBM","September 2017","Safety and Tolerability of NVX-108 in Combination with Radiation and Temozolomide Defined by no Drug related Adverse Events (AE) in No More than 1 Patient per Treatment Group|Progression Free Survival at 6 months","https://ClinicalTrials.gov/show/NCT02189109"
606,"NCT00867568","TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma","Completed","Has Results","Neuroblastoma|Medulloblastoma|Relapse","Drug: TPI 287","Giselle Sholler|Cortice Biosciences, Inc.|Spectrum Health Hospitals","All","12 Months to 21 Years   (Child, Adult)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TPI-287","March 23, 2009","March 2009","February 2016","September 9, 2016","September 2016","May 11, 2016","null","September 2011","Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Tmax of TPI 287in Pediatrics Using Pharmacokinetic (PK) Testing.|Number of Patients With an Overall Response Rate (ORR) of PR or CR|Progression Free Survival (PFS) of Participants Using Days From Start of Study Drug Until Progression|Cmax of TPI 287in Pediatrics Using Pharmacokinetic (PK) Testing.|AUC of TPI 287in Pediatrics Using Pharmacokinetic (PK) Testing.","https://ClinicalTrials.gov/show/NCT00867568"
607,"NCT01800695","Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme","Active, not recruiting","No Results Available","Glioblastoma Multiforme","Drug: ABT-414|Drug: Temozolomide|Radiation: Whole Brain Radiation","AbbVie","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","196","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","M12-356|2012-003884-23","February 5, 2013","April 2, 2013","June 18, 2017","May 1, 2017","May 2017","No Study Results Posted","null","May 15, 2017","Number and percentage of participants with adverse events|Maximum concentration of ABT-414|Number of Dose Limiting Toxicities|Minimum Concentration of ABT-414|Half-life of ABT-414|Biomarker EGFR expression|Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT01800695"
608,"NCT00272870","Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy","Terminated","No Results Available","Glioblastoma Multiforme (WHO Grade IV)|Anaplastic Astrocytoma (WHO Grade III)","Drug: 06Benzylguanine|Genetic: MGMT P140K|Device: Meltenyi CliniMacs","Children's Hospital Medical Center, Cincinnati","All","5 Years to 55 Years   (Child, Adult)","Phase 1","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CCHMCEH003","January 4, 2006","December 2005","August 2012","August 28, 2012","August 2012","No Study Results Posted","null","December 2008","To assess the safety and feasibility of infusing autologous PBSC transduced with MSCV-MGMTP140K construct, using the fibronectin component CH-296 to assist gene transfer.|Assess the efficiency of gene transfer and durability of transgene expression in this clinical setting.|Assess the degree of chemotherapy resistance in transduced cells, and the ability to enrich the population of transduced stem cells with subsequent courses of chemotherapy.","https://ClinicalTrials.gov/show/NCT00272870"
609,"NCT01400958","Nuvigil or Placebo in Newly Diagnosed Malignant Glioma","Terminated","Has Results","Malignant Glioma","Drug: Nuvigil®|Drug: Placebo","H. Lee Moffitt Cancer Center and Research Institute|Cephalon","All","18 Years and older   (Adult, Senior)","Phase 2","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","MCC-16233|C10953/6253","July 21, 2011","December 2010","September 2013","October 25, 2013","October 2013","August 6, 2013","null","December 2012","Occurrence of Improved Fatigue Experience After Treatment|Occurrence of Improved Cognitive Performance","https://ClinicalTrials.gov/show/NCT01400958"
610,"NCT02590263","Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma","Recruiting","No Results Available","Malignant Glioma|Glioblastoma","Drug: ABT-414|Drug: Temozolomide|Radiation: Whole Brain Radiation","AbbVie","All","20 Years to 99 Years   (Adult, Senior)","Phase 1","46","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","M13-714","September 28, 2015","September 7, 2015","July 22, 2018","May 1, 2017","May 2017","No Study Results Posted","null","July 22, 2018","Percentage of participants with adverse events|Maximum plasma concentration (Cmax) of ABT-414|Number of Dose Limiting Toxicities|Area under the plasma concentration-time curve (AUC) of ABT-414|Progression-free survival|Overall Survival|Objective Response Rate|Duration of Overall Response","https://ClinicalTrials.gov/show/NCT02590263"
611,"NCT02685605","Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma","Procedure: Standard surgery (neuronavigation-guided)|Radiation: Intraoperative radiotherapy|Radiation: Radiochemotherapy|Drug: Temozolomide","Universitätsmedizin Mannheim|Carl Zeiss Meditec AG, Oberkochen, Germany","All","18 Years and older   (Adult, Senior)","Phase 3","314","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","INTRAGO-II|ARO-2016-1","February 5, 2016","June 2016","February 2021","March 16, 2017","March 2017","No Study Results Posted","INTRAGO-II","June 2020","Median Progression-Free Survival|Median Overall Survival|PFS within a 1-2 cm margin around the cavity|OS with respect to Age|PFS with respect to Age|OS with respect to KPS|PFS with respect to KPS|OS with respect to thickness of anticipated T1-Gd-enhancing (remaining) tumor margin|PFS with respect to thickness of anticipated T1-Gd-enhancing (remaining) tumor margin|OS with respect to extent of resection|PFS with respect to extent of resection|OS with respect to MGMT promoter methylation status|PFS with respect to MGMT promoter methylation status|Quality of Life (QoL) questionnaire|Activities of daily living (ADL), assessed using the Barthel Index (Mahoney & Barthel, 1965).|Radiation-related (acute / early delayed / late) neurotoxicity","https://ClinicalTrials.gov/show/NCT02685605"
612,"NCT00639639","Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Active, not recruiting","No Results Available","Malignant Neoplasms of Brain","Biological: tetanus toxoid|Biological: therapeutic autologous dendritic cells|Biological: therapeutic autologous lymphocytes","John Sampson|Duke University","All","18 Years and older   (Adult, Senior)","Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Pro00003877|CDR0000589624|DUMC-8108-07-1R1|Discretionary Funds","March 19, 2008","January 2006","December 2019","May 22, 2017","May 2017","No Study Results Posted","ATTAC","June 2019","Feasibility and safety of vaccination with cytomegalovirus pp65-LAMP mRNA-loaded dendritic cells (DCs) with or without autologous lymphocyte transfer|Humoral and cellular immune responses|Time to progression|Differential ability of indium In-111-labeled DCs to track to the inguinal lymph nodes under different skin preparative conditions|Differential ability of indium In-111-labeled DCs to track to lymph nodes on the tumor bearing and non-tumor bearing side of the cervical lymph nodes|Immunologic cell infiltrate in recurrent tumors|Evidence of antigen-escape outgrowth in recurrent or progressive tumors","https://ClinicalTrials.gov/show/NCT00639639"
613,"NCT01704287","Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002)","Active, not recruiting","Has Results","Malignant Melanoma","Biological: Pembrolizumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Dacarbazine|Drug: Temozolomide","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","540","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","P08719|MK-3475-002|2012-003030-17","October 8, 2012","November 20, 2012","July 2, 2018","March 28, 2017","March 2017","October 17, 2016","null","November 16, 2015","Progression-free Survival (PFS)|Overall Survival (OS)|Best Overall Response - Initial Treatment Period|Best Overall Response Among Participants Receiving ICC Who Switched to Receiving Pembrolizumab|Duration of Response (DOR)|Number of Participants Who Experienced an Adverse Event (AE)|Number of Participants Who Discontinued Study Drug Due to an AE","https://ClinicalTrials.gov/show/NCT01704287"
614,"NCT02223884","A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy","Completed","No Results Available","Malignant Melanoma","Drug: docetaxel 35mg/m2|Drug: Carboplatin AUC3","Yonsei University","All","20 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2011-0300","August 17, 2014","July 2011","August 2014","August 27, 2014","August 2014","No Study Results Posted","null","August 2014","Response Rate|disease control rate|progression free survival|overall survival|adverse events","https://ClinicalTrials.gov/show/NCT02223884"
615,"NCT01991977","18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy","Recruiting","No Results Available","Malignant Glioma","Procedure: Diffusion Weighted Imaging|Drug: Fluorine F 18 Fluorodopa|Radiation: Intensity-Modulated Radiation Therapy|Procedure: Perfusion Magnetic Resonance Imaging|Procedure: Positron Emission Tomography|Other: Quality-of-Life Assessment|Drug: Temozolomide","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","150","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Diagnostic","MC1374|NCI-2013-02242|P30CA015083","November 18, 2013","December 2013","December 2018","May 17, 2017","November 2016","No Study Results Posted","null","December 2018","Proportion of grade IV patients that experience confirmed progression-free survival|Overall survival|Progression free survival|Quality of life evaluated with the MD Anderson Symptom Inventory Brain Tumor Module and Mini-Mental Status Exam questionnaires|Rate of acute treatment-related toxicities graded using Common Terminology Criteria for Adverse Events version 4.0|Rate of late treatment-related toxicities using the Radiation Therapy Oncology Group/European Organization for Research and the Treatment of Cancer toxicity criteria","https://ClinicalTrials.gov/show/NCT01991977"
616,"NCT02099487","Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma","Completed","No Results Available","Glioma","Radiation: Radiation","Istituto Clinico Humanitas","All","70 Years and older   (Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","1139","January 24, 2014","July 2013","May 2016","May 19, 2016","January 2014","No Study Results Posted","null","May 2016","PFS|OS","https://ClinicalTrials.gov/show/NCT02099487"
617,"NCT02853565","A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: CAN008","CANbridge Life Sciences Ltd.","All","20 Years to 75 Years   (Adult, Senior)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CAN-B1-008-L-002","July 11, 2016","August 2016","July 2018","September 8, 2016","September 2016","No Study Results Posted","null","July 2017","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Recommended Dose for Phase II [RP2D] measured by the Maximum Tolerated Dose [MTD] or the Maximum Administered Dose [MAD]|PK profile measured by CAN008 serum concentrations|PK profile measured by Maximum Plasma Concentration [Cmax]|PK profile measured by Area Under the Curve [AUC]|Preliminary efficacy (Progression Free Survival after 6 months [PFS6])|Preliminary efficacy (Overall Survival [OS])","https://ClinicalTrials.gov/show/NCT02853565"
618,"NCT02796261","Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients","Recruiting","No Results Available","Anaplastic Astrocytoma|Recurrent Anaplastic Astrocytoma","Drug: Eflornithine|Drug: Lomustine","Orbus Therapeutics, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","OT-15-001","June 3, 2016","July 2016","August 2019","May 23, 2017","May 2017","No Study Results Posted","STELLAR","June 2019","Overall survival|Progression-free survival (PFS)|Objective response rate (ORR)","https://ClinicalTrials.gov/show/NCT02796261"
619,"NCT02208336","Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy","Completed","No Results Available","Brain Tumor","Other: medical chart review","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","Child, Adult, Senior","","79","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CCCWFU 99210|NCI-2014-01602|P30CA012197","August 1, 2014","October 2010","February 23, 2015","April 17, 2017","April 2017","No Study Results Posted","null","February 23, 2015","Frequency of nonadherence (retrospective)|Impact of nonadherence events on myelosuppression severity (retrospective)|Impact of nonadherence events on patient morbidity (retrospective)|Effect of an automated notification program on adherence rates (prospective)","https://ClinicalTrials.gov/show/NCT02208336"
620,"NCT02864368","Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens","Recruiting","No Results Available","Glioblastoma|Glioblastoma Multiforme","Drug: 5-day TMZ|Drug: 21-day TMZ|Biological: PEP-CMV|Drug: Tetanus-Diphtheria booster|Drug: Tetanus Pre-Conditioning","Gary Archer Ph.D.|Annias Immunotherapeutics, Inc.|National Institutes of Health (NIH)|National Cancer Institute (NCI)|Duke University","All","18 Years and older   (Adult, Senior)","Phase 1","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","Pro00034208_1|2R42CA153845-02","July 26, 2016","December 2016","October 2018","March 29, 2017","March 2017","No Study Results Posted","PERFORMANCE","March 2018","Incidence of Treatment-related Adverse Events|Immunologic Response|Antigen Loss","https://ClinicalTrials.gov/show/NCT02864368"
621,"NCT00694837","Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma","Completed","No Results Available","Glioblastoma","Drug: nelfinavir","Maastricht Radiation Oncology|Maastricht University Medical Center","All","18 Years to 65 Years   (Adult)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-09-04/07|EudraCT number 2008-001078-34","June 9, 2008","March 2009","January 2013","April 9, 2015","April 2015","No Study Results Posted","null","January 2013","Fase I: To determine the MTD of nelfinavir as an adjuvant in the radiochemotherapy treatment in primary glioblastoma patients. Fase 2: Progression free survival at 6 months|Fase 1/2: Incidence of acute toxicity; OS; Metabolic ratios of SUV of serial 18F-FDG: assessed by PET-CT.Fase 1:6-months PFS; Relative blood flow measurement by perfusion MRI. Fase 2: PFS at 12 months; Phosphorylation of AKT in tumour tissue.","https://ClinicalTrials.gov/show/NCT00694837"
622,"NCT02617745","Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid","Recruiting","No Results Available","Glioblastoma","Other: Platelet level determination","Centre Henri Becquerel","All","18 Years and older   (Adult, Senior)","Phase 2","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","CHB 15.02","November 16, 2015","November 2015","May 2020","July 27, 2016","July 2016","No Study Results Posted","GLIOPLAK","July 2018","Number of time where platelet level was Under 100 000 per mm3|Overall survival|Therapeutic modifications","https://ClinicalTrials.gov/show/NCT02617745"
623,"NCT02014844","Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma","Completed","No Results Available","Glioblastoma","Drug: aldoxorubicin","CytRx","All","18 Years and older   (Adult, Senior)","Phase 2","28","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ALDOXORUBICIN-P2-GBM-01","December 9, 2013","March 2014","December 2016","January 4, 2017","September 2015","No Study Results Posted","null","December 2016","Objective Response Rate (Complete Response and Partial Response)|Safety","https://ClinicalTrials.gov/show/NCT02014844"
624,"NCT01113463","TPI 287 in Patients With Recurrent Glioblastoma Multiforme","Terminated","Has Results","Brain Cancer","Drug: TPI 287","M.D. Anderson Cancer Center|Cortice Biosciences, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-0759|NCI-2011-01303","April 27, 2010","April 2010","December 2012","September 12, 2016","September 2016","June 8, 2016","null","June 2011","Progression-Free Survival (PFS) at 6 Months|Number of Participants by Response Criteria","https://ClinicalTrials.gov/show/NCT01113463"
625,"NCT02394665","Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma","Terminated","Has Results","Glioblastoma","Radiation: Intensity Modulated Radiation Therapy|Drug: Temozolomide|Behavioral: Functional Assessment of Cancer Therapy-Brain (FACT-Br)|Radiation: Stereotactic Radiosurgery Boost|Radiation: Simultaneous Integrated Boost|Device: 3D MRSI","University of Miami","All","19 Years and older   (Adult, Senior)","Phase 2","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20140540","March 16, 2015","March 2015","September 2016","November 8, 2016","November 2016","November 8, 2016","null","September 2016","Rate of Overall Survival (OS) in Study Patients|Rate of Progression-Free Survival (PFS) in Study Patients|Rate of Grade 3 or Higher Toxicity as a a Consequence of Study Therapy.|Change in Quality of Life From Baseline in Study Participants|Patterns of Failure in Study Participants Post-Protocol Therapy","https://ClinicalTrials.gov/show/NCT02394665"
626,"NCT01165671","Carbon Ion Radiotherapy for Primary Glioblastoma","Unknown status","No Results Available","Primary Glioblastoma","Radiation: Carbon Ion Radiotherapy|Radiation: Proton Radiotherapy","University Hospital Heidelberg","All","18 Years and older   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CLEOPATRA|2009-014668-21|ISRCTN37428883","July 13, 2010","July 2010","null","February 19, 2013","February 2013","No Study Results Posted","CLEOPATRA","June 2014","Overall Survival|Progression-free Survival|Toxicity","https://ClinicalTrials.gov/show/NCT01165671"
627,"NCT01952886","Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients","Withdrawn","No Results Available","Malignant Glioma","Drug: Granisetron|Drug: Ondansetron","Duke University|Prostrakan Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Supportive Care","Pro00041233","September 25, 2013","null","null","September 19, 2014","September 2014","No Study Results Posted","null","September 2014","Satisfaction with Granisetron Transdermal Delivery System (GTDS) versus Ondansetron pill|Complete response (CR) rate of Granisetron Transdermal Delivery System (GTDS) compared to Ondansetron pill|Subject Compliance with Granisetron Transdermal Delivery System (GTDS) and Ondansetron pills|Number of subjects experiencing a grade ≥3 treatment-related toxicity|Patient satisfaction from the Treatment Satisfaction Questionnaire for Medication (TSQM-9 )","https://ClinicalTrials.gov/show/NCT01952886"
628,"NCT00062933","A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma","Completed","No Results Available","Melanoma","Procedure: Laparotomy","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","40","NIH","Interventional","Primary Purpose: Treatment","030221|03-C-0221","June 17, 2003","June 2003","March 2008","August 17, 2012","August 2012","No Study Results Posted","null","September 2007","","https://ClinicalTrials.gov/show/NCT00062933"
629,"NCT00960063","A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)","Terminated","Has Results","Neoplasms|Solid Tumors|Bone Cancer|Kidney Tumor|Neuroblastoma","Drug: Temozolomide|Drug: Vincristine|Drug: Ifosfamide|Drug: Irinotecan|Biological: Robatumumab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Etoposide","Merck Sharp & Dohme Corp.","All","up to 21 Years   (Child, Adult)","Phase 1","4","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P05883|MK-7454-006","August 14, 2009","November 2009","December 2010","January 7, 2016","January 2016","November 19, 2015","null","December 2010","Number of Participants With Dose Limiting Toxicities|Best Overall Response Based on Response Evaluation Criteria in Solid Tumors (RECIST)|Maximum Observed Concentration (Cmax) of Robatumumab|Plasma Level of Insulin-like Growth Factor-I (IGF-I)|Number of Participants Who Developed Anti-robatumumab Antibodies|Time to Maximum Observed Concentration (Tmax) of Robatumumab|Area Under the Curve at the Time of Final Quantifiable Sample (AUCtf) for Robatumumab|Area Under the Curve During a Dosing Interval τ (AUCτ) for Robatumumab|Plasma Level of Insulin-like Growth Factor-2 (IGF-II)|Plasma Level of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2)|Plasma Level of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)","https://ClinicalTrials.gov/show/NCT00960063"
630,"NCT02149225","GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients","Active, not recruiting","No Results Available","Glioblastoma","Drug: APVAC1 vaccine plus Poly-ICLC and GM-CSF|Drug: APVAC2 vaccine plus Poly-ICLC and GM-CSF","immatics Biotechnologies GmbH|Biontech AG|University Hospital Tuebingen|BCN Peptides|EU-funded GAPVAC Consortium","All","18 Years and older   (Adult, Senior)","Phase 1","16","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GAPVAC-101|2013-002801-71","May 16, 2014","October 2014","July 2018","August 1, 2016","August 2016","No Study Results Posted","null","July 2018","Safety profile of patient-tailored APVAC vaccines when administered with immunomodulators concurrent to maintenance TMZ cycles|Frequency of CD8 T cells specific for vaccinated APVAC peptides as measure of immunological response to and biological activity of the vaccine|Frequency of immune cell populations in the blood and concentrations of a large panel of serum and plasma proteins with immunological relevance as a measure of the immune status of the patient|Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT02149225"
631,"NCT00626015","Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery","Completed","No Results Available","Malignant Neoplasms of Brain","Biological: PEP-3-KLH conjugate vaccine|Biological: daclizumab|Drug: temozolomide|Other: placebo|Biological: PEP-3-KLH","John Sampson|National Cancer Institute (NCI)|Duke University","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","16","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00000947|R21CA132891|CDR0000579573","February 28, 2008","March 2007","February 2013","January 20, 2016","January 2016","No Study Results Posted","ZAP IT","February 2013","Functional suppressive capacity of CD4+CD25+CD127- T-regulatory cells|Comparison of proliferative T-cell response to phytohemagglutinin (PHA) among treatment groups (with versus without daclizumab/basiliximab)","https://ClinicalTrials.gov/show/NCT00626015"
632,"NCT02366728","DC Migration Study for Newly-Diagnosed GBM","Recruiting","No Results Available","Glioblastoma|Astrocytoma, Grade IV|Giant Cell Glioblastoma|Glioblastoma Multiforme","Biological: Unpulsed DCs|Biological: Td|Biological: Human CMV pp65-LAMP mRNA-pulsed autologous DCs|Biological: 111In-labeled DCs|Drug: Temozolomide|Drug: Saline|Drug: Basiliximab","Gary Archer Ph.D.|Duke University","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","Pro00054740","October 28, 2014","September 2015","June 2020","April 26, 2017","April 2017","No Study Results Posted","ELEVATE","March 2019","Median overall survival|Percentage of 111In-labeled dendritic cells migrating to the inguinal lymph nodes|Median overall survival in CMV positive participants|Median overall survival in CMV negative participants|Median progression-free survival|Median progression-free survival in CMV positive participants|Median progression-free survival in CMV negative participants","https://ClinicalTrials.gov/show/NCT02366728"
633,"NCT00397072","Epothilone in Recurrent Glioblastoma Patients","Completed","No Results Available","Glioblastoma","Drug: ZK 219477","Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZK219477IV","November 7, 2006","June 2006","December 2008","April 16, 2014","April 2014","No Study Results Posted","null","March 2008","Progression Free Survival at six months (PFS-6).|Response rates (CR +PR)|Safety evaluation according to CTC-AE|Median Survival Time (MST)","https://ClinicalTrials.gov/show/NCT00397072"
634,"NCT02511132","A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma","Recruiting","No Results Available","Ewing's Sarcoma","Biological: Vigil|Drug: Temozolomide|Drug: Irinotecan","Gradalis, Inc.","All","2 Years and older   (Child, Adult, Senior)","Phase 2","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CL-PTL-121","July 28, 2015","July 2015","December 2018","May 4, 2017","May 2017","No Study Results Posted","null","December 2017","Adverse Events, Laboratory Assessments and Physical Examinations|γIFN ELISPOT conversion rate from Blood Collected","https://ClinicalTrials.gov/show/NCT02511132"
635,"NCT02399189","MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma","Recruiting","No Results Available","Primary Central Nervous System Lymphoma","Drug: R-MT followed by auto-HSCT","Jun Zhu|Peking University","All","18 Years to 65 Years   (Adult)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20150301","March 1, 2015","May 2014","April 2019","April 10, 2015","April 2015","No Study Results Posted","null","April 2017","progression-free survival|overall response rate|overall survival|event-free survival","https://ClinicalTrials.gov/show/NCT02399189"
636,"NCT00003567","Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma","Terminated","No Results Available","Brain and Central Nervous System Tumors|Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific","Biological: filgrastim|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: O6-benzylguanine|Drug: carmustine|Drug: temozolomide|Procedure: in vitro-treated peripheral blood stem cell transplantation","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","8","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU2Y97|R21CA076192|P30CA043703|CASE-CWRU-2Y97|NCI-T97-0060|CASE-2Y97","November 1, 1999","May 1999","February 2007","June 9, 2010","June 2010","No Study Results Posted","null","January 2007","Gene transfer expression","https://ClinicalTrials.gov/show/NCT00003567"
637,"NCT02414009","Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Capecitabine|Drug: Temozolomide|Drug: Irinotecan|Drug: Fluorouracil|Drug: Leucovorin","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","All","18 Years and older   (Adult, Senior)","Phase 2","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CAPTEM","February 5, 2015","September 2014","September 2017","March 15, 2017","March 2016","No Study Results Posted","CAPTEM","September 2017","Progression-free survival of FOLFIRI versus CAPTEM|Response rate|Overall survival of FOLFIRI versus CAPTEM|Number of Adverse events by CTCAE version 4.0|Quality of life as measured by EORTC QLQ - CR29 QLQ-C30","https://ClinicalTrials.gov/show/NCT02414009"
638,"NCT01181193","Vitamin D for Treatment of Glioblastoma Multiforme","Unknown status","No Results Available","Glioblastoma Multiforme","Other: Surgery|Radiation: Radiotherapy to tumour bed and/or residual tumour|Drug: Temozolomide|Drug: Vitamin D3","Soroka University Medical Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SOR504110CTIL","July 18, 2010","March 2011","March 2014","March 27, 2011","August 2010","No Study Results Posted","null","March 2013","Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01181193"
639,"NCT00756106","MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma","Terminated","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Other: imaging biomarker analysis","Massachusetts General Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","16","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDR0000600751|MGH-07-292","September 18, 2008","July 2008","null","February 6, 2014","February 2014","No Study Results Posted","null","September 2011","Relative cerebral blood volume/flow, mean transit time, and mean vessel diameter as measured by perfusion-weighted MRI before, during, and after chemoradiotherapy|Permeability-surface area product before, during, and after chemoradiotherapy|Full water self-diffusion tensor before, during, and after chemoradiotherapy|Tensor fractional anisotropy before, during, and after chemoradiotherapy|Relative regional concentrations of choline, N-acetyl-asparate, and myoinositol as measured by magnetic resonance spectroscopy before, during, and after chemoradiotherapy to interrogate cell membrane turnover, neuronal integrity, and glial reactions|Affects of a short period of 100% oxygen inhalation on imaging of tumor and surrounding tissue regions of interest, specifically cerebral blood volume changes in each area as compared to room air|Correlation between imaging changes, molecular markers, and clinical outcome|Correlation between blood and urine biomarkers and tumor expression of these markers","https://ClinicalTrials.gov/show/NCT00756106"
640,"NCT02843230","Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI","Not yet recruiting","No Results Available","Glioblastoma","Radiation: Avastin|Radiation: Lomustine|Radiation: Temozolomide|Device: MRI|Device: MRS|Device: DSC","Massachusetts General Hospital","All","18 Years and older   (Adult, Senior)","","85","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","16-147","July 21, 2016","August 2016","August 2021","July 22, 2016","July 2016","No Study Results Posted","null","August 2019","Progression Free Survival For Patients Receiving Advanced MRI and MRS|Overall Survival For Patients Receiving Advanced MRI and MRS|Progression Free Survival For Patient Receiving Dynamic Susceptibility Contrast|Overall Survival Rate For Patient Receiving Dynamic Susceptibility Contrast","https://ClinicalTrials.gov/show/NCT02843230"
641,"NCT01868906","FMISO-PET in Brain Tumors and SCS Effect","Recruiting","No Results Available","Malignant Glioma","Drug: 18F-FMISO|Procedure: PET without SCS|Device: SCS|Procedure: PET without/with SCS|Radiation: Radiotherapy|Drug: Temozolomide","Bernardino Clavo, MD, PhD|Instituto Tecnologico Servicios Sanitarios, in MD Anderson Cancer Center, Madrid|Instituto de Salud Carlos III|Grupo de Investigación Clínica en Oncología Radioterapia|Instituto Canario de Investigación del Cáncer|RSbiomed|Fundación DISA, Canary Islands, Spain|Dr. Negrin University Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Diagnostic","TC-FMISO-PET-06-1413|2009-015852-11|PI 06/1413, PI 12/02940","May 24, 2010","June 2013","June 2019","February 9, 2017","February 2017","No Study Results Posted","FMISOPETSCS","December 2018","Tumor hypoxia measurement using 18F-FMISO-PET (hypoxic volume and tumor/muscle ratio). Baseline measurement.|Change from baseline tumor hypoxia using 18F-FMISO-PET (hypoxic volume and tumor/muscle ratio) during SCS.|Correlation between 18F-FMISO-PET values and pathological tumor parameters|Correlation with Karnofsky scale.|Correlation with the ECOG (Eastern Cooperative Oncology Group) performance status scale|Correlation with the Quality of Life Questionnaire QLQ-C30 (EORTC)|Overall survival.|Radiological response to treatment|Radiological location of tumor relapse or progression","https://ClinicalTrials.gov/show/NCT01868906"
642,"NCT01639612","Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma","Completed","No Results Available","Grade IV Malignant Glioma","Biological: ALD-451","Henry Friedman|Duke University","All","18 Years and older   (Adult, Senior)","Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","Pro00031192","June 28, 2012","June 2012","April 2016","April 19, 2016","April 2016","No Study Results Posted","null","March 2016","Number of patients with unacceptable toxicity|Number of ALD-451 cells recovered from bone marrow of patients following radiation therapy and chemotherapy|Neurocognition and patient-reported outcomes following ALD-451","https://ClinicalTrials.gov/show/NCT01639612"
643,"NCT00669669","O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas","Active, not recruiting","No Results Available","Glioblastoma|Gliosarcoma","Radiation: 3-Dimensional Conformal Radiation Therapy|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Biological: Filgrastim|Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: O6-Benzylguanine|Drug: Plerixafor|Radiation: Proton Beam Radiation Therapy|Drug: Temozolomide","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2000.00|NCI-2013-00701|8357|P30CA015704","April 29, 2008","February 2009","null","August 10, 2016","August 2016","No Study Results Posted","null","December 2017","Chemoprotection, assessed by the ability to increase the temozolomide dose beyond 472 mg/m^2|Duration of response|Gene transfer efficiency and in vivo selection, assessed by gene marking in peripheral blood and marrow|Incidence of DLT (Part Ii)|Incidence of dose-limiting toxicity (DLT) defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I)|Incidence of replication competent retrovirus or leukemia|Response rate|Survival|Time to progression","https://ClinicalTrials.gov/show/NCT00669669"
644,"NCT00749723","Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children","Active, not recruiting","No Results Available","Recurrent Brain Tumors|Supratentorial PNETs|Medulloblastomas|Ependymomas","Drug: carboplatin|Drug: etoposide|Drug: temozolomide|Drug: thiotepa, carboplatin, etoposide|Drug: temozolomide, thiotepa|Procedure: autologous stem cell transplantation|Drug: etoposide|Drug: trofosfamide/etoposide","University Hospital, Bonn","All","3 Months to 30 Years   (Child, Adult)","Phase 2|Phase 3","160","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","EUDRACT 2005-002618-40|BfArM-4030755|EC-105/05|DKS 2006.01, DK 2008.17","September 5, 2008","February 2006","January 2016","July 7, 2015","July 2015","No Study Results Posted","HIT-REZ-2005","January 2013","P-HIT-REZ 2005 study: two Chemotherapy-arms: progression-free survival from therapy start and response evaluation after the fourth therapy course|E-HIT-REZ 2005 study (Phase II Study ""Oral chemotherapy with temozolomide""): Evaluation of response rate to the 60-days oral chemotherapy with temozolomide|Phase II study ""Intraventricular therapy with etoposide"": Evaluation of response rate to the 5-week intraventricular therapy with etoposide|P-HIT-REZ 2005 study: two Chemotherapy-arms: overall survival from start of therapy|E-HIT-REZ 2005 study: Chemotherapy-arm: progression-free survival from start of therapy|E-HIT-REZ 2005 study: Chemotherapy-arm: overall survival from start of therapy|E-HIT-REZ 2005 study: Chemotherapy-arm: toxicity rate (CTC)|Phase II study ""Intraventricular therapy with etoposide"": toxicity rate (CTC)|P-HIT-REZ 2005 study: two Chemotherapy-arms: toxicity rate (CTC) in both arms","https://ClinicalTrials.gov/show/NCT00749723"
645,"NCT01805453","Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma","Active, not recruiting","No Results Available","Newly-diagnosed Glioblastoma","Drug: Losartan|Drug: Placebo","Assistance Publique - Hôpitaux de Paris|ANOCEF (french association of neuro-oncologists)","All","18 Years and older   (Adult, Senior)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","P120105|2012-004536-34","February 25, 2013","March 29, 2013","May 15, 2017","February 27, 2017","February 2017","No Study Results Posted","ASTER","January 15, 2015","Steroid dosage required to control brain edema on the last day of radiotherapy in each arm|Steroids dosage 1 month after the end of RT|Assessment of cerebral edema on MRI|Tolerance (NCI-CTCAE v3.0)|Blood pressure|HbA1C|glycemia|body weight|side-effects of steroids|Executive functions ( "" Moca test "")|Quality of life (EORTC)|Progression free survival|Overall survival|Survival|Performance status (KPS) at the end, 1 month , and 2 months after the end of RT","https://ClinicalTrials.gov/show/NCT01805453"
646,"NCT00412542","Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas","Completed","Has Results","Glioblastoma Multiforme|Glioma","Drug: Thalidomide|Drug: CPT-11|Procedure: MRI Scan|Procedure: Quantitative Sensory Tests (QST)","M.D. Anderson Cancer Center|Celgene Corporation","All","Child, Adult, Senior","Phase 2","78","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM02-595","December 15, 2006","October 2003","October 2009","February 8, 2012","February 2012","February 8, 2012","null","October 2009","Number of Participants Progression Free at 6 Months With Malignant Gliomas","https://ClinicalTrials.gov/show/NCT00412542"
647,"NCT01091792","Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)","Active, not recruiting","No Results Available","Glioblastoma Multiforme","Drug: Bevacizumab","Dartmouth-Hitchcock Medical Center|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Early Phase 1","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","D0947","March 22, 2010","March 2010","July 2017","August 18, 2016","August 2016","No Study Results Posted","null","August 2012","Changes in the peripheral blood T-reg profile between pretreatment and 4 weeks after completion of treatment with the addition of bevacizumab to RT and TMZ in patients with glioblastoma|Immunologic shift in the phenotypic T cell, B cell, NK cell and DC repertoire induced by RT-TMZ-BEV comparing pretreatment and 4 weeks after completion of treatment","https://ClinicalTrials.gov/show/NCT01091792"
648,"NCT00727506","BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma","Completed","Has Results","Glioma","Drug: BIBW 2992|Drug: TMZ|Drug: BIBW 2992 plus TMZ","Boehringer Ingelheim","All","18 Years and older   (Adult, Senior)","Phase 2","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1200.36","July 31, 2008","July 2008","May 2016","September 30, 2016","September 2016","August 8, 2013","null","January 2011","Progression-free Survival (PFS-6) at Six Months - Phase II Part|Number of Participants With Dose Limiting Toxicities - Phase I Part|Objective Tumor Response (OBR) in Phase II|Objective Tumor Response (OBR) in Phase I","https://ClinicalTrials.gov/show/NCT00727506"
649,"NCT02678975","Disulfiram in Recurrent Glioblastoma","Recruiting","No Results Available","Glioma|Glioblastoma","Drug: Disulfiram|Dietary Supplement: Copper|Drug: Alkylating Agents","Sahlgrenska University Hospital, Sweden|St. Olavs Hospital|Lund University Hospital|Karolinska University Hospital|University Hospital, Linkoeping","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Outcomes Assessor|Primary Purpose: Treatment","no ID yet","January 31, 2016","January 2017","September 2020","April 10, 2017","January 2017","No Study Results Posted","null","December 2019","Survival 6 mo|Progression free survival|Survival 12 and 24 mo|Median overall survival|Health related quality of life|Volumetric tumor assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02678975"
650,"NCT01873469","Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma Multiforme","Radiation: Radiochemotherapy","Technische Universität Dresden","All","18 Years and older   (Adult, Senior)","","99","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STR-PETra-2013","June 4, 2013","July 2013","February 2018","October 19, 2016","October 2016","No Study Results Posted","null","February 2017","Time to recurrence as function of [11C]MET uptake before postoperative radiochemotherapy|overall survival","https://ClinicalTrials.gov/show/NCT01873469"
651,"NCT02772094","Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)","Active, not recruiting","No Results Available","Glioblastoma Multiforme|Glioblastoma","Biological: Single arm, open-label","China Medical University Hospital|Den-Mei Brain Tumor Education Foundation, Taichung, Taiwan|Ministry of Health and Welfare, Taiwan","All","13 Years to 70 Years   (Child, Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DMR94-IRB-043-1","February 3, 2016","May 2005","December 2016","May 12, 2016","May 2016","No Study Results Posted","null","December 2014","Overall survival with measures of medium survival period (in days) and annual survival rates (in %)|Adverse effects, acute and chronic, assessed according to NCI CTCAE Version 3|Disease progression-free period","https://ClinicalTrials.gov/show/NCT02772094"
652,"NCT02015728","Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors","Active, not recruiting","No Results Available","Recurrent Childhood Brain Tumor","Device: Tumor biology testing|Drug: Temozolomide|Drug: Etoposide|Drug: Sorafenib|Drug: Everolimus|Drug: Erlotinib|Drug: Dasatinib","Seattle Children's Hospital|Cures Within Reach","All","1 Month to 30 Years   (Child, Adult)","","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SC-9006","December 13, 2013","December 2013","December 2017","December 14, 2016","December 2016","No Study Results Posted","SEED","November 2016","Feasibility|Efficacy|Survival|Toxicity","https://ClinicalTrials.gov/show/NCT02015728"
653,"NCT02666066","Radiomics for Prediction of Survival in GBM","Recruiting","No Results Available","Glioblastoma|Glioma|Astrocytoma","","Maastricht Radiation Oncology","All","Child, Adult, Senior","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","15-43-05/08-intern","January 24, 2016","January 2016","July 2018","March 28, 2017","March 2017","No Study Results Posted","Radiomics","January 2018","Sensitive value of 6 months survival after radiotherapy with radiomics|Sensitive value of 12 months survival after radiotherapy with radiomics|Specificity value of 6 months survival after radiotherapy with radiomics|Specificity value of 12 months survival after radiotherapy with radiomics","https://ClinicalTrials.gov/show/NCT02666066"
654,"NCT02458508","Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy","Recruiting","No Results Available","Glioblastoma","","University of Pisa|Azienda Ospedaliero, Universitaria Pisana","All","18 Years and older   (Adult, Senior)","","120","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","University of Pisa","May 23, 2015","March 2015","March 2017","May 10, 2016","May 2016","No Study Results Posted","GLIOMELA","December 2016","progression-free survival|overall survival","https://ClinicalTrials.gov/show/NCT02458508"
655,"NCT02302235","Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study","Recruiting","No Results Available","Glioblastoma Multiforme of Brain","Other: Ketogenic Diet|Other: Standardized Diet","Mid-Atlantic Epilepsy and Sleep Center, LLC|Neuroscience Research Foundation, Swickley,PA","All","18 Years to 65 Years   (Adult)","Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","maesc 006","November 24, 2014","February 2014","August 2017","March 17, 2016","March 2016","No Study Results Posted","GBMXRT","August 2016","survival time|time to radiological (MRI) tumor progression|The incidence of treatment-emergent adverse events during treatment|Tolerability of ketogenic diet: Rate of early discontinuation of subjects from the diet because of intolerability, defined as unwillingness by the subject to continue with the diet because of possible diet related side effects","https://ClinicalTrials.gov/show/NCT02302235"
656,"NCT00584883","A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain Tumor","Drug: ABT 510","University of Alabama at Birmingham","All","19 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UAB 0327|ABT510","December 26, 2007","August 2003","July 2008","May 16, 2012","May 2012","No Study Results Posted","null","July 2008","All patients enrolled in this study will be statistically characterized for baseline and disease characteristics using descriptive statistics for continuous measures.","https://ClinicalTrials.gov/show/NCT00584883"
657,"NCT02501551","Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy","Recruiting","No Results Available","Melanoma","Drug: regorafenib","Yonsei University","All","19 Years and older   (Adult, Senior)","Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2014-0573","March 5, 2015","February 2015","June 2018","January 9, 2017","January 2017","No Study Results Posted","null","December 2017","disease control rate as measured by RECIST 1.1","https://ClinicalTrials.gov/show/NCT02501551"
658,"NCT00323115","Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme","Completed","Has Results","Glioblastoma Multiforme","Biological: Autologous Dendritic Cell|Drug: Temozolomide|Procedure: Radiotherapy|Biological: Dendritic Cell Vaccine","Dartmouth-Hitchcock Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D0536","May 4, 2006","May 2006","July 2013","October 8, 2015","June 2014","August 24, 2012","null","April 2008","Tumor-specific Cytotoxic T-cell Response|Feasibility and Toxicity Profile of Intra-nodal DC/Tumor Lysate Vaccination|Progression Free Survival (PFS)and Overall Survival (OS) Comparison to Prognostic Matched Historical Controls|Immunological Parameters With PFS vs Overall Survival|Radiological Response When There is Residual Enhancing Tumor at Baseline MRI","https://ClinicalTrials.gov/show/NCT00323115"
659,"NCT00039000","Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma","Completed","No Results Available","Malignant Melanoma","Drug: HSPPC-96 or Oncophage","Agenus Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C-100-21","June 6, 2002","March 2002","December 2005","September 6, 2012","September 2012","No Study Results Posted","null","December 2005","","https://ClinicalTrials.gov/show/NCT00039000"
660,"NCT00753246","Nimotuzumab in Adults With Glioblastoma Multiforma","Completed","No Results Available","Adults With Glioblastoma Multiforma","Drug: nimotuzumab","Oncoscience AG|Neurological Clinic, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany|University of Bonn|Dep. of Neurosurgery and Policlinic, University Hospital, Dresden, Germany|Heinrich-Heine University, Duesseldorf|Johann Wolfgang Goethe University Hospital|University of Giessen|Universitätsklinikum Hamburg-Eppendorf|University of Kiel|Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany|Neurological Clinic of the University of Tübingen, Tübingen, Germany","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","150","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OSAG101-BSA05","November 20, 2007","August 2007","January 2012","November 30, 2012","November 2012","No Study Results Posted","null","null","Progression-free interval determined by MRI|Overall survival Time to reintervention Response rate according to RECIST criteria Toxicity according to CTC criteria Symptom control Quality of life","https://ClinicalTrials.gov/show/NCT00753246"
661,"NCT01946529","Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","Active, not recruiting","Has Results","Desmoplastic Small Round Cell Tumor|Ewing Sarcoma of Bone or Soft Tissue|Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","Drug: vincristine|Drug: doxorubicin|Drug: cyclophosphamide|Drug: ifosfamide|Drug: etoposide|Drug: temozolomide|Drug: temsirolimus|Drug: bevacizumab|Drug: sorafenib|Procedure: surgery|Radiation: radiation","St. Jude Children's Research Hospital|University of Tennessee Health Science Center|University of Florida|Nemours Children's Clinic","All","up to 25 Years   (Child, Adult)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ESFT13|NCI-2013-01657","September 16, 2013","November 2013","July 2026","April 11, 2017","August 2016","June 30, 2016","null","August 2015","Response to Window Therapy (2 Courses) for Group B (High-risk) - ESFT Participants|Overall Survival|Progression-free Survival|Time to Progression|Local Failure Rate","https://ClinicalTrials.gov/show/NCT01946529"
662,"NCT00846430","Medical Treatment of ""High-Risk"" Neurofibromas","Active, not recruiting","No Results Available","Neurofibromatosis 1","Drug: Peg-Interferon alpha-2b|Drug: Celecoxib (Celebrex)|Drug: Temozolomide (temodar)|Drug: Vincristine Sulfate (Oncovin)","Spectrum Health Hospitals","All","2 Years to 30 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-260","January 16, 2009","October 2008","December 2017","May 20, 2015","May 2015","No Study Results Posted","null","October 2017","Tumor response based on evaluation of symptom assessment, tumor measurements, and MRI studies - Toxicity of treatment combinations based upon laboratory studies and physical examination|Psychological toxicity based upon psychological evaluations - Improved quality of life based upon physical examination and performance scales","https://ClinicalTrials.gov/show/NCT00846430"
663,"NCT00084838","Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT","Completed","Has Results","Central Nervous System Tumor, Pediatric","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: temozolomide|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Radiation: radiation therapy|Drug: Dactinomycin","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-294 DFCI|P30CA006516","June 10, 2004","February 2003","March 2013","December 18, 2015","December 2015","December 14, 2012","null","February 2008","2-yr Overall Survival|Pre-Radiation Therapy Chemotherapeutic Response","https://ClinicalTrials.gov/show/NCT00084838"
664,"NCT01596140","Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer","Active, not recruiting","No Results Available","Advanced Cancer|Solid Tumor","Drug: Vemurafenib|Drug: Everolimus|Drug: Temsirolimus","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Phase 1","114","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2012-0153|NCI-2012-00789","May 8, 2012","December 2012","December 2018","May 8, 2017","May 2017","No Study Results Posted","null","December 2018","Maximum Tolerated Dose (MTD) of Combination Vemurafenib|Tumor Response","https://ClinicalTrials.gov/show/NCT01596140"
665,"NCT01856933","BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)","Completed","Has Results","GBM|Glioblastoma Multiforme|Gliosarcoma","Drug: PSMA ADC","Heinrich Elinzano, MD|Progenics Pharmaceuticals, Inc.|Rhode Island Hospital|University of Texas|Brown University","All","18 Years and older   (Adult, Senior)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","263","January 8, 2013","May 2013","February 2015","June 23, 2015","June 2015","March 5, 2015","null","November 2014","Response Rate (Progression) for Patients With Glioblastoma That Have Progressed After Prior Treatment That Has Included Radiation, Temozolomide and Bevacizumab.|Toxicities (Adverse Events) of PSMA ADC for Patients With Recurrent Glioblastoma.","https://ClinicalTrials.gov/show/NCT01856933"
666,"NCT00098774","Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma","Completed","Has Results","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cytarabine|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: temozolomide","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","47","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-50202|U10CA031946|CDR0000398106","December 8, 2004","October 2004","September 2014","July 1, 2016","July 2016","June 26, 2014","null","January 2010","Complete Response Rate After Remission Induction|4 Year Progression Free Rate|Change From Baseline in Mini-Mental Status Evaluation at 4 Months|4 Year Overall Survival Rate","https://ClinicalTrials.gov/show/NCT00098774"
667,"NCT00766467","A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas","Completed","Has Results","Malignant Glioma","Drug: Armodafinil|Other: Placebo","Eudocia Quant Lee, MD|Dartmouth-Hitchcock Medical Center|University of California, San Diego|Beth Israel Deaconess Medical Center|Cephalon|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","81","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Supportive Care","07-341","October 2, 2008","September 2008","July 2014","June 17, 2016","June 2016","March 4, 2016","null","July 2014","Change From Baseline in Fatigue at Day 43|Change From Baseline in Quality of Life at Days 22, 43 and 56|Number of Grade 3-4 Side Effects at Least Possibly Related to Study Treatment","https://ClinicalTrials.gov/show/NCT00766467"
668,"NCT00936156","Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years","Completed","No Results Available","Metastatic, Cerebral Primitive Neuroectodermal Tumors","Drug: Chemotherapy (carboplatin, etoposide, thiotepa)","Gustave Roussy, Cancer Campus, Grand Paris","All","up to 5 Years   (Child)","Phase 2","67","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PNET HR+ 5|CSET 1329","July 7, 2009","January 2009","January 2012","August 1, 2016","August 2016","No Study Results Posted","null","January 2012","","https://ClinicalTrials.gov/show/NCT00936156"
669,"NCT02432417","The Addition of Chloroquine to Chemoradiation for Glioblastoma,","Not yet recruiting","No Results Available","Glioblastoma|Astrocytoma, Grade IV","Drug: Chloroquine","Maastricht Radiation Oncology","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","156","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CHLOROBRAINII","April 9, 2015","January 2018","January 2022","May 16, 2017","May 2017","No Study Results Posted","null","January 2020","Six-month progression-free survival|Overall survival|Adverse Events (AE) and serious AEs|Gene mutation, deletion or amplification|Tumor hypoxia","https://ClinicalTrials.gov/show/NCT02432417"
670,"NCT02047214","Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy","Terminated","No Results Available","Glioblastoma Multiforme","Drug: TPI 287|Drug: Bevacizumab","Cortice Biosciences, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","17","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TPI-287-18","January 24, 2014","January 2014","December 2015","January 26, 2016","January 2016","No Study Results Posted","null","December 2015","Safety of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ & prior bevacizumab as measured by AEs, physical/neurologic exam, KPS, weight, vital signs, hematology, serum chemistry, & urinalysis|MTD of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ & prior bevacizumab|Efficacy of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ & prior bevacizumab as measured by median progression free survival (PFS), overall response rate, & PFS rate at 4 & 6 months (PFS4 & PFS6)","https://ClinicalTrials.gov/show/NCT02047214"
671,"NCT00045968","Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer","Active, not recruiting","No Results Available","Glioblastoma Multiforme|Glioblastoma|GBM|Grade IV Astrocytoma|Glioma|Brain Cancer|Brain Tumor","Drug: Dendritic cell immunotherapy","Northwest Biotherapeutics","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","348","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","020221","September 17, 2002","December 2006","null","October 12, 2016","October 2016","No Study Results Posted","GBM","November 2016","The primary objective of this study is to compare progression free survival from time of randomization between patients treated with DCVax-L and control patients.|The secondary objective is to compare overall survival and time to disease progression between DCVax-L treated and control patients.","https://ClinicalTrials.gov/show/NCT00045968"
672,"NCT00422682","A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors","Completed","No Results Available","Tumors","Drug: bsi-201 + topotecan|Drug: bsi-201 + temozolomide|Drug: bsi-201 + gemcitabine|Drug: bsi-201 + carboplatin/paclitaxel","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 1","136","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TCD11484|20060102","January 12, 2007","January 2007","October 2012","June 9, 2016","June 2016","No Study Results Posted","null","January 2009","safety and efficacy|Response rate (CR + PR)","https://ClinicalTrials.gov/show/NCT00422682"
673,"NCT01933815","Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: TPI 287|Drug: Bevacizumab","Cortice Biosciences, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TPI-287-17","August 26, 2013","August 2013","February 2018","February 9, 2017","February 2017","No Study Results Posted","null","February 2018","Phase 1: Safety of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ as measured by AEs, physical/neurologic exam, KPS, weight, vital signs, hematology, serum chemistry, & urinalysis|Phase 1: MTD of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ|Phase 2: Efficacy of phase 1 MTD of TPI 287 + bevacizumab versus bevacizumab alone in adults with GBM that progressed following radiation and TMZ as measured by median PFS|Phase 1: Efficacy of TPI 287 + bevacizumab in adults with GBM that progressed following radiation and TMZ as measured by median progression free survival (PFS), overall response rate, & progression free survival rate at 4 & 6 months (PFS4 & PFS6)|Phase 2: Safety of TPI 287 + bevacizumab versus bevacizumab alone in adults with GBM that progressed following radiation & TMZ as measured by AEs, physical/neurologic exam, KPS, weight, vital signs, hematology, serum chemistry, & urinalysis|Phase 2: Efficacy of phase 1 MTD of TPI 287 + bevacizumab versus bevacizumab alone in adults with GBM that progressed following radiation and TMZ as measured by overall survival and overall response rate","https://ClinicalTrials.gov/show/NCT01933815"
674,"NCT03047473","Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma Multiforme of Brain","Biological: avelumab","Clinique Neuro-Outaouais","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CNO-006","January 31, 2017","March 10, 2017","March 2020","May 1, 2017","May 2017","No Study Results Posted","SEJ","September 2019","Safety and tolerability according to emergent adverse event leading to avelumab interruption or termination|iRANO criteria","https://ClinicalTrials.gov/show/NCT03047473"
675,"NCT02727387","Protocol for the Treatment of Metastatic Ewing Sarcoma","Recruiting","No Results Available","Ewing's Sarcoma (ES)","Drug: TEMIRI|Drug: ADM|Drug: IFO|Drug: CYC|Drug: ETO|Drug: BUMEL|Drug: VIN","Italian Sarcoma Group","All","up to 40 Years   (Child, Adult)","Phase 2","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ISG/AIEOP EW-2","March 23, 2016","May 2009","May 2020","March 17, 2017","March 2017","No Study Results Posted","EW-2","May 2018","Overall Survival (OS)|Event Free Survival (DFS)|Safety - Incidence and grade of treatment-emergent Adverse Events|Quality of life","https://ClinicalTrials.gov/show/NCT02727387"
676,"NCT02596828","Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma","Recruiting","No Results Available","Pineoblastoma","Drug: Temozolomide|Drug: Irinotecan|Drug: Dasatinib|Drug: Rapamycin","University of Regensburg","All","up to 25 Years   (Child, Adult)","Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RIST-rPB-2015-P","October 28, 2015","April 2016","April 2020","December 29, 2016","December 2016","No Study Results Posted","null","April 2019","The primary endpoint is progression-free survival (PFS)|Overall survival (OS)|Response to the investigational treatment after 4 and 8 courses of I/T and 1-year-follow-up in the RIST treatment arm|Duration until adequate response to this treatment regimen|Assessment of quality of life (Lansky and Karnofsky Scores)|Toxicity of this combination of drugs in children, adolescents and young adults with rNB - Assessment according to the latest version of the CTC criteria|Safety and tolerability of the investigational treatment - Assessment according to the latest version of the CTC criteria","https://ClinicalTrials.gov/show/NCT02596828"
677,"NCT00392886","Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: methotrexate|Drug: temozolomide|Drug: thiotepa|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Hospital Los Angeles|National Cancer Institute (NCI)","All","up to 10 Years   (Child)","Phase 3","120","Other","Interventional","Primary Purpose: Treatment","CDR0000503990|CHLA-HEAD-START-III|CHLA-HSIII|CHLA-2004-020|CHLA-04.020|UMN-MT2004-06","October 25, 2006","March 2004","null","December 17, 2013","October 2010","No Study Results Posted","null","December 2010","Time to tumor progression, disease recurrence, or death of any cause|Event-free survival at 2 years|Toxicity|Response to induction as assessed by one-time tumor measurements at baseline and after completion of induction chemotherapy|Time to death|Overall survival","https://ClinicalTrials.gov/show/NCT00392886"
678,"NCT01737346","Procarbazine and Lomustine in Recurrent Glioblastoma","Unknown status","No Results Available","Recurrent Glioblastoma Multiforme","Drug: lomustine and procarbazine","Incheon St.Mary's Hospital|National Cancer Center, Korea","All","20 Years and older   (Adult, Senior)","Phase 2","52","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KNOG-1201","November 27, 2012","October 2012","April 2014","November 30, 2012","November 2012","No Study Results Posted","null","September 2013","6-month progression free survival","https://ClinicalTrials.gov/show/NCT01737346"
679,"NCT01827384","Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors","Recruiting","No Results Available","Advanced Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm","Drug: Carboplatin|Drug: Everolimus|Other: Laboratory Biomarker Analysis|Drug: Temozolomide|Drug: Trametinib|Drug: Veliparib|Drug: WEE1 Inhibitor AZD1775","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","700","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2013-01588|MPACT|130105|P121047|9149|ZIABC011078","April 4, 2013","December 31, 2013","null","May 23, 2017","May 2017","No Study Results Posted","null","May 5, 2019","Objective response rate|PFS","https://ClinicalTrials.gov/show/NCT01827384"
680,"NCT00813566","Multi-Tracer PET Assessment of Primary Brain Tumors","Recruiting","No Results Available","Brain Tumors|Cancer","Radiation: Multi-tracer PET exams of 18F-FDG, 18F-FLT, 11C-ACE, and 15O-H2O","University of Utah","All","18 Years and older   (Adult, Senior)","","20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HCI31335","December 16, 2008","December 2008","July 2018","December 28, 2016","December 2016","No Study Results Posted","null","July 2018","Rapid, single-scan multi-tracer PET imaging can recover PET imaging biomarker information of each tracer that are not significantly different from those obtained from conventional, single-tracer scans of each tracer.|Multi-tracer PET biomarkers, obtained in conjunction, are better able to predict tumor aggressiveness than individual-tracer biomarkers or conventional radiographic imaging.|Multi-tracer PET biomarkers, obtained in conjunction, are better able to detect functional changes in tumor state that occur in response to therapy than individual-tracer biomarkers or conventional radiographic imaging.|Characterization of multiple aspects of tumor function (glucose metabolism, proliferation, membrane growth, and perfusion) provides new insight into tumor status that can guide selection of the most appropriate therapy.","https://ClinicalTrials.gov/show/NCT00813566"
681,"NCT01861990","Valproic Acid in Childhood Progressive Brain Tumors","Withdrawn","No Results Available","Pediatric Brain Tumor|Glioma|Anaplastic Astrocytoma|Medulloblastoma|Glioblastoma","Drug: Valproic Acid","Medical University of South Carolina","All","1 Year and older   (Child, Adult, Senior)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VA2013|IRG-97-219-14","May 22, 2013","May 2013","December 2013","May 21, 2015","May 2015","No Study Results Posted","null","December 2013","Completion of protocol|Time to progression","https://ClinicalTrials.gov/show/NCT01861990"
682,"NCT02619864","mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma Multiforme","Drug: AZD2014","Canadian Cancer Trials Group|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","52","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","I222","November 26, 2015","November 2015","December 2018","March 13, 2017","January 2017","No Study Results Posted","null","May 2018","Recommended phase II dose (RP2D) of AZD2014|6 month progression-free survival rate|Number and severity of adverse events|Response rate per RANO criteria|T evaluate the plasma levels of AZD2014 alone at the time of resection","https://ClinicalTrials.gov/show/NCT02619864"
683,"NCT00111007","A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma","Completed","Has Results","Melanoma","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Carboplatin/Paclitaxel|Drug: Placebo","Bayer|Amgen","All","18 Years and older   (Adult, Senior)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11718|2005-000941-12","May 16, 2005","May 2005","January 2009","October 23, 2014","October 2014","January 27, 2011","null","September 2006","Progression Free Survival (PFS)|Overall Survival (OS)|Time to Progression (TTP)|Duration of Response (DOR)|Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status to the Visit When the Best Tumor Response Was Noted","https://ClinicalTrials.gov/show/NCT00111007"
684,"NCT01666600","NOA-12: BIBF1120 and R-RT in Glioblastoma","Terminated","No Results Available","Glioblastoma Multiforme","Drug: BIBF 1120|Radiation: radiotherapy","Prof. Dr. Wolfgang Wick|University Hospital Heidelberg","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NONK-3/NOA-12","July 12, 2012","August 2012","September 2017","May 16, 2017","May 2017","No Study Results Posted","null","March 2017","Maximal tolerated dose of BIBF 1120 in combination with reirradiation (Phase I)|Number of participants with adverse events as a measure of safety and tolerability of BIBF1120|Progression-free survival|Objective response rates (OR)|Overall survival|Quality of life as determined by EORTC QLQ-C15 PAL and the EORTC brain module QLQ-BN 20|Cognitive function determined by MMSE","https://ClinicalTrials.gov/show/NCT01666600"
685,"NCT02986815","[11C]Acetate PET in Patients With Glioma","Recruiting","No Results Available","Glioma","Other: [11C]Acetate Brain Imaging","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Senior)","","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","STU 052016-034","November 22, 2016","December 2016","December 2021","December 20, 2016","December 2016","No Study Results Posted","null","December 2021","Visual differences from normal brain in patients with grades 2, 3 or 4 gliomas|Decrease in [11C]Acetate uptake following treatment of grade 2 glioma|Decrease in [11C]-acetate uptake following treatment of grade 3 and 4 glioma|Change in [11C]-acetate uptake following treatment at time of progression in grade 3 and 4 gliomas","https://ClinicalTrials.gov/show/NCT02986815"
686,"NCT01854099","Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens","Withdrawn","No Results Available","Glioblastoma","Biological: PEP-CMV|Biological: PEP-CMV|Biological: PEP-CMV","University of Florida|American Brain Tumor Association","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PERFORMANCE","May 11, 2013","January 2014","January 2014","January 13, 2014","January 2014","No Study Results Posted","PERFORMANCE","January 2014","Safety","https://ClinicalTrials.gov/show/NCT01854099"
687,"NCT01478178","Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma","Completed","No Results Available","Glioma|Glioblastoma|Glioblastoma Multiforme|GBM|Brain Cancer","Drug: VAL-083 (Dianhydrogalactitol)","DelMar Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","55","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","DLM-10-001","November 14, 2011","October 2011","October 2016","January 19, 2017","January 2017","No Study Results Posted","null","December 2015","Determination of maximum tolerated dose (MTD)|Evaluate tumor response in patients with recurrent malignant glioma|Characterization of Cycle 1 plasma pharmacokinetics","https://ClinicalTrials.gov/show/NCT01478178"
688,"NCT01308632","Metronomic Temozolamide in Patients With Recurrent Glioblastoma","Unknown status","No Results Available","Glioblastoma","Drug: Temozolamide, irinotecan","Grupo Español de Investigación en Neurooncología","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GENOM-007","January 24, 2011","November 2007","June 2012","March 2, 2011","March 2011","No Study Results Posted","null","June 2012","Efficacy of the treatment (Phase I)|Progression-free survival (Phase II)|Assess the toxicity of the treatment|Progression-free survival at 6 months|overall survival","https://ClinicalTrials.gov/show/NCT01308632"
689,"NCT00800917","A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme","Completed","No Results Available","Glioblastoma Multiforme","Drug: Temsirolimus|Drug: Bevacizumab","Rigshospitalet, Denmark|University of Copenhagen|Wyeth is now a wholly owned subsidiary of Pfizer|Roche, Copenhagen","All","18 Years and older   (Adult, Senior)","Phase 2","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BEV-CCI-779-GBM-02|Eudract no.: 2008-003679-40","December 1, 2008","November 2008","February 2010","June 1, 2010","April 2010","No Study Results Posted","null","February 2010","Progression-free survival in months|Adverse events|Objective tumor response rate|Pre- vs post-treatment measurements of biomarkers and vascular system/immune system parameters|Correlation with biomarkers","https://ClinicalTrials.gov/show/NCT00800917"
690,"NCT02876003","Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma","Withdrawn","No Results Available","Glioblastoma","Drug: G-202","GenSpera, Inc.|John Wayne Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","0","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","G-202-008","August 18, 2016","September 2016","October 2020","February 22, 2017","February 2017","No Study Results Posted","null","October 2019","6-month progression-free survival|Safety|Objective tumor response rate, best overall response|Duration of PFS|Overall survival","https://ClinicalTrials.gov/show/NCT02876003"
691,"NCT02067156","Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma","Completed","No Results Available","Glioblastoma Multiforme","Drug: G-202","GenSpera, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","G-202-004|R01FD005077","February 16, 2014","February 2014","February 2017","February 22, 2017","February 2017","No Study Results Posted","null","December 2016","6-month progression-free survival|Safety|Objective tumor response rate, best overall response|Duration of PFS|Overall survival|G-202 pharmacokinetics and pharmacodynamics","https://ClinicalTrials.gov/show/NCT02067156"
692,"NCT01105988","Evaluating Tumor Pseudoprogression With FLT-PET and MRI","Terminated","No Results Available","Glioblastoma","Other: Radiologic exams","Massachusetts General Hospital|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Early Phase 1","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","10-008","April 15, 2010","May 2011","October 2011","January 4, 2012","January 2012","No Study Results Posted","null","October 2011","Primary Outcome Measure|Secondary Outcome Measure","https://ClinicalTrials.gov/show/NCT01105988"
693,"NCT02751138","Determination of Immune Phenotype in Glioblastoma Patients","Recruiting","No Results Available","Glioblastoma Multiforme","Procedure: Surgery","University of Ulm","All","18 Years and older   (Adult, Senior)","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","University Hospital Ulm","April 19, 2016","March 2016","March 2018","April 25, 2016","April 2016","No Study Results Posted","null","March 2018","Overall survival|Progression free survival|Quality of life|Karnofsky performance score","https://ClinicalTrials.gov/show/NCT02751138"
694,"NCT00094653","MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma","Completed","Has Results","Melanoma|Metastases","Drug: MDX-010 (anti-CTLA4) monoclonal antibody|Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine","Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 3","1783","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MDX010-20|CA184-002","October 21, 2004","September 2004","October 2009","June 29, 2011","June 2011","April 22, 2011","null","August 2009","Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone|Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 Monotherapy Versus gp100 Melanoma Peptide Vaccine Alone and MDX-010 in Combination With gp100 Melanoma Peptide Vaccine Versus MDX-010 Monotherapy|12-, 18-, and 24-Month Survival Rates|Progression Free Survival (PFS)|Percentage of Participants With Progression Free Survival (PFS) at Week 12 and Week 24|Time to Progression (TTP)|Best Overall Response (BOR): Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressed Disease (PD)|Determination of Best Overall Response Rate (BORR)|Time to Response|Duration of Response|Disease Control Rate (DCR)|Delayed Response (Response Beyond Week 24)|Change From Baseline in Health-Related Quality of Life (QOL) as Measured by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Instrument at Week 12|Percentage of Participants With On-Study Adverse Events (AEs) and AEs With an Outcome of Death|Percentage of Participants With Immune-Related Adverse Events (irAEs)|Percentage of Participants With Worst On-Study Hematological Abnormalities|Percentage of Participants With Worst On-Study Liver Abnormalities|Percentage of Participants With Worst On-Study Renal Abnormalities|Clinically Meaningful Changes in Vital Signs and Physical Examinations","https://ClinicalTrials.gov/show/NCT00094653"
695,"NCT02664363","EGFRvIII CAR T Cells for Newly-Diagnosed GBM","Recruiting","No Results Available","Glioblastoma","Biological: EGFRvIII CAR T cells","Gary Archer Ph.D.|Duke University","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Pro00069444","January 22, 2016","February 1, 2017","February 2024","February 6, 2017","February 2017","No Study Results Posted","ExCeL","February 2020","MTD|DLT","https://ClinicalTrials.gov/show/NCT02664363"
696,"NCT02104882","INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study","Completed","No Results Available","Glioblastoma Multiforme","Radiation: Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)","Universitätsmedizin Mannheim","All","50 Years and older   (Adult, Senior)","Phase 1|Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INTRAGO-I/II","March 26, 2014","March 2014","September 2016","October 14, 2016","October 2016","No Study Results Posted","null","September 2016","Maximum Tolerated Dose (MTD)|Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02104882"
697,"NCT02062372","Spatial Analysis and Validation of Glioblastoma on 7 T MRI","Recruiting","No Results Available","Glioblastoma","Device: 7 T MRI|Procedure: Biopsy","Maastricht Radiation Oncology|The Limburg University Fund","All","18 Years and older   (Adult, Senior)","","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","1335-1812-intern-6485|47894","February 12, 2014","May 2015","January 2018","July 14, 2016","July 2016","No Study Results Posted","null","September 2017","The co-localisation of the Gross Tumour Volume (GTV) on 7T MRI and 3T MRI|The correspondence between glioblastoma cells found in the biopsies and region of interest (ROI) on the 7T MRI scan.|The co-localisation of the Clinical Target Volume (CTV) on 7T MRI and 3T MRI|The co-localisation of the organs at risk (OAR) on 7T - and 3T MRI|The correlation between the first tumour recurrence on 3T MRI follow-up images and ROI on the 7T MRI scan|The quantification of tumour heterogeneity on 7T MRI and 3T MRI|The visibility of white matter tracts on 7T MRI and 3T MRI|Tolerability and side effects 3T MRI and 7T MRI scan","https://ClinicalTrials.gov/show/NCT02062372"
698,"NCT02443194","The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients","Terminated","No Results Available","Depression","Drug: duloxetine|Drug: PLACEBO","michal roll|Tel-Aviv Sourasky Medical Center","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Prevention","0124-15 TLV","May 3, 2015","May 2015","November 2015","December 2, 2015","December 2015","No Study Results Posted","null","November 2015","changes in patients mood and cognitive function according to the neuropsychological assessment","https://ClinicalTrials.gov/show/NCT02443194"
699,"NCT01403285","Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma","Terminated","No Results Available","Glioblastoma","Drug: Cyclophosphamide|Biological: IMA950 plus GM-CSF|Biological: IMA950|Drug: Imiquimod","immatics Biotechnologies GmbH|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","6","Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMA950-102|11C0192","July 21, 2011","August 2011","April 2014","May 16, 2014","May 2014","No Study Results Posted","null","April 2014","Safety and tolerability of IMA950 administered with granulocyte macrophage colony stimulating factor (GM-CSF) and topical imiquimod together following a single low-dose application of cyclophosphamide.|Immunogenicity of IMA950|Immune status parameters|Biomarker assessment and correlation to clinical and immunological response|Clinical anti-tumor activity (response rate, 6-month progression-free survival)|Influence of corticosteroids on immunogenicity of IMA950|Health-related quality of life","https://ClinicalTrials.gov/show/NCT01403285"
700,"NCT00088400","Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors","Completed","No Results Available","Glioblastoma","Drug: TransMID","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 3","30","NIH","Interventional","Primary Purpose: Treatment","040244|04-N-0244","July 23, 2004","July 2004","November 2005","September 21, 2016","September 2016","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00088400"
701,"NCT02466828","qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.","Recruiting","No Results Available","Glioblastoma|Hypoxia","Drug: Feraheme®","Sunnybrook Health Sciences Centre|St. Michael's Hospital, Toronto","All","18 Years and older   (Adult, Senior)","Early Phase 1","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Diagnostic","127-2014","November 21, 2014","March 2015","December 2018","January 18, 2017","January 2017","No Study Results Posted","null","December 2018","Oxygen saturation in GBM with qBOLD MRI and its correlation with histological markers of tissue hypoxia and angiogenesis|Oxygen saturation in GBM with qBOLD MRI and its correlation with targeted intraoperative oxygen measurement","https://ClinicalTrials.gov/show/NCT02466828"
702,"NCT00706810","Combination of Hydroxyurea and Verapamil for Refractory Meningiomas","Completed","Has Results","Cancer|Brain Cancer|Meningioma","Drug: Hydroxyurea|Drug: Verapamil","University of Utah","All","18 Years and older   (Adult, Senior)","Phase 2","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HCI25089","June 26, 2008","December 2007","September 2015","March 1, 2017","March 2017","October 12, 2016","null","September 2015","Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating Conditions.|Median Progression-free Survival Rates of the Treatment Population.","https://ClinicalTrials.gov/show/NCT00706810"
703,"NCT02663271","TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma","Recruiting","No Results Available","Glioblastoma Multiforme|Glioblastoma|Malignant Glioma|GBM","Drug: Bevacizumab|Device: Optune|Other: Brain MRI|Other: Quality of Life Questionnaires","University of Florida|NovoCure Ltd.","All","22 Years and older   (Adult, Senior)","Phase 2","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IRB201600074","January 21, 2016","August 2016","May 2018","April 14, 2017","April 2017","No Study Results Posted","null","May 2018","Progression-free survival between the groups|Number of adverse events|Karnofsky Performance Scale|Mini-Mental Status Exam|Response Assessment in Neuro-Oncology (RANO) Measurement Form","https://ClinicalTrials.gov/show/NCT02663271"
704,"NCT02310451","Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes","Recruiting","No Results Available","Metastatic Melanoma","Biological: blood test","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Senior)","","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","14-AOI-10","November 13, 2014","December 2014","December 2016","March 21, 2016","March 2016","No Study Results Posted","EXOSOMES","December 2015","number of exosomes|number of patient with a detection test of exosomes positive measured|survival|Tumoral response","https://ClinicalTrials.gov/show/NCT02310451"
705,"NCT02820857","Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer","Not yet recruiting","No Results Available","Neuroendocrine Carcinomas","Drug: Folfiri-bevacizumab|Drug: Folfiri","Hospices Civils de Lyon","All","18 Years and older   (Adult, Senior)","Phase 2","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","69HCL14_0442","June 29, 2016","January 2017","January 2020","June 29, 2016","June 2016","No Study Results Posted","BEVANEC","June 2019","Proportion of patients alive","https://ClinicalTrials.gov/show/NCT02820857"
706,"NCT01867593","MET-PET for Newly Diagnosed Glioblastoma","Completed","No Results Available","Glioblastoma","Device: C-11 methionine PET","Massachusetts General Hospital","All","18 Years and older   (Adult, Senior)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","13-018","May 16, 2013","January 2014","null","October 19, 2016","October 2016","No Study Results Posted","null","September 2016","Effect of C-11 methionine PET on progression free survival|Evaluate for discordance in tumor volumes|Compare pre-radiation and follow-up C-11 methionine PET imaging in predicting sites of failure|Compare pre-radiation and follow-up C-11 methionine PET in predicting occurrence of pseudoprogression","https://ClinicalTrials.gov/show/NCT01867593"
707,"NCT00256230","Disulfiram in Patients With Metastatic Melanoma","Completed","No Results Available","Stage IV Melanoma","Drug: Disulfiram (DSF)","John P. Fruehauf|University of California, Irvine","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 01-01|2001-2038","November 17, 2005","January 2002","August 2007","December 6, 2016","December 2011","No Study Results Posted","null","August 2007","Determine response rate|Evaluate the toxicity of disulfiram administration","https://ClinicalTrials.gov/show/NCT00256230"
708,"NCT00541840","Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma","Unknown status","No Results Available","Soft Tissue Sarcoma","Drug: Sorafenib","Grupo Espanol de Investigacion en Sarcomas","All","18 Years to 72 Years   (Adult, Senior)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEIS01-07","October 9, 2007","October 2007","April 2010","May 8, 2008","May 2008","No Study Results Posted","null","April 2009","Phase I: Safety profile and to determine maximum tolerated dose (MTD) / Recommended Dose (DR) of Sorafenib in combination with Ifosfamide. Phase II: Activity profile evaluating of the combination in patients with advanced soft tissue sarcoma.|Phase II: Efficacy evaluation","https://ClinicalTrials.gov/show/NCT00541840"
709,"NCT02283944","TMS Electrochemotherapy for Glioblastoma Multiforme","Suspended","No Results Available","Glioblastoma","Device: TMS","University of Aarhus","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15102014","November 3, 2014","January 2015","January 2018","August 22, 2016","October 2014","No Study Results Posted","null","January 2018","Time to death|Time to progression|Quality of Life","https://ClinicalTrials.gov/show/NCT02283944"
710,"NCT02129335","Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner","Terminated","No Results Available","Neoplasms|Glioblastoma","Other: stress","University Hospital, Basel, Switzerland|University Hospital, Zürich|Luzerner Kantonsspital|University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Senior)","","12","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TOGETHER","April 7, 2014","April 2014","May 2017","May 16, 2017","May 2017","No Study Results Posted","TOGETHER","October 2016","Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02129335"
711,"NCT01663012","Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma","Completed","Has Results","Anaplastic Astrocytomas|Anaplastic Oligodendrogliomas|Glioblastomas (GBM)","Drug: Etirinotecan pegol","Lawrence Recht|Nektar Therapeutics|Stanford University","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB-24833|SU-06212012-10228|NCI-2012-01288|BRN0021","August 2, 2012","July 2012","February 2015","January 25, 2016","January 2016","May 28, 2015","null","February 2015","Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria|Survival From the Time of First NKTR-102 Dose for Patients With BEV-resistant Glioma Receiving NKTR-102 to Date of Death|Overall Survival From Time of Diagnosis","https://ClinicalTrials.gov/show/NCT01663012"
712,"NCT00293423","GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: HSPPC-96|Procedure: conventional surgery","University of California, San Francisco|National Cancer Institute (NCI)|Agenus Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","41","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05103|P30CA082103|UCSF-05103|UCSF-H41995-27311-01","February 16, 2006","October 2005","August 2013","November 12, 2014","November 2014","No Study Results Posted","null","August 2013","Safety and maximum tolerated dose|Frequency of gp96 heat shock protein-peptide complex vaccine (Phase I [closed to accrual as of 7/25/2007])|Toxicity (Phase I [closed to accrual as of 7/25/2007])|Progression-free survival at 6 months (Phase II)|Immunological response (Phase I [closed to accrual as of 7/25/2007])|Safety (Phase II)|Tumor response as measured by neuro-imaging and neurologic exam (Phase II)|Survival (Phase II)|Immunological response (Phase II)","https://ClinicalTrials.gov/show/NCT00293423"
713,"NCT01880008","Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma","Completed","No Results Available","Glioblastoma","","Washington University School of Medicine|Barnes-Jewish Hospital","All","18 Years and older   (Adult, Senior)","","5","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","08-0073","July 30, 2010","April 2008","August 2012","June 13, 2013","June 2013","No Study Results Posted","null","February 2010","Change in FLT uptake, measured by SUV tumor/SUV normal contralateral white matter|Survival|Ki-67|Radiographic progression defined by MacDonald criteria|O(6)-methylguanine DNA-methyltransferase (MGMT) activity|Time to progression","https://ClinicalTrials.gov/show/NCT01880008"
714,"NCT02622620","Study on Neuroepithelial Tumor Grading and Pseudoprogression After Glioma Therapy Using Advanced Functional MRI Techniques","Not yet recruiting","No Results Available","Glioma|Neoplasms","","Tang-Du Hospital","All","Child, Adult, Senior","","86","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2014JZ2-007","November 18, 2015","July 2016","November 2018","March 28, 2016","March 2016","No Study Results Posted","null","November 2018","To prospectively acquire multiparameter MR variables at 3T MRI from treated high grade glioma patients to assign tissue signatures for tumor recurrence and pseudoprogression as established by pathologic examination|To compare the predictive values of the multiparameter MR tissue signatures acquired at 3T","https://ClinicalTrials.gov/show/NCT02622620"
715,"NCT01499823","Permeability Map to Distinguish Progression From Pseudoprogression in High-Grade Glioma","Unknown status","No Results Available","High Grade Glioma","","Seoul National University Hospital","All","18 Years and older   (Adult, Senior)","","74","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-1108-032-372","December 19, 2011","December 2011","December 2013","December 27, 2013","December 2013","No Study Results Posted","null","December 2011","Permeability Map to Distinguish Progression From Pseudoprogression in High-grade glioma","https://ClinicalTrials.gov/show/NCT01499823"
716,"NCT01692496","Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial","Active, not recruiting","No Results Available","Advanced and / or Metastatic Liposarcoma","Drug: Pazopanib","Grupo Espanol de Investigacion en Sarcomas|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","52","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEIS-30|2012-002745-38","September 14, 2012","January 2013","December 2016","February 18, 2016","February 2016","No Study Results Posted","null","December 2016","Progression-free survival (PFS) assessed 12 weeks after start of treatment|Overall progression free survival (median PFS)|Objective tumor response|Time to onset of response|Duration of response|Overall survival (OS)|Clinical benefit rate|Growth Modulation Index (GMI)|Safety profile (according CTCAE, version 4.0)","https://ClinicalTrials.gov/show/NCT01692496"
717,"NCT02848794","Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma","Not yet recruiting","No Results Available","High-grade Glioma","Drug: Apatinib and Irinotecan","The First People's Hospital of Lianyungang|Shandong Cancer Hospital and Institute|The Affiliated Hospital of Medical College of Qingdao University|Yankuang Group General Hospital|Lianyungang Hospital Affiliated Bengbu Medical College|Suzhou Kowloon Hospital","All","15 Years to 75 Years   (Child, Adult, Senior)","Phase 1|Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AI-001","July 22, 2016","July 2016","December 2017","July 27, 2016","July 2016","No Study Results Posted","null","December 2017","Progression-Free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response（DOR）|Quality of life (QOL)|Incidence of treatment-related adverse events","https://ClinicalTrials.gov/show/NCT02848794"
718,"NCT02854228","PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon","Recruiting","No Results Available","Pituitary Tumor","","Hospices Civils de Lyon","All","Child, Adult, Senior","","1300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL16_0506","July 27, 2016","February 2007","December 2020","July 29, 2016","July 2016","No Study Results Posted","PITUICARE-Lyon","December 2015","Progression free survival after pituitary surgery according to the clinicopathological classification (HYPOPRONOS)|Correlation between percentage of SSTR expression of the pituitary tumor and somatostatine analogs efficacy.|Correlation between percentage of MGMT expression of the pituitary tumor and tumor response to temozolomide.","https://ClinicalTrials.gov/show/NCT02854228"
719,"NCT02613988","Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas","Recruiting","No Results Available","Adult Glioblastoma","Radiation: Radiation|Device: 3 Tesla magnetic resonance imaging|Device: Chemical exchange saturation transfer MRI|Device: Diffusion weighted MRI|Device: Dynamic contrast enhancement MRI|Device: Dynamic susceptibility contrast MRI","Asan Medical Center","All","18 Years and older   (Adult, Senior)","","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","AsanMCHSKim_01","November 18, 2015","December 2015","null","December 2, 2015","December 2015","No Study Results Posted","null","February 2017","Diagnostic Performance of Response Rate|Progression Free Survival (PFS)|Quantitative changes to tumor protein content and tumor acidosis|Quantitative changes to tumor cellularity|Quantitative changes to tumor perfusion using dynamic susceptibility contrast MRI|Quantitative changes to tumor perfusion using dynamic contrast enhancement MRI","https://ClinicalTrials.gov/show/NCT02613988"
720,"NCT02465268","Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma Multiforme|Glioblastoma|Malignant Glioma|Astrocytoma, Grade IV|GBM","Biological: pp65-shLAMP DC with GM-CSF|Biological: unpulsed PBMC and saline|Drug: Td|Drug: Saline|Drug: pp65-flLAMP DC with GM-CSF","University of Florida|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","IRB201400697|R01CA175517","May 27, 2015","August 2016","June 2024","January 6, 2017","January 2017","No Study Results Posted","ATTAC-II","June 2023","Change in median overall survival|Changes in immune response|Change in progression-free survival","https://ClinicalTrials.gov/show/NCT02465268"
721,"NCT00902577","MRI and PET Scan Using 18F-Fluoromisonidazole In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme","Active, not recruiting","No Results Available","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma","Drug: 18F-Fluoromisonidazole|Procedure: Magnetic Resonance Imaging|Procedure: Positron Emission Tomography","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","50","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Diagnostic","NCI-2011-01912|CDR0000640413|ACRIN 6684|ACRIN-6684|U01CA080098","May 14, 2009","August 24, 2009","null","May 23, 2017","October 2016","No Study Results Posted","null","January 31, 2018","Association of baseline FMISO PET uptake (HV and T/Bmax) and MRI parameters (Ktrans and CBV) with OS as assessed using Cox-regression model|Association of baseline FMISO PET uptake (HV and T/Bmax) and MRI parameters (Ktrans and CBV) with TTP and PFS-6 as assessed using multi-variate Cox model and multi-variate Logistic regression model|Correlation between other MRI parameters (T1Gd, VCI, small vessel CBV, ADC, NAA-Cho ratio, changes in BOLD signal, and T2 lesion volume) and OS, TTP, and PFS-6|Correlation between T/Cmax and T/Bmax|Reproducibility of the baseline FMISO PET uptake parameters as assessed by baseline ""test"" and ""retest"" PET scans","https://ClinicalTrials.gov/show/NCT00902577"
722,"NCT02654041","Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients","Suspended","No Results Available","Glioblastoma Multiforme (GBM)","Drug: Combined T3 and Methimazole treatment","Musli Thyropeutics Ltd.|Tel-Aviv Sourasky Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","30","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","MusliGBM002","January 11, 2016","March 2016","February 2017","November 14, 2016","November 2016","No Study Results Posted","null","February 2017","Response rate at 6 months (6 months PFS)|Response rate at 2 months (2 months PFS)|Response rate at 4 months (4 months PFS)|Time to disease progression or cancer-related death|Safety endpoint evaluation","https://ClinicalTrials.gov/show/NCT02654041"
723,"NCT02567539","Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma","Recruiting","No Results Available","Recurrent High Grade Glioma","Radiation: IMRT with or without radiosensitive therapy|Drug: Radiosensitive therapy","Istituto Clinico Humanitas","All","18 Years and older   (Adult, Senior)","","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1394","September 28, 2015","April 2015","April 2021","February 26, 2016","October 2015","No Study Results Posted","null","April 2019","Progression free of participants|Overall survival of participants|Incidence of radionecrosis|Questionnaire assessment of neurocognitive function","https://ClinicalTrials.gov/show/NCT02567539"
724,"NCT02598011","A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care","Not yet recruiting","No Results Available","Newly Diagnosed High Grade Glioma (HGG)","Biological: Toca 511|Drug: Toca FC","Tocagen Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Tg 511-15-03","November 3, 2015","March 2016","null","December 28, 2015","December 2015","No Study Results Posted","Toca7","November 2022","Dose limiting toxicities","https://ClinicalTrials.gov/show/NCT02598011"
725,"NCT03055208","Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma","Recruiting","No Results Available","Glioblastoma","Radiation: gamma knife radiosurgery (15 Gy to 50% isodose)","Frederik Wenz|Universitätsmedizin Mannheim","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Gamma-GBM","February 9, 2017","February 8, 2017","September 2020","February 16, 2017","February 2017","No Study Results Posted","Gamma-GBM","February 2020","Median Progression-Free Survival Time (PFS)|Median Overall Survival Time (OS)|Radiation-related (acute / early delayed / late) neurotoxicity|Incidence of symptomatic radionecrosis","https://ClinicalTrials.gov/show/NCT03055208"
726,"NCT03165292","An International Multicenter Phase II Randomised Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy","Not yet recruiting","No Results Available","Very High Risk Neuroblastoma","Radiation: 131I- mIBG|Drug: Topotecan|Drug: Thiotepa|Procedure: Autologous stem cell transplant","Gustave Roussy, Cancer Campus, Grand Paris|SIOPEN|French National Cancer Institute","All","Child, Adult, Senior","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2015-003130-27|2015/2294","May 23, 2017","June 2017","June 2025","May 23, 2017","May 2017","No Study Results Posted","VERITAS","June 2023","Event Free Survival (EFS)","https://ClinicalTrials.gov/show/NCT03165292"
727,"NCT02813135","European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","Recruiting","No Results Available","Children, Adolescents and Young Adults With Refractory or Recurrent Malignancies","Drug: Ribociclib|Drug: Topotecan|Drug: Temozolomide|Drug: Everolimus|Drug: AZD1775|Drug: Carboplatin|Drug: Olaparib|Drug: Irinotecan|Drug: AZD2014|Drug: Nivolumab|Drug: Cyclophosphamide|Radiation: Radiotherapy","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France","All","up to 18 Years   (Child, Adult)","Phase 1|Phase 2","285","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2016-000133-40|2016/2396","June 16, 2016","June 2016","December 2020","August 22, 2016","August 2016","No Study Results Posted","ESMART","December 2020","Objective tumor response|Time to progression","https://ClinicalTrials.gov/show/NCT02813135"
728,"NCT01811992","Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma","Recruiting","No Results Available","Malignant Glioma|Glioblastoma Multiforme","Biological: Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L","University of Michigan|Phase One Foundation","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HUM00057130|UMCC 2015.024","February 13, 2013","December 2013","December 2018","October 20, 2016","October 2016","No Study Results Posted","null","December 2018","Maximum Tolerated Dose (MTD)|Number of Patients Alive at 12 and 24 Months","https://ClinicalTrials.gov/show/NCT01811992"
729,"NCT03032484","TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma","Not yet recruiting","No Results Available","Astrocytoma","Drug: Bevacizumab|Drug: TVB-2640","The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Senior)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CTMS# 16-0136","January 24, 2017","June 10, 2017","April 10, 2021","April 24, 2017","April 2017","No Study Results Posted","null","April 10, 2021","Tumor response per RANO (Response Assessment in Neuro-Oncology) criteria|Incidence, nature and severity of adverse events and serious adverse events, graded according to NCI - Common Toxicity Criteria for Adverse Events version (4.03)","https://ClinicalTrials.gov/show/NCT03032484"
730,"NCT03011528","First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years","Recruiting","No Results Available","Ewing Sarcoma Family of Tumors","Drug: VDC-IE x2|Drug: VDC-IE|Drug: TEMIRI|Drug: Consolidation BuMel|Drug: Maintenance|Procedure: Local treatment by surgery|Radiation: Local treatment by radiotherapy","Institut Curie|UNICANCER","All","2 Years to 50 Years   (Child, Adult)","Phase 2","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IC 2015-13 CombinaiR3","December 6, 2016","December 2016","December 2022","March 23, 2017","March 2017","No Study Results Posted","CombinaiR3","May 2020","Anti-tumour effect of the treatment strategy assessed by the number of patients event-free survival (EFS) at 18 months|Anti-tumour effect of the dose-intensified induction chemotherapy assessed by the response rate of patients|Anti-tumour effect of the dose-intensified induction chemotherapy assessed by the number of patients eligible for consolidation phase|Overall survival (OS) is assessed by the number of patients still alive at the end of the three years of treatment|3-years event-free survival (EFS) is assessed by the number of patients without any event at the end of treatment phase|Number of patients with treatment-related adverse events as assessed by CTCAE v4.03|Number of patients with treatment-related toxicities on laboratory data as assessed by CTCAE v4.03 of the different phases of treatment|18F-FDG PET evaluation efficacy assessed by primary tumour uptake|18F-FDG PET evaluation efficacy assessed by metabolic tumour volume (MTV)|Percentage of circulating tumour cells in blood and bone marrow to correlate with patient outcome (EFS). Ancillary study|Comparison of transcriptomic profiles between those of primary disease and those of bone marrow metastases to determine if they are the same or not. Ancillary study","https://ClinicalTrials.gov/show/NCT03011528"
731,"NCT02747407","Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors","Recruiting","No Results Available","Astrocytoma|Glioma|Oligodendroglioma","Biological: Hepatitis A Vaccine|Other: Laboratory Biomarker Analysis|Biological: Tetanus Toxoid Vaccine|Biological: Trivalent Influenza Vaccine","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","50","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCCWFU 01316|NCI-2016-00472|P30CA012197","April 19, 2016","May 2016","May 2017","February 20, 2017","February 2017","No Study Results Posted","null","May 2017","Proliferative ability of lymphocytes by carboxyfluorescein diacetate succinimidyl ester assay|The quantity of cells determined by flow cytometry|Response of the tetanus toxoid vaccine-specific IgG antibody|Vaccine-specific total antibody response after hepatitis A vaccination. In hepatitis A exposed patients, hepatitis B will be used.","https://ClinicalTrials.gov/show/NCT02747407"
732,"NCT01587040","Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen","Active, not recruiting","No Results Available","Neoplasm Malignant","Drug: SAR245408|Drug: SAR245409","Sanofi","All","Child, Adult, Senior","Phase 1|Phase 2","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TED12414|2011-006140-78|U1111-1124-1403","April 25, 2012","July 2012","April 2018","March 16, 2017","March 2017","No Study Results Posted","null","April 2018","Safety and tolerability as measured by the incidence and frequency of adverse events (AEs) and laboratory abnormalities","https://ClinicalTrials.gov/show/NCT01587040"
733,"NCT00003273","Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor","Withdrawn","No Results Available","Brain and Central Nervous System Tumors|Neuroblastoma|Retinoblastoma|Sarcoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: temozolomide|Drug: thiotepa|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","New York University School of Medicine","All","up to 10 Years   (Child)","Phase 2","0","Other","Interventional","Primary Purpose: Treatment","CDR0000066174|NYU-P9712|NCI-V98-1400","November 1, 1999","November 1997","null","November 30, 2015","November 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003273"
734,"NCT00811993","A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors","Terminated","No Results Available","Neoplasms","Drug: RG1507|Drug: RO1507|Drug: bevacizumab [Avastin]|Drug: capecitabine [Xeloda]|Drug: carboplatin|Drug: cetuximab|Drug: docetaxel|Drug: erlotinib [Tarceva]|Drug: etoposide|Drug: gemcitabine|Drug: irinotecan|Drug: mFOLFOX6|Drug: paclitaxel|Drug: pemetrexel|Drug: sorafenib|Drug: temozolomide|Drug: trastuzumab [Herceptin]","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 1","104","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NO22068","December 18, 2008","February 2009","December 2012","November 1, 2016","November 2016","No Study Results Posted","null","December 2012","Adverse events, laboratory parameters, vital signs|Trough levels of R1507","https://ClinicalTrials.gov/show/NCT00811993"
735,"NCT02717962","Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma","Recruiting","No Results Available","Glioma|Glioblastoma|Glioblastoma Multiforme|GBM|Brain Cancer","Drug: VAL-083, Dianhydrogalactitol","DelMar Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","48","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","DLM-16-001","March 16, 2016","January 20, 2017","June 2021","May 3, 2017","May 2017","No Study Results Posted","null","September 2020","Overall Survival|Estimate Progression-free Survival|Estimate Median Progression-Free Survival|Estimate Median Overall Survival|Estimate Overall Response Rate|Estimate Duration of Response|Safety evaluation of VAL-083 in patients|Quality of Life|Plasma Pharmacokinetics","https://ClinicalTrials.gov/show/NCT02717962"
736,"NCT01089244","FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma","Active, not recruiting","No Results Available","Astrocytoma|Oligoastrocytoma|Oligodendroglioma","","Ludwig-Maximilians - University of Munich|Deutsche Krebshilfe e.V., Bonn (Germany)","All","18 Years and older   (Adult, Senior)","","38","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GGN-CP4","March 17, 2010","June 2008","December 2015","September 18, 2015","September 2015","No Study Results Posted","null","December 2015","Overall survival|Progression Free survival","https://ClinicalTrials.gov/show/NCT01089244"
737,"NCT01743157","Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma","Completed","No Results Available","Metastatic Melanoma","Drug: Biochemo + bevacizumab then ipilimumab","California Pacific Medical Center Research Institute","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BBI Total Therapy","April 4, 2011","December 2010","May 2013","August 28, 2013","August 2013","No Study Results Posted","BBI","May 2013","A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy and Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)","https://ClinicalTrials.gov/show/NCT01743157"
738,"NCT01678352","Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas","Recruiting","No Results Available","High Risk WHO Grade II Glioma|Recurrent/Post-Chemotherapy WHO Grade II Glioma","Biological: Tumor Lysate Vaccine|Drug: Imiquimod","University of Pittsburgh|University of Minnesota - Clinical and Translational Science Institute","All","18 Years and older   (Adult, Senior)","Early Phase 1","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11-136","August 30, 2012","October 2012","September 2017","January 12, 2016","January 2016","No Study Results Posted","null","September 2016","Safety|Induction of BTIC Lysate-specific T-cell response","https://ClinicalTrials.gov/show/NCT01678352"
739,"NCT01089868","Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients","Completed","No Results Available","Glioblastoma Multiforme","","Ludwig-Maximilians - University of Munich|Deutsche Krebshilfe e.V., Bonn (Germany)","All","18 Years and older   (Adult, Senior)","","79","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GGN-ZP9","March 17, 2010","January 2007","July 2012","August 5, 2012","August 2012","No Study Results Posted","null","June 2011","Overall Survival|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01089868"
740,"NCT01576692","Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma","Active, not recruiting","No Results Available","Neuroblastoma","Biological: Humanized anti-GD2 antibody|Drug: Chemotherapy|Other: Cytokines|Biological: Natural killer cells|Device: CliniMACS","St. Jude Children's Research Hospital|CURE Childhood Cancer, Inc.","All","up to 21 Years   (Child, Adult)","Phase 1","34","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GD2NK|NCI-2012-00495","April 10, 2012","April 2012","February 2019","March 30, 2017","February 2017","No Study Results Posted","null","October 2014","Number of patients experiencing unacceptable toxicity associated with humanized anti-GD2 antibody/chemotherapy (course 1) and anti-GD2 antibody/chemotherapy/NK cells (course 2).|Response to treatment|Time to progression.|Event free survival.|Overall survival","https://ClinicalTrials.gov/show/NCT01576692"
741,"NCT00072358","Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma","Active, not recruiting","No Results Available","Neuroblastoma","Biological: anti-GD2 murine IgG3 monoclonal antibody 3F8|Biological: anti-GD2 murine IgG3 monoclonal antibody 3F8","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","340","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","03-077|MSKCC-03077","November 4, 2003","July 2003","December 2017","October 10, 2016","October 2016","No Study Results Posted","null","December 2017","Efficacy at completion of treatment|Relapse-free survival every 3 months|Compare granulocyte activation in patients treated with short-term vs prolonged daily exposure to sargramostim (GM-CSF) after 4 courses|Simplify treatment with consequent reduction in cost","https://ClinicalTrials.gov/show/NCT00072358"
742,"NCT01567202","Study of DC Vaccination Against Glioblastoma","Unknown status","No Results Available","Glioma|Glioblastoma Multiforme|Neoplasms","Procedure: Surgery|Drug: Chemotherapy|Radiation: Radiotherapy|Biological: DC vaccination|Drug: blank placebo","Huashan Hospital|Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DC81001115","March 26, 2012","March 2012","December 2016","May 19, 2015","May 2015","No Study Results Posted","null","December 2016","Overall survival|Progression free survival|To correlate and characterize the immune response to the clinical response|To explore the association of GBM molecular subtype with immune response|To evaluate the effect of residual tumor volume on the immune response.","https://ClinicalTrials.gov/show/NCT01567202"
743,"NCT03072134","Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma","Recruiting","No Results Available","Glioma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma Multiforme|Astrocytoma, Grade III|Astrocytoma, Grade IV|Brain Cancer","Biological: Neural stem cells loaded with an oncolytic adenovirus","Northwestern University","All","18 Years and older   (Adult, Senior)","Phase 1","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","STU00203933","February 20, 2017","April 24, 2017","April 1, 2019","April 24, 2017","April 2017","No Study Results Posted","null","March 30, 2019","Determine the maximum number of neural stem cells loaded with the oncolytic adenovirus.|Assessment of tumor response or progression to treatment on MRI.","https://ClinicalTrials.gov/show/NCT03072134"
744,"NCT01441388","A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.","Withdrawn","No Results Available","Carcinoma, Renal Cell|Glioblastoma|Carcinoma, Hepatocellular","Drug: Crizotinib plus VEGF inhibitor combinations|Drug: Crizotinib plus axitinib|Drug: Crizotinib plus sunitinib|Drug: Crizotinib plus axitinib|Drug: Crizotinib plus sunitinib|Drug: Crizotinib plus bevacizumab|Drug: Crizotinib plus sorafenib","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 1","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A8081030","September 23, 2011","December 2011","November 2013","December 19, 2011","December 2011","No Study Results Posted","null","November 2013","Dose Limiting Toxicities (DLTs).|Duration of Response (DR)|Progression free survival (PFS)|Area under the plasma concentration versus time curve (AUC) of crizotinib and each VEGF inhibitor|Best overall response, as assessed using the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 or , in the case of GBM (glioblastoma multiforme , RANO (Response Assessment in Neuro-Oncology) criteria.|Overall survival (OS) up to 12 months|Pre- and post-dose levels of soluble peripheral blood biomarkers.|Tumor tissue biomarkers.|6-month progression free survival proportion (PFS6) for glioblastoma patients|Peak plasma concentration (Cmax) of crizotinib and each VEGF inhibitor","https://ClinicalTrials.gov/show/NCT01441388"
745,"NCT00685750","Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma","Terminated","No Results Available","Lung Cancer, Non-Small Cell","Procedure: Collection of tumor and blood samples","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","","219","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Screening","109752","May 23, 2008","April 2008","December 2013","March 2, 2017","March 2017","No Study Results Posted","null","December 2013","Expression of tumor antigens|Occurrence of a pre-defined gene-expression signature to Antigen-Specific Cancer Immunotherapeutic|The serum proteome|Correlation of relevant markers of the pre-identified gene-expression signature as measured by immunohistochemical methods and by quantitative PCR.|For NSCLC patients (where possible), the consistency of the occurrence of the gene-expression signature and tumor antigens in distinct concomitant tumor lesions obtained at the same time from the same patient.|For metastatic melanoma patients treated with ipilimumab explore predictive value to clinical activity of pre-identified immune-related gene-expression signature by evaluating the patient's best clinical response to this treatment.","https://ClinicalTrials.gov/show/NCT00685750"
